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Abstract
Although there are a variety of high-throughput technologies used to perform bio-
logical experiments, DNA microarrays have become a standard tool in the modern
biologist’s arsenal. Microarray experiments provide measurements of thousands of
genes simultaneously, and offer a snapshot view of transcriptomic activity. With the
rapid growth of public availability of transcriptomic data, there is increasing recog-
nition that large sets of such data can be mined to better understand disease states
and mechanisms. Unfortunately, several challenges arise when attempting to perform
such large-scale analyses. For instance, public repositories to which the data is being
submitted to were designed around the simple task of storage rather than that of
data mining. As such, the seemingly simple task of obtaining all data relating to a
particular disease becomes an arduous task. Furthermore, prior gene expression anal-
yses, both large and small, have been dichotomous in nature, in which phenotypes
are compared using clearly defined controls. Such approaches may require arbitrary
decisions about what are considered “normal” phenotypes, and what each phenotype
should be compared to.
Addressing these issues, we introduce methods for creating a large curated gene
expression database geared towards data mining, and explore methods for efficiently
expanding this database using active learning. Leveraging our curated expression
database, we adopt a holistic approach in which we characterize phenotypes in the
context of a myriad of tissues and diseases. We introduce scalable methods that
associate expression patterns to phenotypes in order to assign phenotype labels to new
expression samples and to select phenotypically meaningful gene signatures. By using
a nonparametric statistical approach, we identify signatures that are more precise
than those from existing approaches and accurately reveal biological processes that are
hidden in case vs. control studies. We conclude the work by exploring the applicability
of the heterogeneous expression database in analyzing clinical drugs for the purpose
of drug repurposing.
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The science-fiction film GATTACA depicts a world in which a person’s susceptibility
to different diseases is known at birth based on an analysis of the newborn’s genetic
code. Although the bleak outlook of the future presented in this film is plagued by
the detrimental use of genetic information to form social castes, imagine a rosier view
in which a person’s genetic information can be used not only to prevent certain dis-
eases, but also to provide personalized treatment that is attuned to an individual’s
exact biological and environmental properties. For example, imagine the amount of
pain and suffering that can be avoided if a surgeon where to be able to conclusively
determine the origin and exact subtype of a tumor and compare the treatment out-
comes of patients with similar biological and clinical properties such that the most
efficacious treatment can be implemented. This will become the norm in the near
future. In order for this to become a reality, however, a vast amount of data needs
to be leveraged and combined to produce accurate predictors for the wide array of
clinical outcomes.
While there are many types of biological data that can be used to aid in answering
the question of what makes a certain tissue different from another, or a certain disease
similar to some other seemingly dissimilar disease, gene expression analyses have
become standard in high-throughput analyses of tissues and diseases. Simply stated,
a gene expression experiment (also known as a microarray experiment) provides a
snapshot view of thousands of genes and denotes whether they are turned “on” and
19
“off” (see Section 1.1.3 for more details). Such snapshots can be used to compare
different types of tissue (e.g. lung vs. brain tissue) or different states of a tissue (e.g.
normal vs. diseased). For example, Alizadeh et al. [6] performed an analysis of a
large B-cell lymphoma, a malignancy of the lymphatic system, by analyzing which
genes were turned “on” and “off” in the resected lymphatic tissue of patients. Based
solely on the gene expression patterns, they were able to find two distinct clusters of
patients. What made these two sub-populations different? A dramatic difference in
mortality rate. By “merely” looking at the genes that were expressed in lymphatic
tissue they were able to generate a diagnosis with great clinical relevance. Imagine if
we could perform such analyses for all types of diseases.
To make these sorts of analyses and potential subsequent clinical applications
routine, however, we require a large curated database of thousands, or even hundreds
of thousands, of samples across multiple phenotypes. Leveraging the data in such
a database, we can then not only examine the outcomes of a single disease, but
rather, begin to understand the biological underpinnings of hundreds of diseases and
their subtypes. Furthermore, it becomes imperative not to perform these analyses in
isolation, but rather in the context of other tissues and diseases from various types of
patients. For instance, the treatment course for the same disease may be markedly
different for two individuals based on other diseases they may also have. With rapidly
growing repositories of public microarray data (see Figure 2-1), the notion of using
hundreds of samples spanning various tissues and diseases to perform detailed gene
expression based analyses has become feasible. Similarly, with the constant decrease
in price and complexity of performing microarray experiments, the clinical application
of microarrays is within reach. Unfortunately, without a so-called “black box” that a
clinician can use to test a given patient’s gene expression data against, gene expression
data cannot be used as a diagnostic tool.
Other recent work utilizing large disparate datasets by Butte et al. [19] and Segal
et al. [116] show that it is possible to find genes and gene modules that are significantly
associated with various phenotypes. Alternatively, Dudley et al. [28] recently showed
how the genes that are expressed in various diseases can be used for repurposing drugs.
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Commercial ventures such as NextBio [67] and Oncomine [103] have also begun to
take the results from disparate biological experiments to elucidate novel insights.
Building upon the foundation of the ideas and insights of these large-scale analyses,
we show how we can build a large, curated gene expression database (Chapter 2)
and then how it can be used to accurately label previously unseen expression samples
with their phenotypic labels (Chapter 3), elucidate sets of phenotype specific “marker
genes” (Chapter 4), expand an expression database through active learning (Chapter
5), and how it can be applied to analyze drugs (Chapter 6).
1.1 Biology and terminology
Before delving deeper, let us review (or, for some, learn for the first time) some
introductory biology. For those of you who are familiar with transcriptional biology
and the workings of microarray technology, feel free to skip to the next chapter.
1.1.1 Basic biology
At the most basic level, living organisms are made up of individual cells. Some
very simple organisms, such as bacteria, are unicellular and are called prokaryotes1.
Humans, on the other hand, are eukaryotic organsism and are not only multicellular,
but are comprised of cells that have a nucleus. Although there are many different
types of cells in complex multicellular organisms (liver cells, brain cells, blood cells,
etc.), each cell contains the entire blueprint, or genetic code, for that particular
organism. As such, it could theoretically be possible to make a whole new organism
by taking any cell from that organism and copying it (just like they did in the book,
and later movie, Jurassic Park). This genetic information is stored in the form of
DNA (deoxyribonucleic acid) and is primarily found in the nucleus of the cell2. When
one refers to an organism’s “genetic code,” one generally means the arrangement of
1More accurately, organisms that are comprised of cells that lack a cell nucleus are called prokary-
otes. Eukaryotes are organisms that are made up of cells that have a cell nucleus.
2There is also a small amount of mitochondrial DNA (mtDNA) in the energy producing structures
called the mitochondria.
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the four chemical bases (also called nucleotides) adenine (A), guanine (G), cytosine
(C), and thymine (T) that make up the DNA (Figure 1-1). While all humans share
about 99% of the 3 billion bases, the differences in the arrangement of the A, C, T,
and Gs for the remaining 1% is what differentiates you from me [84]. Importantly,
in the double helix of DNA, adenine always pairs with thymine, and guanine always
pairs with cytosine. Although outside the scope of this introduction, it is vital that
these pairings remain constant, as during cell replication, it is imperative that each
daughter cell can make a full double helix of DNA from just one strand of DNA.
Figure 1-1: Adenine pairs with Thymine, and Guanine pairs with Cytosine to make
the familiar double helix of DNA [84].
If the DNA is considered the blueprint document of an organism, the genes that
are encoded in this DNA can be considered to be the individual specifications for
the rooms, stairwells, and so forth. The 3 billion bases of DNA are subdivided into
smaller regions known as genes. Currently it is estimated that humans have between
20,000 and 25,000 genes [84]. Each of these genes, which can be as short as a few
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hundred DNA bases to over 2 million bases, are the instructions for building molecules
known as proteins. Proteins are the workhorses of the cells and are required for the
function, structure, and regulation of the tissues and organs in the body.
1.1.2 Transciptional biology
As the contents of this work deals with gene expression of humans3, let us explore the
process of how proteins are synthesized from DNA. As aforementioned, the DNA of
a eukaryotic cell is located in the nucleus. Most of the work that is performed by the
cell, however is undertaken by proteins in the cytoplasm outside of the nucleus. The
genetic code of the gene4 located on the DNA is not directly converted into protein in
the nucleus, but first converted to RNA (ribonucleic acid) that then moves out of the
nucleus and is used as a “carbon copy” of the DNA blueprint to create the protein.
Just like DNA, RNA is comprised of four nucleotides. Unlike DNA, however, uracil
is used in the place of thymine (the RNA alphabet is A, C, U, and G). This process
of converting DNA to RNA is called transcription and the specific type of RNA that
is produced is called messenger RNA (mRNA)5.
Once the mRNA has been exported out of the nucleus into the cytoplasm, it makes
its way to the ribosomes, the protein factories of the cell. Here, the protein is built as
a chain (polymer) of amino acids where the sequence of amino acids is determined by
the template provided by the mRNA. Unlike the one-to-one translation of DNA to
RNA (except for the T that becomes a U), the nucleotides of the RNA are processed
3The data that we use for this work is all human data, but it could just as easily be applied to
any other organism.
4Although colloquially one says that genes are what become proteins, it is actually the open
reading frame (ORF) within the gene that is transcribed to RNA. As a gene is any heritable piece
of DNA it also includes other information, such as promoter regions, that are not directly used in
the creation of a protein. Thus, the mRNA that is produced starts from the 5’ (read five-prime)
region of the ORF that begins with a start codon, and goes until a stop codon is reached in the 3’
area. Bits of DNA before the start codon are considered “upstream” of the ORF and are known
to be located in the 5’ untranslated region (UTR). Similarly, DNA past the stop codon are in the
downstream 3’ UTR. It is well known that there are many proteins (known as transcription factors)
that bind to specific promotor regions in the UTR and activate or deactivate the transcription of
the downstream ORF.
5Other types of RNA include transfer RNA (tRNA) that bring amino acids to the site of protein
synthesis, and ribosomal RNA (rRNA) that is the catalytic component of ribosomes.
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in groups of three. Although there are 64 possible combinations of of trinucleotides
(commonly known as codons) there are only 20 common, naturally occurring amino
acids. Thus, there are several codons that code for the same nucleotide6. Also, a
few of these codons do not represent amino acids, but rather the start (or initiation)
and stop (or termination) codons that aptly describe the location to start and stop
converting the mRNA into the protein. This entire process of using mRNA as a
blueprint for generating a new protein molecule is called translation.
Both programmed events within the cell and external events can cause the initi-
ation of transcription and translation. For example, the genetic machinery for cir-
cadian rhythm includes transcriptional events that happen approximately every 24
hours without any external stimuli. The model of rhythm generation in Drosophila is
detailed in the work of Wilsbacher and Takahashi [139]. Alternatively, pathological
events within the cell can start transcriptional activity. For instance, self-destruction
(apoptosis) can be triggered by self-repair or damage-detection programs internal to
the cell when something “breaks” the DNA within the nucleus. On the other hand,
the external piezoelectric forces7 generated in the bones caused by walking can grad-
ually cause bone remodeling by stimulating transcriptional activity of certain bone
cells8. An “in-between” example is where hormones secreted from distant organs bind
to the receptors on the cell, triggering the transcriptional process.
1.1.3 Gene expression experiments
The term gene expression experiment (also known as a microarray experiment) has
been previously used but never clearly defined. In essence, a microarray experiment
is a snapshot view that simultaneously measures the expression levels of thousands
of genes in a sample. The higher the expression level, the more “turned on” the gene,
and the lower the expression level, the more “turned off.” Although they are called
“gene” expression experiments, they actually measure the quantity of mRNA that is
6A biological instance of the famed “pigeonhole principle.”
7Piezoelectricity is the charge that builds up in bone and DNA (and other solid materials) caused
by the application of mechanical pressure or stress.
8Osteoblastic and osteoclastic cells, to be exact.
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present (expressed) in the sample. The assumption is that if more mRNA is present,
more proteins corresponding to that mRNA will be generated in the cell. In this
manner, we can compare the quantity of mRNA corresponding to thousands of genes
across different phenotypes. By analyzing what genes are “turned on” and “turned
off” (i.e. which genes are being transcribed and translated into proteins) in different
phenotypic conditions, we can hope to identify what causes brain tissue to be brain
tissue and not skin tissue. It is important to note that microarray technology is not
special because it can uniquely measure gene expression, but rather because it can do
it in a high-throughput manner. Instead of measuring the expression of one gene at
a time, microarrays allow researchers to analyze the expression of thousands of genes
simultaneously.
Figure 1-2: The basics of microarray technology. Fluorescence-tagged cDNA sample
probes for a tissue or system of interest are hybridized to a microarray chip containing
cDNA probes. After the hybridization process, the chip is scanned using a laser, and
the intensity levels at each probe location are measured to determine the expression
level for a particular gene.
For most common microarrays, a scientist starts by extracting mRNA from a tis-
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sue or system of interest (e.g. brain) and creates a fluorescence-tagged complimentary
DNA (cDNA) copy of this mRNA9 (Figure 1-2). These sample probes are then hy-
bridized to a microarray chip (also known as a platform)) that have cDNA probes
attached to the surface in a predetermined grid pattern. The underlying idea behind
this process is that a sample probe will only bind to its complementary probe, thus
allowing a scientist to measure the quantity of the sample probe present. After leav-
ing the microarray chip submerged in the solution containing the sample probes for
several hours, any excess unhybridized sample probes are washed off. The microarray
is then scanned using laser light and a digital image scanner records the brightness
level at each probe location. The brightness at a particular spot is correlated with
the RNA level in the original tissue or system of interest [112] and is thus used as
the expression level for that gene. Since the probes that are on the sample chip are
the same for the different conditions being tested (i.e. exact duplicates of the chip are
used) in a single “dataset” generated by a researcher, the differences in the expression
levels for the genes can be attributed to the biological differences and not technical
differences (Figure 1-3).
Throughout this work, the following definitions will be used unless explicitly stated
otherwise. A microarray dataset (series) will be a set of microarray experiments (sam-
ples) that were conducted by a specific lab for a specific purpose. For example, if a
group of scientists were studying lung cancer and performed ten microarray exper-
iments, five disease state experiments and five control experiments, then the set of
these ten experiments is a dataset. Each experiment will also have associated with
it a sample chip (platform or array). The platform is the actual chip that the mi-
croarray experiment was conducted on, for example the Affymetrix HGU-133A chip.
Figure 1-3 shows a pictorial representation.
There are multiple different forms of microarray technologies, the two major ones
being spotted cDNA arrays and oligonucliotide arrays. While both of them measure
gene intensity levels, the approach of how they are created and the way in which the
9Recall that adenine always pairs with thymine, and guanine always pairs with cytosine. Because
this always is true, we can create the complementary DNA (i.e. if it was an A it becomes a T, if it
was a T it becomes an A).
26
Figure 1-3: The relationship of a dataset, an experiment, and a platform. For a single
dataset there are multiple different samples produced (in this case 6), all of which are
performed on a single chip (platform) type (in this case the Affymetrix HGU-133A).
intensities are measured differ. The former was introduced by Mark Shena et al. [112]
in 1995 and is also known as a cDNA microarray. Typically, a robotic spotter picks up
cDNA that has been amplified using Polymerase chain reaction (PCR) and places it
on a glass slide. When performing the experiment, two conditions are actually tested
simultaneously, each with a different fluorescent color. The intensity levels are then
measured as a ratio of the two conditions. On the other hand, oligonucleotide arrays
are generated by a photolithographic masking technique first described by Stephen
Fodor et al. [37] and made popular by Affymetrix. Unlike the cDNA arrays, oligonu-
cleotide arrays only measure one condition at a time. One therefore needs to perform
multiple experiments in order to compare multiple conditions. A more in-depth ex-
planation about microarray technology and the various types of microarrays can be
found in Microarrays for an Integrative Genomics [65]. Our work will exclusively
deal with oligonucleotide array data performed on the Affymetric HG-U133 Plus 2.0
array.
Difficulties in dealing with microarrays
Although microarray technology enables one to get a genome-wide snapshot of the
quantity of RNA levels in a sample, there are many factors that make this data difficult
to deal with. Simply put, the data is noisy. For example, a replicate experiment
that uses exactly the same experimental setup can, and often does, report different
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expression levels. While this may seem disconcerting, this irreproducibility of data is
not limited to microarray technology, but also occurs in most types of experiments in
which miniscule quantities are measured with a highly sensitive device. The standard
approach to dealing with this problem is to make many replicates and hope that the
intensity values of the repeats converge to the true measure (this is one of the reasons
why generating a large curated database of expression data is useful). Unfortunately,
not only are microarray experiments very expensive, but these sort of repeats tend
to eliminate noise caused by measurement errors and not the biological variation
inherent in the samples being studied.
Another major obstacle in dealing with microarray technology is the lack of cross
platform reproducibility. As detailed in [65], high intensity levels in a cDNA experi-
ment did not correspond well with high levels in oligonucleotide experiments. In light
of these findings, the current work only uses single channel data. Furthermore Hwang
et al. [57] performed a study where they compared two human muscle biopsy datasets
that used two generations of the Affymetrix arrays (HG-U95Av2 and HG-U113A) and
showed that they obtained differences in both cluster analysis and the differentially
expressed genes. While this is an unfortunate conclusion, this sort of noise is in-
evitable and cannot be countered. For this reason, we only use gene expression data
from a single gene expression platform (Affymetrix HG-U133 Plus 2.0).
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Chapter 2
Concordia: The system and its
application to GEO
The widespread adoption of electronic storage media throughout the medical and
biomedical research communities presents significant new challenges and opportuni-
ties. The American Recovery and Reinvestment Act of 2009 will invest $19 billion
in a program to promote the adoption of information technology throughout the
American health care infrastructure in the coming years. In particular, the Act em-
phasizes widespread implementation of electronic health record (EHR) systems. By
recent estimates, only 17% of doctors and 10% of hospitals are currently utilizing
such systems [16]. The financial incentive schedule included in the program, valued
at approximately $17 billion, is intended to motivate doctors and hospitals to adopt
technologies that interoperate with other parts of the healthcare system by 2015, or
face financial penalty in subsequent years [16]. The volume of data generated by this
mandate over the coming years will be tremendous.
In addition to the imminent proliferation of electronic medical records, a variety of
high-throughput biomedical assays have been refined over the past decade, and more
continue to be developed today. It is expected that the data derived from these assays
will eventually be brought to bear on clinical diagnostics as well as therapeutic drug
design. The volume of data available from some of these sources (e.g., NCBIs Gene
Expression Omnibus repository [31, 13], the European Bioinformatics Institute’s Ar-
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rayExpress [97]) has already outstripped our ability to perform large-scale, automated
discovery of relevant patterns among records with shared phenotype. Moreover, at
present, there exist no systems capable of associating these assay records in a stan-
dardized and meaningful way with relevant EHRs or other clinical narrative. Such
cross-pollination would enable sophisticated quantitative clinical diagnostic systems,
as well as accelerate the pace of therapeutic innovation.
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Figure 2-1: The number of gene ex-
pression samples has been growing at
a dramatic rate since the inception of
NCBI’s Gene Expression Omnibus 10
years ago.
In addition, there are no open,
scalable, standardized systems for
cataloging and searching large vol-
umes of medical data that leverages
existing expert knowledge. Many
institutions have developed propri-
etary in-house solutions that tend to
be ad hoc, lack portability between
problem domains (e.g., systems de-
signed for retrieving medical records
cannot be easily adapted to the task
of retrieving medical literature) and
require a major technical undertak-
ing. The applications that consume
such services must interact with sev-
eral different systems that cannot in-
teroperate with one another in any natural, meaningful way.
To this end, we have developed a scalable, standards-based infrastructure for
searching multiple disparate databases by mapping their corresponding textual con-
tents onto a structured medical ontology. Although we only present several targeted
use cases for this system, the framework can be leveraged against any database where
free-text attributes are used to describe the constituent records (for example, medi-
cal images might be associated with a short description, or clinical lab results with
doctor’s notes). Similar to the spirit in which a traditional search engine allows one
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free text-query to search for multiple content types (web pages, images, maps, etc.)
through an open API, the system likewise provides a platform built to open stan-
dards, able to support a diverse suite of applications that need to query a variety
of clinically relevant content (EHRs, biomedical assays, journal publications) using
Web 2.0 methodologies. Such a system would form the cornerstone backend search
tool required to build portable applications that leverage the wide variety of data-rich
resources that are becoming available, thus addressing one of the core challenges in
personalized healthcare practice: identifying clinically distinct subgroups to which a
particular patient belongs [64].
We envision the utility of such a query tool to increase over time as the volume
of biological assay data and “traditional” medical information converted to electronic
form grows. Rather than simply providing persistent storage of such documents (as
is the case microarray databases such as GEO and ArrayExpress), a unified, generic
search and retrieval tool will give the practitioner of medical, biological, or information
sciences the ability to query a wide variety of document sources, and navigate the
results in an intuitive and meaningful way. As previous endeavors to mine narrative
text associated with biological experiments [19] and medical records [109, 108] have
shown, there is a substantial amount of useful information that is readily available.
In a clinical setting, applications of data mining projects include identification of
populations for recruitment and for sample acquisition, observational studies married
to sophisticated time-series analysis for pharmacovigilance, quality improvement and
biosurveillance [72]. Furthermore, deeper understanding of the systems biological
processes can be gleaned by incorporating the vast amount of publicly available data.
For example, Lukk, et al. used gene expression experiments of various phenotypes
from ArrayExpress and depicted a map of human gene expression [77].







Figure 2-2: Both the text from the
source documents [1] and the free-text
queries [2] get mapped to UMLS con-
cepts. Querying for the parent concept
[2] will return all documents relating
to child concepts as they relate to the
more specific concepts.
Concordia is a framework for map-
ping both queries and source doc-
uments onto a structured ontology.
This enables users to leverage both
the textual information inherent in
the document and the ontological as-
sociations among the relevant key-
words. More concretely, we take
the free-text associated with a given
record (the description of the con-
tents of a medical image, for exam-
ple) and use a natural language pro-
cessing (NLP) program (see 2.1.1)
that maps this free-text to the pre-
defined concepts in the ontological
vocabulary. For instance, the text
associated with an x-ray of broken
bone may read, “Compound trans-
verse fracture of tibia caused by ski-
ing accident.” We then insert this
record in an ontological index such
that a query for all of the concepts
that it directly was mapped to (e.g.
“tibia” and “compound transverse fracture”) by the NLP program and any of the
ancestor concepts (e.g. “leg” or “fracture”) would return the record. Queries to this
system can either be performed using one or more of the concepts in the ontological
vocabulary or via free-text that is then converted to a set of keywords automatically.
When the query is in the form of free-text, the same NLP program used to index the
documents is used to obtain the concepts for the provided input. Using this frame-
work, therefore, it is possible to perform arbitrarily specific queries for uses such as
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data mining or patient recruitment for a particular study. For a further example
that depicts the mapping of a “Lung adenocarcinoma” gene expression sample into a
structured medical ontology see Figure 2-3.
In addition to simple queries based on single concepts, the system can efficiently
aggregate documents that match arbitrarily complex logical combinations of concepts.
This has been implemented as a standard stack-based algorithm [91] for evaluating in-
fix set logic expressions. Here, the operands will be set operators (union, intersection,
difference) and the arguments will be UMLS concepts. Conceptually, the algorithm
works by replacing the stack entry for each UMLS concept in the expression with
the set of database records that reference it, then proceeding with the logical evalua-
tion as usual. This will enable the user to perform free-text queries such as “anemia
and cancer” or “lung cancer and metastasis but not smoking” against the library of
documents.
2.1.1 Why use an ontology? What ontology should we use?
With the growing argument for letting the data drive the associations between related
concepts [51], why are we relying on a manually curated ontology to drive the associ-
ations between concepts? First, and foremost, unlike traditional text-based domains
such as web-search or document retrieval, the aim of the Concordia framework is not
only to query for documents related to concepts, but also to enable the integration
of various sources of possibly non-textual data. As others have previously noted, the
conceptual representation of data using an ontology allows such disparate databases
to be linked in a transparent way to facilitate data analysis [136]. Furthermore, there
are two major challenges that arise when searching free-text medical literature as it
appears in electronic medical records, medical reference volumes or other relevant doc-
uments: resolving synonyms and identifying conceptual relationships between medical
terms.
Multiple synonymous phrases are often used to describe one common medical or
biological concept. For example, the terms “malignant neoplasm of the lung” and





























Figure 2-3: The free-text associated with a record is analyzed using a natural lan-
guage processing program that maps the free-text to the predefined concepts in the
ontological vocabulary. Using this model, we can combine existing expert knowl-
edge (in the form of the associations in the ontology) and the information inherent
in the text of the records. In this example, therefore, we can associate the data of
GSM10 with the concept “Adenocarcinoma of the lung,” and all of its ancestors in
the hierarchy.
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on which term should be used to describe the one underlying concept, a malignant
cancerous growth appearing in the lung. To see where this becomes a challenge,
consider searching a database for the phrase “lung cancer” where all of the constituent
documents refer to “malignant neoplasm of the lung.” Searching the database by
simple string matching will fail to find the documents related to the query. The use
of a controlled vocabulary, however, mitigates this issue as there is one “correct”
concept for “lung cancer.”
As for the case of potentially complex associations between various concepts, the
relationships between concepts are clearly defined by the ontological structure of
the controlled vocabulary. As depicted in Figure 2-3, for example, we see the clear
relationship between the concept “Neoplasm” and “Adenocarcinoma of Lung.” While
this link may be relatively trivial as both terms reference a word related to “cancer,”
the relationship between “Inflammatory disorder” and “Asthma” is more opaque.
Furthermore, the expert associations provided by an ontology allow queries to be
made for concepts that may not have been directly mentioned in any of the source
text of the corresponding data records. Continuing with the previous example, it may
be the case that there are only records for “Asthma” and “Arthritis” in the database.
Due to the hierarchic relationships in the ontology, however, we can return all records
associated with “Asthma” and “Arthritis” when a user queries for “Inflammatory
disorder.” Thus, this hierarchical index allows us to efficiently traverse the ontology
and retrieve records related to a particular concept and its descendants (or ancestors).
Although it may be possible to generate a de novo taxonomization of the medi-
cal vocabulary with a large enough corpus of medical data, both of these challenges
can be addressed by employing the cumulative expert knowledge that is represented
in well-established ontologies of a controlled vocabulary. While countless ontologies
exist, and the Concordia framework can employ any one of them, the National Li-
brary of Medicines Unified Medical Language System (UMLS) [87] provides the ideal
hierarchically structured controlled vocabulary for generating a database that allows
users to insert and query documents along the lines of medically relevant concepts.
Using the MetaMorphosys tool provided by the National Library of Medicine, we
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created a custom ontology, known as a Metathesaurus, built from the expert curated
thesauri of UMLS, SNOMED and MeSH.
Mapping documents and queries onto UMLS Metathesaurus
In order to be able to use the UMLS medical ontology, the Metathesaurus, we first
have to map the free-text associated with each record to the set of standardized
concepts. To do this, we employ the the MetaMap [7] tool that matches syntactic
noun phrases from an input text to UMLS concepts, effectively “standardizing” the
text to a set of unique concepts. The method is comprised of the five following steps:
1. Parsing: The text is parsed into noun phrases using the SPECIALIST minimal
commitment parser [83].
2. Variant Generation: Variants are generated for each phrase using the SPE-
CIALIST lexicon and a database of synonyms.
3. Candidate Retrieval: The “candidate set” of all strings in the Metathesaurus
that match at least one of the variants is generated.
4. Candidate Evaluation: Each of the candidates in the candidate set is evalu-
ated against the input text.
5. Mapping Construction: Candidates from disjoint parts of each input phrase
are combined and are then scored. The combined candidate mappings with the
highest scores correspond to MetaMap’s best interpretation of the input text.
In our setting, the application of MetaMap to the textual portions of data records
allows us to resolve the problems of synonyms. One of the major benefits of this
approach is that when we later query the database, we can apply the same stan-
dardization to the input query as was used to transform the original source text. In
this manner, we can search for database entities matching the query in the struc-
tured space of standardized UMLS concepts rather than free-text. In addition, when
a practitioner later wishes to perform large-scale data mining on such a database,
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we can treat the UMLS concepts associated with the database entities as a discrete
labeling thereof, without applying ad-hoc text searches to identify groups of related
records.
MetaMap, however, only provides the direct mappings from the free-text to the
exact UMLS concepts that are referenced in that text. To leverage the full potential
of the UMLS ontology, we map each of the directly hit concepts (the concepts that
MMTx actually labeled the free-text with) up the hierarchy in order to provide the
aforementioned functionality of returning records referencing “Asthma” and “Arthri-
tis” when a user queries for “Inflammatory disorder.” The downside of performing
this mapping is that nodes high up in the hierarchy can become severely bloated as
they contain record IDs for all records that its descendant nodes contain. However,
empirical testing showed that the dramatic speed increase obtained from not having
to recursively traverse descendants of a node to obtain all record IDs made this a
worthwhile tradeoff.
2.1.2 Software infrastructure
As depicted in Figure 2-4, the Concordia framework acts as a piece of middle-ware
between user interfaces and the underlying data repositories. All communications
to, from, and within the framework are via standards based protocols. Open to the
public are a set of Simple Object Access Protocol (SOAP) methods that allow a user
to query for information such as all record IDs in the database, the set of record IDs
corresponding to a given concept, the set of record IDs corresponding to an arbitrary
logical combination of concepts, the set of ancestor (or descendant) concepts for a
given concept, and so forth. For a detailed user-interface example, see Section 2.2.
The current implementation has this SOAP service implemented in Microsoft’s C#
and is running on a Windows 2000 Server1.
1This server has been virtualized and currently is merely a virtual Windows 2000 Server running





















Figure 2-4: The Concordia framework acts as a piece of standards based middleware
between user interfaces and traditional data repositories to provide the functionality
of querying the data along the lines of concepts (and their relationships) as defined
by some arbitrary ontology. To allow for maximum portability and scalability, Inter-
actions from the user interface(s) are sent to the framework via SOAP which then
interacts with Concordia over XML-RPC. Once the record indicies have been iden-
tified in the ontology, XML-RPC requests are sent to the underlying databases that










Figure 2-5: Scalability of the Con-
cordia system architecture. Due to
the use of XML-RPC calls between all
parts of the system, the system can
be extended to include multiple worker
nodes that fulfill the request of a head
node.
The SOAP interface interacts
with the Concordia framework via
XML Remote Procedure Calls (RPC).
Within the framework itself, we also
employ XML RPCs for the commu-
nication between NLP engine and
the ontological index. If the user
wishes to obtain the actual data
records, the system will then com-
municate with the underlying source
database(s) to obtain the records.
Although the system allows for mak-
ing queries to the underlying source
databases (which may be located on
different servers of different organi-
zations) via XML RPCs, it is also
capable of directly communicating
to underlying databases without the
use of XML RPCs. If only the record
IDs are requested, they are simply returned without interacting with any (possibly)
outside database. These results, regardless of whether they are just the IDs or the
full records, will be passed back to the user via the SOAP interface.
The persistent hierarchical database in the Concordia framework is written in Java
and utilizes the Oracles’s BerkeleyDB JE package. Although there is a longstanding
debate [89, 79, 59] as to whether hierarchic database models (e.g. the IBM Informa-
tion Management System, the Microsoft Windows Registry, and XML) offer better
performance than relational databases (e.g. MySQL, Microsoft SQL Server, Postgres,
etc.) we find that the ability to efficiently store and retrieve large blocks of data
outweigh the benefits of the flexibility provided by a traditional relational database.
Furthermore, the in-core nature of the BerkeleyDB allows us to easily serialize the
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data structures manipulated by our search algorithms without the communication
overhead incurred when interacting with an out-of-core database service.
The use of XML RPC based communication between the various parts of the
framework allows for a scalable, federated system. Similar in spirit to Googles MapRe-
duce methodology [24], queries can be processed by a head node which in turn requests
that multiple worker nodes perform the database search in parallel (see Figure 2-5).
Each of these worker nodes will be capable of searching a separate portion of the
database. Results can then be returned to the head node, aggregated, and returned
to the client. In addition, this infrastructure enables us to scale to meet future needs
by simply adding additional worker nodes. Although the example federated structure
in Figure 2-5 only depicts a single layer of worker nodes, it is entirely possible to have
worker nodes make XML-RPC requests to other worker nodes that are responsible
for different parts of the database. Furthermore, this system can be made fault tol-
erant in a mission-critical environment by replicating worker nodes or dynamically
reassigning the responsibilities of a failed node.
An example browser interface for gene expression data that has been processed
using the Concordia framework is detailed in Section 2.2.5.
2.2 Concordification of GEO
2.2.1 GEO in a nutshell
Although there are a large variety of biological and medical data sources that could
be indexed using Concordia, we limited the scope of this work to the gene expression
samples from the Gene Expression Omnibus (GEO) [13]. GEO is a public database
containing gene expression and molecular abundance provided by the National Center
for Biotechnology Information (NCBI). GEO data is divided into GEO Data Sets
(GDS), GEO Series (GSE), GEO Samples (GSM), and GEO Platforms (GPL) files
(Figure 2-6). GDS and GSE files are datasets, GSM files are individual samples, and
GPL files are the microarray platforms (arrays) on which the samples were prepared.
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The difference between a GDS and GSE file is that a GDS file contains additional
meta information that the curators of GEO added to the original GSE file that was
uploaded. For example, GDS files contain subset information about each experiment
such that one can see what condition a given experiment has in the dataset. The
dataset with the identifier GDS1, for instance, was an experiment conducted to find
genes related to reproductive tissue in Drosophila melanogaster. The various subset
information provided includes information such as gender of the fly for the given
sample and the tissue the sample was created from. Another important difference
between GDS and GSE files is that a GDS may only contain experiments that were
conducted on a single GPL platform. It is possible for a GSE to contain experiments
with multiple platforms because there are instances when an experimenter compared
multiple microarray platform technologies or performed a cross-species study. It is
important to note that there are many more GSE files in GEO than GDS files, as
there are many datasets which have yet to be manually annotated. Due to the large
size of the GEO database, we only downloaded the human microarray data performed
on the Affymetrix HG-U133 Plus 2.0 array. A complete list of the 192 series and 3030
samples that were downloaded can be found in Appendix A.
Figure 2-6: The relationship of GEO files as represented by a UML diagram.
2.2.2 Normalizing the gene expression samples
Our database is comprised of 3030 gene expression samples belonging to 192 distinct
series performed on the Affymetrix HG-U133 Plus 2.0 arrays that were obtained
from GEO (Appendix A). The original CEL files were downloaded from GEO and
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MAS 5.0 normalization was performed on each sample before summarizing all probe
specific values to gene specific values using a trimmed mean. MAS 5.0 was chosen
over other more “aggressive” normalization methods because it can be performed on
a per sample basis unlike other methods that require the entire dataset (or in our
case entire database) to be used for normalization.



























































































Figure 2-7: The Concordia database for GEO is comprised of a database of gene
expression samples mapped to Unified Medical Language System (UMLS) concepts
that is used to classify new input microarray samples. The free-text associated with
each sample is processed using the National Library of Medicines MetaMap program
to map each sample to a set of UMLS concepts. These concepts are then mapped up
the ontology so that all ancestor concepts of the ones deemed relevant by MetaMap are
also included as correct annotations for each respective sample. The gene expression
values for these samples are then normalized and inserted into the Concordia database.
Unlike previous endeavors, new data can be added to this system continually, without
causing any interruption to the classification engine.
As aforementioned, a major obstacle to recovering signal from biological data (in
this case transcriptional signals from microarray array samples) lies in the inconsistent
ways in which the samples are described through their associated free-text metadata.
Furthermore, there is no easy way to download a large set of disparate experiments
and perform large-scale analysis without substantial effort. We follow the lead of
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Butte, et al. [19] and extracted the title, description, and source fields from each of
the 3030 expression samples and annotated them using the Java implementation of
the National Library of Medicines (NLM) MetaMap program, MMTx [7]. A custom
Unified Medical Language System [17] (UMLS) thesaurus was generated using NLMs
MetaMorphosys program that only contained the concepts from the UMLS, MeSH,
and SNOMED ontologies. These automated annotations were then verified by hand
(see 2.2.4) such that we were left with 672 distinct UMLS concepts. Since these con-
cepts only represented the most detailed level of annotation, we mapped the concepts
back up the ontology such that a sample labeled with a very specific concept also
received labels corresponding to all of its ancestor concepts. Due to the domain of
the data, we filtered the concepts down to only those that are descendants of either
“Disease” or “Anatomy,” resulting in a total of 1489 unique concepts. The full list of
UMLS concepts that were used can be found in Appendix A.
2.2.4 UMLS noise filtering
A major shortcoming of the approach of indexing biological and medical literature
with concepts from the Metathesaurus using MetaMap (and many other natural lan-
guage processing techniques), is the overabundance of false-positive results. This
problem has been cited in the literature over the past several years [87]. Butte et al.
[19] point out that poor text formatting, poor choice of identifiers, irrelevant text, and
spelling errors all contributed to mis-annotations. For example, running MetaMap
on the series description of GEO series 2230 (GSE2230), the abbreviation “PD” er-
roneously maps to the concept “Parkinson’s Disease.” When we examine the original
text we see that the author intended no association with the concept “Parkinson’s
Disease”:
Analysis of gene expression by Affymetrix microarray in a CD4+ T lym-
phocyte clone transduced with hTERT-GFP vector after after 44 and
80 population doublings (PDs). The untransduced (32 PDs) and GFP-
control vector transduced (47 PDs) T cell clone populations served as
43
controls.
The MetaMap method simply operates on syntactic fragments and cannot discern
the context from which the abbreviation was taken, and hence cannot infer the mean-
ing of the “PD” abbreviation. To overcome such problems of over-sensitivity, we per-
formed manual validation of the annotations automatically generated by MetaMap.
We developed a simple C# based application that obtained the raw annotation results
from MetaMap, and then allowed us to manually indicate the correct set of concepts
for each record (Figure 2-8). In Chapter 5 we delve into more detail about how to
efficiently curate a large database using the results from the NLP software along with
leveraging the expression signal provided by each sample.
Figure 2-8: A screen shot of the application that was used to perform manual curation
of UMLS concepts. Through this application one can select the concept(s) that are
relevant to a given GEO series, dataset, and sample. It is also possible to add concepts
manually that were missed by the NLP program.
2.2.5 Ontology based browsing of GEO
We also developed a sample front-end to the Concordia framework in an AJAX based
web application that allows a user to browse the UMLS hierarchy and view the gene
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expression samples that have been mapped to the concepts (Figure 2-9). The top
panel allows the user to navigate through the library of experiments based on the
hierarchical organization of UMLS concepts. The lower panel allows the user to
view and interact with the data for experiments that were labeled at or below any
particular location in the concept hierarchy. The user can select the experiments of
interest and then download a large matrix of the expression intensity values for all of
the experiments along with their respective UMLS concepts.
Figure 2-9: A screen shot of a web application built in front of a the Concordiafied
gene expression data from GEO. The top panel allows the user to navigate through
the library of experiments based on the hierarchical organization of UMLS concepts.
The lower panel allows the user to view and interact with the data for experiments
that were labeled at or below any particular location in the concept hierarchy.
Having data available in this format, it becomes easy for a researcher to quickly
download various types of phenotypic data and perform analyses. Examples of the
types of analyses that can be performed with a curated database of gene expression





Localizing expression samples in a
heterogeneous transcriptomic
landscape
Although gene expression microarrays have been a standard, widely-utilized biological
assay for many years, we still lack a comprehensive understanding of the transcrip-
tional relationships between various tissues and disease states. When microarray
technology first became available, the high cost of performing these gene expression
experiments was a likely cause for the small number of samples in early microarray
studies. However, today, even with the hundreds of thousands of expression array
data sets available through public repositories such as NCBIs Gene Expression Om-
nibus (GEO) [13], the lack of standardized nomenclature and annotation methods has
made large-scale, multi-phenotype analyses difficult. Furthermore, it is often chal-
lenging to obtain the appropriate number of tissue samples from humans [65], and
thus new studies are limited in the number of replicates for a given tissue or in the
number of types of tissues. Thus, expression analyses have typically used the decade
old approach of comparing expression levels across two states (e.g., case vs. con-
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trol) or a limited number of phenotype classes [30, 48, 133]. Even recent large-scale
gene expression investigations, whether they have attempted to elucidate phenotypic
signals [73, 93, 103] or applied those signals for downstream analyses such as drug
repurposing [68, 122], involved comparisons between two states or classes.
Comparative analyses, where transcriptional differences are directly measured be-
tween two phenotypes, inherently impose subjective decisions about what constitutes
an appropriate control population. Importantly, such analyses are fundamentally lim-
ited in scope and cannot differentiate between biological processes that are unique to
a particular phenotype or part of a larger process that is common to multiple pheno-
types (e.g. a generic “cancer pathway”). Moreover, the results of such comparative
analyses can be limited in generalizability as they make assumptions about the phe-
notypes being compared [102]. Alternatively, in a data-rich environment, we can take











Figure 3-1: A comprehensive perspective on expression analysis enables the elucida-
tion of biological signals that are thematically coherent but provide an alternative
view to traditional dichotomous approaches. For example, the gene-signature for
“breast cancer” is enriched for breast specific development and carbohydrate and
lipid metabolism in our comprehensive approach, as opposed to being dominated by
a more general “cancer” signal.
We introduce a scalable and robust statistical approach that leverages the full
expression space of a large diverse set of tissue and disease phenotypes to accurately
perform and glean biological insights. By viewing a given phenotype in the context of
this comprehensive transcriptomic landscape, we circumvent the need for predefined
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control groups and presupposed relationships between phenotypes (Figure 3-1). We
devise, implement and validate the accuracy of an enrichment statistic that provides
detailed phenotypic information for new samples when they are mapped onto and
compared with the transcriptomic landscape (http://concordia.csail.mit.edu).
3.1 Sample correlation as a distance metric
As a practical example, supervised learning (classification) on gene expression data
has long held the promise of improved clinical diagnostics. Indeed, many analyses
over the last decade have noted that a variety of human diseases are associated with
aberrant transcriptional activity ([19, 48, 55, 65, 135, 141] to name but a few). In
this setting, a large, diverse “training” database of microarray data would be assem-
bled where each sample is labeled according to phenotype (e.g., “squamous cell lung
cancer”, “lobular breast carcinoma”, “type II diabetes”). New unlabeled samples
(e.g., hybridized from the peripheral blood of a patient with a tumor of unknown
primary origin) could then be compared to the database of training data, allowing
the system to generate a “best guess” about the phenotype of the new sample. In our
example, such a system would provide an additional and significant piece of evidence
for aphysician determining a course of treatment.
One of the major challenges associated with building such a system revolves
around generating coherent labeling of the training data against which the unla-
beled samples are compared. Using the Unified Medical Language System (UMLS)
[17] labels produced by annotating the free-text descriptions associated with gene
expression samples from the Gene Expression Omnibus (GEO) [13] as explained in
Section 2.2, we see that the Concordia system is capable of recovering these coherent
labelings for a large database of gene expression studies. Furthermore, we see that
there is strong agreement between these labels and the transcriptional signal encoded
in the array data.
A subset of the samples available from GEO was indexed using our prototype
system. Figure 3-2(a) shows a clustering of experiments from 14 distinct GEO series
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Phenotype (Row) Color Codes
Malignant neoplasm of breast






















(a) Correlation clustering of 8 phenotypes
Phenotype (Row) Color Codes
Ductal Breast Carcinoma
Lobular Breast Carcinoma
(b) Correlation clustering of 2 types of
breast carcinoma
Figure 3-2: (a) A clustering of gene expression experiments extracted from the
database. Eight different disease states broadly cluster together, even across data
series. (b) Here, the expression data for two subtypes of breast cancer cluster accord-
ing to the breakdown of their UMLS concept labelings, as retrieved by the Concordia
representation of GEO.
based on a nonparametric Spearman correlation statistic that measures similarity
between expression profiles for each experiment.1 The experiments were extracted
from this database by searching for 8 different phenotypes (glioma, breast cancer,
lung cancer, arthritis, etc.). The column of colors down the left-hand side of the
plot indicates the UMLS concept associated with each experiment; the row of colors
across the top of the plot indicates the data series (logical grouping of experiments
submitted to GEO as a batch) from which the experiments were derived. Of particular
interest, experiments that were returned by querying our prototype system for each
concept clearly clustered together, and this clustering is coherent between data series.
Figure 3-2(b) shows the clustering of the lobular and ductal breast cancer experiments
from GEO Series GSE2109. Here we see that with only a few exceptions, the two
1The Spearman correlation is equivalent to the Pearson correlation between the rankings of the
data. In other words, the raw gene expression intensities Xi and Yi of the two expression samples




where x¯ and y¯ are the means of x and y.
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subtypes of breast cancer are grouped according to their respective type. Thus, not
only can we cluster experiments across significantly different phenotypes, but we can
also differentiate different subtypes of cancers.
This provides evidence that there are strong transcriptional signals that describe
the phenotype of the samples in this database and that, when properly processed with
our proposed infrastructure, those signals are immediately apparent. Concordia, thus
provides the missing link between large, data-rich but loosely-curated resources (such
as GEO) and the enormous potential that they hold.
3.2 Making sense of the transcriptomic landscape
As a first step towards a holistic approach to gene expression analysis, we must make
sense of the substructure of the global transcriptomic landscape. As mentioned in
Chapter 2, we constructed a curated gene expression database of 3030 diverse samples
(from 192 distinct series) obtained from NCBIs Gene Expression Omnibus [13] (GEO).
These samples were annotated with their phenotypes (tissue of origin, disease state,
etc.) using the anatomical and disease concepts in a custom subset of the Unified
Medical Language System [17] (UMLS) concept ontology via both natural language
processing (NLP) and manual validation (see Section 2.2 for details).
3.2.1 The transcriptomic landscape
While visualizing the full transcriptomic landscape encompassing all genes is not fea-
sible, the first two principal components (PCs) of the centered and scaled expression
level of 20252 genes across the database provide a representation of the phenotypic
relationships that captures roughly 20% of the variance in the data. The pheno-
typic clusters portrayed by shaded convex hulls were created by iteratively using the
convex hull function (chull) in the R statistical language package. Although oth-
ers have suggested that the primary factors driving the organization of the global
transcriptomic landscape can largely be attributed to hematopoietic and malignant































Figure 3-3: The gene expression landscape, as represented by the first two principal
components of the expression values of 20252 genes from 3030 microarray samples
separates into three distinct clusters: blood, brain, and soft tissue (A). The shading
of the regions corresponds to the amount of data located in that particular region of
the landscape such that the darker the color, the more data exists at that location.
Interestingly, the area where the soft tissue intersects the blood tissue corresponds to
bone marrow samples, and where it intersects the brain tissue, mostly corresponds
to spinal cord tissue samples. There is a clear separation of reproductive and gas-
trointestinal tissue samples when the analysis is limited to just the soft tissue cluster
(B).
brain, and soft tissue are dominant (Figure 3-3). Indeed, when analyzing the tissue
specific characteristics of these clusters, we observe the over-expression of fibrillar and
epithelial genes such as COL3A1, COL6A3, KRT19, KRT14, and CADH1 in the soft
tissue cluster and neural genes such as GFAP, APLP1, GRIA2, PLP1, and SLC1A2
in the brain cluster. The density estimate plots of the expression intensity values for
the top 20 over-expressed tissue specific genes and the GO enrichment analysis of
the top 250 tissue specific genes for each cluster further points to over-enrichment for
terms related to each of the three tissue types (Appendix B)
These tissue specific genes were selected by performing permutation t-tests com-
paring, for example, the log-normalized expression values for the blood samples for
a given gene to the log-normalized expression values of the samples associated with
brain and soft tissue. Each permutation run consisted of computing the t statistic
for the actual labeling of the samples and comparing it to the t statistics produced
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when the labels were randomly permuted 200 times while keeping the sample size
distribution constant. To counter the potential influence of sampling bias, this entire
procedure was performed 100 times, each time using only a random 75% of the data
for each tissue type. Genes that were deemed significant were those that had a false
discovery rate corrected p-value of 0.05 or lower in all 100 runs. The genes were then
sorted such that a gene that had a larger difference in means between the phenotypes
was ordered before those that had a smaller difference. GO enrichment was performed
on the top 50, 100, and 250 genes for each tissue type using FuncAssociate 2 [15]. We
report only the GO terms that had a resampling-based p-value less than 0.05.
By additionally performing principal component analysis on 1065 soft tissue sam-
ples (all non-cancerous samples that are also not blood or brain), it becomes apparent
that the notion of phenotypic grouping seen in the full landscape is conserved on
multiple levels of phenotypic granularity. Not only are individual tissue samples in
confined regions, they are also organized by functionality. Tissues that are sensitive
to reproductive hormones (ovary, uterus, myometrium, endometrium, prostate, pe-
nis, and breast) group together to form a distinct sub-region in the smooth landscape
(Figure 3-3). Juxtaposed to them are primarily gastrointestinal tract samples from
tissues such as colon, stomach, intestine, liver, and esophagus.
3.2.2 Tissue similarity network
While the aforementioned transcriptomic landscape provides a view of the various
phenotypes by placing them in a two dimensional plane, a tissue “network” can be
constructed to further detail the relationship between the various phenotypes. This
similarity network was generated by computing correlations of a representative sample
of a tissue type to all other representatives of the other tissues. The representative
was chosen to be the sample that was closest to the centroid in the set of samples
for that phenotype. To contend with sampling bias, the correlations were computed
100 times; the centroid for each phenotype having been chosen from a random 75%
subset of the samples for that phenotype. The similarity network was then created








Figure 3-4: Tissue correlation network recapitulates gene expression landscape. A
tissue network constructed from the correlations that averaged greater than 0.8 across
100 random sub-samplings runs between the various tissues mirrors the structure
of the larger expression continuum while simultaneously showing more fine-grained
relationships between various phenotypes. The thickness of the line indicates the
strength of the correlation, while the color of the nodes corresponds to the higher-
level biological groupings of brain, blood, gastrointestinal, and reproductive. The grey
nodes indicate tissues that do not belong to the aforementioned types. Similar to the
view provided by the visualization of the transcriptomic landscape, we see the distinct
grouping of brain, blood, and soft tissues. Here we also see strong intra-relationships
between the gastrointestinal tissues and the reproductive tissues.
across all 100 subsampling runs. The colors of the nodes denote the general tissue
class (blood, brain, gastrointestinal, reproductive, and other). The figure itself was
rendered using Cytoscape [118].
This tissue similarity network, for example, identifies the functionally related tis-
sues of the myometrium, endometrium and ovary, and also highlights the intercon-
nectedness of blood, the lymph nodes, and spleen. It even depicts the relationship
between tongue and other skeletal muscle tissue while still showing the similarity
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tongue tissue has with the other gastrointestinal phenotypes. In contrast to previ-
ous efforts that illustrated this phenomenon using known genetic associations [75],
this sort of de novo quantification of tissue specificity is relevant to understanding
the biological similarities and differences of various phenotypes, the development of
large-scale clinical prognostication engines, the quantification of diagnostic accuracy
of putative biomarkers [66], and for developing suitably broad-spectrum or targeted
therapeutics.
3.3 Phenotypic concept enrichment
Although correlation analyses and the visual representation of the transcriptomic
landscape provide insight into the broad relationships between various phenotypes,
our ability to harness these expression signals to map new, previously unseen samples
into a database of expression samples is compelling. Beginning with our customized
UMLS concept annotation of the 3030 samples, we restricted the set of UMLS con-
cepts to the 1489 anatomy and disease concepts that mapped to at least three ex-
pression samples (Figure 2-7). We developed a sample-centric method based on the
Kolmogorov-Smirnov statistic to label new samples with UMLS concepts that are
over-represented in their local expression neighborhoods (Section 3.3.1). It is note-
worthy that no hard boundaries are drawn when a new input sample is labeled,
but rather the concepts pertinent to the transcriptomic neighborhood for the input
sample are reported. Furthermore, as it is often difficult to define an appropriate
comparator (how does one define a truly “normal” tissue sample in a clinical setting
[86, 99]?), this approach has the advantage that it does not require case-control type
input but, rather, just a single microarray sample. To illustrate its function, we pro-
vide a web-based resource (http://concordia.csail.mit.edu) that allows users to
submit their own microarray samples performed on the popular Affymetrix HG-U133
Plus 2.0 array and obtain their over-enriched tissue and disease concepts (see Section
3.3.7 for details).
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Figure 3-5: A user submits a gene expression profile to the database that then com-
putes the similarity to all other samples in the database. Based on the similarity, an
enrichment score is computed for each UMLS concept for which data exists in the
database and the concepts are returned to the user in order of statistical significance.
We use the database of gene expression samples to assess over-enrichment for
particular disease- and tissue-specific signals. Given a new expression profile, for
each concept represented in the database, we calculate a statistic that measures the
strength of association between the sample and concept, as implied by its similarity
to the labeled database samples.
We measure the similarity of the new expression profile to those contained in the
database by computing the Spearman rank correlation, ρ, between the profile and all
database samples. For a particular concept, we then calculate an enrichment score
that measures the difference between the distributions of correlation coefficients for
the database samples that map to the concept versus those that do not map to the
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concept (Figure 3-5).
Algorithmically, the statistic is calculated as follows: First, the database consisting
of n curated expression samples {s1, s2, s3, . . ., sn} is sorted (in decreasing order)
according to each observations Spearman correlation with the new profile. Let s′1, s
′
2,
s′3, . . ., s
′







, . . ., ρ′s′n . For a given concept c in the set C, the set of all UMLS concepts in
our database, let Sc be the set of all database samples associated with the concept.














Intuitively, when si is associated with the concept in question, the xi value corre-
sponds to the fraction of total correlation between the new sample and all database
samples associated with the concept. All of the xi values for the concept “hits” sum
to 1, and all of the xi values for the concept “misses” sum to -1.
Then we compute a running sum of xi across all n database samples and take the







This sum across all n samples is zero. We are interested in concepts where there is
strong positive deviation from 0. These are the concepts whose associated samples are
more highly correlated with the new profile than those samples that are not associated
with the concept.
Figure 3-6 provides a pictorial example of the enrichment score calculation process
for a breast cancer sample (GSM175794) for the concepts “breast” and “brain.” The
x-axis refers to the index in the sorted list of samples (index 0 is the sample that is
most correlated to GSM175794) and the y-axis refers to the enrichment score. The
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black line depicts the running sum of Equation 3.1 while the red line provides an
indication of the maximal score obtained (Equation 3.2). Since the score quickly
increases in Figure 3-6(a) we can infer that the samples most highly correlated with
GSM175794 are other breast samples (that is why they are first in the sorted list). On
the other hand, the samples that are associated with the concept “brain” are very far
away (in correlation space) from the breast cancer sample. Thus we obtain a concept
enrichment score of 0.58 for “breast” while we barely get a positive score for “brain.”
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Figure 3-6: Two example enrichment score plots for a breast cancer sample
(GSM175794) for the concepts “breast” and “brain.” The x-axis refers to the in-
dex in the sorted list of samples (index 0 is the sample that is most correlated to
GSM175794) and the y-axis refers to the enrichment score. The black line depicts the
running sum of Equation 3.1 while the red line provides an indication of the maximal
score obtained (Equation 3.2). As is to be expected from a breast cancer sample
biopsied from breast tissue, we obtain a concept enrichment score of 0.58 for “breast”
while we barely get a positive score for “brain.”
3.3.2 Quantifying performance
We performed leave-one-sample-out cross-validation to validate the accuracy of our
method for correctly assigning an unknown sample to the correct phenotype (i.e.,
UMLS concepts for both anatomy and disease). The receiver operating characteristic
(ROC) curve was computed for each of the 1489 UMLS concepts, and the standard
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measure of area under the curve (AUC) that summarizes both the true-positive and
false-positive rates was used as a measure of accuracy represent the full spectrum of
performance characteristics available under a variety of enrichment score thresholds.
We compute the ROC curves for each concept as follows (see Figure 3-8 for an
example ROC curve). For each concept c in the database, we iteratively leave out each
sample s, and compute ss enrichment score for c using the remaining samples in the
database. The samples are then sorted from highest to lowest by their enrichment
score for c. By walking down this list of sorted samples we calculate the running
true- and false-positive counts. The true-positive (TP) count is incremented if the
ith sample in the list is actually labeled with concept c. If the sample is not actually
labeled with concept c, the false-positive (FP) count is incremented. Dividing the TP
and FP respectively by the number of known positives and negatives at each position
i, we obtain the true-positive (TPR) and false-positive rates (FPR). By plotting the
TPR vs. FPR we obtain the ROC curve. The larger the area under the ROC curve
(AUC), the greater the gene expression signal for that concept as the samples with
the highest enrichment scores for the concept were truly labeled with that concept.
When using this method to label a new sample, we compute its ES (w.r.t. the
entire database) for each concept. We then report the systems estimated FPR for
each concept at the samples observed concept-specific enrichment score. These FPR
values are derived from the running statistics used to generate the ROC plots: simply
look up the new samples score position in the list of sorted scores, and report the
FPR at that position (or the next-lowest score, i.e., next-worst FPR, if there is not
an exact match among the database scores).
We use the area under the curve (AUC) and an empirical false positive rate (FPR)
to characterize the systems ability to recover signal rather than random sampling or
permutation testing (as performed by another Kolmogorov-Smirnov statistic based
method, GSEA [129] for several reasons. If we work with the null hypothesis that
the samples ES for a given concept looks like the ES of a random permutation of
the database samples (e.g., the ordering prescribed by the correlation scores between
this sample and the rest of the database are the result of random shuﬄing), then
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we have not accounted for the correlation structure among the database samples
themselves. Because the expression values of samples for a given concept (assuming
the concept has some signal in gene expression space) will be highly coordinated,
they will appear grouped together regardless of the phenotype of the new sample,
resulting in a localized “bump” in the running enrichment score. This localized
“bump” is often large enough to cause us to reject the null hypothesis, even when the
new sample shouldnt be associated with the concept in question.
If instead we attempt to randomize the input and reject the null hypothesis that
the new samples concept-specific ES looks like the ES of a random point in gene
expression space for this concept, we run into a different problem: how do we param-
eterize such a sampling procedure? Because in vivo gene expression programs contain
highly correlated subprograms [116], there are large portions of gene expression space
that are unavailable to a living cell (i.e., there are relationships among the genes
expression intensities that one never observes in nature). Surely these “impossible”
expression inputs should not be considered when generating the null distribution.
If we try to overcome this sampling problem by using real human gene expression
observations, we arrive at the cross-validation strategy described above. Rather than
set a threshold learned from this data for accepting or rejecting a concept outright,
we find it more informative to let the user understand the overall amount of signal
present in the data for a given concept (ROC plots), and report an expected false
positive rate for the concept at the ES observed for the new sample.
3.3.3 Performance results
We see an average accuracy of 92.8% (AUC value of 0.928) after restricting the set of
UMLS concepts to the 1209 that have samples from two or more expression series in
GEO to ensure that a diverse set of data is used. Even when we restrict the concepts
to the 450 that have at least 50 distinct samples originating from at least five dif-
ferent data series, the average accuracy is approximately 89.8%. Table 3.1 contains
the performance of a selection of UMLS concepts, along with the number of samples
and series that were associated with that concept. Unsurprisingly, “broader” con-
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Concept AUC Num Series Num Samples
Malignant Neoplasms 0.82 74 855
Malignant neoplasm of breast 0.97 9 69
Malignant neoplasm of ovary 0.99 4 51
Malignant neoplasm of lung 0.97 4 98
Leukemia 0.99 13 151
Soft Tissue 0.69 98 1513
Breast 0.93 13 195
Ovary 0.95 8 103
Lung 0.95 9 131
Inflammatory disorder 0.79 13 91
Rheumatoid Arthritis 0.93 7 31
Inflammatory Bowel Diseases 0.99 2 24
Table 3.1: Cross-validation performance for a selected subset of UMLS concepts. The
complete table can be found in Table C.1 in Appendix C.
cepts have poorer performance compared to the more specific concepts, as the former
encompass a much more diverse expression signal. The complete list of performance
values can be found in Appendix C. Note that many of these concepts are similar
and thus have many database samples in common; as a direct consequence, many of
the concepts have similarly high (low) AUC values.
In general, deeper concepts in the hierarchy have both fewer samples associated
with them and have higher accuracies (Figure 3-7). Although it may be tempting to
draw the conclusion that fewer samples mean higher accuracies, it is actually that the
deeper concepts correspond to gene expression samples that have greater biological
similarities. For example, the deeper concept Malignant neoplasm of breast has a
higher predictive power with 69 samples than the broader concept Primary malignant
neoplasm with 833 samples.
3.3.4 Quantification of the “batch” effect
There have been several reports that data from different datasets are not comparable
as the dataset (aka “batch”) signal is dominant [102, 94] . While the localization
of phenotypes as seen in the expression landscape (Figure 3-3), regardless of se-
ries of origin, depict the lack of a dataset effect in principal component space, the
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Figure 3-7: A plot depicting the relationship between the number of samples, the
depth in the UMLS hierarchy and the AUC such that each point represents one of
the disease or tissue concepts. Notice that the deeper in the ontology a concept is
(i.e. more specific), the higher its AUC.
cross-validation performance shows that this phenomenon holds true when all gene
expression data is considered. Although the area-under-the-curve (AUC) and receiver
operating characteristic (ROC) curves are generally used to quantify the performance
of classifier, they can also be used as a proxy to quantify the significance of a batch
effect. As high AUC values can only be attained through accurate identification of
phenotypes in cross-validation, it is a necessary precondition for samples associated
with a given phenotype to be more closely related to each other than those associated
with another phenotype.
In addition, by associating the series of origin for each sample used to generate
the ROC plot, we can visually inspect the degree of the batch effect by the cluster-
ing of the samples from these series. For instance, the ROC curve for the concept
“leukemia” (Figure 3-8) shows that: 1) samples with the phenotype, regardless of
dataset, are closer to the other samples with the same phenotype, and 2) samples
from various datasets are intermingled. The leukemia samples were more closely re-
lated to other leukemia samples with a mean intra-phenotype, inter-series correlation
of 0.1 higher compared to other samples within their own dataset that were non-
62




































Figure 3-8: The ROC curve for leukemia. The colors plotted along the curve corre-
spond to the series of origin for each of the samples used to generate the curve. The
intermingling of series points to the robustness of the phenotypic signal: samples with
the same phenotype cluster together before all other phenotypes, and samples from
different data series are intermingled within a phenotype.
leukemia samples (inter-phenotype, intra-series). We see that this trend is evident in
the ROC curves across all types of phenotypes. Intuitively, if this were not the case,
not only would the AUC values for concepts that have samples from multiple series
have to be substantially lower than those with fewer series, but also the phenotypic
localization evident in the transcriptome landscape would have been overshadowed
by dataset localization.
In an effort to quantify the dataset effect (DE) from the correlation structure of
the gene expression samples used in the construction of the transcriptome landscape,
we compared the mean difference in correlation between all samples in a series with
the phenotype to all other samples in other series with that phenotype to the mean
difference in correlation of samples with a given phenotype in a series against all
other samples in that series without the phenotype. In the event that the signal
from the data series is greater than that of the phenotype, one would expect that the
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Tissue Dataset Effect P Value
Spleen -0.22 0
Esophagus -0.2 0
Salivary Glands -0.2 0
Cerebellum -0.18 0
Prostate -0.17 0
Lymph Node -0.17 0
Myometrium -0.14 0
Tongue -0.14 0
Liver and/or Biliary Structure -0.14 0
Kidney -0.13 0
Skeletal Muscle -0.12 0
Spinal Cord -0.11 0
Stomach -0.11 0
Endometrium -0.11 0
Spinal Nerve Structure -0.1 0
Heart -0.1 0
Brain -0.08 0










Bone Marrow -0.01 0






Table 3.2: The dataset effect was measured the mean difference in correlation between
all samples in a series with the phenotype to all other samples in other series with that
phenotype to the mean difference in correlation of samples with a given phenotype
in a series against all other samples in that series without the phenotype. A negative
dataset effect value implies that the phenotypic signal dominated the dataset signal
while a positive value implies that the dataset signal was greater.
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intra-series correlation between differing phenotypes is greater than the inter-series
correlation between samples corresponding to identical phenotypes. The p-values
(Pv) were computed by randomly shuﬄing the phenotype labels on the samples and
computing the dataset effect 100 times for each tissue type. The empirical p-value
was determined by finding the position in the sorted list of sampled dataset effect
values. The majority of the tissues for which sufficient data was available (at least
two series with the phenotype, and at least one series containing both the phenotype
of interest and at least one other phenotype), do not exhibit the existence of a batch
effect. For example, across 6 series with normal prostate tissue, the correlation of
prostate samples to other prostate samples in other series is on average 0.17 higher
than the correlation of those samples to other samples within their own series. In the
few instances where the correlation within the dataset is higher, it generally is due
to the highly similar nature of the samples and that the tissue signal dominates the
disease signal. In the case for the blood series, for instance, normal blood is being
compared to diseased blood. Table 3.2 provides these numbers the tissues that are
represented in the tissue similarity network (Section 3.2.2) such that a negative batch
effect implies that the phenotypic signal dominated the dataset signal.
3.3.5 Scalability
Due to the non-parametric data-driven nature of this method, we are not constrained
by the amount of gene expression samples that are present in the database. However,
the question arises as to whether or not adding more samples to the transcriptomic
landscape provides a higher resolution picture, or if it merely muddles the picture.
In an effort to resolve this question quantitatively, we computed the classification
accuracy of each concept when the number of samples that were used to compute the
enrichment score for that given concept was set to 50%, 60%, 70%, 80%, and 90%. For
example, using all 69 samples for “Malignant neoplasm of breast” yields an accuracy of
96.5%. Then, keeping all else constant, we randomly removed half of the “Malignant
neoplasm of breast” samples and recomputed the enrichment score. This random
re-computation was performed five times for each concept at each threshold. In the
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(a) Density estimates of performance with vary-
ing amounts of data
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(b) Average AUC values with varying amounts
of data
Figure 3-9: Improvement of accuracy of the enrichment statistic with the increase of
data in the database. (a) Density estimate of the performance of the method over
various amounts of data. (b) The average AUC values over all concepts when varying
the amount of data used to compute the enrichment scores. For example, when using
only 50% of the data for a given concept, the average AUC drops down to 42%.
case of “Malignant neoplasm of breast,” for instance, the average accuracy across the
five runs using only 34 samples is a mere 37%. We see that the average accuracy
across all concepts drastically increases from 44% to roughly 93% when increasing
the amount of data used (Figure 3-9). It is also noteworthy that the concepts that
are the most susceptible to change are specific concepts (e.g., “Pluripotent stem cells”
and “Myeloid Leukemia”), while the classification accuracy of the broad topics (e.g.,
“soft tissue” and “disorders”) are unaffected by the quantity of data as the underlying
gene expression values are so vastly different.
This implies that the power of this type of macroscopic analysis increases with the
amount of underlying data, as the signal of the phenotype becomes more apparent.
Since our approach employs a non-parametric enrichment statistic that only requires
the concept annotation of the samples in the original gene expression database, it can
be updated in real-time without having to “retrain” the database. A system such as
this could thus be deployed in a research or clinical setting where new samples are
continually being added and analyzed, with minimal alteration of normal protocols.
As new samples are added, the system would continually improve its understanding
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of the biological signals that constitute individual phenotypes.
With our database primed with the 3030 labeled samples ranging from normal
breast to blood from children with septic shock, we applied Concordia to 15904 other
GEO samples performed on the Affymetrix HG-U133 Plus 2.0 array and mapped
each sample onto the transcriptomic landscape. In this manner, we are able to pro-
vide the concept enrichment scores for 1489 anatomy and disease related concepts for
other samples based on the current biological “knowledge-base” of Concordia. These
concept enrichment scores can thus be used as an additional source of biological in-
formation when performing future large-scale gene expression analyses. For example,
if a researcher is looking for expression samples relating to “breast” tissue, he could
both examine the text that is associated with each sample, and look at the expression
similarity of that particular sample and the concept for “breast.”
3.3.6 Specificity of the conventional classification of tissue
and disease
Employing the classification accuracies of the conventional clinical categories as de-
fined by the UMLS hierarchy allows us to systematically estimate the classification
robustness of conventional clinical labels as compared to molecular pathophenotypes
[75]. The sub-tree of the ontology rooted at “Inflammatory disease,” is a striking
illustration of the faithful reflection of specificity as a function of depth in the tree
(Figure 3-10). As conventional wisdom would dictate, concepts relating to broad
phenotypic topics that span multiple tissue or disease categories have lower classifica-
tion potential than specific concepts located deeper in the ontology that have a more
conserved gene expression pattern. For instance, we see the classification accuracy of
the more specific concept, “Chronic arthropathy” (98%), is significantly higher than
that of “Inflammatory disorder” (78.9%). In general, we see that the conventional
clinical classification of tissue and disease mirrors the underlying gene expression sig-
nature. If, for example, the opposite effect were observed, such that concepts higher





















Figure 3-10: Specificity of conventional clinical classification of disease. Part of the
UMLS ontology rooted at “Inflammatory disease” in which the color of the node indi-
cates the classification accuracy; the size, the number of samples in the database with
that concept; and the thickness of the line, the number of different datasets to which
the samples belong. As conventional wisdom would dictate, labels corresponding to
broad phenotypic topics appear higher in hierarchy and have lower predictive power.
be put into question. It is important to note that the ordering based on depth in the
UMLS hierarchy is not global, but a local phenomenon. For example, as shown in
Figure 3-10, “Arthritis” splits into two sub-trees in which the side rooted at “Chronic
arthropathy” has a high predictive value all the way down the sub-tree, while the
other sub-tree that has a wider variance in predictive accuracies.
3.3.7 Concept enrichment web interface
In order to provide concept enrichment statistics for new samples performed by other
researchers, we have developed an online resource (http://concordia.csail.mit.
edu) that allows users to submit their own expression samples performed on the
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Figure 3-11: A screenshot of concept enrichment web interface. In this example, a
gene expression sample corresponding to normal entorhinal cortext (brain) tissue was
submitted. The blue dot in the midst of the orange dots represents the location of
this sample in the transcriptomic landscape. After performing the concept enrichment
using the database primed with 3030 gene expression samples, we see that this new
sample is (correctly) over-enriched for concepts relating to the brain. When selecting
all samples in our database associated with the concept “Brain” (the orange dots),
we see that this new sample indeed lies within their midst.
Affymetrix HG-U133 Plus 2.0 array. Once the sample has been uploaded to the server,
the expression values are ranked normalized and the concept enrichment is computed
as detailed in Section 3.3.1. These scores are then reported to the user (along with
the enrichment score curve, the ROC curve for each concept as obtained through the
cross validation procedure, and all of the samples in our database corresponding to
that concept). In addition to these concept enrichment scores, we also provide the
user with the visual representation of the transcriptomic landscape and the location
of their submitted sample in the landscape.
For example, in Figure 3-11 we see a gene expression sample corresponding to
normal entorhinal cortex (brain) tissue that was submitted. The blue dot in the
midst of the orange dots represents the location of this sample in the transcriptomic
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landscape. After performing the concept enrichment using the database, we see that
this new sample is (correctly) over-enriched for concepts relating to the brain. When
selecting all samples in our database associated with the concept “Brain” (the orange
dots), we see that this new sample indeed lies within their midst.
3.4 Tissue specific signal of tumor metastases
The clinical problem of distinguishing whether a cancerous lesion represents a primary
tumor, or a metastasis from a distant malignancy, presents a test case for our ability
to localize a sample to the appropriate phenotypic group within the transcriptomic
landscape. By combining the aforementioned sample- and gene-centric methods, we
are able to map new tumor metastasis tissue samples onto the gene expression land-
scape, providing an unbiased measure of their phenotypic predisposition based on
gene expression. It is commonly known by pathologists that tumor metastasis tissue
biopsies viewed under the microscope resemble the tissue of the primary site rather
than that of a tissue in the metastasized location. Indeed, we find that metastatic
tissue samples localize in the vicinity of their tissue of origin in the transcriptomic
landscape (Figure 3-12), even without the use of specially-tuned primary site detec-
tion methods [18, 111].
For instance, using mapping metastasized breast cancer samples (GSE14107) on to
the transcriptomic landscape, we see that all of the metastases, regardless of whether
they were removed from the lung, brain, or bone, more closely resemble breast tissue
than their biopsy locations (A). Some of the over-enriched UMLS concepts include
White Adipose Tissue, Subcutaneous Fat, Subcutaneous Tissue, Lactiferous duct,
Mammary lobe, and Glandular structure of breast. The 15 of the 17 colorectal cancer
samples from GSE10961 (B) were all labeled with Rectum and sigmoid colon, Colonic
Diseases, Functional, and Colon carcinoma with a false positive rate of below 0.05;
the other two samples had a FPR of 0.06 for Colon Carcinoma. A table of other
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Fig. 5
Figure 3-12: Principal component analysis shows that metastatic samples more closely
resemble their primary sites. Along with the concept enrichment, the first two princi-
pal components of the gene expression data show that the gene expression signature
of tumor metastases more closely resembles that of their primary site location than
that of their metastasized sties. (A) Breast tumors that metastasized to the lung,
brain, and bone still appear to be more closely related to other breast samples than
to their metastasis sites. (B) Colon tumors that metastasized to the liver lie proximal
to colon tissue and are enriched for concepts such as Rectum and sigmoid colon and
Colon carcinoma. (C) While we were not able to correctly identify the exact primary
site location, the lung adenocarcinoma samples that metastasized to the brain look
nothing like brain tissue that is located in the top right cluster (see Figure 3-3).
(D) In the context of the entire transcriptome landscape, there is significant overlap
in breast and ovarian tumor and tissue samples; this makes it difficult to properly
distinguish between them.
Those metastases that were mislabeled provide a measure of the unbiased degree
of overlap between these metastases, reflecting the lack of hard boundaries in the
continuum of the transcriptomic landscape. This is particularly evident within the
soft-tissue cluster (bottom left Figure 3-3), in which the tissue specific signal can be
dwarfed by the larger variances caused by the blood and brain tissue samples. Al-
though the use of a supervised learning approach, such as in Schaner et al. [111], could
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mitigate these issues and be used to identify the tissue of origin, these approaches
minimize the significant biological overlap of some of these samples, which may have
implications for therapeutic selection [29]. Thus, for example, our approach appro-
priately does not label brain metastasis samples (GSE14108) with brain descriptors,
yet a transcriptome-wide approach such as ours that encompasses samples ranging
from normal tissue to blood samples from autistic patients, cannot label them with
the correct primary epithelial site other than correctly identifying it as a form of
adenocarcinoma (C). Similarly, due to the close proximity of breast and ovarian tis-
sue samples in the transcriptomic landscape, we had trouble distinguishing between
breast and ovarian metastases (GSE20565) (D).
3.5 Conclusion
With the ever-growing repositories of data, both public and private, it has become
not only possible, but also imperative to embrace the full transcriptomic continuum
of tissue and disease. Employing a comprehensive, non-case vs. control approach
and making use of the multi-dimensional nature of gene expression data, we capture
biological processes that are typically overshadowed in traditional analyses. Fur-
thermore, we are able to recapitulate the biological and medically relevant concepts
relating to merely a single new expression sample. Indeed, as the power of this macro-
scopic analysis increases with the amount of underlying data, this approach has the
potential to more fully leverage large, public databases with biological data, and to
benefit further as more data are added. Although we have presented our sample- and
gene-centric methods utilizing medically relevant concepts, the data-driven nature of
these methods implies that by changing the scope or domain of these labels, they can
be applied to analyses in different contexts with relative ease.
As suggested by some [75], systematic application of molecular pathology mea-
surements will allow a useful shifting of the conventionally employed diagnostic classi-
fication boundaries to include the notion that there are intermediate pathotypes that
cross the boundaries of the conventional medical classifications. These intermediate
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pathotypes are more closely coupled to the actual underlying pathology, thus revealing
not only shared pathology but also opportunities for development of shared treatment
[29, 35]. It may be the case that the gene expression signatures of disease provide
clues to a disease network [12] other than what classical medical knowledge dictates,
thus providing new insights into relationships between diseases that previously were
unknown.
It has been proposed that the future of personalized medicine, and the proper
application of genomic and genetic data, requires an understanding of both who the
patient is and the characteristics of the subpopulation to which the patient belongs
[64]. Clinical applications of our approach, in conjunction with other genetic, environ-
mental and phenotypic information, could more accurately and consistently annotate
clinical samples and provide an impartial view of the landscape of clinico-pathological
classification. As well as pointing out differences between tissues and diseases, our
approach provides an unbiased perspective on the overlapping biology of diseases with
the attendant implications for therapy selection in personalized medicine. In addition,
it could also be used to error check human annotations by analyzing the concordance
of the gene expression signatures of the patient with the textual information provided
by the clinician. Furthermore, as it makes use of an enrichment statistic that only
requires the usual standard of care in the labeling of samples, this system could be de-
ployed in a clinical setting with minimal alteration of normal procedures. By shifting
away from a dichotomous view and employing the global transcriptomic landscape,
we hope to address one of the key requirements of personalized medicine and begin
to answer one of its fundamental questions, what other samples am I most similar to





Marker genes in a
non-dichotomous world
The notion of a marker gene is nothing new. By definition, a marker gene, is a
gene that provides some information about a phenotype. For example, genes BRCA1
(breast cancer 1, early onset) and BRCA2 (breast cancer 2, early onset) are known
to be tumor suppressors and that mutations to to these genes can cause increased
susceptibility to breast and ovarian cancer [34]. While BRCA1 and BRCA2 are
individual genes that are linked to certain phenotypes, it is often the case that no
single gene uniquely that sets of genes. So called marker gene sets are sets of genes
that are used to define a phenotype. For example, MammaPrint [45] is a clinical test
that measure the expression of 70 genes to determine the risk that a breast tumor
will metastasize to other parts of the body. Similarly, OncotypeDX [95] is a 21 gene
predictor for women who have ER+ breast cancer to select those at higher risk for
recurrence and those more likely to benefit from aromatase inhibitor or tamoxifen
treatment.
Using the curated database of 3030 gene expression samples from GEO that was
introduced in Chapter 2, we shift from the sample centric analyses of Chapter 3 to
gene centric analyses. As in the previous chapter, we shy away from the traditional
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case vs. control methodology adopted by others, but view the expression patterns of
genes in a holistic manner. Our new perspective on interpreting gene expression space
helps uncover phenotype-specific marker genes beyond those discovered by traditional
dichotomous views of gene expression. When we apply our method to identify marker
genes for various cancers, we find that the marker genes are highly specific to the
particular cancer as opposed to generic cancer processes such as cell-cycle and cell
adhesion that are found by others that employ case vs. control experiment design
[104]. Furthermore, capitalizing on the hierarchical nature of the phenotypic labels
associated with our samples1, we also demonstrate that genes previously linked to
specific types of carcinomas may actually be part of a broader “carcinoma” process.
Finally, we illustrate how metastasized tumor samples are transcriptomically more
proximal to other cancer samples from their respective primary sites, as opposed to
cancerous tissue from the metastasis sites from which the samples were resected.
4.1 Marker gene finding: Finite impulse response
filter
We developed a method to identify marker genes that characterize a specific phe-
notype in the context of broad transcriptomic landscapes, and not in the context
of dichotomous classes. Instead of defining a marker gene as one that is over- or
under-expressed in a case vs. control study, we define a marker gene as a gene that
has a “localized” expression signature for a phenotype; i.e., how grouped together
are all of the samples corresponding to that phenotype for that gene. If all of the
samples for a phenotype have a very similar expression level (all very high, all very
low, etc.), the gene may be considered a marker gene for that phenotype. We employ
a standard signal processing tool, a finite impulse response filter (FIRF) [82], on each
genes expression values across the entire database of 3030 diverse expression samples
to quantify the degree of expression level localization for a given phenotype.
1Recall, we are using the UMLS ontology and such we have parent and child relationship infor-
mation for all phenotypic labels. For details see Chapter 2.
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In contrast to a standard t-test based approach, this approach does not require us
to define a specific control phenotype against which we test for separation, a poorly
defined task when comparing against such a diverse database. Moreover, this method
identifies genes with expression levels that are highly localized for a given phenotype,
thereby allowing for the diverse population of other samples to express these genes at
simultaneously higher and lower levels (something for which a t-test cannot directly
account). For example, the gene DBC1 exhibits a highly specific range of expression
across the stem cell samples, and ranked highly (among the top 0.5% of all genes)
in its ability to localize the stem cell samples by the described method. However,
the non-stem cell samples demonstrate both higher and lower expression levels of this
gene, causing a standard Students t-test (treating all non-stem cell samples as the
control group) to rank this gene at only the 24.6% strongest among all genes.
A gene’s marker gene score2, the level of localization of the expression intensities,
is computed using a FIRF. For each gene g phenotype p pair we first sort all of the
expression samples by their expression intensities for g. Using a “sliding window”
of size equal to the number of samples corresponding to p, we compute the fraction
of samples in that window that are associated with p. If all samples in the window
are associated with p, then the score for that window is 1, if none are associated
with p, then the score is 0. This window is iteratively moved across the sorted list of
samples so that we obtain a score for all possible positions. The marker gene score
for a particular gene-phenotype pair is the maximum score that is achieved in any of
the windows. A p-value is computed for each score based on a binomial distribution.
Figure 4-1 portrays a pictorial representation of the scores produced by the the
FIRF for two genes LRRTM2 (26045) (Figure 4-1(a)) and OR1J4 (26219) (Figure
4-1(b)). As outlined above, the samples are sorted in order from lowest to highest
expression value for the respective genes and the enrichment of brain samples in the
sliding window is calculated. The x-axis shows the index in this sorted list. The
red line corresponds to the score of FIRF (the fraction of the samples in the sliding
2We may alternatively use the term marker gene localization score or expression localization score
interchangeably with marker gene score.
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Figure 4-1: The marker gene FIRF score plots for genes (a) LRRTM2 (26045) and (b)
OR1J4 (26219). The samples are sorted in order from lowest to highest expression
value for the respective genes and the enrichment of brain samples in the sliding
window is calculated. The red line corresponds to the score of FIRF for each of the
genes for brain tissue. The green and blue lines depict the binomial and sampling
based confidence intervals. The former gene (leucine rich repeat transmembrane
neuronal 2) is considered a marker gene for brain as its score is significantly outside the
confidence intervals. On the other hand, the score for the latter (olfactory receptor,
family 1, subfamily J, member 4) is wholly contained within the confidence intervals
and thus is (correctly) not a marker gene for brain tissue.
window that are brain samples) for each of the genes. The green and blue lines depict
the binomial and sampling based confidence intervals. The former gene (leucine rich
repeat transmembrane neuronal 2) has a marker gene score of 0.95 (i.e. there was a
window in which 95% of the samples were brain samples) and is thus considered a
marker gene for brain. We see that this score is significantly outside the confidence
intervals. Furthermore, as to be expected of a neuronal gene, we see that the marker
gene score peaks at the right hand side of the plot, the side where all of the samples
with high expression intensity values for LRRTM2 are located. On the other hand,
the score for the latter gene (olfactory receptor, family 1, subfamily J, member 4) is
wholly contained within the confidence intervals and thus is (correctly) not a marker
gene for brain tissue.
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4.1.1 Specificity of marker genes
It has been suggested that the so-called “incidentalome” of incidental findings is a
threat that has yet to be addressed in either biological or clinical settings [66]. The
consequences of non-comprehensive views of biomarkers, such as prostate specific
antigen, continue to cause needless harm and costs [125]. As an example of the
utility of the marker gene scores used in conjunction with our database of expression
samples that have highly curated ontological phenotypic labels, we can show that
many genes are not specific to a single disease. This sort of quantification of phenotype
specificity is of course relevant to the diagnostic accuracy of putative biomarkers and
for developing suitably broad-spectrum or targeted therapeutics.
To illustrate this, we took the 459 carcinoma tissue samples in our database and
computed the “carcinoma” marker gene localization scores by comparing them to the
270 other tumor samples. As the UMLS concepts are in a structured ontology, we
computed the marker gene scores for the 13 concepts subordinate to “carcinoma”
(such as “adenocarcinoma,” “Adenosquamous carcinoma,” etc.) for which we had
at least three expression samples. From the list of genes sorted by their carcinoma
marker gene score p-value, we removed all genes that had a better p-value in any of
the 13 subordinate concepts. This yielded a list of 5805 genes that had better p-values
at the more general concept “carcinoma” than at any of the more specific subordinate
carcinoma types. Functional enrichment analyses of the top 10, 20, 50, 100, and 150
genes in this list reveals processes such as ”regulation of cell adhesion,” ”response to
growth factors,” and various other morphogenesis and development terms. Further-
more, within the sorted list of carcinoma genes, we see genes previously implicated
in carcinomas such as COL1A1 [78, 100, 143] and ELF3 [22] in the top 5. As such,
we see that these genes that have previously been implicated in particular types of
carcinomas may instead be part of a larger “carcinoma” process, rather than specific
to breast or colorectal cancer.
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4.2 Phenotype marker gene sets
















Figure 4-2: The histogram of the num-
ber of the number of genes that were
below a 0.001 binomial p-value cutoff
across 1489 UMLS concepts. The to-
tal heights of the histogram adds up
to 1489. A count is added to, for ex-
ample, bin 500 if there was a concept
which had 500 genes with a p-value of
below 0.001.
An astute reader may have noticed
that that marker gene scores for each
phenotype merely provide a ranking
of genes. In other words, genes with
a high marker gene score have a high
degree of expression intensity local-
ization while those that have a low
score do not. Although computing a
p-value based on either the binomial
distribution or randomized trials as
depicted in Figure 4-1 is a good
start at keeping only the “good”
ones, a significant number of genes
have low binomial p-values. For in-
stance, if we set a p-value threshold
at 0.001, and count the number of
genes that are below that threshold
for the 1489 UMLS concepts avail-
able in the Concordiafied version of
GEO (see Chapter 2 for details), we
see that a large number of concepts
have at least half of the genes below
the threshold (Figure 4-2). To go beyond the simple rankings of all genes for a phe-
notype as provided by the marker gene score, we generate gene sets that optimally
describe that phenotype. We identify the cutoff for the number of genes to include
in the set by balancing the gene sets ability to accurately classify samples of its own
phenotype while minimizing the presence of non-phenotype specific signal (Methods).
Not only does this method sidestep the requirement of defining the appropriate com-
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parator phenotypes, but it also facilitates the identification of thematically coherent
gene signatures that reveal very different aspects of biology from traditional ones.
4.2.1 Generating phenotype specific gene sets
Algorithm 1: Computing marker gene AUCs
Input: M : The list of genes sorted from high to low by their marker gene
score.
Input: S: The set of all samples such.
Input: Spheno: The set of samples ∈ S for a given phenotype.
Input: E: The matrix of gene expression values with gene IDs in the rows and
sample IDs in the columns.
Output: A: A matrix of AUC values with sample IDs in the rows and index
into M in the columns.
for i in 1...length(M) do
Ei ← E[1:i, ]
for i in 1...length(S) do
s← S[i]
S ′ ← S\{s}
corrs← The correlations of vector Ei[, s] to sub-matrix Ei[, S ′]
S ′′ ← S ′ sorted by the correlations, corrs, from highest to lowest
v ← generateHitMissIndicatorV ector(S ′′, Spheno)
A[s, i]← computeAUCFromHitMissV ector(v)
To generate phenotype specific marker gene sets, we use an additional method
to determine the appropriate cut-off for the number of genes required to describe a
particular phenotype p. As detailed in Algorithm 1, first, the genes are sorted accord-
ing to their marker gene score from highest to lowest. We then iteratively examine
the quality of the top i genes, balancing their positive predictive capability with the
amount of noise that they add. Starting with the first two highest scoring genes, we
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iteratively remove each sample s and compute its correlation to all other samples (S ′)
using only those two genes. We generate a receiver operating characteristic (ROC)
curve for s and use the area under the curve (AUC) of as a summary statistic. The
ROC curve is generated by sorting all samples by their correlation to s, and incre-
menting the true-positive (TP) count when that sample is associated with p, and
increment the false-positive (FP) count when that sample is not associated with p.
If, all samples of the phenotype of interest are all more correlated to the sample being
studied, then we achieve an area under the curve (AUC) of 1. For the sake of clarity,
let us assume that we store each of these AUC values in matrix A such that A[s, i]
contains the AUC value for sample s when we use the top i genes to compute the
correlations. Once all AUCs are computed for two genes, we add the next highest
scoring gene, and re-compute all AUC values.
As portrayed in Algorithm 2, once we have the matrix A containing all of the
AUC values for each sample for all number of marker genes, we determine the optimal
number of genes by computing the ratio of the mean AUC values for all samples that
indeed are associated with the current phenotype to the mean AUC of all samples
that are not associated with the current phenotype. Intuitively this ratio works as
follows. The mean “hit” AUCs is the average AUC that we get when attempting
to classify samples of the current phenotype. If the marker genes truly do represent
the signal of the current phenotype, then using the top i marker genes should make
samples of the phenotype have higher correlations resulting in higher AUC values.
The more genes that we use (the greater i is) the more of the signal we can capture,
and thus, hope to increase the average AUC value. On the other hand, the more
genes that we include, the more likely we are to include signal that is not associated
with the phenotype in question. Therefore, the more genes we include, the greater
the mean AUC for the samples that are not associated with the current phenotype
becomes. By taking the maximal value of the ratio of these two means, we find the
number of genes that is required that not only does a great job of classifying the
phenotype in question, but also does a poor job of classifying others.
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Algorithm 2: Computing optimal number of marker genes
Input: M : The list of genes sorted from high to low by their marker gene
score.
Input: S: The set of all samples.
Input: Spheno: The set of samples ∈ S for a given phenotype.
Input: Sother: The set of all other samples ∈ S (Spheno ∈ Sother = ∅).
Input: A: A matrix of AUC values with sample IDs in the rows and index
into M in the columns as computed in Algorithm 1.
Output: Moptimal: The list of optimal number of marker genes.
µhit ← mean(A[Spheno, ])
µmiss ← mean(A[Sother, ])
ratio← µhit
µmiss
Moptimal ←M [0 : max(ratio)]
This is exactly the behavior that we see in Figure 4-3. Here we plot the “hit”
and “miss” AUC curves for the phenotype “breast.” As to be expected, we see that
the “hit” curve (in black) is improving as more genes are added. Similarly, after an
initial decrease, the “miss” AUC curve (in red) begins to increase as well. When we
take the ratio of the two curves, it becomes apparent that using the top 164 genes
provides the optimal gene set of the phenotype “breast.”
Figure 4-4 shows the same behavior depicted in Figure 4-3 but without taking
the mean. Although we use the mean hit and miss AUCs to determine the optimal
number of genes to use in the gene set, this heatmap shows the AUC values for each
sample (in the rows) for each number of genes used in the gene set (in the columns)
such that high AUC values are yellow and low AUCs are red. The AUC values for
all breast samples (denoted by the blue color on the bottom left of the plot) is high
across all ranges of top number of genes to include. However, the AUCs that are
initially low for the non-breast samples improve as more genes are added to the gene
set.
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Figure 4-3: The plot on the left depicts the mean AUCs for all of the hit (black line)
and miss (red line) samples for generating a marker gene set for breast tissue. The
hit line is generated by taking the average of all AUCs for each sample that is a hit
(breast tissue) at each of the number of top marker genes (from 0 to 500). The red
line, is generated the same way for all samples that are not breast tissue. The plot
on the right depicts the ratio of the average hit and miss AUC curves. The circled
location is where the ratio is maximized and represents the optimal number of top
marker genes to use to create a breast marker gene set.
4.2.2 Breast cancer gene set
Using the aforementioned marker gene set generation process, we derived the breast
cancer gene set from a landscape of 673 samples representing 17 different cancer-
ous tissues. The 74 genes (Table 4.1) that comprise this set are functionally en-
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Figure 4-4: Although we use the mean hit and miss AUCs to determine the optimal
number of genes to use in the gene set, this heatmap shows the AUC values for each
sample (in the rows) for each number of genes used in the gene set (in the columns)
such that high AUC values are yellow and low AUCs are red. The AUC values for
all breast samples (denoted by the blue color on the bottom left of the plot) is high
across all ranges of top number of genes to include. However, the AUCs that are
initially low for the non-breast samples improve as more genes are added to the gene
set.
riched for processes related to breast specific development, and carbohydrate and
lipid metabolism. The complete list of over-enriched GO terms can be found in Ap-
pendix D. These pathways, revealed through gene expression, are consistent with
independent clinical and genetic data suggesting an important role for carbohydrate
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and lipid metabolism in breast cancer. For example, women with type 2 diabetes may
have higher susceptibility to breast cancer [85]. Three genes specifically implicated
in this analysis, ENPP1, ADIPOQ and PPARA, are of particular interest. ADIPOQ
is expressed in adipose tissue exclusively. Variants in the ADIPOQ gene and protein
levels are implicated in prostate cancer [26] and breast cancer [61]. Similarly, ENPP1
levels have been correlated to progression-free survival in tamoxifen-treated patients
with breast cancer [137]. PPARA is one of a family of nuclear transcription factors
that has been found to stimulate both adipocyte (fat cell) differentiation and fatty
acid oxidation [70]. Moreover, the PPARA signaling pathway has been implicated
in breast cancer progression [119], and in a case-control study a polymorphism of
PPARA was identified to be associated with a two-fold increase in breast cancer [47].
Notably missing from this list of enriched pathways are processes commonly as-
sociated with cancer, such as cell-cycle and cell-adhesion [104]. We can recreate
this conventional perspective by selecting the set of candidate marker genes using
a method based on a permutation t-test. We performed a t-test for each gene and
computed the empirical p-value based on 1000 random permutations of the pheno-
type labels. As many of the p-values were 0, we sorted the list of genes by the z
score of the actual t statistic as compared to the 1000 t statistics generated by the
random permutations. Using this metric, we were able to sort the genes even if they
had equal p values. Enrichment analysis of gene ontology (GO) [8] terms was then
performed using the Bioconductor GOstats [32] library in R. This method based on
the traditional permutation t-test reveals enrichment for processes that are associated
with cancer in general, but not specific to breast cancer, such as “cellular response to
tumor necrosis factor,” “induction of apoptosis,” and other tumor related processes.
Furthermore, according to the permutation t-test method, PPARA is less significant
than nearly 17% of the other genes (ADIPOQ is in the top 2% and ENPP1 is in the
top 0.5%). In comparison, using the FIRF-based method, the tumor necrosis related
genes, such as RIPK1, TRADD, and TNFRSF25, do not appear until, respectively,
18%, 54%, and 97% of the other more breast cancer-specific genes appear first.
To ascertain the “cancer” gene set using our method based on expression local-
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Breast Tissue ANKRD30A, hCG 25653, VTCN1, TBC1D9, TRPS1,
SCUBE2, STC2, CCL28, KRT14, ROPN1, OXTR, SFRP1,
FIGF, NFIB, ELF5, INHBB, IRX2, KRT6C, CYP4Z1,
PROL1, DSG3, KRT5, IRX3, LYPD3, IRX5, PLIN, EGR2,
MGP, TSHZ2, IRX1, FABP4, GABRP, MIA, SEMA3C,
SAV1, TFAP2B, SERPINB5, SFN, SLC39A6, PI15, CTSO,
DSC3, CX3CL1, TFAP2C, KCNMB1, DUSP4, XBP1,
ANO1, ADIPOQ, AZGP1, KLK5, LEP, SCGB2A2, FXYD3,
ADAMTS5, SAA2, AMIGO2, GATA3, TNN, TRIM29,
RERG, GLYATL2, ALB, RPS4P13, TAT, MUCL1, FOXA1,
KRT7, MUC15, PPL, SCGB3A1, FMO2, C1orf226, RPL3P7,
ITGB6, KIT, PER2, LTF, C4orf7, PLAT, CIDEC, RLBP1L1,
CD300LG, GRP, PLEKHG4, NTN4, SERPINA3, ZNF750,
MMP7, AMOTL2, C4orf32, S100A2, AGR3, KRT6B, CITED4,
TM4SF1, C10orf81, EGR3, FGF10, GRHL1, ARHGDIB,
SRPX, NA, MAB21L1, KIAA1881, FMO1, GHR, EFCAB4A,
C1orf116, TP63, TMC5, MYLK, AGR2, COL8A2, CPB1,
CRABP2, RPL3, TAGLN, NA, ACTA2, MAPT, CREB3L4,
CITED1, CRNDE, COL6A6, SCGB1D2, BNIPL, RBBP8,
RPS8, SFRP2, FAT2, THRSP, NA, MPZL1, VPS8, RPL13A,
CNN1, RPS10, SCN2A, ESR1, TGFBR3, IL6ST, KRT17,
KLHL13, C9orf152, MEIS3P1, WFDC2, SLC16A4, SLC34A2,
TM4SF18, PTPRZ1, RPS3, FOXI1, TFF3, STARD4, FAM46B,
LGR6, MB, RPL10A, CRISPLD1, PIP, PTHLH, TUSC5,
C16orf61
Breast Cancer Tissue ANKRD30A, EFHD1, SCGB2A2, hCG 25653, TRPS1, PIP,
CYP4Z2P, TBC1D9, PRLR, GATA3, COX6C, TFAP2B,
AZGP1, SERPINA3, FLJ45983, XBP1, SPDEF, CYP4Z1,
NA, NME3, MAGED2, PLIN, MUCL1, SCUBE2, TFAP2A,
NAT1, DCAF10, MB, SYCP2, CCDC74B, RPS6KA3, FOXA1,
RNF128, MAPT, MGP, CREB3L4, IRX5, ARSG, RABEP1,
TPRG1, ENPP1, WWP1, RET, CUX1, RMND5B, FSIP1,
TBX3, ESR1, ABCC11, TFAP2C, AR, SLC39A6, ACOT4,
PM20D2, PIK3R3, METRN, ACADSB, C6orf211, LRRC15,
ODC1, ADIPOQ, HSD17B11, COL10A1, CPB1, TMEM25,
THRSP, CCDC82, HDAC11, RBM7, TTC39A, KDM4B,
ERP44, PBX1, PPARA
Table 4.1: The 164 breast tissue and 74 breast cancer marker genes selected using the
finite impulse response filter (FIRF) followed by setting the cutoff at the number of
genes to as to maximized the sets ability to properly predict the members of its own
phenotype class while minimizing the presence of non-phenotype specific signal.
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ization, however, we expanded the landscape of data to include not only 17 cancers,
but also 2187 samples across 30 non-cancerous tissue types. By comparing all can-
cers against all non-cancers, we unsurprisingly then find that the most significant
genes are functionally enriched for processes that are typically associated with tu-
mors: “cell division,” “cell cycle,” and “DNA repair,” to name but a few. Taken
together, landscape-based gene signature discovery can recapitulate canonical cancer
pathways, but also can identify a complementary set of gene signatures with distinct
biological implications.
4.3 Tissue specific signal of tumor metastases re-
visited
The clinical problem of distinguishing whether a cancerous lesion represents a primary
tumor, or a metastasis from a distant malignancy, presents a test case for our ability
to localize a sample to the appropriate phenotypic group within the transcriptomic
landscape. By combining the sample-centric concept enrichment method (Chapter 3)
and gene-centric methods detailed above, we are able to map new tumor metastasis
tissue samples onto the gene expression landscape, providing an unbiased measure
of their phenotypic predisposition based on gene expression. It is commonly known
by pathologists that tumor metastasis tissue biopsies viewed “under the microscope”
resemble the tissue of the primary site rather than that of a tissue in the metastasized
location. Indeed, we find that metastatic tissue samples localize in the vicinity of their
tissue of origin in the transcriptomic landscape (Figures 3-12 and 4-5), even without
the use of specially-tuned primary site detection methods [18, 111].
As was show in Section 3.4, when we analyze the 29 metastasized breast cancer
samples resected from lung, brain, and bone (GSE14107), they more closely resem-
ble breast tissue than their biopsy locations (Figure 4-5) in the expression landscape
of all 3030 samples. UMLS concepts from Concordia that are over-enriched in the
metastasized samples include “White Adipose Tissue,” “Subcutaneous Fat,” “Subcu-
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taneous Tissue,” “Lactiferous duct,” “Mammary lobe,” and “Glandular structure of
breast.” Furthermore, when we restrict the analysis to use only the 164 genes in the
breast gene set identified using our aforementioned FIRF-based method, we observe
that these metastasized breast samples lie within the context of other primary breast
cancer samples in the database, which in turn are juxtaposed to normal breast tissue.
Figure 4-5: Sample- and gene-centric expression analyses show that metastasized
samples more closely resemble their primary sites than their biopsy site. (A) Breast
tumors that metastasized to the lung, brain, and bone (GSE14107) still appear to be
more closely related to other breast samples than to their metastasis sites when placed
in the transcriptomic landscape of 3030 other expression samples. (B) Recomputing
the PCs using only the 164 genes of the breast gene set, as opposed to all 20252 genes,
recapitulates the proximity of the metastasized breast cancer samples to breast tissue
samples, and shows that they lie within the confines of the other breast cancer samples
in the database.
4.4 Stem cell marker genes
Using the marker gene scores as defined before, we now turn to finding the genes
that are most highly associated with stem cell activity. There have been numerous
investigations, from a variety of perspectives, into the relationship between normal
organogenesis programs and malignancy, particularly with respect to the stem cell
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properties of self-renewal and pluripotentiality [107, 114, 128]. At the molecular
level, certain malignant tumors and developing tissues have been shown to exhibit
shared transcription factor activity, regulation of chromatin structure and signaling
characteristics [90]. Stem cell-like enrichment patterns for well-characterized gene sets
have been observed in breast cancers as well as bladder cancers and poorly differen-
tiated glioblastomas [14]. Stem cell populations have been identified that are specific
to individual tissues, yet share some of the same gene expression characteristics of
embryonic stem cells [140]. Similarly, diverse malignancies have been shown to share
broad developmental gene expression programming [90]. Multiple controversies con-
tinue to circulate around the role of particular genes in stem cells vs. differentiated
tissues (e.g. N-cadherin [71]), and the extent to which the activation of various stem
cell-like programs and pathways occurs across various tissues and diseases.
The cancer stem cell hypothesis asserts a model of tumorigenesis that may tie
some of these observations together. The theory suggests that only a small frac-
tion of tumor cells (cancer stem cells) maintain the ability to self renew, with the
majority of a tumors mass composed of the progeny of these stem cells, themselves
lacking proliferative potential [138]. This model implies a hierarchical organization
of tumorigenesis that closely reflects normal tissue development, thus accounting for
the high degree of functional heterogeneity observed in solid tumors [27, 54]. Under
these assumptions, expression profiles derived from resected tumor samples (compris-
ing both the hypothesized cancer stem cells and their progeny) would be expected to
broadly resemble those of the normal tissue of origin, with a degree of stem cell like
activity also apparent.
Originally identified in hematopoietic cancers, leukemic stem cells were observed
to express several markers in common with normal stem cells [36]. Subsequently,
analogous models have been developed for a number of solid tumors (e.g., brain [121],
breast [5], skin [33], ovarian epithelial [11], prostate [23], bone [43], and colon [105]
cancers), primarily through the identification of a small population (typically less
than 5%) of tumor cells that were unique both in their expression of a set of specific
surface markers as well as their ability to induce phenocopies of their original tumors
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in xenograft and transplant models.
Although the cancer stem cell model and the experimental approach to identify-
ing cancer stem cell populations have been replicated across a variety of tissues, the
exact molecular signatures derived from the proliferative cells have varied widely. As
yet, the extent to which there exist any molecular fingerprints commonly attributable
to multiple types of cancer stem cells remains unclear. For example, leukemia stem
cells have been identified by a CD34+CD38− phenotype shared with hematopoietic
stem cells [74], while brain cancer and colon cancer stem cells have been isolated
among CD133+ cells [105, 121]. Breast cancer stem cells have been defined by a




+ populations [23]. Bone sarcoma cells with pro-
liferative potential have been shown to express activated Stat3 [43]. These cells also
expressed a subset of the embryonic stem cell-associated genes (Oct3/4, Nanog), but
again, the degree to which these trends may be apparent across other populations of
cancer stem cells is unknown [142].
4.4.1 Creating the stem cell marker gene set
Using the method based on the finite impulse response filter (FIRF) explained in
Section 4.1, we identified a set of genes with highly specific stem cell expression
intensities. Previous studies have examined the expression patterns of literature-
curated gene sets relating to embryonic stem cell-like activity among a variety of
malignancies [14]. In contrast, we have constructed a gene set in silico that reflects
only those transcriptional signals with the greatest ability to localize the stem cell
samples within the spectrum of human tissues and diseases.
A variety of thresholds were evaluated according to the ability of the implied gene
sets to differentiate between stem cell samples and the other phenotypes in the dataset
via an analysis of variance (ANOVA). For each possible number of top-scoring stem
genes from 3-502 (displayed at the top of Figure 4-6), we project all of the samples
in the database into the first two principal components of gene space (panel on top
right), and highlight in color 6 relevant phenotypes (as in Figure 4-7): embryonic /
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Figure 4-6: A variety of thresholds were evaluated according to the ability of the
implied gene sets to differentiate between stem cell samples and the other phenotypes
in the dataset via an analysis of variance (ANOVA). Here we show the result when the
189 genes that are part of our stem cell gene set are used. For each possible number
of top-scoring stem genes from 3-502 (displayed at the top of the figure), we project
all of the samples in the database into the first two principal components of gene
space (panel on top right), and highlight in color 6 relevant phenotypes (as in Figure
4-7): embryonic / induced pluripotent stem cells in magenta; mesenchymal stem
cells in cyan; immortalized cell line samples in blue; blood precursor cells in orange;
leukemia samples in green; normal blood in red. The panel below the PCA scatter
plot shows the distribution of stemness index values (PC1 projection coordinates) for
each highlighted phenotype. The plot on the left of the frame shows the ANOVA
score (including all highlighted phenotypes) for the clustering defined by the current
stemness index highlighted by a magenta dot on the curve showing all ANOVA scores
for all of the depicted FIRF thresholds. Higher ANOVA scores indicate better multi-
way separation of the individual phenotypes along the stemness index. The genes
presented here represent a set capable of simultaneously separating the pluripotent,
multipotent, progenitor, malignant and normal samples, while also retaining tissue-
specific features (e.g., clearly separating normal blood, neural and epithelial tissues)
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induced pluripotent stem cells in magenta; mesenchymal stem cells in cyan; immor-
talized cell line samples in blue; blood precursor cells in orange; leukemia samples in
green; normal blood in red. The panel below the PCA scatter plot shows the dis-
tribution of stemness index values (PC1 projection coordinates) for each highlighted
phenotype. The plot on the left of the frame shows the ANOVA score (including
all highlighted phenotypes) for the clustering defined by the current stemness index
highlighted by a magenta dot on the curve showing all ANOVA scores for all of the
depicted FIRF thresholds. Higher ANOVA scores indicate better multi-way sepa-
ration of the individual phenotypes along the stemness index. The genes presented
here represent a set capable of simultaneously separating the pluripotent, multipo-
tent, progenitor, malignant and normal samples, while also retaining tissue-specific
features (e.g., clearly separating normal blood, neural and epithelial tissues). Here
we used an ANOVA as opposed to the previously introduced “hit” vs. “miss” AUC
ratio as we were trying to maximize the difference in not just two clusters (hit and
miss) but rather six.
After various iterations, we found that using the top 189 stem cell marker genes
yielded the best results. Henceforth, these 189 genes will be referred to as the stem
cell gene set and the complete list of genes can be found in Tables D.3 - D.6 in
Appendix D. While we will not delve into the topic here, we shall see how these stem
cell marker genes can be used to find potential drugs that effect cell-cycle (Section
6.3.1).
4.4.2 Stem-like signature stratifies a diverse expression database
by pluripotentiality and malignancy
Via principal component analysis (PCA), we examined the transcriptional profile
of the stem cell marker genes across the entire collection of normal tissues, cancers
and stem cells. Performing PCA across only the stem cell marker genes (including
all samples in the data set) allowed us to measure the extent to which the specific
transcriptional activity observed in the stem cell population was apparent in each of
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the other phenotypes. Figure 1 
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Figure 4-7: The stem cell signature genes stratify a phenotypically diverse database
according to pluripotentiality. Each panel shows the entire expression database plot-
ted on the principal coordinates defined by the stem cell signature genes. PC1 is
represented on the x-axis of each plot, while PC2 is on the y-axis. In each plot,
the pluripotent stem cells (IPS and ES) are clustered on the extreme right-hand
side (magenta), followed by mesenchymal stem cells (cyan) and immortalized cell
lines (blue). Taken together, the panels demonstrate that, across tissue types, this
stem cell signature draws a coherent picture of pluripotentiality and differentiation.
While the distinction between the pluripotent stem cells and normal tissues represents
the predominant signal (PC1) in the data, the contrast in the expression profiles of
hematopoietic and neural tissues apparently defines the second strongest signal (PC
2). Even so, both tissues respective malignancies show a common tendency to exhibit
greater stem-like activity, as demonstrated by their closer proximity to the pluripo-
tent stem cell cluster (A, B, C, D) Blood, breast, neural and colon all demonstrate
the same enhanced stem-like expression activity among their respective malignancies.
This analysis revealed a striking trend apparent in the first two principal compo-
nents (PCs) of the gene set; most importantly, PC1 captured a measure of cellular
potency, while PC2 reflected the broad transcriptional differences between hematopoi-
etic, neural and epithelial tissues. These trends are demonstrated in Figure 4-7. Each
panel highlights in color the PCA region occupied by a particular normal tissue pop-
ulation (red) and its associated malignancies (green), as well as any related precursor
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cells (orange), immortalized cell line samples (cyan), multipotent (blue) and pluripo-
tent stem cells (magenta) (PCA was computed jointly across all samples; each cancer
is highlighted individually for clarity). The pluripotent stem cells included in this
analysis were a combination of both embryonic stem cells and induced pluripotent
stem cells. The locations of all other samples in the data set are shaded gray to
provide context.
The dominant characteristic of PC 1 is its ability to separate the pluripotent stem
cells from the normal tissue samples (e.g., the normal tissues shown in Figure 4-7
blood, breast, brain, colon, shaded red, consistently lie on the extreme left side of
the plots, whereas the pluripotent stem cells, shaded magenta, lie on the extreme
right). Moreover, PC1 apparently reflects a finer-grained continuum of cellular po-
tency: the multipotent stem cells are clustered near the pluripotent stem cells, with
the hematopoietic progenitors (the only progenitors in our dataset) slightly farther
away.
Further, the hematopoietic, neural and epithelial cancers (shaded green in Figure
4-7) contained in our data all clustered directly between the stem cell populations
and their associated normal non-malignant samples. This suggests that the stem
cell marker genes captures a kernel of stem cell-like transcriptional activity that is
concurrently apparent in a variety of malignancies. These findings build on previous
observations that genes associated with stem cell-like activity demonstrate differential
expression in a variety of epithelial cancers with respect to their normal tissue coun-
terparts [140]. Our analysis reveals that stem-like expression profiles are observable
not only in epithelial cancers, but also in neural and hematopoietic malignancy as
well.
We will use the coordinates of an expression profiles projection into the first prin-
cipal component of the gene space defined by the stem cell marker genes as a relative
measure of “stemness”, our stemness index.
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4.4.3 Functional diversity of the stem cell gene set
Hierarchical clustering of these genes transcriptional activity in a population of pluripo-
tent stem cells revealed four distinct coexpression modules. For each module, we then
identified a set of over-enriched GO biological processes [8]. Figure 3 
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Figure 4-8: Four distinct expression modules (row clusters) are apparent within the
stem cell genes. To demonstrate the transcriptome-wide implications of these pro-
files, this figure displays a series of cell types, ranging from fully differentiated (nor-
mal breast), through the associated malignancy, partially committed stem cells, and
pluripotent stem cells. Each gene (row) has been independently z-score normalized
to improve readability and highlight cluster-specific trends. Biological significance of
each cluster was determined by GO analysis (see Tables D.7 - D.10 in Appendix D).
The individual genes represented in each cluster can be found in Tables D.3 - D.6 in
Appendix D.
To illustrate the gene expression trends apparent within each gene cluster, Fig-
ure 4-8 shows a heatmap of their profiles across pluripotent and partially committed
stem cells, as well as malignant and normal breast samples. Genes active in DNA
replication, cell cycle regulation and RNA transcription (see Tables D.7, D.8 in Ap-
96
pendix D) are most highly expressed in the pluripotent stem cells, and less so, respec-
tively, through increasing levels of cellular differentiation / decreasing pluripotential-
ity, consistent with prior studies of the dynamics of stem cell cycling and regeneration
[101, 130]. Genes related to metabolism and hormone signaling (Table D.9) show
peak expression intensity among the partially committed stem cells, while exhibiting
low intensity among the fully differentiated tissue and tumor samples. Correspond-
ingly, genes responsible for multicellular signaling and cellular identity (Table D.10)
are most highly expressed in the fully differentiated tissue and malignant samples.
Within each functional module, the tumor samples trend away from the respective
normal tissue, echoing stem cell-like transcriptional activity.
4.4.4 Grading of tumors
We used the stemness index that we derived from the stem cell gene set to evaluate the
transcriptional profiles of several graded tumor data sets. Our goal was to evaluate
whether our molecular marker for tissue-agnostic stem cell-like transcriptional activity
was representative of poor clinical prognosis. We included four publicly-available data
sets in this analysis. For each data set, we computed the samples stemness index (via
PCA over the stem cell gene set) to identify the dominant differences between the
samples within the context of the stem cell genes.
We identified four independent data series containing expression profiles for graded
tumors of various tissue types in GEO (GSE4290, GSE23593, GSE17537, GSE18842)
on Affymetrix HG-U133 Plus 2.0. Each series was pre-processed (MAS5.0 normalized,
summarized) as previously described. Within each series, the stem cell gene set
summary values were computed, again, via PCA over this gene set, allowing us to
associate a value with each sample indicating its relative stem-like expression activity.
This analysis revealed that our stemeness index correlates with tumor grade for a
variety of primary tissues. Figure 4-9 shows the distribution of stemness index values
for the four tissue types graded tumor samples. In each case, the transcriptional
activity of the stem cell gene set defines a clear separation between the high- and
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Figure 4-9: Stem cell-like activity correlates with tumor grade in various solid malig-
nancies. Each panel displays the distribution, within the space of the stem cell genes,
of graded tumor samples for one particular tissue type. Our stemness index consis-
tently separates high-grade tumors from low grade ones. Based on this transcriptional
index, the mid-grade tumors are less well defined.
expression for the clinical difficulty in classifying mid-grade tumors. [40, 134]
4.4.5 Biological implications
The increasing volume of evidence supporting a pervasive connection between cancer
and stem cells suggests significant therapeutic implications. Current therapies are
evaluated based on their ability to reduce the overall size of a tumor. Regimens that
target cancer stem cells, however, may have more success in preventing long-term
recurrence [138]. Molecular signatures that are capable of grading pluripotentiality
and proliferative potential represent an important step in designing such regimens
and guiding therapeutic procedures.
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Indeed, gene expression signatures derived from breast cancer stem cells have been
shown to separate patients with early-stage breast cancer into high-risk and low-risk
groups [76]. Similar methods with broad applicability will pave the way for indi-
vidually tailored treatment strategies. Diverse malignant tissue samples have been
shown to exhibit a broadly similar trend within a large gene expression database, but
no specific connection has been made in this context to stem cell-like activity [77].
Identifying an unbiased transcriptional measure of stemness conserved across embry-
onic and adult stem cells, and relating that signature to malignancy, has remained a
challenge [38, 101, 140].
While a large volume of evidence indicates that only a small number of tumor cells
are capable of self-renewal, controversy remains as to the exact origin of these cells.
The hierarchical cancer stem cell hypothesis suggests that these cells arise from nor-
mal pluripotent or multipotent stem cells that have lost the ability to regulate their
proliferative activity. Under this model, the phenotypic diversity observed in many
tumors is viewed as the result of this defective stem cell population mismanaging the
process of normal organogenesis. Alternatively, the stochastic model of tumorigenesis
suggests that proliferative tumor cells arise from normal fully differentiated or com-
mitted progenitor cells that acquire the ability to self renew [90], and that tumor cell
phenotype variation is the result of these mutated cells differentiating in a random
fashion [50].
Regardless of the origin of proliferative tumor cells, our results indicate that there
is a high degree of stem cell-specific gene expression programming observable in het-
erogeneous tumor samples. Our data indicates the need for more detailed transcrip-
tional assays comparing proliferative tumor cells to both ES / iPS cells and bulk
heterogeneous tumor cells, as well as normal tissue cells. Our data suggests the hy-
pothesis that the gene expression patterns observed in heterogeneous tumor samples
may be due to the effect of a small population of cancer stem cells in combination
with a large number of partially differentiated cells. It is plausible that, while the
partially differentiated mass of the tumor behaves transcriptionally similar to healthy
tissue, the small population of proliferative tumor cells push the observation of the
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aggregate mRNA back along the spectrum of stem cell-like activity.
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Chapter 5
Data begets data: Efficiently
expanding an existing curated
expression database
Building large, highly curated databases of gene expression data is a task that has
been attempted by many. Although some have the financial resources to generate new
data [2], the repurposing of existing gene expression data sets is the more common
(and economical) route. In general, this curation effort takes two forms: highly
specific sample curation for a specific analysis or classification task (e.g. [53, 113, 115,
119, 124, 133]), or the accumulation of a vast array of samples for the purpose of
having a diverse dataset to perform various data mining procedures (e.g. [3, 19, 39,
56, 63, 77, 81, 116]). Indeed, our work here falls into the latter category, but has the
potential to be used for the former.
An ideal expression database is one that can be searched for a phenotype (or a
set of phenotypes) to obtain the expression vectors for all samples relating to that
phenotype. The National Library of Medicine’s Gene Expression Omnibus (GEO) [13]
does allow for searching by phenotype1, but it simply returns webpages of dataset as
opposed to pre-processed data that can be used as-is in an analysis. While it is a
1Searching GEO works like any other search – one types in some keywords and the user is given
a page with all of the results that are deemed to be related to the search query.
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simple matter to write a program that obtains the datasets that are deemed relevant
by GEO’s search logic (GEO provides FTP access to the raw expression data), one
of the largest stumbling blocks to the repurposing of existing datasets is the lack of
standardized nomenclature when defining the content of the data series and samples
[19]. This means that multiple queries have to be made for a given phenotype in
order to obtain complete coverage. Althought the use of the standardized concepts
in the Unified Medical Language System (UMLS) [17] does circumvent this issue to
a large degree, the automated labeling procedure using the MetaMap [7] program
(or any other NLP based program) is unfortunately plagued with both false positives
and false negatives (refer to Chapter 2 as to how we used MetaMap and the UMLS
ontology to build our Concordiafied version of GEO). Thus, as also described by Butte
et al. [19], manual intervention is necessary to verify the labelings. Regrettably, this
process is both time consuming and error prone.
The beauty of working with expression data, however, is that not only do we
have the text that describes the experiment that was performed, but also the actual
expression intensity values for each of the samples. As we showed in Chapter 3, we
can take new expression samples, and with a high degree of accuracy, label it with its
UMLS concepts by just using the expression data. Taking this into account, could
we not combine both textual and expression information when querying for samples
of interest? Although previous work shows that it is possible to query for expression
samples using an expression vector as input [39], here we focus on the task of efficiently
expanding a curated database. By combining the contextual information provided by
the text and hints to the underlying process provided by the gene expression data we
can expand an existing curated database very quickly.
5.1 Seeing is believing: Active learning
The fundamental problem is that building a curated database is a tiresome endeavor.
Furthermore, it is often the case that when building such a database not all pheno-
types are equally important. For example, if a research group is currently studying
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autism, it would much rather add a lot of autism samples to the database than a
random selection of samples that cover a wide range of phenotypes. Taking this into
account, we want to be able to increase the size of a curated database as quickly
and as efficiently as possible. Assuming that every entry into the database has to
be manually verified for accuracy by an “expert”2, the most efficient way to add all
samples for a given phenotype is to return all of the samples that have yet to be
curated for that phenotype. Clearly, if we had a highly trained classifier (whether
it uses just text, just expression, or a combination of both) that can do this for us,
that would be great. Unfortunately, creating such a classifier requires training data
– both positive and negative examples that can be used to teach the classifier as to
what truly is an autism sample.
This is where the supervised learning paradigm of active learning can be applied.
The active learning framework makes use of samples that have previously been cor-
rectly labeled to guide the labeling of future samples. Rather than having an expert
annotate all samples (since we assume that to annotate all samples for a given phe-
notype, this expert must have also had to annotate, or skip over, many samples that
were not for this phenotype) to create a highly accurate classifier, we seed the classi-
fier with a handful of annotated samples, and then have it improve its understanding
of the phenotype as more samples are annotated. Therefore, at first the classifier
may return poor results, but as the expert curates the database, (s)he will be pro-
vided with better and better samples (i.e. at some point every sample being looked
at should be of the phenotype in question). Not only does this improve annotation
speed, it also ensures a higher degree of accuracy.
Traditionally, active learning is used to reduce the amount of data that needs to
be labeled to train an accurate classifier. Active learning is comprised of repeatedly
training a classifier, selecting the next set of samples to annotate based on the clas-
sification results, annotating those samples, and the retraining the classifier with the
updated training set to repeat the procedure again (see Algorithm 3). At each round,
2It probably wouldn’t be too far from the truth to state that in most cases this expert is a new
graduate student.
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the set of samples that are chosen to be labeled are removed from the unlabeled set
(TU,i) and then added to the labeled set to be used for the next round of learning
(TK,i+1). For example, Singh et al. [120] used active learning to reduce the number
of microarray experiments that need to be performed for time-series experiments. As
our task is to build a large, curated database, unlike these previous works, however,
we employ active learning not to reduce the number of samples to be labeled to create
a great classifier, but rather to reorganize the samples to be presented to the expert
labeler in an order that is conducive for fast and accurate labeling. For a full review
of active learning and its applications see the Active Learning Literature Survey [117].
Algorithm 3: Active learning
Input: TU : The set of unlabeled gene expression samples
Input: TK,0: A small set of known labeled samples
Input: TT : A set of testing data used to evaluate the trained classifier
Input: C: A classifier
Output: TK : The set of labeled samples






TU,i+1 ← TU,i \ TC∗,i
TK,i+1 ← TK,i ∪ TC∗,i
5.2 The baseline: What do we have to beat?
Before we continue, an important question to ask is whether or not we need to perform
active learning at all. Since we are already using MMTx [7] to annotate the free text
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for each sample with its corresponding Unified Medical Language System (UMLS)
[17] concepts, if a user is interested in concept c, can we just assume that MMTx is
correct and return all samples annotated with c to the user? Although there is noise
associated with the labelings produced by MMTx, they are not all incorrect (if they
were, why would anyone use MMTx?).
When we annotated 3030 gene expression samples from NCBI’s Gene Expression
Omnibus (GEO) [13] with MMTx (as explained in Chapter 2), there were a total of
2267 unique UMLS concepts. The annotations associated with these samples were
then manually verified and about a third of them (633 unique concepts) were kept.
We also added 39 new concepts that MMTx did not return for any of the 3030
samples. Although these concepts were then “mapped back up” the ontology3 in the
Concordiafied version of GEO that we used in the analyses of the previous chapters,
here we just use the raw results returned by MMTx without any additional processing.
Using just the 633 concepts that were kept after manual verification, we can
then compute the accuracy of MMTx in regards to its labeling of the text. Four
common statistics that are measured are sensitivity, specificity, precision, and recall.
Sensitivity is defined as the fraction of actual positives which are correctly identified
as positives (e.g. the fraction of all breast samples that were annotated as being from





where TP is the number of true positives (the number of samples that were correctly
labeled) and FN is the number of false negatives samples (the samples that were
incorrectly not labeled with the concept but should have been). Sensitivity is also
know as the true positive rate. Specificity, on the other hand, is the fraction of nega-
tives which are identified as negatives (e.g. the fraction of samples that are not breast
samples, that were identified as not being breast tissue samples) and is computed as
3Recall, that if a sample was annotated with “breast cancer” we then also annotated that sample
with all ancestor concepts in the UMLS ontology. Continuing the example, the sample would then
also be annotated with concepts such as “malignant neoplasm” and ”disease.” See Chapter 2 for
details.
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Figure 5-1: The distribution of sensitivity and specificity values of the 633 UMLS






where TN is the number of true negatives (the number of samples that were correctly
labeled as not having the phenotype) and FP is the number of false positives samples
(the samples that were incorrectly not labeled with the concept with they should not
have been). Sensitivity and specificity are also referred to as type I and type II errors.
Closely related to sensitivity and specificity are precision and recall. Precision is





where TP is the number of true positives and FP is the number of false positives.






where TP is the number of true positives and FN is the number of false negatives.
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Figure 5-3: The MMTx sensitivity and specificity values for the 633 UMLS concepts
that were kept. Table 5.1 contains the concepts with low sensitivity values.
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correctly assuming that the text was there to begin with. As shown in the density
estimates of sensitivity, specificity, precision, and recall in Figures 5-1 and 5-2, we
see that a significant number of the concepts annotations were accurate. This tells
us that by just parsing the text available to us using MMTx, a large portion of
the hard work has been completed for us. Of course, we must not forget that we
are only measuring the results for the 633 UMLS concepts that we deemed to be
relevant after having removed 1634 irrelevant concepts. When we plot sensitivity vs.
specificity for each of the 633 concepts (Figure 5-3), we again see that the majority of
the concepts perform well. What we see from the concepts that had a low sensitivity
(Table 5.1) is that many of the are concepts that can be easily obtained incorrectly.
For example, “Adult” has a sensitivity of 0.25. In several of the texts that contain
the word “Adult,” the words “child” (which maps to the concept “Childhood” with
sensitivity of 0.1) or “Adolescent” (sensitivity of 0.17) are also used. For instance, an
excerpt from the series description for GSE2842 is (bold face added for clarity):
Glucocorticoids (GC) are in most chemotherapy protocols for lymphoid ma-
lignancies, particularly childhood acute lymphoblastic leukemia (ALL) for
their ability to induce apoptosis in malignant blast. The underlying mecha-
nism, however, has so far only been investigated in model systems. . . . For
comparison, expression profiles were generated from an adult ALL patient,
peripheral blood lymphocytes from GC-exposed healthy donors, GC-sensitive
and -resistant ALL cell lines and mouse thymocytes treated with GC in vivo
and in vitro.
Not only do we have to contend with contradictory concepts (such as “adult”
and “childhood”) as indicated above, shorthand or uncommon abbreviations cause
other erroneous mappings. For instance, a nightmare scenario would be a sentence
like, “This experiment compared breast cancer (BC), lung cancer (LC), and prostate
cancer (PC) samples to matched normals.” Running this through MMTx results in
the concepts in Table 5.2.
As one can see, all of the correct concepts are identified by MetaMap (“Normal,”

















Precursor Cell Lymphoblastic Leukemia Lymphoma 0.166666666666667
Acute leukemia 0.152173913043478
Blood specimen 0.13953488372093





Leukemia, Myelocytic, Acute 0.0307692307692308





Whole blood sample 0
Infection 0
Injury 0
Cancer of Neck 0




Pregnant - adjective 0
Monozygotic twins 0
Hypertensive disease 0
Table 5.1: The concepts and sensitivity values for the UMLS concept that had a
specificity of 0.4 or less.
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To - dosing instruction fragment To
Matches Normal
Specimen from breast Malignant neoplasm of breast
Breast Entire breast
Malignant neoplasm of lung Malignant Neoplasms
Primary malignant neoplasm Bicarbonates
Malignant neoplasm of lung Lung
Entire lung Specimen from prostate




Table 5.2: The UMLS concepts as a result of running MMTx on the sentence, “This
experiment compared breast cancer (BC), lung cancer (LC), and prostate cancer (PC)
samples to matched normals.” Although there are many correct concepts, there are
also many spurious ones.
plasm of prostate,” “Breast,” “Lung,” and “Prostate”). However, unless each of the
individual samples in the series has the correct phenotypic label describing which of
the labels is correct, which it usually does not, we have no way to tell which sample
corresponds to which phenotype. This sort of scenario is, unfortunately, the norm
and not the exception.
5.3 Expanding the database using only text
Having examined the accuracy of the MMTx [7] as a labeling engine, let us turn
our attention to using those UMLS [17] concept annotations produced by MMTx for
the task of building and expanding a curated database. As this section only deals
with the text itself, these results are applicable to a broad audience (not just those
building an expression database). As is common with text based classification (e.g.
spam filtering), we will assess the performance of a na¨ıve Bayes classifier when applied
to this task.
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5.3.1 Brief introduction to na¨ıve Bayes classifiers
Although not necessary for the understanding of the results below, here we present a
(very) brief (and non mathematical) introduction to na¨ıve Bayes classifiers. Interested
readers should refer to the book Introduction to Information Retrieval [80] for a
detailed (and mathematical) discussion of the topic.
A na¨ıve Bayes classifier is a probabilistic classifier that is based on Bayes theorem
with a strong assumption of independence. Unlike other probabilistic models such as
a Bayesian network, each of the features in the model are completely independent.
For example, if one aims to classify whether a given vehicle is an Aston Martin DB5
(James Bond’s car), the features that may be included in the model may include:
number of wheels, size of wheels, number of doors, size of engine, etc. Thus, when
creating a na¨ıve Bayes classifier, we assume that all of these features are completely
independent. In other words, the number of wheels that a vehicle has has no rela-
tionship with the number of doors. While this strong assumption of independence
is usually not accurate4, it is a good approximation that works well in many areas
(especially text classification, such as spam filtering [25]).
To train the classifier, we simply provide it with positive and negative examples
to learn from. Each of the examples is presented to the classifier as a feature vector.
A feature vector is a list (a vector) of values for each of the features that we have
data for (the number of doors, size of wheels, etc.). The parameters of the model
(the probability that the vehicle is a DB5 given the number of doors, etc.) are then
estimated by maximum likelihood estimation (MLE). Simply stated, MLE tries to
compute the probability of a vehicle being the DB5 given the current data. Thus,
if we had 5 examples for the “number of doors” parameter as shown in Table 5.3
the probability of being a Aston Martin DB5 is 50% if the vehicle as 2 doors (it’s
either the DB5 or the M3) and 0% if it has any other number of doors. Once we have
trained the classifier and all of its parameters, we show it a new feature vector and
4If the vehicle has two wheels it most likely has no doors (it’s a motorcycle), if it has four wheels
it most likely has two or four doors (a regular car), and if it has 18 wheels it probably has 2 doors
(a truck). Of course, in this example, any vehicle that doesn’t have four wheels can immediately be
assumed not to be the DB5.
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it computes the probability that that car as described by that feature vector is an
Aston Martin DB5.
Car No. of Doors
Aston Martin DB5 2
BMW M3 2
VW GTI 3
BMW 7 Series 4
Toyota Prius 4
Table 5.3: Example input for a na¨ıve Bayes classifier parameter. After seeing these 5
examples, the classifier would say that the probability of being a Aston Martin DB5
is 50% if the vehicle as 2 doors (it’s either the DB5 or the M3) and 0% if it has any
other number of doors.
5.3.2 Learning from text
Now that we have a basic understanding of how the classifier works, we show how it is
applied to the task of classifing whether a sample is indeed related to the phenotype
of interest (e.g. is it really a lung tissue sample) or not. We define the feature vector of
a sample by the indicator vector of UMLS concepts that the free text was associated
with. Each entry in the vector corresponds to whether or not the given sample was
annotated with that concept by MMTx, and is set to 1 if it was and 0 if it was not.
For example, Table 5.4 depicts two samples and their corresponding indicator values
for six concepts. Sample s0’s free text was annotated with concepts c0, c1, and c3,
while sample s1 was annotated with c0, c3, c4, and c5.
We tested the efficacy of performing active learning on merely the concepts that
each sample was associated with by employing a na¨ıve Bayes classifier. For example,
c0 c1 c2 c3 c4 c5
s0 1 1 0 1 0 0
s1 1 0 0 1 1 1
Table 5.4: An example of two samples and their indicator vectors corresponding to
which concepts they have been labeled with. Sample s0’s free text was annotated
with concepts c0, c1, and c3, while sample s1 was annotated with c0, c3, c4, and c5.
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can we look at all of the concepts and predict whether or not a sample is a breast can-
cer sample. Thus, using the nomenclature of the active learning algorithm described
in Algorithm 3, each round of learning consists of training a na¨ıve Bayes classifier with
the current set of labeled concept indicator feature vectors, evaluating the classifier
on a held out testing set for classification performance, and then choosing a set of
new samples to label. These labeled samples are then removed from the unlabeled
set and placed in the labeled set for the next iteration of learning.
5.3.3 Scoring strategies
The hardest part of performing effective active learning is in the step where the set
of samples to be labeled is chosen. In order to have active learning be useful, we need
to pick the samples that will help us the most in future rounds of active learning. In
order to understand the efficacy of active learning, we implemented several scoring
functions. Although a typical use-case is to return one sample at a time at each
iteration, we chose to return five at a time.
Maximum (minimum) entropy
Given a classifier, the maximum entropy scoring method scores the samples closest to
the decision boundary the highest. For instance, this scoring method has previously
been used for statistical natural language parsing [131]. For example, assume that
we have a two-class classification problem such that the output is either “positive” or
“negative.” The sample that should be chosen next is the one that the classifier is the
most unsure of; the one closest to the classifier’s decision boundary. This “closeness”
to the decision boundary can be summarized by the following entropy (H) function.
H(s) = −p(pos)× log(p(pos))− p(neg)× log(p(neg)) (5.5)
If the probability of being in either the “positive” or “negative” case is high, then
entropy will be low. On the other hand, if the probability of being in either one
is 50%, then the entropy will be high. Thus, by picking samples that have a high
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entropy, we are guaranteeing that at each iteration the sample that causes the most
confusion for the classifier is labeled to be added to the next iteration’s training set.
We also implemented the minimum entropy function. Unlike the maximum en-
tropy function, the samples that the classifier is most confident about at each iteration
are chosen to be added to the next iteration’s training set. Although this function
may be the incorrect choice when attempting to minimize the number of labeling
steps required to maximize the classifier accuracy, it is more in line with the under-
lying requirements of a large-scale annotation effort. In other words, the minimum
entropy function will return the samples that the classifier is most confident about,
and thus provide us with the set of most-likely-to-be-correct samples that should be
annotated.
MMTx labeling
Instead of using a na¨ıve Bayes classifier to compute which samples should be labeled
based on an entropic measure, we can trust the labeling of MMTx to guide us in the
process of making the choice. Intuitively, if a sample has a given concept, then it is
much more likely to actually being whatever that concept says it is than if it were
not labeled with it. Thus, by simply returning high scores for samples that have been
labeled with the concept for which the classifier is being turned for, we are returning
MMTx’s best guess as to how to train the classifier.
For this strategy we also implemented two variations. The first was to simply re-
turn all MMTx labeled samples (subsequently denoted as allsamples) and the second
was to return three samples corresponding to the MMTx label along with two random
ones (subsequently denoted as mostwithconcept). Although it might have been a bit
obscure as to why we chose to return five samples at each iteration, it was to allow
for a bit of randomness in this step. In other words this mostwithconcept strategy is
akin to letting the method explore random parts of the text space.
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Random
Finally, in order to measure the performance of the aforementioned scoring strategies,
we also implemented a random scoring function that arbitrarily scores each sample.
This amounts to ignoring the active learning framework completely and provides a
baseline to compare the other metrics against.
5.3.4 Quantifying performance
To measure the performance of the active learning procedure using the various scoring
schemes the following was performed: for a given concept c, 10 samples, five that were
known to be positively associated with the concept of interest and five that were not,
were randomly chosen and used for the initial starting set (TK,0). At each of the 500
iterations, the classifier was trained on the set of samples with known labels (TK,i).
The samples with unknown labels (TU,i) were then each scored and the top five highest
scoring samples were then chosen for subsequent labeling. We ran this for each UMLS
concept that we had data for.
In order to ensure reproducibility, we performed cross validation on this active
learning approach. We randomly split the data into 75% training and 25% testing
sets 5 times. All of the active learning was performed on only the training set. The
performance of at each iteration for all of the scoring schemes was measured using
only the testing set. We also ensured that for each split of the data, the starting set
of 10 samples was identical for each scoring strategy.
5.3.5 Performance
Classifier tuning performance
In an attempt to minimize confusion, first let us first examine the actual performance
of the na¨ıve Bayes classifier. In this scenario, the aim is to maximize the predictive
performance of the classifier itself. In other words, we are attempting to answer the
question, “which samples should I annotate next to build the best classifier?” Note,
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that this does not answer the original aim of “which sample is most likely one that I
am looking for?” However, it is clear that this can be viewed as a dual problem. If
we have a good classifier that can predict whether or not something is, for example
a lung sample, then it will be easy to return the next lung sample to be labeled.
However, we don’t actually want to spend the time to build this classifier (since we
do not want to waste time training it), and would rather just have a black box that
gives us the best one to annotate next, regardless of how it affects the performance
of the underlying classifier.
Figure 5-4 depicts the performance of a na¨ıve Bayes classifier across 500 iterations
of active learning. We use the F-measure to report a single value for the performance.
The F-measure is the harmonic mean of precision and recall:
F = 2× precision× recall
precision+ recall
(5.6)
As to be expected, the scoring strategy that performs the best (i.e. shows the
most improvement in the performance of the classifier during the active learning) is
the maximum entropy method. Since this strategy continually picks the samples that
are most confusing the the classifier, it becomes easier and easier as more iterations
are performed. On the other hand minimum entropy and allwithconcept perform the
worst since they continually return concepts that the doesn’t help the classifier learn
something new. Interestingly the mostwithconcept does a lot better than the previous
two; much more on par with random.
Not only is the performance of the text based classification method underwhelm-
ing, it does not really address the underlying problem of sorting the samples in the
most favorable way such that labeling becomes easier. Since we are building a classi-
fier at each iteration of learning, we are actually tuning a classifier instead of tuning
the sorting method. In other words, this active learning procedure attempts to make
the best na¨ıve Bayes classifier at predicting whether, given just the concept indicator
vector, a sample is associated with a certain concept with the fewest number of sam-
ples. Although choosing samples closest to the decision boundary is typically what
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Figure 5-4: The na¨ıve Bayes classifier performance for various sample choosing metrics
for blood samples. Here we see that the only sample scoring method that performs
better than random is maximum entropy. Although this is only one example, the
maximum entropy strategy was generally the best method for all other concepts as
well.
one wants to do when trying to improve the classification accuracy of classifier, in
our application of active learning, we do not want to tune a classifier as we are only
looking to increase the size of the database as efficiently and with as few errors as
possible. In other words, we want to do exactly the opposite of the optimal solution
of finding the samples near the decision boundary (maximum entropy) and return the
samples that we are most sure about.
Database labeling performance
Unlike the previous section which attempted to show the improvement of the classifier
performance, we now turn to examining the performance of how well each of the
scoring strategies fares when we attempt to minimize the number of iterations needed
to label the samples of interest. Again, here we do not care about how well the
underlying classifier performs, but rather want to minimized the amount of work
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Figure 5-5: The performance of the various scoring schemes at the task of returning
samples to be labeled under the assumption that the minimum number of iterations
should be performed. (a) shows the true positive rate across 500 iterations while (b)
shows the fraction of blood samples that were find by the i-th iteration.
the user must perform. What we see is that the methods that performed poorly in
training the classifier, performed well under this metric, and vice versa (Figure 5-5).
For example, using just the results from MMTx and returning those samples,
outperforms both methods that attempt to learn what it means to be a blood sample.
In other words, attempting to use the other UMLS concepts associated with a sample
to try to predict whether or not a new sample is a blood sample performs worse
than just assuming that a sample is a blood sample if MMTx labeled it as such.
Furthermore, the method that works best at building the best classifier the quickest
(maxentropy) performs the worst in this scenario. This makes intuitive sense as
returning the samples that the classifier is least sure about (the ones with the maximal
entropy) are the least likely ones to be blood samples.
As can be seen in Figure 5-5(b), the largest drawback to using only the text based
data is that any sample that is not labeled by MMTx to be of a given type, will most
likely not be picked up. For example, by about the 80th iteration the method that
simply returns the blood samples labeled by MMTx (allwithconcept) goes from being
nearly perfect to random.
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Figure 5-6: We can visualize the performance of the labeling performance of the
various scoring schemes by viewing the labeling progress on the transcriptomic land-
scape. Here we show the labeling progress at iteration 10 and 100 for allwithconcept
and maxentropy. We clearly see that allwithconcept does a much better job of picking
the blood samples (see Section 3.2.1).
We can visualize the performance of the labeling performance of the various scor-
ing schemes by viewing the labeling progress on the transcriptomic landscape. Recall
from Section 3.2.1 that the upper left hand cluster of the transcriptomic landscape
corresponds to blood tissue samples. Figure 5-6 shows the labeling progress at itera-
tion 10 and 100 for allwithconcept and maxentropy. We clearly see that allwithconcept
does a much better job of picking the blood samples. Although we only use the expres-
sion information here as a way to visualize the performance of the scoring methods,
the following section will cover a method to include the gene expression information
to enhance the labeling procedure.
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5.4 Expanding the database using text & expres-
sion data
Although the training of a classifier to improve its classification accuracy, such as the
na¨ıve Bayes classifier in the previous section, is the general use-case for active learning,
it is not exactly what we are after. As aforementioned, we are looking for an optimal
sorting such that an expert labeler has the minimum amount of work to do. While
this sorting can be achieved with a traditional classifier by ordering all unlabeled
samples by they classification confidence, as in the use of the previously detailed
minimum entropy function, we will be examining non-classifier based methods. In
addition to the sorting rather than classifying paradigm shift, gene expression data
will be incorporated to aid in the sorting process.
The two main ways that one could use multiple sources of information to gener-
ate a sorting (or a classification) is either by performing the sorting (classification)
independently for each source of information and then combining them or by first
combining the sources of information together into one rich feature vector and sorting
(classifying) the data based on that single feature vector. Both methodologies have
their relative merits. The former “feature poor” method, allows one to independently
use each source of information and use a domain specific sorting (classification) engine
for the particular source of information. However, this strength is also its weakness
as it requires the tuning of the weights used to combine the independently generated
results and does not allow any possible correlations between the sources of informa-
tion to “boost” the signal during the sorting (classification) process. On the other
hand, the “feature rich” method uses a single sorting (classification) methodology on
one large feature vector allowing the algorithm to “decide” what the relative merits of
each feature are. This method, however, requires the combination of all data sources
into one feature vector as input to a single sorting (classification) method, and is
difficult to apply when the sources of information come from vastly different domains
(such as text and gene expression, for example).
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5.4.1 Scoring strategies
To include both textual and expression data in labeling data, we score each data
type (text and expression) independently and then compute a weighted score based
on a linear combination of the two scores. The score for each sample is computed as
follows:
Score = α× Scoreexpression + (1− α)× Scoretext (5.7)
where α is the weight used to tune the importance of the expression data. As we shall
see, each of the two score components (Scoreexpression and Scoretext) range between
0 and 1, and thus the final combined score also ranges between 0 and 1.
Text based scoring
As we saw in the previous section, a classifier based text scoring method (e.g. using
a na¨ıve Bayes classifier) did not yield favorable results in minimizing the number of
labeling rounds to perform. Thus, we limited our scoring metrics here to two that
were based on the MMTx derived concept annotations. The first scoring method is
identical to the one used in the previous section. Namely, if a sample was annotated
by MMTx to be associated with a concept, it was given a score of 1; if not labeled
with the concept, it was given a score of 0 (scores ranged between 0 and 1 where 1
is the highest possible score). If there were multiple samples with the same score,
a sample was simply chosen at random among them. We call this scoring metric is
binary.
The second variation that was tested was a weighted version (aptly called weighted)
where the weights were based on all of the concepts associated with the samples that
had been previously annotated. The score of a new sample was 0 if it was not labeled
with the concept of interest (e.g. if we were looking for brain samples and the current
sample was not annotated with the concept for brain by MMTx). If it was labeled
with the concept of interest, then the score was a value between 0 and 1 depending
on how similar all of the concepts that it was labeled with were to concepts of those
samples that had already been labeled in previous iterations. Formally, the distance
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between a new sample and a previously labeled sample was computed as the Manhat-
tan distance5 of the of the samples’ concept indicator vectors (see Table 5.4). This
distance was computed to all previously labeled samples, and the score of the new
sample was the mean of all of the Manhattan distances. This method, while still only
yielding non-zero scores for samples that have actually been annotated by MMTx
with the concept of interest, allows for a ranking of samples depending on the other
concepts it was labeled with.
Expression based scoring
The expression based score for each sample is based on its correlation to the samples
that have already been labeled. The correlation was computed using all 20252 genes
measured on the Affymetrix HG-U133 Plus 2.0 array. Thus, samples having a high
correlation to the previously labeled samples with the phenotype of interest have
higher scores than those that have a lower correlation. We shall call this group
of samples that have previously been labeled to be associated with phenotype p of
interest as Sp.
As there is always more than one sample in Sp (we start with five positively
labeled samples), we must summarize the distance of each unlabeled sample s, to Sp.
Two summarization methods were chosen: mean and centroid. When using the mean
method, we simply take the mean distance of s to all samples in Sp. Alternatively,
when using the centroid method we first find the sample in Sp that is closest to the
centroid of Sp and then compute the distance of s to that “centroid” sample
6.
5The Manhattan distance a version of Euclidean distance and is defined as
√∑n
i=1 xi − yi where
x and y are the input vectors. Unlike Euclidean distance, the (xi − yi) is not raised to the power
of two. However, since we are applying this Manhattan to binary indicator vectors, the Manhattan
distance is equivalent to the Euclidean distance.
6The true centroid of a cluster (in this case Sp) is the point that minimizes the distance to all
points in the cluster. Since this is an artificial point and may not actually exist, we find and use the
point in the cluster that is closest to the centroid as the centroid.
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5.4.2 Quantifying performance
To measure the performance of the active learning procedure using the various scoring
schemes the following was performed: for a given concept c, 10 samples, five that were
known to be positively associated with the concept of interest and five that were not,
were randomly chosen and used for the initial starting set (TK,0). At each of the 2000
iterations, the “classifier” was trained on the set of samples with known labels (TK,i).
The samples with unknown labels (TU,i) were then each scored and the highest scoring















Figure 5-7: To ensure reproducibility of the results we performed cross validation.
In each of the runs, 25% of the data was withheld and used as a testing set; the
remaining 75% of the data was used to perform the active learning. At each iteration
in the learning process, we scored the unchosen samples using a weighted score that
was based on both the expression data’s signal and the signal from the text. The
highest scoring samples were then chosen and labeled before repeating the learning
step again.
In order to ensure reproducibility, we performed cross validation on this active
learning approach. We randomly split the data into 75% training and 25% testing
sets 10 times. All of the active learning was performed on only the training set. The
performance of at each iteration for all of the scoring schemes was measured using
only the testing set. We also ensured that for each split of the data, the starting set
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of 10 samples was identical for each scoring strategy.
5.4.3 Performance
As the goal of the labeling task is to be able to label all samples in the database with
a given phenotype as quickly and efficiently as possible, we compute the true positive
rate (sensitivity) and the fraction of positive samples found at each iteration. The
true positive rate at iteration i shows how correct we have been at picking out the
samples of the phenotype of interest p in the last i iterations. For example, if we
have picked 10 samples related to p of interest in 10 iterations, then our true positive
rate at iteration 10 is 1. The fraction of samples found shows how quickly we find all
the samples associated with p. If we have found half of the samples that are truly
associated with p at iteration 20, then the value for the fraction of samples found at
iteration 20 is 0.5.
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Figure 5-8: Database labeling performance for blood samples when using text and
gene expression information. Figure (a) shows the true positive rate, while (b) shows
the fraction of samples found. The three curves are the average across 10 cross
validation runs when we set α, the weight of the expression signal to 0 (red), 0.5
(green), and 1(blue). When the expression data is included (when α is 0.5 or 1), we
are able to label all of the blood samples in the database much faster.
Figures 5-8 - 5-10 depict the sensitivity and the fraction of samples found for three
phenotypes, blood, liver, and lung, when using the binary method for the textual
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Figure 5-9: Database labeling performance for liver samples when using text and gene
expression information. Figure (a) shows the true positive rate, while (b) shows the
fraction of samples found. The three curves are the average across 10 cross validation
runs when we set α, the weight of the expression signal to 0 (red), 0.5 (green), and
1(blue). Unlike the case with the blood samples (Figure 5-8), just using the expression
data (α set to 1) results in poor labeling performance.
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Figure 5-10: Database labeling performance for lung samples when using text and
gene expression information. Figure (a) shows the true positive rate, while (b) shows
the fraction of samples found. The three curves are the average across 10 cross vali-
dation runs when we set α, the weight of the expression signal to 0 (red), 0.5 (green),
and 1(blue). Here is an example were all there methods perform comparatively.
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data and the centroid method for the expression data. Each of the lines in the figures
represents the average true positive rate (sensitivity) or average fraction of samples
found across the 10 cross validation runs for three different expression weights (α set
to 0 (red), 0.5 (green), and 1(blue)). We find that depending on the phenotype, the
utility of the expression data signal varies widely. For example, when labeling all of
the blood samples in the database (Figure 5-8), the expression signal provides the
majority of the signal such that we find almost all blood samples in about 500 labeling
iterations when we set α to 0.5 or 1. On the other hand, when labeling liver samples
(Figure 5-9), the expression signal alone does not perform well. Labeling the lung
samples (Figure 5-10) provides us with an example where the textual information is
initially much better than the expression data, but after about the 700th labeling
iteration, they behave almost identically.
Interestingly, we obtain the best of both worlds when we set α to 0.5. This
suggests, that by combining the textual information with the biological signal from the
expression data, we can quickly and efficiently label new samples to grow an existing
curated expression database. Neither source of information results in consistently
good results when used independently, but when combined we are able to leverage
the strengths of each one. While we only show the results for one of the scoring
method combinations, binary concept vector and centroid based expression distance,
the results for the other combinations of scoring schemes behaved similarly.
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Chapter 6
Drug similarity: A transcriptomic
view
High costs in drug design and development have resulted in the use of computational
methods to help reduce both production time and cost [132]. For instance, Pfizer
recently created a tool that combines multiple sources of data to “visualize” the
drug target landscape in order to generate therapeutical hypotheses about chemical
compounds [20]. Other researchers have taken multiple sources of drug data to predict
drug-drug relationships [49] and provide possible new indications for existing drugs
[122].
The use of gene expression data in providing targeted therapeutics or showing the
effect a drug has on a certain disease has also become common place. For example,
gene expression based high-throughput screening revealed that all-trans retinoic acid
(ATRA) showed clinical promise for a rare subtype of leukemia known as promyelo-
cytic leukemia (APL) [127]. Similarly, gefitinib was shown to induce myeloid differ-
entiation of acute myeloid leukemia in a cell-line based study [126]. To provide broad
access to such gene expression based drug data, the Connectivity Map (CMAP) [69]
was introduced in 2006, and enables researchers to obtain relevant drugs based on
up- and down-regulatad genes (see Section 6.1.1).
After analyzing various of sources of data independently (Section 6.1), we create
a drug-drug similarity network by combing disparate sources of data (Section 6.2).
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Leveraging the tissue specific marker genes introduced earlier (Chapter 4), we show
how we can create tissue specific drug-similarity rankings using a large curated ex-
pression database (as introduced in Chapter 2). As one of the goals of computational
drug analysis methods is to enable targeted therapeutics, we anticipate that methods
such as these can provide the foundation for future researchers.
6.1 Types of drug data
6.1.1 Connectivity Map
The goal of the Connectivity Map (CMAP) is to “provide a generic solution to this
problem by attempting to describe all biological statesphysiological, disease, or in-
duced with a chemical or genetic constructin terms of genomic signatures” [69]. Us-
ing a Kolmogorov-Smirnov statistic based pattern matching strategy, the CMAP
database will return the list of drugs by how closely it resembles the user submitted
pattern of input gene signatures. Ultimately, this is useful if, for instance, we know
a set of genes that are differentially regulated in a certain disease condition that we
hope to find a counteracting drug for. For example, if the we submit the genes g1, g2,
and g3 as up-regulated genes and g4 and g5 as the set of down-regulated genes, CMAP
will return an ordered list of drugs based on how closely they match the given input
pattern of genes. Thus, drugs that very closely match the up- and down-regulation
patterns of the input genes are drugs that mimic the expression response of the dis-
ease, while drugs that have an opposite response could potentially be used to counter
the effects of the disease by repressing the up-regulated genes and over-expressing the
down-regulated ones.
The current version of CMAP is comprised of 7056 microarray samples divided
into 956 controls and 6100 drug treatment samples. These 6100 samples correspond
to a total of 1309 unique drugs performed across five difference cell lines (Table
E.1). The control samples are used by CMAP to generate difference profiles for each
treatment sample by subtracting the baseline expression of an untreated sample from
128
HL60 MCF7 PC3 SKMEL5 ssMCF7 Total
HG-U133A 396 218 148 22 23 807
High Throughput HG-U133A 1010 3149 1870 0 0 6029
High Throughput HG-U133A EA 0 220 0 0 0 220
Total 1406 3587 2018 22 23 7056
Table 6.1: Cross-tab of the number of CMAP samples that were performed on the
various gene expression platforms and the corresponding cell lines.
the expression of samples that were treated with a drug compound. Unlike many
expression studies that try to minimize the technical variables, not only where these
samples performed on three different platforms and two different mediums (Tables
6.1, 6.2 and Appendix E), there is also a wide discrepancy in the number of times a
particular drug’s expression response was measured (Table 6.2). For example, there
are a total of 182 trichostatin A samples while only a single sample for drugs such as
cantharidin and gefitinib.
Although there are some discrepancies in the CMAP data, researchers have used
the Connectivity Map for such things as to find potential therapeutic agents for colon
cancer [42], for cancers that have become resistant to chemotherapy [106], and to
discover possible treatments for diseases that affect particular pathways [110]. More
recently Sirota et al. [122] generated disease profiles from public expression data and
validated the drug cimetidine for use in treatment for lung adenocarcinoma in a mouse
model.
Batch effect in CMAP
Before using the data provided by CMAP, we performed some data validation. Using
the transcriptomic landscape detailed in Chapter 3, we plotted all of the raw CEL file
data used by the Connectivity Map onto this landscape (Figure 6-1). Unsurprisingly,
what becomes immediately apparent is the cell line effect. Regardless of the drugs
that the samples were treated with, the dominant signal is the tissue of origin (Figure
6-1(a)). A second “batch effect” is related to the platform that the experiment was
performed on. As can be seen by the HL60 cell line samples (in red in Figure 6-
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HL60 MCF7 PC3 SKMEL5 ssMCF7 Total
trichostatin A 34 92 55 0 1 182
tanespimycin 12 36 12 1 1 62
LY-294002 13 34 12 1 1 61
valproic acid 14 31 10 1 1 57
sirolimus 10 25 8 0 1 44
fulvestrant 6 21 12 0 1 40
estradiol 8 19 8 0 2 37
haloperidol 7 19 6 0 0 32
monorden 4 12 5 1 0 22
tretinoin 5 13 4 0 0 22
thioridazine 4 11 5 0 0 20
chlorpromazine 4 11 4 0 0 19
fluphenazine 4 10 3 1 0 18
wortmannin 4 10 2 1 1 18
clozapine 4 10 3 0 0 17
genistein 3 11 3 0 0 17
alpha-estradiol 3 9 3 0 1 16
prochlorperazine 4 9 3 0 0 16
trifluoperazine 4 9 3 0 0 16
troglitazone 4 7 4 1 0 16
15-delta prostaglandin J2 3 8 3 1 0 15
geldanamycin 3 10 2 0 0 15
nordihydroguaiaretic acid 3 8 2 0 2 15
rosiglitazone 4 7 3 0 0 14
acetylsalicylic acid 3 8 2 0 0 13
alvespimycin 3 7 2 0 0 12
vorinostat 3 7 2 0 0 12
pioglitazone 0 6 5 0 0 11
metformin 1 7 2 0 0 10
naproxen 2 4 3 0 0 9
Table 6.2: Cross-tab of the number of CMAP samples that were performed for the
top 30 most frequent treatments and their corresponding cell lines.
1(a)), they are distinctly separated by the array type in Figure 6-1(b). Since this
clear separation is seen when the CMAP samples are viewed in the context of the
transcriptomic landscape, it is not surprising that we see the same clustering by cell
line type and array technology when we perform the PCA analysis solely on the 7056
CAMP samples (Figures 6-1(c) and 6-1(d)).




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































l l lll ll
llll
lll








































































































































































































































































































































































































l l lll ll
llll
lll



















































































Figure 6-1: The 7056 samples (processed directly from the raw CEL files) from CMAP
plotted on the transcriptomic landscape and (b) colored by the array technology
and (a) cell line types that were used. Figures (c) and (d) depict the principal
component analysis of just the 7056 CMAP samples without mapping it in to the
transcriptomic landscape. We see the same pattern of clear separation by cell line
and array technology.
to just those performed on the MCF7 breast cancer cell line and using the high
throughput HG-U133A array, we see that the samples group together by the batch in
which they were performed. Although these sorts of batch effects are not uncommon
in expression studies, it points as to why the method used by the Connectivity Map
uses differential profiles based on a control for each batch. Furthermore, these strong
131
data artifacts mean that any subsequent analysis of this data must also use some sort









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6-2: The first two principal components of the ranked raw expression data
performed using the MCF7 breast cancer cell line on the high throughput HG-U133A
array show such that each point in the figure is a sample and the color depicts the
batch it originated from. There is a distinct batch effect even when we restrict the
expression samples to only one cell line and one platform.
Thus, in order to contend with the multitude of experimental parameters (various
expression platforms, cell-line types, etc)˙ we limited our subsequent analyses to only
the difference profiles for the 3149 samples performed on the high throughput HG-
U133A platform using the MCF7 cell line. This subset of data only used DMSO as
the medium treating the cell-lines with the small molecule compounds. Although this
is less than half of the data that is available in CMAP, it represents the largest subset
of data that was performed on the most similar of experimental conditions.
After the initial trimming of samples, we performed a first pass analysis on the
difference profiles that CMAP uses to perform its analysis. Interestingly, the first
two principal components of a PCA analysis of the samples across all genes generates









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6-3: The first two principal components of the difference profiles of the MCF7
samples reveals two distinct clusters. (a) The bottom cluster is mainly comprised of
samples treated with trichostatin A and at first glance appears to indicate a “tricho-
statin A signal.” Unfortunately, we see four other trichostatin A samples in the main
cluster and thus indicates that this may be an artifact of the data rather than a novel
finding. (b). Shows the the clusters colored by batches. There does not appear to be


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6-4: Unlike the two clusters that resulted from the PCA analysis of the MCF7
data (Figure 6-3), the first two principal components of the PC3 cell line data reveals
one single cluster. (a) Coloring the samples that were in the bottom cluster in the
MCF7 PC plot shows that they can be found in the middle of the cluster of PC3
samples. (b). Coloring the plot by batch does not reveal and clear “batch effect.”
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treated with trichostatin A have a very different expression profile compared to all
other treated samples. Unfortunately, not only do we find four other trichostatin
A samples in the midst of all other treated MCF7 samples, this same finding not
recapitulated in the PC3 cell line data (Figure 6-4(a)). If we examine the batches
that these samples originated from (Figures 6-3(b) and 6-4(b)) it does not seem to
indicate a single “bad apple.” Although a previous study found a relationship between
the drugs found in the bottom cluster [58], as we could not verify the cause of this
clustering, the 86 samples corresponding to the bottom cluster were also removed
from subsequent analyses.
6.1.2 DrugBank
Unlike the Connectivity Map that contains the expression response of various cell lines
to different small molecule compounds, DrugBank [63] is a database that contains
various information such as the chemical formula, indication, toxicity, manufactures,
and target genes for 6707 small molecule and drug compounds. While it does not
contain any biological data like CMAP, it can be an integral source of information. For
example, PREDICT [49], a method for identifying drug relationships, makes heavy
use of the data available in DrugBank.
Drug target gene relationship network
One interesting piece of information provided by DrugBank is the set of genes that a
given drug targets. These target genes are the genes corresponding to the protein(s)
that a drug targets. Using this information one can perform various genomic studies
to quantify the relationships between various drugs. Without any additional sources
of data, we can create a drug relationship network based on the number of target
genes that they share. The intuition here is that drugs that have similar gene targets
should have a similar purpose. Such a target gene relationship network is depicted in
Figure 6-5 in which each node represents a drug and an edge exists if the two drugs
it connects have five or more target genes in common. The nodes of the network are
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Figure 6-5: A drug relationship network based on common target genes of drugs.
Each node depicts a single drug and an edge is drawn between two drugs if they
have at least 5 target genes in common. The weight of the edge indicates a relative
measure of how many target genes two drugs have in common. The nodes are colored
by the Anatomical Therapeutic Chemical Classification System (ATC) code for that
drug. There is distinct clustering by the ATC code of what the drug is indicated to
be used for.
colored by the Anatomical Therapeutic Chemical Classification System1 (ATC) code
for that drug. Interestingly, we see clear groupings of many cardiovascular drugs.
represented as green nodes, and of drugs that are related to the “nervous system”
(anesthetics, anti-parkinson drugs, psycholeptics, etc.), which are represented as pink
nodes. Furthermore, we see that many anti-neoplastic drugs cluster together (circular
cluster of light purple nodes near the bottom of the figure). We will expand on this
1The ATC codes are a system of alphanumeric codes developed by the World Health Organi-
zation to classify drugs and other medical products that has 14 main groups: “Alimentary trac-
tandmetabolism”, “Bloodandblood forming organs”, “Cardiovascular system”, “Dermatologicals”,
“Genito-urinary systemandsex hormones”, “Systemichormonalpreparations, excluding sex hormones
and insulins”, “Antiinfectivesfor systemic use”, “Antineoplasticandimmunomodulatingagents”,
“Musculo-skeletal system”, “Nervous system”, “Antiparasiticproducts,insecticidesandrepellents”,
“Respiratory system”, “Sensory organs”, and “Various”.
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introductory analysis in Section 6.2.
Drug target genes and CMAP expression
DrugBank
1823






Figure 6-6: The overlap of drugs in the DrugBank database and those in CMAP.
Distribution of Differential Expression Values
















Figure 6-7: The distribution of differential expression ranks in CMAP for the genes
deemed to be the target genes according to DrugBank.
In an effort to ascertain the effect a drug has on the gene expression of the genes
corresponding to the protein that it targets, we analyzed the target genes in DrugBank
[63] and their expression patterns in the Connectivity Map. Of the 6826 drugs present
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in DrugBank, 4268 of them had gene target information that corresponded to a human
NCBI Entrez gene identifier. Of these, 4672 are represented in CMAP (6-6). The
mapping between DrugBank and CMAP was done by simple string matching; if the
drug had the same name (ignoring capitalization) in both DrugBank and CMAP, it
was deemed to be the same drug. Using the differential expression profiles provided by
CMAP, Figure 6-7 depicts the distribution of the ranks of gene expression differences
in CMAP for the genes that are deemed to be the target genes for the corresponding
treatments. A low rank indicates that the difference between the expression value in
the treatment and control samples was the small, while a high rank indicates that
the differential expression was substantial. In other words, if a particular drug’s
effect on expression is high, then it should have a high rank. As a baseline, we
compare these ranks with 100 distribution of ranks obtained by randomly selecting
target genes for each drug (in red). What we find is that there is no clear evidence
for a statistically significant effect on expression when examining the target genes in
combination with the CMAP difference profiles. Interestingly, the random sampling
indicates (unsurprisingly) a uniform distribution of differential expression ranks, while
the actual distribution of target gene expression difference ranks looks approximately
normal.
6.2 Drug similarity networks
As we were not able to draw any broad conclusions from the transcriptomic differences
caused by the drugs’ effects on the target genes using the CMAP data, we turned
to a more fine-grained approach. As we had done when generating the target gene
relationship network (Figure 6-5), we created similarity networks for drugs based
on various sources of information. This type of network analysis was previously
employed in such endeavors as generating a human disease network [46] and finding
relationships between phenotypes and genotypes [19]. The underlying assumption is
2Recall that although CMAP contains expression information for 1309 different small compounds,
we are only using the data corresponds to the subset of samples performed using the MCF7 cell line
on the high throughput HG-U133A array.
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that drugs have various properties, and each of these properties can provide a source
of information about how similar two drugs are. For example, if two drugs target the
same genes, they are probably more similar than two drugs that do not.
6.2.1 Similarity measures
Although there are a plethora of possible similarity measures for drugs, we used five
metrics that were based on chemical structure, drug target genes, and the drug’s
effect on expression.
Atom pair distance
The first measure of similarity that we used was atom pair distance, which is “defined
in terms of the atomic environments of, and shortest path separations between, all
pairs of atoms in the topological representation of a chemical structure.” [21] Atom
pair distances have become widely used in searching for chemical compounds in large
databases and virtual screening efforts [62] as they provide a metric for computing
the similarity between chemical compounds based on it’s atomic structure. For the
purpose of this work we used the R interface of the publicly available ChemMine
toolkit [10] called ChemminR to compute the atom pair distances between the chem-
ical compounds found in DrugBank. We shall refer to this distance as the atom pair
distance or structure distance.
Target gene based distances
We employed three distance metrics based on the target genes for the drugs. First, we
computed the similarity between two drugs based on the number of target genes they
have in common. To account for varying numbers of target genes for different drugs,
we used the Jaccard index. The Jaccard index of two drugs X and Y with respective
set of target genes x and y is the number of intersecting target genes divided by the
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number of total target genes. Mathematically, that is:
JIX,Y =
x ∪ y
x ∩ y (6.1)
In other words, drugs that target all of the same genes have a Jaccard index of 1,
while those that target completely disjoint sets of genes have a Jaccard index of 0.
We shall refer to this distance as the target gene overlap distance.
Another source of information provided by DrugBank is the target protein family
(Pfam) domain [123] that the drug targets. Briefly, Pfam is a database that contains
evolutionarily related proteins (protein families) and provides the multiple sequence
alignment and hidden Markov model (HMM) for the the proteins in each of the
families. Using the Pfam domains that each of the drugs target, we can compute
the Jaccard index (in the same fashion as with the target genes), to compute the
similarity between two drugs.3 This distance metric will be referred to as the Pfam
overlap distance.
The final target gene based distance uses the target genes for each drug in con-
junction with a protein-protein interaction (PPI) network to see how close the target
genes are. For this, we employed the curated PPI network data that was used for
IsoBase [96]. The distance between two drugs X and Y with respective set of target
genes x and y is the minimum number of hops in the PPI network between any of




Here we try to capture a more abstract sort of similarity between the target genes
that takes into account how these genes (well, the proteins that theses genes encode
for) interact. Even if two drugs have differing target genes, if those genes are very
close together in PPI space (it could be the case the drug X’s target genes directly
3Although we did not perform this in this work, a future step would be to not just use the direct
Pfam domain hits by the drug, but also include similar Pfam domains. Expanding the data as such,
we could hope to find other genes that this drug may bind to due to non-specific binding.
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interact with one or more of drug Y ’s target genes) then these two drugs should be
considered similar. We shall refer to this distance metric as PPI distance.
Expression effect distance
The final source of similarity metric is the effect the drug has on expression. Here
we made use of the CMAP [69] data and computed the correlation of each drug’s
expression difference profile (see Section 6.1.1) to all others. Thus, drugs that have
highly correlated difference profiles should be more similar as they have a similar
effect on gene expression. Again, it is important to note, that due to the various
dataset effects in the CMAP data, we only used the data corresponding to the sam-
ples performed using the MCF7 breasts cancer cell line and performed on the high
throughput HG-U133A platform. This final distance metric will be referred to as
expression distance.
Restricting the similarities
As each of the above similarity metrics produces a similarity measure for all pairs
of drugs, the network representation would yield a fully connected graph. As this is
completely uninformative, we discarded any similarity score that was below a 95%
cutoff. Although there are other methods of defining a cutoff as to the amount of
similarity is to be deemed as significant, we chose to use a simple percentile cutoff to
ensure that each of the networks had roughly the same number of edges.
6.2.2 Comparing the similarity networks
Given a matrix of similarity scores (in our case, we have five matrices, each corre-
sponding to one of the aforementioned scoring metrics), we convert it to a network
representation by drawing an connection (edge) between two drugs (nodes) such that
the weight of the edge is the similarity score. Note, since we restricted the similarity
matrices to only contain the top 5% of the scores, we are not left with a complete
graph. After having converted each similarity matrix into a graph, we then examined
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Figure 6-8: A pairwise comparison between all five types of similarity networks.
Each bar represents the number of edges in the respective network such that light
blue part of the bar corresponds to the number of edges shared by the two networks
being compared and the other two colors are the remaining edges in the network.
how much overlap there is between the five similarity measures by counting the num-
ber of edges that were shared among the various networks. Figure 6-8 depicts the
pairwise similarities between all five networks where we count the number of edges
that are common in both networks. Each bar in the graph represents a comparison
between two networks such that the light blue segment at the bottom is the number
of edges that they had in common. As to be expected, the three networks that had
the most in common were those that were derived from the same source informa-
tion: target gene overlap, Pfam overlap, and PPI. Interestingly however, all of these
distance metrics are at least 50% different from each other. The distance metric
that provided the most differing set of similarities was the expression based distance.
Thus, it appears that the structural similarity of a drug is more closely aligned with
the genes that it targets.
6.2.3 Consensus similarity network
While examining each similarity network in isolation can provide insights as to how
similar drugs are in the particular domain the similarity score was computed for, by
aggregating the results across multiple networks we can see which drugs are similar
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in more than one domain. We call this “stacking” of similarity networks a consensus
network. To generate a consensus network we take each of the five aforementioned
networks and convert the similarity score matrices into binary indicator matrices such
that there is a 1 if the edge exists in that network, and 0 if it does not. Recall, that we
previously limited each of the similarity networks to only contain the top 5% of the
edges and thus we will not obtain a complete graph. By adding these binary indicator
matrices we are left with a consensus matrix that contains numbers between 0 (no
edge between the two drugs) and 5 (all similarity networks said these two drugs were
similar).
Figure 6-9: A consensus similarity network such that each node represents a drug
and an edge exists between two drugs if they were found to be similar (i.e. had an
edge) in at least 3 of the 5 independent similarity networks. The weight of the edge is
relative to the number of networks that contained the edge; it is thickest when all five
networks deemed the two drugs connected by the edge to be similar. The coloring
of the nodes indicate interesting highly connected clusters. For example, the drugs
represented by the purple nodes (bottom right) are mostly anti-inflammatory drugs
while many of the drugs in yellow cluster are adrenergic beta-antagonists.
Further restricting our view of drug similarity to only keep the edges that are
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present in three or more of the similarity networks (we shall refer to this as the 3,5
concensus network as it contains at least three out of the five independent networks),
we are left with a network that looks like Figure 6-9. As before, each node in the
network represents a drug and there is an edge between two drugs if it was deemed
similar (in this case in at least 3 of the 5 independent similarity networks). The
weight of the edge is relative to the number of networks that contained the edge; it
is thickest when all five networks deemed the two drugs connected by the edge to be
similar. The coloring of the nodes indicate interesting highly connected subgraphs
clusters such that the subgraph has an edge connectivity of more than half of the
number of nodes in the subgraph [52]. For example, the drugs represented by the
purple nodes (bottom right) are mostly anti-inflammatory drugs while many of the
drugs in yellow cluster are adrenergic beta-antagonists. Also of note, the uncolored
subgraph that is above the purple component consists of many hypoglycemic agents.
Drugs Similarities
rimexolone, budesonide, and fluocinonide Anti-inflammatory glucocorticoid steroids.
atropine, mepenzolate bromide, and
difenidol
Atropine and mepenzolate bromide are
both parasympatholytics (anti-muscarinic)
while mepenzolate Bromide and difenidol
are both diphenylmethanes.
carteolol, nadolol, and levobunolol All beta blockers. carteolol and nadolol are
used for treatment of angina, arrhythmia,
and hypertension.
testosterone and cyproterone Cyproterone suprresses testosterone
daunorubicin and dauxorubicin Chemotherapy drugs; Anthracycline an-
tibiotics
irinotecan and camptothecin Anticancer; irinotecan is an analog of
camptothecin
selegiline and pargyline MAO-B inhibitors
Table 6.3: The set of related drugs when we enforce that the drugs be similar using
all five similarity metrics.
When we require that there be an edge between two drugs in all five networks (i.e.
complete consensus, or a 5,5 consensus network) we are left with three subgraphs
containing three drugs each along with several drug pairs (Table 6.3). It is worth
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noting that these drugs are indeed very similar to each other and that there are
examples of these drugs used together. For instance, daunorubicin and dauxorubicin
are used in chemotherapy [9] and were part of a Phase III clinical trial for AIDS-
related Kaposi’s sarcoma [44].
6.2.4 Potential applications
It is promising to see that the use of a method based on the consensus of similarity
across a wide range of drug properties (structure, target genes, and effect on expres-
sion) can provide us with a way to glean new insight into the relationship between
various drugs. By expanding this work to include such things as side-effects we could
not only infer the similarity of drugs, but possibly provide potential alternatives to
existing drug therapies. Furthermore, it could also point to novel applications of
existing drugs to treat conditions that they were not initially indicated for. Unlike
other methods that are based on predicting drug class [49], the use of a network allows
researchers to effortlessly explore the connections between drugs.
As additional example, in the original CMAP paper [69], put forth two interesting
drug associations as “test cases.” First, 17B-estradiol (ER ligand) was analyzed
and found to be similar to estradiol, fluvestrant and genistein. Indeed, using our
3,5 consensus network, we see that estradiol, fluvestrant, and dienstrol (also an ER
agonist) are in a clique. Furthermore, we find that genistein is connected to dienestrol,
thus recapitulating their findings. Their second example made use of phenothiazine
for which they had strong similarity findings for trifluoperazine, thioridazine, and
fluphenazine. They, however, were only able to find a weak association to another
anti-psychotic drug, haloperidol. When we searched for these drugs in our consensus
network, we were able to not only recapitulate their findings, but also show a clear
connection between fluphenazine and haloperidol.
Although clinical applications of this method is still distant, an expansion of this
type of analysis that allows researchers to layer various similarity measures upon each
other to find interesting connections between drugs may well aid in finding new uses
for existing drugs or finding better alternatives to therapies with detrimental side
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effects.
6.3 Leveraging Concordia stem cell marker genes
We showed in Section 4.4 how we can make use of 189 stem cell marker genes to not
only stratify pluripotentiality and malignancy, but also to provide clinical gradings
for various types of tumors. Naturally, one would inquire as to how these genes
fair in the context of the Connectivity Map. As the stem cell marker genes were
derived from data performed on the HG-U133 Plus 2.0 array, there unfortunately is
not a complete overlap with the set of genes for which data is available in CMAP
(which was performed using the HG-U133A array). As such, the following analysis is
performed using only the 140 genes out of the 189 genes that were common to both
platforms.
6.3.1 Stem cell genes as a CMAP query
The first, and most na¨ıve, analysis that we can perform with these genes is to perform
a traditional CMAP query with these genes. As CMAP requires a list of up- and
down-regulated genes for its input query signatures4, we computed mean difference
of expression for the each of the 140 genes as compared to the background expression
intensity. For example, one of the marker genes in the list is FGF2 fibroblast growth
factor. To compute whether FGF2 is up- or down-regulated in stem cells, we took
all samples associated with stem cells (the same ones used to derive the stem cell
marker gene set) and computed the mean expression for FGF2. Similarly, using all
samples not associated with stem cells we computed the mean background expression
for FGF2. The set of up-regulated stem cell genes was thus the ones that had a
mean expression level greater than the background, and conversely, the set of down-
regulated genes were those that had a mean expression that was lower than the
4The default CMAP tool (http://www.broadinstitute.org/cmap/) requires probe level iden-
tifiers for its input query signature. To perform this query based on the stem cell marker genes, we
set up a local instance of CMAP and summarized all of the probe level data from CMAP to gene
level data (each gene’s value is the mean of all probe values for that gene). Other than this gene
level summarization, our local instance is identical to the original online tool.
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background.5 Table E.5 contains the set of 140 genes along with their respective
mean differences from the background distributions.
The result of a CMAP query is a sorted list of the 6100 treated samples in the
CMAP database such that those with the highest “similarity” to the input gene sig-
nature are those that have all of the up-regulated input genes up-regulated and all
of the down-regulated input genes down-regulated. As such, the treatments corre-
sponding to those samples can be viewed as having the same effect as the input gene
signatures. Conversely, if we are searching for a treatment that has the opposite effect
of the input gene signature (i.e. if we are looking for a drug that undoes the transcrip-
tomic effect of a particular disease) then the treatments that are most “dissimilar,”
having the up-regulated input genes down-regulated and the down-regulated input
genes up-regulated, are of interest. Since we saw that the stem cell marker gene set is
related to malignancy, we would thus want to find the most “dissimilar” treatments
that undo what the cancer does. Note, as we are using the traditional use-case of
CMAP, we are including all 6100 treatment samples regardless of cell line and array
technology that was used.s
When we perform the CMAP query with the 109 up-regulated and 31 down-
regulated stem cell maker genes we find that the treatments that occur most frequently
in the top 50 “dissimilar” (i.e. undoes what the stem cell signature does) samples are
trichostatin A, LY-294002, trifluoperazine, and sirolimus. For instance, trichostatin
A inhibits histone deacetylase (HDAC) enzymes and inhibits cell cycle during the
beginning of the growth stage. It has also recently been shown to have a potential for
the regulation of hematopoietic progenitor/stem cell frequencies [92]. LY-294002 is a
derivative of quercetin, which, according to the American Cancer Society, “has been
promoted as being effective against a wide variety of diseases, including cancer.”6
However, they also state that there is no clinical evidence that shows that it can
prevent or treat cancer. Similarly, trifluoperazine has been found to inhibit DNA
repair to induce cell death in non small cell lung carcinoma [98] while sirolimus has




been shown to block cell cycle in keratinocyte stem cells [60]. Although this analysis
is far from conclusive, it is promising to see that stem cell marker genes found using a
large heterogeneous database of gene expression data indeed are related to drugs that
have previously been implicated to affect the cell cycle process and in the treatment
cancer treatment.

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 6-10: To examine the four drugs (trichostatin A, LY-294002, trifluoperazine,
and sirolimus) from the previous section, we took the (a) 6100 difference profiles and
the (b) 2740 MCF7 samples performed on the high throughput HG-U133A array and
computed their first two principal components using only the 140 stem cell marker
genes. Interestingly wee see that the majority of the samples for the four drugs appear
in one localized neighborhood of the plot.
Instead of using the the stem cell marker genes to form an input query to CMAP,
we can use them as a lens to view the CMAP difference profiles (just like we used
the breast gene set to view the metastasized breast cancer samples in Section 4.3).
To further examine the results from the previous section, we took the 6100 difference
profiles and computed their first two principal components using only the 140 stem
cell marker genes7 and overlaid the location of the samples that were treated with
7Note, we are only using 140 because this is the set of genes of the 189 stem cell marker genes
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trichostatin A, LY-294002, trifluoperazine, and sirolimus (Figure 6-10). Regardless of
whether we use all of the 6100 profile samples available in CMAP (Figure 6-10(a)) or
restrict our view to just the 2740 that were performed using the MCF7 breast cancer
cell line on the high throughput HG-U133A array (Figure 6-10(b)), the samples for
the four drugs appear to be localized in one neighborhood of the plot.
If we then identify the treatments of the samples in the local neighborhood of
the upper left corner (PC1 < 2 and PC2 > 2) of the PCA plot in Figure 6-10(b)
we find HDAC inhibitors such as scriptaid and vorinstat(Table 6.4). Furthermore
thioridazine, trifluoperazine, and chlorcyclizine were found to reverse chemotherapy
resistance in KB carcinoma8 cells [4]. Although it is hard to draw conclusions about
the treatments that have only a few samples, it is interesting to see HDAC inhibitors
and cancer therapy drugs such as gefinitib in the local neighborhood of drugs that
we previously found to be related to cell-cycle and cancer therapy using the CMAP
query signature in the previous section.
that are present on both the HG-U133A and HG-U133 Plus 2.0 arrays.
8KB carcinoma cells are a cell line derived from a human carcinoma of the nasopharynx.
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Drug In Neighborhood Total Percentage
scriptaid 3 3 1
MS-275 2 2 1
quinostatin 2 2 1
cantharidin 1 1 1
dexverapamil 1 1 1
gefitinib 1 1 1
HC toxin 1 1 1
oxamic acid 1 1 1
PHA-00665752 1 1 1
tyrphostin AG-1478 1 1 1
vorinostat 11 12 0.92
trichostatin A 154 182 0.85
amantadine 3 4 0.75
daunorubicin 3 4 0.75
emetine 3 4 0.75
etoposide 3 4 0.75
ouabain 3 4 0.75
perhexiline 3 4 0.75
suloctidil 3 4 0.75
fendiline 2 3 0.67
latamoxef 2 3 0.67
nystatin 2 3 0.67
reserpine 2 3 0.67
rifabutin 2 3 0.67
STOCK1N-35215 2 3 0.67
terfenadine 2 3 0.67
LY-294002 38 61 0.62
thioridazine 12 20 0.6
trifluoperazine 8 16 0.5
chlorcyclizine 3 6 0.5
Table 6.4: The top 30 treatments (by percentage) of the treatments found in the upper
left neighborhood of Figure 6-10(b). The first column indicates the number of samples
that were found in the neighborhood while the second indicates the total number of
samples in all of CMAP for that drug. Although it is hard to draw conclusions about
the treatments that have only a few samples, it is interesting to see HDAC inhibitors
such as scriptaid and vorinstat in a neighborhood of drugs that we previously deemed
to have an effect on cell-cycle and cancer.
6.4 Drug target genes and Concordia expression
While the Connectivity Map [69] provides a laudable piece of work that allows for
finding potential therapeutic agents for various conditions, its greatest asset (the
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difference profile) is also it’s greatest weakness. Although they attempt to treat
various cell lines with different chemical compounds, it is not possible for them to
perform a gene expression experiment for each drug on every type of tissue. For
example, just because a drug caused the up-regulation of a certain gene in the MCF7
breast cancer cell line, that does not mean it will have the same effect on lung tumor
tissue sample. However, if one hopes to repurpose existing drugs (or even screen
novel compounds that have yet gone to market), it is imperative to be able to see
their potential effect on expression in the context of different tissues.
As such, what we need is a way to quantify the importance of a drug in the context
of various tissues. In Chapter 3 we detailed a method of curating the publicly available
gene expression samples in the NCBI Gene Expression Omnibus (GEO) [13] which
we then used in Chapter 4 to generate tissue specific marker gene scores. Using this
framework, we can provide a tissue specific view of the effects of a drug.
6.4.1 Concordia marker gene scores to examine drug target
genes
In two earlier sections of this chapter (Sections 6.1.2 and 6.2) we showed how we can
use the target gene information of a drug provided by DrugBank [63] to generate
drug relationship networks. Here we want to identify whether the target genes of a
drug are genes that are implicated as being marker genes for the tissue in which the
disease that the drug addresses occurs. Stated another way, we want to see whether
the drug is targeting genes that are deemed “important” in the tissue in which the
disease occurs.
To test whether the target genes of drugs are indeed related to tissue specific
marker genes, we took 121 drugs across five drug classes (hypoglycemic agents, anti-
inflammatory agents, antipsychotic agents, HMG-CoA reductase inhibitors, and an-
tineoplastic agents) as indicated by DrugBank [63] and examined the marker gene
scores (see Section 4.1) of their target genes for various types of tissues. More specifi-


































































































































































Figure 6-11: A heatmap of the drug target gene marker gene scores. Each row
corresponds to one of the 121 and each column a tissue type. The color of each
i, j entry corresponds to the marker gene score for that target genes for drug i in
tissue type j such that red is low and yellow/white is high. Interestingly, many of
the hypoglycemic agents’ target genes have high marker gene scores in kidney tissue
while anti-psychotics have high marker gene scores in liver tissue.
gene scores for each of it’s target genes for each tissue. For example, the drug Tem-
sirolimus used to treat advanced renal cell carcinoma has one target gene, MTOR.
We then compute the marker gene score for MTOR for each tissue type and compute
the z-score of MTOR’s marker gene score as compared to the marker gene scores for
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all other genes for each tissue type. If a drug has more than one target gene (many
of them do), we take the the maximum value as this indicates the drug’s maximum
possible affect on a marker gene for that tissue (Figure 6-11).
Several insights can to be gleaned from this. First, many of the hypoglycemic
agents have high target gene scores in the kidney, one of the two organs in which
insulin is removed from the body (the liver is the other organ). When we examine
these hypoglycemic drugs more closely, we see, for example, that glyburide’s target
genes have a high marker gene score for adrenal gland tissue. Interestingly, it is known
that glyburide may cause adrenal insufficiency. Secondly, many antipsychotic drugs
appear to have an affect on genes with high marker gene scores for the liver. It has
been shown that a significant number of patients treated with antipsychotic drugs
have alterations of liver function tests [41]. Furthermore, Imatinib, a drug used treat
certain types of leukemia, is currently in phase II clinical trials for treating ovarian
cancer [1]; in Figure 6-11 we see a clear indication that Imatinib targets genes related
to expression activity in the ovary. Interestingly, the drug that had the highest target
gene score for the adrenal gland (and the highest overall scoring target gene score)
was Mitotane, a drug that is used to treat cancer in the adrenal gland. Although these
results only pertain to a small fraction of the available drugs and possible tissue types,
we see that by combining the marker gene score data from Chapter 4 we can provide
new insight into the workings of drugs on a molecular level without performing any
new gene expression study.
6.4.2 Drug target gene expression correlation
In the previous section we explored the “marker geneness” of the target genes of drugs
and showed that in several instances the target genes of drugs indeed are related to
marker genes for various tissues. While that analysis provides useful insight as to
how “important” the target genes of a drug are for various tissues, it does not give
us a way to easily compare different drugs under different tissue conditions. In other
words, it doesn’t address whether the target genes of drugs act in a more coordinated
fashion in one tissue than another. Furthermore, it doesn’t allow us to provide a
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ranking of how similar other drugs are to a given drug in different tissue contexts.
Computing the tissue specific drug target gene similarities
Figure 6-12: We compute the similarity between two drugs by computing the “dif-
ference” in the observed distribution of expression correlations for the pair’s target
genes as compared to the correlation distribution of random samplings of genes.
To compute tissue specific drug similarity scores for drugs we take each drug
pair and compute the expression correlation of their target genes and compare how
the distribution of these correlations differs from random (Figure 6-12). Since we
are only interested in the “cross-talk” between the target genes for the two drugs,
we only examine the expression correlations in the upper right hand corner of the
correlation matrix (i.e. the intersection of the correlations of the target genes for drug
pair of drugs). We then take these gene-gene correlation scores and convert their
distribution into a cumulative density function (CDF) which is then compared to the
expression correlation CDFs of random samplings of genes equivalent in number to
the observed set. We ensure that if the drug pair being tested has any target genes
in common, that the number of overlapping genes in the random set is equivalent to
the number in the drug pair’s target genes. We then compute the z-score (standard
score) of the observed CDF as compared to the mean and standard deviation of the
randomly generated CDFs at fixed intervals. We set the fixed intervals to start at a
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correlation of 0 and increment the interval by 0.01 each time yielding a total of 100
z-scores between a correlation of 0 and 1. This method is very similar to computing
the Kolmogorov-Smirnov (KS) statistic but can be done more efficiently. If the sum
or the z-scores is negative (i.e. the observed CDF is shifted to the right of the random
CDFs) then the target genes of the two drugs are more correlated than by random
chance. The more negative, the more significant the result. If, on the other hand the


































Figure 6-13: The CDFs of the correlations distribution of (a) haloperidol vs. molin-
done’s and (b) haloperidol vs. voglibose’s target genes and their immediate PPI neigh-
bors. The black line in each of the plots depicts the actual CDF of the distribution of
correlation while the yellow line depicts the mean of 100 randomly sampled correla-
tion distribution CDFs. The red lines depict each of the 100 random CDFs that were
generated. In both cases we used the gene-gene correlations as computed using only
the brain tissue samples. (a) shows an example of two drugs that have target genes
who’s expression is more correlated than random while (b) depicts the opposite.
We also extended the above method to not just incorporate the target genes of each
of the drugs, but also their immediate neighbors in protein-protein (PPI) interaction
space. In other words, if a drug is indicated as having a single target gene, we find
all neighbors of that target genes in the PPI network and add them to the list of the
drug’s target genes. Again, we used the same PPI network data that was used for for
IsoBase [96]. The intuition for this is that it is not just the coordinated expression of
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only the exact targets of a drug that is important, but also the coordinated expression
of the genes that are interaction partners.9
Thus far we have not talked about how we get tissue specific drug similarities. To
account of different tissues, the gene-gene correlations that were used to compute the
drug similarities were generated by using different subsets of the manually curated
gene expression data (see Chapter 3) we obtained from GEO [13]. For example, to
see how related the effect of a drug is in brain tissue, we computed the gene-gene
correlations using just the gene expression samples corresponding to brain tissue.
As an example, Figure 6-13 depicts the CDFs of the correlations distribution of
haloperidol vs. molindone’s (Figure 6-13(a)) and haloperidol vs. voglibose’s (Figure
6-13(b)) target genes and their immediate PPI neighbors. The black line in each of
the plots depicts the actual CDF of the distribution of correlation while the yellow
line depicts the mean of 100 randomly sampled correlation distribution CDFs. The
red lines depict each of the 100 random CDFs that were generated. In both cases we
used the gene-gene correlations as computed using only the brain tissue samples. Here
we see that the expression correlation for haloperidol and molindone’s target genes
are more correlated than chance while haloperidol and voglibose’s are less correlated.
This makes sense as the former are both used to treat psychotic disorders while
voglibose is a hypoglycemic agent.
To compare the efficacy of using the target gene’s correlations to one another, we
also computed the Jaccard index between the overlap target genes of the drugs (as
in Section 6.2) as a baseline. This was done for both the cases: 1) when just the
target genes and 2) when the target gene list was expanded by the target gene’s PPI
neighbors. Furthermore, instead of using the raw Jaccard index, we performed 1000
random samplings and computed the empirical p-value. The random sampling was
done in the same manner as previously described. The use of these p-values provides
us with a baseline of what just the target genes tell us about the drug similarity
9Again, it is not that these genes are interacting in the cell, it is the proteins that are encoded
by these genes that interact. However, we are assuming that if the proteins that the genes encode
for interact, then the genes that encode for these proteins should also have some sort of coordinated
expression.
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without including any expression information.
Analyzing tissue specific drug target gene similarities
The drug-drug similarity scores were computed for 121 drugs form five drug classes
(hypoglycemic agents, anti-inflammatory agents, antipsychotic agents, HMG-CoA
reductase inhibitors, and antineoplastic agents) as indicated by DrugBank [63] across
eight distinct tissue types along with one case where all tissue data was used. Given
a drug and a tissue type, we can now examine what other drugs are deemed to be
similar in the context of the target genes and the correlated expression patterns of
those target genes. We find that when we use a specific tissue for the gene-gene
correlations and include the neighbors of the target genes that we do a better job of
finding drugs of similar class to a given drug than if we do not.
For example, Figure 6-14(a) depicts the 120 drugs sorted in order form most
similar to most different to haloperidol (an anti-psychotic drug) when just the target
genes and all tissue samples (brain, blood, lung, colon, etc.) are used to compute the
gene-gene correlations. Figure 6-14(b) depicts the result when we used just the brain
tissue samples to compute the gene-gene correlations. The black dots in the figures
represent the actual sum of z-scores for each drug as computed in the aforementioned
manner. The horizontal blue line indicates the 5% significance cutoff. Any values
below this line are scores that are in the top 5% of all scores. The colored squares
indicate the drug type category for each of the drugs. For example, the leftmost entry
in Figure 6-14(a) is voglibose, a hypoglycemic agent. The colors of these squares are
a gradient from red to yellow such that red indicates the lowest score and yellow is
the highest. This just provides another visual indication as to how good the score for
that drug is.
Two things are immediately apparent. First, in both cases, regardless of whether
or not we use all of the tissue samples or just the brain tissue samples, hypoglycemic
agents appear to be the most similar to the anti-psychotic drug haloperidol. Second,
although we see hypoglycemic agents as being the most similar to haloperidol when
using the brain tissue samples, we see that only one of the results is significant.
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Figure 6-14: These figures depict the 120 drugs sorted in order form most similar
to most different to haloperidol when just the target genes are used to compute the
similarity to haloperidol. (a) shows the result when all tissue (brain, blood, lung,
colon, etc.) is used to compute the similarities while (b) shows the result when only
the brain tissue is used. The black dots in the figures represent the actual sum of z-
scores for each drug as computed in the aforementioned manner. The horizontal blue
line indicates the 5% significance cutoff. Any values below this line are scores that
are in the top 5% of all scores across all 7260 drug-drug similarities (121 drugs results
in 121×120
2
total distances). The colored squares indicate the drug type category for
each of the drugs. For example, the leftmost entry in (a) is voglibose, a hypoglycemic
agent. The colors of these squares are a gradient from red to yellow such that red
indicates the lowest score and yellow is the highest. This just provides another visual
indication as to how good the score for that drug is.
If instead of looking at just the expression correlation of the target genes of the
drugs, but rather expand the set of genes to include the immediate PPI network
neighbors, we see than most of the drugs that are similar to haloperidol are indeed
157
anti-psychotic drugs (Figure 6-15). Furthermore, when we restrict the gene-gene
correlations to be computed on only the brain tissue samples, we see that there is
only one drug (etidronic acid) that is significantly similar to haloperidol.
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Figure 6-15: These figures depict the 120 drugs sorted in order form most similar
to most different to haloperidol when target genes along with their immediate PPI
neighbors are used to compute the similarity to haloperidol. (a) shows the result
when all tissue (brain, blood, lung, colon, etc.) is used to compute the similarities
while (b) shows the result when only the brain tissue is used. The meaning of the
dots, 5% threshold line, and colored boxes is identical to Figure 6-14.
We then compared these results to when just the empirical p-value of the Jaccard
indices of the target gene overlaps were used to see if the correlation structure of the
expression data is providing us with any additional useful information. Figure 6-16
shows the same 120 drugs and how similar they are to haloperidol when when use
just to target genes (Figure 6-16(a)) and when we expanded the set to include the
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PPI neighbors (Figure 6-16(b)). Unlike in the previous plots where points below the
horizontal blue line corresponded to the top 5% most similar values, here the blue
line indicates a hard 5% p-value cutoff. Any value below the line had an empirical
p-value of less than 0.05. Again, just as in the case when we used just the correlation
of the target genes of the drugs, the most similar drugs to haloperidol appear to be
hypoglycemic agents. However, when we use the PPI neighbors we do see that many
of the anti-psychotic drugs cluster together (Figure 6-16(b)).
Now that we have looked at a particular example (haloperidol’s most similar drugs
under various conditions), let us take an aggregate look at the results. To see how
well a particular variation (tissue type, whether or not to include the PPI neighbors)
does, for each drug we computed the number of other drugs that were of the same
drug category below and below the 5 % threshold. In other words, of the results that
were significant, we want to see how many of them were similar drugs. Figures 6-17
and 6-18 respectively show these results for when only the target genes are used and
when the PPI neighbors are included. The values in both of these figure range from 0
(none of the drugs below the 5% threshold were of the same drug category) and 1 (all
of the drugs under the 5% threshold were of the same category). For instance, in the
row for “Insulin recombinant” in Figure 6-17 we see that in the all tissue data and
blood tissue data conditions many of the most similar drugs were also hypoglycemic
agents.
Interestingly we see that both the hypoglycemic agents and anti-inflammatory
agents appear to be performing better when the PPI neighbors are not included.
In the case of the hypoglycemic agents we see that they perform very well even
when all of the tissue data was used. An explanation for this may be that a large
portion of the signal from all of the data is recapitulated in the blood only gene
correlations. Furthermore, since the expression signal of blood tissue is very distinct
(Section 3.2.1), it makes intuitive sense that the expression signature of the target
genes of the hypoglycemic agents is also very similar.
On the other hand, the results for anti-psychotic and anti-neoplastic agents ap-
pears to be better when the PPI neighbors are included. For example, we see that
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Figure 6-16: These figures depict the 120 drugs sorted in order form most similar to
most different to haloperidol when the empirical p-value of the Jaccard index of the
target gene overlap is used to compute the similarity to haloperidol. (a) shows the
result when only the target genes are used while (b) shows the result when this set
is expanded to include the PPI neighbors of the target genes. The black dots in the
figures represent the empirical p-value of the Jaccard index for the overlap between
haloperidol and the drug noted on the x-axis. The horizontal blue line indicates
the 5% significance cutoff. Any values below this line are p-values that are below
0.05. The colored squares indicate the drug type category for each of the drugs. For
example, the leftmost entry in (a) is voglibose, a hypoglycemic agent. The colors of
these squares are a gradient from red to yellow such that red indicates the lowest
score and yellow is the highest. This just provides another visual indication as to
how good the score for that drug is.
a large portion of the anti-neoplastic drugs have other anti-neoplastic drugs as close
neighbors when either color or kidney tissue gene correlations are used. Furthermore,






























































































































Figure 6-17: A heatmap that depicts the “performance” of the finding the most
similar drugs when only the target genes for each drug are used. Each row is the
result for one drug across the 9 different tissue conditions. The color in each cell is
related to the fraction of the similar samples for the the drug in the row were below
the 5% threshold and of the same drug category. The values range from 0 (none of
the drugs below the 5% threshold were of the same drug category) and 1 (all of the
drugs under the 5% threshold were of the same category) For instance, in the row
for “Insulin recombinant” we see that in the all tissue data and blood tissue data
conditions many of the most similar drugs were also hypoglycemic agents.
drugs perform relatively well when the brain tissue gene correlations are used.
While these results are preliminary, and a more in-depth study is required, it
provides the potential for tissue specific analysis of the effects of drugs. For instance,
if we find two drugs that target similar target genes in different tissues, it may be
a good idea to investigate the possibility of an adverse interaction between the two
drugs. In future work it will be necessary to ensure that we include more tissue types,
and include tissue specific PPI networks. Tissue specific PPI networks are imperative
161
because not all proteins are present in all tissues. For example, if a given protein is
never expressed in a particular tissue, we should not include the gene corresponding
to that protein when looking at the target gene neighbors. Thus, in combination with
the similarity network results from Section 6.1.2 and marker gene based results from
Section 6.4.1 this sort of analysis can provide useful insights to drug repurposing, may































































































































Figure 6-18: A heatmap that depicts the “performance” of the finding the most similar
drugs when both the target genes and their immediate PPI neighbors are used. Each
row is the result for one drug across the 9 different tissue conditions. The color in
each cell is related to the fraction of the similar samples for the the drug in the row
were below the 5% threshold and of the same drug category. The values range from
0 (none of the drugs below the 5% threshold were of the same drug category) and 1




In this work, we have detailed an ontological database framework called Concordia and
showed how it can be applied to create a curated gene expression database (Chapter
2). Employing this large set of expression samples labeled with specific phenotypic
identifiers, we showed how we can label new expression samples (Chapter 3), how
we can elucidate phenotype specific marker genes (Chapter 4), and how it can be
applied to creating tissue specific drug similarity scores (Chapter 6). As we will want
to expand this database in the future, we also covered active learning based techniques
that can be used to efficiently grow the expression database (Chapter 5).
The impact of this enabling technology is extremely broad and significant, find-
ing application in both clinical and biomedical research communities. Our open,
standards-based framework for making medical text machine-intelligible may eventu-
ally allow our system to lie at the core of large electronic medical record systems, im-
proving the ability of medical professionals and researchers alike to answer questions
about both individual patients and patient populations as a whole. In addition, it has
been noted that the lack of reproducibility in scientific research has been detrimental
to the biomedical community [88]. By making a highly curated phenotype-genotype
expression database like ours available to the public, we can make it possible for re-
searchers to perform analyses of their results against a large corpus of data, limiting
the effect of the “incidentalome” [66].
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7.1 Future work
7.1.1 Applying the Concordia framework to other domains
Having shown the preliminary feasibility of this methodology using the microarray
data from NCBI’s Gene Expression Omnibus (GEO) [13], we intend to further develop
the GEO prototype and then create an application for electronic health records using
the same framework. Current medical record software appear to index their records
on some basic patient identifier(s) (name, date of birth, social security number, etc.)
and are optimized for searching based on those identifiers. This clearly is not ideal for
finding the set of all patients with a given phenotypic condition for a clinical study.
By using MetaMap [7] to annotate the various fields in each record (doctor’s notes,
diagnoses, etc.) we can map each record to the set of UMLS concepts that describe its
contents. A user of the application derived from the Concordia framework can then
search for records based on any medical concept found in UMLS. For example, one
can query for skin rashes and cancer to find patients for a study on paraneoplastic
processes. Since the UMLS concepts reside in an ontology, even if a patient record
never explicitly mentions the general term “cancer,” but rather a more specific type of
cancer, the system would correctly include this patient’s record in the search results.
Although these two individual systems (expression and EHR) can provide useful
insights on their own, they could be combined for an even greater impact. If gene
expression experiments were to be introduced as a diagnostic tool, then a clinician
could find where in the space of diseases this patient’s expression profile lies by sim-
ply finding the other gene expression experiments that are most similar. We have
shown that, indeed, experiments pertaining to the same phenotypic condition cluster
together even if they originated from different data sets. Using this information, the
clinician could then find all patients that have had the same diagnosis and quickly
identify a treatment option. Furthermore, if the gene expression experiments being
searched were not the publicly available ones from GEO, but were the actual experi-
ments performed on other patients, one could efficiently locate the other patients that
not only had the most similar expression profiles but also the most similar background
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(gender, ethnicity, weight, etc.). This type of cross data searching and matching is
infeasible with current clinical software but would represent only the beginning of
what could become possible with the proposed framework.
7.1.2 Expanding the expression database
As it currently stands, we have a highly curated expression database containing 3030
gene expression samples performed on the Affymetrix HG-U133 Plus 2.0 platform.
While we were able to perform various studies and extract meaningful biological re-
sults using this database, a larger database with more samples for each phenotype
and more overall phenotypes, would undoubtedly yield other novel findings. As we
demonstrated in Chapter 5, we can use active learning techniques to efficiently ex-
pand an existing database for samples relating to particular phenotypes. In addition,
we could expand upon the approach we detailed, and employ the concept enrich-
ment statistics described in Chapter 3 in place of (or in addition to) the expression
correlation based method.
Furthermore, it would behoove us not to expand the database to include data per-
formed on other organisms and microarray platforms. While this new expression data
may not be directly comparable to the data that currently resides in the database, it
would enable us to map the results from a greater range of biological studies on to
the transcriptomic landscape of tissue and disease.
7.1.3 Concept enrichment using marker genes
The current implementation of the concept enrichment utilizes the sample correlations
based on all 20252 genes on the Affymetrix HG-U133 Plus 2.0 platform. However, in
Chapter 4 we detailed a method that allows us to compute the relative importance of
each gene to a phenotype via the marker gene score. As there are genes that provide
no additional signal (and may actually be adding noise) in the expression space of
a particular phenotype, it would be worthwhile to explore the effect of using only
the most significant genes (highest marker gene scores) when computing the sample
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correlations. This, however, adds additional complexity when labeling new samples
as the correlations need to be computed not just once to all samples in the database,
but once for every phenotype to all samples (since we are using a different set of genes
to compute the correlations).
7.1.4 Targeted drug therapeutics
As was mentioned in Chapter 6, targeted therapeutics are the future of drug de-
sign and administration. By leveraging expression data, we can provide tissue (or
any other phenotype) specific similarity measures for drugs. As such, it would be
feasible to expand this work to find novel repurposing of existing drugs so that it
can be administered for the treatment of a different disease. Unlike the Connectiv-
ity Map (CMAP) [69], the use of untreated tissue samples to examine the possible
transcriptomic effect of drugs will enable much larger scale high-throughput studies.
As an alternative to using existing expression profiles to generate hypotheses about
the potential effects of drugs, it may be possible to use gene expression data of patients
to provide them with highly targeted therapeutic regiments. For example, we could
create a database of expression profiles for all patients (or a significant subset) that
visit a hospital. Using this expression data, in conjunction with their medical records,
it could potentially be plausible to find the “most similar patients” and administer




A.1 GEO data in Concordia
A.1.1 GEO series
These are the 192 distinct GEO Series (GSEs) for which there is data in Concordia:
GSE15431, GSE15578, GSE5040, GSE13314, GSE13313, GSE12172, GSE3077, GSE7896, GSE11045, GSE5764, GSE14302, GSE13067,
GSE5460, GSE12583, GSE8121, GSE7224, GSE15389, GSE7821, GSE13309, GSE2435, GSE6364, GSE13732, GSE14434, GSE7757,
GSE7553, GSE13300, GSE13307, GSE8023, GSE6575, GSE6891, GSE3284, GSE14054, GSE6791, GSE15583, GSE8545, GSE11151,
GSE15392, GSE7753, GSE11348, GSE15396, GSE15636, GSE10780, GSE15395, GSE16059, GSE16054, GSE5109, GSE14103, GSE5372,
GSE15773, GSE3202, GSE13828, GSE7117, GSE14429, GSE10317, GSE6764, GSE15455, GSE3744, GSE14886, GSE4183, GSE15459,
GSE4182, GSE14746, GSE11375, GSE4250, GSE15645, GSE14618, GSE9576, GSE6969, GSE5060, GSE14519, GSE5264, GSE8052,
GSE2125, GSE12891, GSE7127, GSE5058, GSE14380, GSE9891, GSE3061, GSE14615, GSE3062, GSE7637, GSE15132, GSE9899,
GSE3526, GSE4107, GSE16032, GSE7832, GSE10715, GSE10714, GSE6004, GSE3325, GSE15658, GSE13887, GSE12417, GSE14801,
GSE13059, GSE9440, GSE14386, GSE2817, GSE2634, GSE9593, GSE10927, GSE14491, GSE15918, GSE14020, GSE16028, GSE5081,
GSE10334, GSE8514, GSE15148, GSE2677, GSE5281, GSE11083, GSE14825, GSE14905, GSE13975, GSE13351, GSE6532, GSE6465,
GSE11100, GSE4567, GSE13355, GSE10327, GSE6460, GSE14711, GSE13471, GSE14017, GSE2842, GSE13670, GSE13141, GSE13671,
GSE14479, GSE8507, GSE13205, GSE15499, GSE12195, GSE15329, GSE4086, GSE2109, GSE2555, GSE12453, GSE13136, GSE10846,
GSE6257, GSE14844, GSE4498, GSE15602, GSE12452, GSE14468, GSE14841, GSE14842, GSE4737, GSE15460, GSE7152, GSE12390,
GSE7153, GSE4218, GSE15368, GSE4219, GSE4217, GSE7888, GSE7305, GSE12667, GSE7011, GSE15090, GSE7307, GSE15091,
GSE12662, GSE3678, GSE11882, GSE13294, GSE15176, GSE5110, GSE15175, GSE16130, GSE13911, GSE4488, GSE13506, GSE6872,
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GSE15615, GSE13987, GSE15477, GSE6351, GSE13985, GSE15083, GSE3292, GSE13904, GSE15709, GSE11135, GSE15209, GSE15372
A.1.2 GEO samples
These are the 3030 distinct GEO samples (GSMs) for which there is data in Concordia:
GSM175794, GSM170979, GSM175795, GSM46884, GSM175796, GSM175797, GSM170978, GSM175790, GSM175791, GSM46888,
GSM175792, GSM117730, GSM203686, GSM402327, GSM175793, GSM175798, GSM353935, GSM175799, GSM159011, GSM352110,
GSM353933, GSM203696, GSM318104, GSM402317, GSM117720, GSM203699, GSM46878, GSM159001, GSM117710, GSM402307,
GSM353915, GSM159031, GSM152689, GSM318124, GSM117700, GSM152681, GSM379868, GSM117701, GSM46898, GSM352123,
GSM353925, GSM159021, GSM152699, GSM318114, GSM379858, GSM363401, GSM260997, GSM194307, GSM363406, GSM363403,
GSM117770, GSM117772, GSM187610, GSM261007, GSM187611, GSM350298, GSM318144, GSM187616, GSM194309, GSM187617,
GSM194308, GSM187618, GSM187619, GSM187612, GSM187613, GSM187614, GSM152669, GSM187615, GSM194313, GSM194314,
GSM194311, GSM353905, GSM194312, GSM199397, GSM117763, GSM194310, GSM76489, GSM117761, GSM261017, GSM117756,
GSM187621, GSM67186, GSM187622, GSM117755, GSM152670, GSM187620, GSM318134, GSM350288, GSM187629, GSM152679,
GSM187627, GSM187628, GSM187625, GSM187626, GSM187623, GSM187624, GSM175777, GSM175776, GSM260977, GSM175779,
GSM175778, GSM76499, GSM117751, GSM175775, GSM187630, GSM337197, GSM152649, GSM337199, GSM337198, GSM385721,
GSM363411, GSM175789, GSM363412, GSM175788, GSM260987, GSM175787, GSM325807, GSM175782, GSM175781, GSM117741,
GSM175780, GSM175786, GSM363415, GSM175785, GSM175784, GSM175783, GSM280370, GSM152659, GSM361954, GSM391367,
GSM211122, GSM280847, GSM371106, GSM148611, GSM148610, GSM211132, GSM325817, GSM85486, GSM325812, GSM361964,
GSM391357, GSM280837, GSM325827, GSM148605, GSM211142, GSM148606, GSM148607, GSM148608, GSM148609, GSM85496,
GSM260967, GSM279060, GSM279061, GSM279062, GSM279063, GSM279064, GSM279065, GSM211102, GSM46824, GSM348321,
GSM325837, GSM46828, GSM211112, GSM151998, GSM151999, GSM151996, GSM151997, GSM151994, GSM151995, GSM151992,
GSM151993, GSM151990, GSM46818, GSM151991, GSM46817, GSM85476, GSM238798, GSM201248, GSM238799, GSM201249, GSM201246,
GSM201247, GSM201244, GSM201245, GSM270842, GSM270843, GSM270844, GSM270840, GSM261088, GSM231885, GSM270841,
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GSM249981, GSM151304, GSM158841, GSM114535, GSM176173, GSM176174, GSM176171, GSM176172, GSM261292, GSM176170,
GSM387809, GSM114534, GSM261282, GSM176169, GSM51700, GSM176168, GSM176167, GSM176166, GSM176165, GSM176164,
GSM277691, GSM249971, GSM113802, GSM114506, GSM158831, GSM114504, GSM114505, GSM125086, GSM261272, GSM387819,
GSM249961, GSM85227, GSM85226, GSM85228, GSM158821, GSM85221, GSM85220, GSM85223, GSM85222, GSM85225, GSM114515,
GSM85224, GSM114516, GSM125096, GSM176186, GSM387829, GSM261262, GSM249950, GSM402152, GSM335522, GSM150209,
GSM386291, GSM249940, GSM312934, GSM161820, GSM102512, GSM80800, GSM287323, GSM261252, GSM387839, GSM361610,
GSM102518, GSM371309, GSM371306, GSM371305, GSM371308, GSM371307, GSM371302, GSM327292, GSM371301, GSM371304,
GSM371303, GSM249930, GSM150201, GSM150208, GSM161810, GSM335512, GSM161811, GSM287333, GSM161812, GSM161813,
GSM361620, GSM312924, GSM102508, GSM387849, GSM102507, GSM261242, GSM327282, GSM150210, GSM161819, GSM249920,
GSM161818, GSM161815, GSM161814, GSM161817, GSM161816, GSM312911, GSM312912, GSM155672, GSM312910, GSM155671,
GSM287343, GSM387859, GSM261232, GSM312913, GSM312914, GSM361242, GSM161806, GSM161805, GSM161804, GSM161803,
GSM249910, GSM161809, GSM155681, GSM161808, GSM161807, GSM312900, GSM312901, GSM287353, GSM312906, GSM312907,
GSM312908, GSM387869, GSM312909, GSM261222, GSM312902, GSM312903, GSM312904, GSM312905, GSM155691, GSM249900,
GSM183234, GSM261212, GSM387879, GSM102553, GSM102555, GSM102556, GSM155651, GSM102558, GSM183230, GSM386245,
GSM335572, GSM387889, GSM155668, GSM155669, GSM261202, GSM155665, GSM155666, GSM155667, GSM183240, GSM102548,
GSM155661, GSM155670, GSM391596, GSM386255, GSM335562, GSM152009, GSM102538, GSM152006, GSM152005, GSM152008,
GSM152007, GSM287303, GSM152002, GSM152001, GSM152004, GSM152003, GSM387899, GSM152000, GSM335552, GSM386225,
GSM335938, GSM171597, GSM199027, GSM286700, GSM152017, GSM102528, GSM152016, GSM152015, GSM287313, GSM152014,
GSM183220, GSM260703, GSM152013, GSM312944, GSM260702, GSM152012, GSM152011, GSM152010, GSM335532, GSM335542,
173
GSM386235, GSM377465, GSM335942, GSM335941, GSM335940, GSM199037, GSM327202, GSM80868, GSM80867, GSM80869, GSM80874,
GSM80870, GSM80871, GSM80872, GSM80873, GSM333446, GSM199047, GSM151294, GSM327212, GSM198042, GSM80887, GSM80888,
GSM80885, GSM80886, GSM80883, GSM80884, GSM80881, GSM80882, GSM333436, GSM317934, GSM317933, GSM151284, GSM199057,
GSM198052, GSM80845, GSM198053, GSM198050, GSM327222, GSM198051, GSM198049, GSM198048, GSM80851, GSM198047,
GSM198046, GSM80853, GSM198045, GSM198044, GSM198043, GSM151274, GSM199067, GSM80861, GSM80865, GSM80866, GSM80864,
GSM333456, GSM287383, GSM93939, GSM80823, GSM93938, GSM80824, GSM80825, GSM80826, GSM199077, GSM337202, GSM199087,
GSM337203, GSM279998, GSM337200, GSM337201, GSM80831, GSM93944, GSM93943, GSM93941, GSM287373, GSM93946, GSM350413,
GSM93948, GSM337205, GSM337204, GSM337207, GSM74882, GSM337206, GSM337209, GSM337208, GSM337210, GSM337211,
GSM337212, GSM337213, GSM337214, GSM199097, GSM93954, GSM80844, GSM80843, GSM80842, GSM80841, GSM93950, GSM287363,
GSM93952, GSM80801, GSM80802, GSM80803, GSM80804, GSM350423, GSM80805, GSM80806, GSM80807, GSM80808, GSM80809,
GSM337219, GSM337218, GSM337217, GSM337216, GSM337215, GSM337224, GSM337225, GSM337222, GSM337223, GSM337220,
GSM337221, GSM80811, GSM286660, GSM80810, GSM80814, GSM80815, GSM80812, GSM93927, GSM80813, GSM80818, GSM287393,
GSM80819, GSM80816, GSM80817, GSM337227, GSM371403, GSM337226, GSM350433, GSM337229, GSM337228, GSM337233, GSM337234,
GSM337235, GSM337236, GSM337230, GSM337231, GSM337232, GSM80822, GSM80821, GSM80820, GSM286650, GSM176128, GSM176129,
GSM38094, GSM158891, GSM337241, GSM176120, GSM337240, GSM176121, GSM337243, GSM176122, GSM337242, GSM176123,
GSM337245, GSM176124, GSM337244, GSM176125, GSM76640, GSM337247, GSM272315, GSM176126, GSM337246, GSM176127,
GSM337237, GSM337238, GSM350443, GSM337239, GSM176130, GSM125106, GSM286690, GSM286670, GSM176139, GSM337250,
GSM75563, GSM337254, GSM176133, GSM337253, GSM176134, GSM337252, GSM176131, GSM337251, GSM176132, GSM378160,
GSM337258, GSM176137, GSM76630, GSM337257, GSM176138, GSM337256, GSM176135, GSM337255, GSM176136, GSM337248,
GSM48672, GSM350453, GSM337249, GSM176141, GSM176140, GSM286680, GSM337260, GSM158871, GSM75553, GSM119369,
GSM176146, GSM176147, GSM337269, GSM176148, GSM176149, GSM176142, GSM89001, GSM176143, GSM176144, GSM176145,
GSM176150, GSM74892, GSM242033, GSM176152, GSM242032, GSM176151, GSM350463, GSM337259, GSM158861, GSM277681,
GSM158881, GSM119379, GSM176159, GSM337279, GSM176157, GSM176158, GSM176155, GSM199107, GSM176156, GSM89011,
GSM176153, GSM176154, GSM176163, GSM350473, GSM176162, GSM176161, GSM176160, GSM175998, GSM175999, GSM175996,
GSM175994, GSM277678, GSM175995, GSM175992, GSM175993, GSM175990, GSM175991, GSM38054, GSM89021, GSM76600, GSM179780,
GSM337289, GSM350168, GSM359509, GSM199117, GSM50703, GSM139018, GSM139017, GSM139019, GSM151264, GSM179790,
GSM89031, GSM242031, GSM38064, GSM337299, GSM38068, GSM350178, GSM119359, GSM119354, GSM199127, GSM179784, GSM179786,
GSM89041, GSM139002, GSM176103, GSM139003, GSM176102, GSM139004, GSM176105, GSM139005, GSM176104, GSM80891,
GSM80890, GSM76620, GSM176101, GSM176100, GSM38074, GSM199137, GSM80899, GSM176107, GSM80898, GSM350188, GSM176106,
GSM80897, GSM176109, GSM176108, GSM80889, GSM103559, GSM89046, GSM150196, GSM150197, GSM150198, GSM150199, GSM139015,
174
GSM176116, GSM139016, GSM176115, GSM139013, GSM176114, GSM89051, GSM139014, GSM176113, GSM139011, GSM176112,
GSM139012, GSM176111, GSM76610, GSM176110, GSM139010, GSM350198, GSM38084, GSM199147, GSM176119, GSM176118,
GSM176117, GSM139009, GSM139008, GSM139007, GSM125116, GSM139006, GSM194087, GSM194088, GSM194089, GSM203643,
GSM194083, GSM194084, GSM96897, GSM194085, GSM203646, GSM96898, GSM158911, GSM194086, GSM343815, GSM159051,
GSM187752, GSM281300, GSM231907, GSM231906, GSM194091, GSM194090, GSM102458, GSM194093, GSM194092, GSM102455,
GSM387029, GSM312875, GSM102450, GSM102451, GSM203656, GSM158901, GSM194096, GSM194097, GSM194094, GSM194095,
GSM261192, GSM343825, GSM231916, GSM159041, GSM187762, GSM261184, GSM249890, GSM281310, GSM102447, GSM199297,
GSM102449, GSM102448, GSM387019, GSM312862, GSM158931, GSM203666, GSM159071, GSM211450, GSM158463, GSM158464,
GSM187732, GSM377358, GSM231926, GSM349749, GSM211449, GSM249880, GSM387009, GSM176098, GSM176099, GSM312894,
GSM102478, GSM312896, GSM312897, GSM312898, GSM312899, GSM211446, GSM281320, GSM211447, GSM199287, GSM211448,
GSM194075, GSM158921, GSM159061, GSM194078, GSM194079, GSM203676, GSM402247, GSM194076, GSM194077, GSM176097,
GSM187742, GSM176096, GSM176095, GSM343805, GSM176094, GSM176093, GSM176092, GSM231936, GSM176091, GSM349739,
GSM176090, GSM249870, GSM176089, GSM176087, GSM318094, GSM176088, GSM402257, GSM194082, GSM281330, GSM102468,
GSM194081, GSM194080, GSM199277, GSM170833, GSM187792, GSM176080, GSM176081, GSM176082, GSM231946, GSM176083,
GSM176084, GSM176085, GSM176086, GSM159091, GSM158951, GSM152569, GSM281340, GSM402267, GSM102498, GSM272305,
GSM249860, GSM176077, GSM318084, GSM176076, GSM176079, GSM176078, GSM261151, GSM261152, GSM85506, GSM170835,
GSM176070, GSM176071, GSM176074, GSM176075, GSM176072, GSM231956, GSM176073, GSM231950, GSM388192, GSM158941,
GSM231952, GSM159081, GSM152579, GSM102488, GSM402277, GSM176068, GSM85513, GSM261146, GSM176067, GSM85514,
GSM261143, GSM176066, GSM85515, GSM249850, GSM176065, GSM85516, GSM318074, GSM170823, GSM85517, GSM261142, GSM85518,
GSM85519, GSM176069, GSM176061, GSM170850, GSM176062, GSM231966, GSM176063, GSM359583, GSM176064, GSM170855,
GSM353428, GSM261182, GSM170853, GSM187772, GSM343837, GSM176060, GSM203626, GSM152589, GSM158971, GSM388182,
GSM402287, GSM158981, GSM335602, GSM261172, GSM170858, GSM176059, GSM176058, GSM261174, GSM170857, GSM176055,
GSM176054, GSM249840, GSM176057, GSM176056, GSM176052, GSM231976, GSM176053, GSM359593, GSM176050, GSM249820,
GSM152594, GSM176051, GSM343847, GSM170841, GSM187782, GSM170844, GSM170843, GSM152599, GSM203636, GSM158961,
GSM203641, GSM323169, GSM402297, GSM323168, GSM176049, GSM176048, GSM261162, GSM170848, GSM176047, GSM171011,
GSM170849, GSM176046, GSM249830, GSM171012, GSM176045, GSM176044, GSM176043, GSM261113, GSM211032, GSM261112,
GSM329007, GSM261117, GSM261116, GSM137954, GSM287463, GSM387731, GSM386393, GSM335622, GSM155968, GSM367219,
GSM155969, GSM315621, GSM280907, GSM231986, GSM249810, GSM211042, GSM261102, GSM315622, GSM183301, GSM315623,
GSM183300, GSM315624, GSM315625, GSM183302, GSM329017, GSM137964, GSM387741, GSM117629, GSM261109, GSM335612,
GSM117632, GSM249800, GSM312816, GSM277128, GSM277129, GSM277126, GSM277127, GSM277125, GSM261134, GSM211052,
175
GSM261132, GSM287443, GSM335642, GSM261138, GSM261137, GSM137934, GSM137931, GSM38376, GSM155989, GSM335652,
GSM155988, GSM277132, GSM277131, GSM277130, GSM280927, GSM277137, GSM277138, GSM277139, GSM211062, GSM277133,
GSM261122, GSM277134, GSM277135, GSM277136, GSM387721, GSM137945, GSM335632, GSM137944, GSM287453, GSM261127,
GSM117649, GSM38386, GSM373559, GSM280917, GSM137994, GSM277109, GSM287423, GSM277108, GSM277103, GSM277102,
GSM277101, GSM277100, GSM277107, GSM277106, GSM277105, GSM277104, GSM201302, GSM377338, GSM201301, GSM201300,
GSM155920, GSM277110, GSM280947, GSM201304, GSM201303, GSM155923, GSM155922, GSM155921, GSM38356, GSM155928,
GSM155927, GSM287433, GSM155919, GSM387789, GSM158465, GSM158466, GSM158467, GSM158468, GSM312826, GSM158469,
GSM353885, GSM377348, GSM158471, GSM280937, GSM158470, GSM158473, GSM158472, GSM158475, GSM158474, GSM335662,
GSM38366, GSM287403, GSM102438, GSM353895, GSM280967, GSM155948, GSM155947, GSM287413, GSM137984, GSM102428,
GSM312849, GSM211022, GSM211012, GSM280957, GSM101301, GSM38346, GSM117610, GSM80725, GSM272192, GSM80724, GSM272193,
GSM80727, GSM327342, GSM272190, GSM80726, GSM335582, GSM272191, GSM80729, GSM386311, GSM80728, GSM280979, GSM138034,
GSM272295, GSM183260, GSM80730, GSM239824, GSM80731, GSM239825, GSM80732, GSM272185, GSM239826, GSM80733, GSM80734,
GSM272183, GSM80738, GSM335592, GSM80737, GSM386301, GSM272180, GSM80736, GSM272181, GSM80735, GSM327352, GSM272182,
GSM117587, GSM80739, GSM337309, GSM280989, GSM138044, GSM80740, GSM272177, GSM80741, GSM286730, GSM272176, GSM183250,
GSM272172, GSM80742, GSM272175, GSM80743, GSM272174, GSM327322, GSM183290, GSM386331, GSM272170, GSM53113, GSM272171,
GSM80749, GSM80748, GSM280999, GSM138054, GSM272169, GSM134694, GSM272164, GSM272163, GSM272162, GSM272275,
GSM272161, GSM286720, GSM272168, GSM80750, GSM80751, GSM272165, GSM386321, GSM183280, GSM80759, GSM327332, GSM80758,
GSM53103, GSM80757, GSM272160, GSM134690, GSM134691, GSM134692, GSM134693, GSM272159, GSM134688, GSM272158,
GSM134687, GSM134689, GSM272151, GSM272150, GSM272152, GSM272155, GSM272154, GSM183270, GSM272285, GSM272157,
GSM80761, GSM387799, GSM286710, GSM272156, GSM337339, GSM201279, GSM401293, GSM201278, GSM201277, GSM316703,
GSM53133, GSM137924, GSM201286, GSM201287, GSM201284, GSM201285, GSM201282, GSM201283, GSM201280, GSM201281,
GSM119685, GSM119684, GSM119683, GSM119682, GSM179801, GSM201267, GSM119688, GSM179800, GSM201266, GSM119687,
GSM201269, GSM337349, GSM119686, GSM201268, GSM119681, GSM53123, GSM119680, GSM316713, GSM137912, GSM137910,
GSM80701, GSM80700, GSM138004, GSM201273, GSM138003, GSM201274, GSM119679, GSM138002, GSM201275, GSM201276,
GSM137916, GSM201270, GSM137914, GSM201271, GSM201272, GSM179810, GSM201299, GSM337319, GSM80706, GSM53153,
GSM117577, GSM80707, GSM80708, GSM316723, GSM80709, GSM80702, GSM80703, GSM80704, GSM80705, GSM80710, GSM80712,
GSM80711, GSM347925, GSM347924, GSM137904, GSM347923, GSM347922, GSM347921, GSM138014, GSM201289, GSM201288,
GSM124996, GSM179820, GSM337329, GSM80719, GSM80717, GSM80718, GSM53143, GSM80715, GSM352629, GSM179827, GSM80716,
GSM80713, GSM80714, GSM80723, GSM272194, GSM80722, GSM272195, GSM80721, GSM272196, GSM80720, GSM272197, GSM347916,
GSM272198, GSM272199, GSM347918, GSM347917, GSM162960, GSM201290, GSM162961, GSM201291, GSM162962, GSM201292,
176
GSM201293, GSM201294, GSM201295, GSM201296, GSM138024, GSM201297, GSM201298, GSM119649, GSM176025, GSM162954,
GSM119648, GSM176026, GSM359603, GSM162957, GSM119647, GSM176027, GSM272215, GSM170867, GSM162956, GSM119646,
GSM176028, GSM176021, GSM176022, GSM176023, GSM199217, GSM176024, GSM53173, GSM158991, GSM176029, GSM53170,
GSM378838, GSM378837, GSM378836, GSM378831, GSM119651, GSM378830, GSM170862, GSM119652, GSM179830, GSM176031,
GSM119650, GSM176030, GSM378835, GSM170865, GSM162958, GSM119655, GSM378834, GSM170866, GSM162959, GSM119656,
GSM378833, GSM119653, GSM378832, GSM119654, GSM119636, GSM176038, GSM119635, GSM176039, GSM272225, GSM119638,
GSM176036, GSM162943, GSM119637, GSM176037, GSM162942, GSM176034, GSM162941, GSM119639, GSM176035, GSM162940,
GSM176032, GSM176033, GSM53163, GSM199227, GSM378826, GSM378825, GSM95473, GSM378828, GSM378827, GSM95475, GSM95474,
GSM378829, GSM95477, GSM53167, GSM95476, GSM95479, GSM370399, GSM176042, GSM95478, GSM176041, GSM378820, GSM119640,
GSM176040, GSM179840, GSM119641, GSM378822, GSM119642, GSM378821, GSM119643, GSM378824, GSM119644, GSM378823,
GSM119645, GSM176000, GSM176001, GSM162931, GSM176002, GSM162930, GSM176003, GSM162933, GSM176004, GSM162932,
GSM176005, GSM162935, GSM119669, GSM176006, GSM162934, GSM119668, GSM176007, GSM95480, GSM176008, GSM176009,
GSM95488, GSM95487, GSM119670, GSM95486, GSM378819, GSM95485, GSM378818, GSM95484, GSM378817, GSM95483, GSM378816,
GSM95482, GSM378815, GSM95481, GSM378814, GSM378813, GSM162936, GSM119677, GSM378812, GSM337359, GSM162937,
GSM119678, GSM378811, GSM162938, GSM119675, GSM162939, GSM159101, GSM119673, GSM119674, GSM119671, GSM95489,
GSM119672, GSM179850, GSM176012, GSM176013, GSM199207, GSM176010, GSM179870, GSM176011, GSM272205, GSM119658,
GSM176016, GSM272204, GSM119657, GSM176017, GSM176014, GSM272202, GSM119659, GSM176015, GSM272201, GSM95490,
GSM176018, GSM95491, GSM176019, GSM53183, GSM281280, GSM95497, GSM95496, GSM281290, GSM95499, GSM95498, GSM95493,
GSM95492, GSM95495, GSM45796, GSM95494, GSM119664, GSM162928, GSM119665, GSM337369, GSM159111, GSM119666, GSM119667,
GSM119660, GSM176020, GSM179860, GSM119661, GSM162929, GSM119662, GSM119663, GSM272143, GSM301693, GSM272144,
GSM272145, GSM152619, GSM80771, GSM272146, GSM199257, GSM80778, GSM80777, GSM272140, GSM80776, GSM272255, GSM272141,
GSM272142, GSM272147, GSM179880, GSM272148, GSM272149, GSM159122, GSM327302, GSM301687, GSM80783, GSM272134,
GSM80782, GSM272135, GSM80785, GSM80784, GSM152609, GSM80787, GSM80786, GSM301680, GSM80789, GSM199267, GSM80788,
GSM350078, GSM272265, GSM162902, GSM272138, GSM272139, GSM179890, GSM80781, GSM272136, GSM80780, GSM272137,
GSM162906, GSM162905, GSM162904, GSM159132, GSM399579, GSM80779, GSM327312, GSM301677, GSM80799, GSM80798, GSM80797,
GSM80796, GSM80795, GSM199237, GSM80794, GSM80793, GSM80792, GSM80791, GSM80790, GSM119628, GSM119629, GSM272235,
GSM249790, GSM119626, GSM119627, GSM119624, GSM119625, GSM119634, GSM119633, GSM119632, GSM119631, GSM119630,
GSM159142, GSM152639, GSM238763, GSM301667, GSM272245, GSM199247, GSM152629, GSM119617, GSM119618, GSM119619,
GSM119615, GSM119616, GSM119621, GSM119620, GSM119623, GSM119622, GSM159152, GSM301657, GSM152624
177
A.2 UMLS concepts in Concordia
A.2.1 Direct concept hits for the text associated with the
3030 GEO samples
These are the 1489 Unified Medical Language System [17] (UMLS) that we used to
annotate the 3030 GEO samples in the database:
3,4-Methylenedioxyamphetamine; Abdominal mass; Abdominal Pain; Acromegaly; Adenocarcinoma; Papillary adenocarcinoma;
adenoma; Adipose tissue; Adrenal Cortex; Adrenal Glands; Adult; Alcohol consumption; Ethanol; Aldosterone; Alzheimer’s Disease;
American Indians; Amniocentesis; Amniotic Fluid; Amygdaloid structure; Androgens; Refractory anaemia with excess blasts; Aorta;
Appendix; Arsenic; Arthritis; Rheumatoid Arthritis; Asthma; Ataxia; Autistic Disorder; Autophagy; B-Lymphocytes; Benign prostatic
hypertrophy; Bifidobacterium; Biopsy; Black race; Bladder; Blood; In Blood; Blood Cells; Bone Marrow; Bone Marrow Cells; Brain;
Brain Neoplasms; Branchioma; Breast; Malignant neoplasm of breast; Breast Diseases; Bronchi; Bronchoscopy; Burkitt Lymphoma; Ma-
lignant Neoplasms; Carcinoid Tumor; Carcinoma; Malignant tumor of colon; Rectal Carcinoma; Malignant neoplasm of skin; Malignant
neoplasm of thyroid; Basal cell carcinoma; Bronchioloalveolar Carcinoma; Adenocarcinoma, Mucinous; Carcinoma, Non-Small-Cell
Lung; Carcinoma, Papillary; Renal Cell Carcinoma; Squamous cell carcinoma; Carcinoma, Transitional Cell; Cartilage; Caucasoid
Race; Cecum; Cell Line; Cell Line, Transformed; Cells; Cultured Cells; Cerebellum; Cerebral cortex; Cervix Uteri; Oral Tobacco; Child;
Chondrosarcoma; Chronic Disease; Cisplatin; Colon; Colonic Neoplasms; colonoscopy; Carcinoma of the Large Intestine; Constipation;
Contraceptive Agents; Contraceptives, Oral; Corpus Callosum; Coughing; Cystadenocarcinoma; Cyst; Diarrhea; Dimethyl Sulfoxide;
Disease; Duodenum; Embryo; Emetine; Endometriosis, site unspecified; Endometrium; Endothelium; Epithelial Cells; Epithelium;
Herpesvirus 4, Human; Escherichia coli; Esophagogastric Junction; Esophagus; Limb structure; Mammalian Oviducts; Fatigue; Fe-
male; Fetus; Fibroblasts; Nonproliferative fibrocystic disease; fibrosarcoma; Ficoll; frontal lobe; Gallbladder; Ganglia; Ganglia, Spinal;
gastric fundus; Gastritis; Gingiva; Glioblastoma; Glioma; Globus Pallidus; Glucocorticoids; Growth Factor; Head; Headache; Heart;
Heart Atrium; Heart Ventricle; Hela Cells; Hematopoietic stem cells; Hemoptysis; Primary carcinoma of the liver cells; Hippocampus
(Brain); Hispanic Americans; Hodgkin Disease; hypercholesterolemia; Hypercholesterolemia, Familial; Hypertensive disease; Hypotha-
lamic structure; ileum; Bone structure of ilium; Infection; Human Papillomavirus; Inflammatory Bowel Diseases; Intestinal Mucosa;
Large Intestine; Intestines, Small; Intestines; Irritable Bowel Syndrome; jejunum; Job’s Syndrome; Joints; Kidney; Structure of cortex
of kidney; Structure of medulla of kidney; Kidney Neoplasms; Knee; leiomyosarcoma; leukemia; Chronic Lymphocytic Leukemia; Acute
Erythroblastic Leukemia; Lymphoblastic Leukemia; Acute lymphocytic leukemia; Leukemia, Lymphocytic, Acute, L1; Acute mono-
cytic leukemia; Leukemia, Myelocytic, Acute; Myeloid Leukemia; Leukemia, Myelomonocytic, Acute; Acute Promyelocytic Leukemia;
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Leukemia, T-Cell; Leukocytes; liposarcoma; Liver; Lung; Chronic Obstructive Airway Disease; Lymph; lymph nodes; Lymphocyte; Lym-
phoma; Lymphoma, Follicular; Reticulosarcoma; Lymphoma, Non-Hodgkin’s; Macaca mulatta; macrophage; Male gender; Malignant
neoplasm of stomach; Mammography; Mediastinum; medulloblastoma; melanoma; Melena; Tissue membrane; Mental Retardation; Mid-
brain structure; Cercopithecus aethiops; Monkeys; monocyte; Oral mucous membrane structure; Mucous Membrane; Multiple Myeloma;
Multiple Sclerosis; Muscle; Muscular Atrophy; Spinal Muscular Atrophy; Muscular Dystrophies; Mutation; myometrium; Nasopharynx;
Neck; African race; Neoplasm Metastasis; Neoplasms; Neuroblastoma; neutrophil; Nipples; Nodule; Nose; Nucleus Accumbens; Obesity;
Occipital lobe; Omentum; osteosarcoma; Ovarian Carcinoma; Ovary; Pain; Pancreas; Papillomavirus; Parathyroid gland; Parathyroid
Neoplasms; Parietal Lobe; Parkinson Disease; Parotid Gland; Pectoralis Muscles; Pelvis; penis; Pericardial sac structure; Periodontitis;
Peritoneum; Pharyngeal structure; Phycoerythrin; Pituitary Adenoma; Pituitary Gland; Placenta; Plasma Cells; Plasmids; Pontine
structure; prednisolone; Pregnant Women; Primates; Prostate; Psoriasis; Pulmonary artery structure; Structure of putamen; Pylorus;
Radiation therapy; Androgen Receptor; Rectum; Rhabdomyosarcoma; Rheumatism; Rhinovirus; Riboflavin; Salivary Glands; Saphenous
Vein; Metastatic to; Sezary Syndrome; Septic Shock; Sigmoidoscopy (procedure); skin disorder; Skin Neoplasms; Smoking; sperm cell;
Sphingosine; Spinal Cord; Spleen; Starvation; Stem cells; Steroid 11-beta-Monooxygenase; Stomach; Streptococcus; Substantia nigra
structure; Synovial Fluid; Synovial Membrane; T-Lymphocyte; Tamoxifen; Temporal Lobe; Testis; Thalamic structure; Thymus Gland;
Thyroid Gland; thyroid neoplasm; Body tissue; Tobacco; Encounter due to tobacco use; Tongue; Palatine Tonsil; Trachea; Structure of
trigeminal ganglion; Twin Multiple Birth; Monozygotic twins; Umbilical vein; Ureter; Urethra; Urinary tract; Uterine Fibroids; Uterus;
Vagina; Veins; Vena caval structure; Vestibular nucleus structure; Visual Cortex; Vomiting; Vulva; Body Weight decreased; Caucasians;
Woman; Wounds and Injuries; arsenic trioxide; matrigel; Rolipram; sphingosine 1-phosphate; Aldosterone Synthase; Asians; Branchial
Clefts-Congenital disorder; B-Cell Lymphomas; Lymphoma, Diffuse; Diffuse Large B-Cell Lymphoma; Lymphoma, T-Cell, Cutaneous;
Macrophages, Alveolar; alpha-beta T-Cell Receptor; Helicobacter; Acute leukemia; African American; Hispanics; Homo sapiens; Syn-
ovial biopsy; Bleeding of vagina; Structure of superior frontal gyrus; Structure of middle temporal gyrus; Structure of subthalamic
nucleus; Malignant neoplasm of tongue; Malignant neoplasm of gallbladder; Uterine Cancer; Malignant neoplasm of ureter; Malignant
neoplasm of brain; Umbilical Cord Blood; Stromal Cells; Prefrontal Cortex; Structure of entorhinal cortex; Ventral Tegmental Area;
Injury; Blood specimen; Muscle biopsy; Fiberoptic bronchoscopy; Bronchial; Coronary artery; Cervical; Dorsal; Peripheral; Basal;
chronic; Induced; Invasive; Malignant - descriptor; Nodular; Normal; Papillary; Lobular; Uninvolved; Undifferentiated; Adenocarci-
noma, Oxyphilic; Adolescent; Undifferentiated carcinoma; Posterior root of spinal nerve; Adenosquamous carcinoma; Malignant Mixed
Tumor; Endometrial Stromal Sarcoma; Adrenal Cortical Adenoma; Adenoma, Villous; Adenomatous Polyps; Adenocarcinoma, Clear
Cell; Adrenocortical carcinoma; Carcinoma, Endometrioid; Carcinoma, Lobular; Mucoepidermoid Carcinoma; Carcinoma, Neuroen-
docrine; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Carcinoma, Large Cell; Rhabdoid Tumor; Lesion; Epithelial;
Squamous epithelial cell; Skin structure of nipple; Subcutaneous Fat; Collecting duct; Lactiferous duct; Iliac crest structure; Struc-
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ture of deltoid muscle; Entire biceps brachii; Structure of vastus lateralis muscle; Structure of synovial tissue of joint; Synovial fluid
mononuclear cell; soft tissue; Endothelial Cells; Transitional epithelial cell; Oral cavity; Papilla of tongue; Fundus of abomasum; Colonic
epithelium; Transverse colon; Renal pelvis; Body of uterus; Endometrio-; Foreskin of penis; Frontal lobe gyrus; Temporal lobe gyrus;
Cerebellar hemisphere structure; Cerebellar vermis structure; Hematopoietic; lymphoblast; peripheral blood; Pelvic peritoneum; Child-
hood; Autistic thinking; Memory impairment; Gallbladder Carcinoma; Endometrium normal; Uterus normal; Nonhuman Primates;
Gastrointestinal Stromal Tumors; Muscular Dystrophy, Facioscapulohumeral; Carcinoma of Nasopharynx; Papillary thyroid carcinoma;
Epidermal Growth Factor; Malignant neoplasm of lung; mucosa-associated lymphoid tissue lymphoma; Skeletal muscle structure; Sys-
temic Inflammatory Response Syndrome; Systemic infection; Cyclin-Dependent Kinases; control; Interferon beta-1a; Multiple tumors;
Skeletal bone; Dermatomyositis, Childhood Type; Childhood asthma; Acute gastric mucosal erosion; Retroperitoneal mass; Rhinovirus
infection; Red stools; Subcutaneous Tissue; Cancer of Head and Neck; Malignant Bone Neoplasm; Refractory anemia with excess blasts
in transformation (clinical); Mixed Oligodendroglioma-Astrocytoma; Caco-2 Cells; atorvastatin; Cervix carcinoma; Organic arsenic;
Human rhinovirus; Acinar; Normal tissue morphology; Septic; Depletion; Myeloma cell; Metaplastic polyp; Metaplastic; Secretory en-
dometrium; [M]Squamous cell carcinoma, metastatic NOS; Squamous cell carcinoma, keratinizing; Papillary transitional cell carcinoma;
[M]Adenocarcinoma, metastatic, NOS; Papillary serous cystadenocarcinoma; Serous surface papillary carcinoma; Mucin-producing ade-
nocarcinoma; Blast (physical force); Smoker; Non-smoker; Endometriosis of uterus; Malignant neoplasm of liver; Cancer of Intestines;
Malignant neoplasm of pancreas; Pelvic mass; Blast Cell; whole blood; Marrow; Malignant neoplasm of prostate; Escherichia coli O157;
Fibroblast Growth Factor 2; CBFbeta-MYH11 fusion protein; Bone Tissue; Chemotherapy Regimen; Lupus Erythematosus; Indian
ethnic group; Developmental delay (disorder); Human cells; Bone marrow specimen; Primary operation; Myeloid; Follicular; Cirrhotic;
Tobacco smoke; Fetal brain; Serous; Human tissue; Oral; Salivary; Paravertebral; subcutaneous; Whole blood sample; Synovial fluid
cells; Whole; Non-small cell; Tobacco smoking behavior; Chewed tobacco consumption; Entire temporal lobe gyrus; Airway structure;
Cigarette consumption; Tumor tissue sample; Pulmonary lymphoma; Spinal; Oropharyngeal; Rectum and sigmoid colon; Adrenal; Fetal;
Probiotics; Small Intestine - Duodenum; Balanced salt solution; Tobacco use; Malignant neoplasm of esophagus; Thyroid carcinoma;
Ewings sarcoma; Pregnant - adjective; Chronic Childhood Arthritis; Exocrine pancreas; Malignant Glioma; Colorectal; Tongue Carci-
noma; Persistent cough; Placenta healthy; Vulva normal; Vagina normal; Normal ovary; Breast normal; Nipple normal; Fallopian tube
normal; Joint normal; Skeletal muscle normal; Biopsy of jejunum; Tongue normal; Stomach normal; Liver normal; Penis normal; Gastric
biopsy sample; Colonic biopsy sample; Basal Cell; Embryonic Stem Cells; Steroid biosynthesis; Nasal Epithelium; Ureter Carcinoma;
Prostate carcinoma; epoxomicin; Cigarette; Epithelial ovarian cancer; Breast Carcinoma; Skin tissue; Carcinoma of lung; Regression
- mental defense mechanism; Duct (organ) structure; Umbilical Blood; Colon Carcinoma; Stomach Carcinoma; Skin carcinoma; Bone
carcinoma; Small; Fundus; Malignant neoplasm of kidney; Cancer of Neck; Sarcoma, metastatic; Brain Tumor, Primary; Cancer of Head;
Tonsil; Uterine carcinoma; Radiation; Pluripotent Stem Cells; R-1881; Stromal Neoplasm; ovarian neoplasm; Microsatellite Instability;
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Mammary gland; Inorganic arsenic; Cholecystolithiasis; Hurthle Cells; adalimumab; Skin; Invasive Ductal Breast Carcinoma; Malig-
nant neoplasm of ovary; ezetimibe; kinase inhibitor; Ezetrol; Ductal Carcinoma; Lymphatic Endothelial Cells; Mesenchymal Stem Cells;
HCT116 Cells; sarcoma; Bifidobacterium lactis; Chromophobe Renal Cell Carcinoma; Collecting Duct Carcinoma (Kidney); Metaplas-
tic carcinoma; Superior mediastinal lymph node; Entire pulmonary artery; Entire substantia nigra; Entire thalamus; Skin fibroblast;
Cutaneous lymphoma; Entire fallopian tube; Entire limb; Entire skeletal muscle (organ); Branchial Clefts; Entire oropharynx; Entire
hypothalamus; Entire pons; Entire superior frontal gyrus; Entire middle temporal gyrus; Entire subthalamic nucleus; Entire putamen;
Entire rib; Entire entorhinal cortex; Inflammatory disorder; Abdominal bloating; Amniotic fluid specimen; Precursor B-cell lymphoblas-
tic leukemia; Entire synovial tissue of joint; Medulla; Primary malignant neoplasm; Papillary Renal Cell Carcinoma; Peripheral blood
mononuclear cell; Entire vastus lateralis muscle; Acute myelomonocytic leukemia with abnormal eosinophils; Classical Hodgkin’s Lym-
phoma; Stromal sarcoma; Adrenal carcinoma; Renal carcinoma; Metastatic Carcinoma; Gastric erosion; Systemic onset juvenile chronic
arthritis; torcetrapib; Tumor Necrosis Factor-alpha; Mammary Neoplasms; Ductal; Pediatric; Pectoral; Coronary; metastatic qualifier;
Mediastinal; urinary; Colorectal Cancer; Ductal Breast Carcinoma; Adenocarcinoma, Endometrioid; Glioblastoma Multiforme; Cirrho-
sis; Gastric; Ventral; Fetal Stem Cells; Acute myeloid leukemia without maturation; Acute Myeloid Leukemia (AML-M2); Embryonic





Differentially expressed genes in
brain, blood, and soft tissue
B.1 Over-expressed genes in soft tissue
Table B.1:
GO ID GO Term P Value
GO:0005584 collagen type I 0.017
GO:0005583 fibrillar collagen 0




GO:0048407 platelet-derived growth factor binding 0
GO:0030199 collagen fibril organization 0
GO:0005520 insulin-like growth factor binding 0
GO:0005581 collagen 0
GO:0032963 collagen metabolic process 0
GO:0044259 multicellular organismal macromolecule metabolic process 0
GO:0044236 multicellular organismal metabolic process 0.001
GO:0044420 extracellular matrix part 0
GO:0005201 extracellular matrix structural constituent 0
GO:0030198 extracellular matrix organization 0
GO:0005604 basement membrane 0
GO:0043588 skin development 0.001
GO:0005200 structural constituent of cytoskeleton 0.001
GO:0010035 response to inorganic substance 0.033
GO:0001649 osteoblast differentiation 0.039
GO:0009612 response to mechanical stimulus 0
GO:0043062 extracellular structure organization 0
Continued on Next Page. . .
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Table B.1 – Continued
GO ID GO Term P Value
GO:0006956 complement activation 0.001
GO:0070161 anchoring junction 0.018
GO:0002541 activation of plasma proteins involved in acute inflammatory response 0.002
GO:0009987 cellular process 0.013
GO:0005911 cell-cell junction 0.036
GO:0016043 cellular component organization 0.048
GO:0031960 response to corticosteroid stimulus 0
GO:0031012 extracellular matrix 0
GO:0005578 proteinaceous extracellular matrix 0
GO:0016337 cell-cell adhesion 0.008
GO:0019838 growth factor binding 0
GO:0030154 cell differentiation 0
GO:0008201 heparin binding 0
GO:0051384 response to glucocorticoid stimulus 0
GO:0001525 angiogenesis 0.017
GO:0008544 epidermis development 0
GO:0005539 glycosaminoglycan binding 0
GO:0005198 structural molecule activity 0
GO:0006959 humoral immune response 0.041
GO:0001871 pattern binding 0
GO:0030247 polysaccharide binding 0
GO:0030855 epithelial cell differentiation 0.004
GO:0048869 cellular developmental process 0.017
GO:0044421 extracellular region part 0
GO:0009628 response to abiotic stimulus 0.049
GO:0005576 extracellular region 0
GO:0005615 extracellular space 0
GO:0048545 response to steroid hormone stimulus 0
GO:0050896 response to stimulus 0.05
GO:0007584 response to nutrient 0.028
GO:0009888 tissue development 0
GO:0007155 cell adhesion 0
GO:0022610 biological adhesion 0
GO:0009725 response to hormone stimulus 0
GO:0009719 response to endogenous stimulus 0.008
GO:0010033 response to organic substance 0
GO:0009605 response to external stimulus 0.02
GO:0048856 anatomical structure development 0
GO:0042221 response to chemical stimulus 0
GO:0032502 developmental process 0
GO:0006950 response to stress 0.023
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Figure B-1: Expression intensity distribution of the top 20 over-expressed soft tissue
genes. Each plot corresponds to the kernel density estimate of expression values for
the gene named above each plot for the three broad tissue types, blood, brain, and
soft tissue. We see that the expression values of soft tissue specific genes such as
COL3A1, COL6A3, KRT19, KRT14, and CADH1 are markedly higher in samples
corresponding to soft tissues than in samples of the other two types.
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B.2 Over-expressed genes in blood


















































































































































































Figure B-2: Expression intensity distribution of the top 20 over-expressed brain tissue
genes. Each plot corresponds to the kernel density estimate of expression values for
the gene named above each plot for the three broad tissue types, blood, brain, and
soft tissue. We see that the expression values of brain specific genes such as GFAP,
APLP1, GRIA2, PLP1, and SLC1A2 are markedly higher in samples corresponding
to brain tissue than in samples of the other two types.
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Table B.2:
GO ID GO Term P Value
GO:0042105 alpha-beta T cell receptor complex 0
GO:0045730 respiratory burst 0.008
GO:0050857 positive regulation of antigen receptor-mediated signaling pathway 0.041
GO:0005833 hemoglobin complex 0
GO:0005344 oxygen transporter activity 0.001
GO:0042101 T cell receptor complex 0.002
GO:0050854 regulation of antigen receptor-mediated signaling pathway 0.005
GO:0031640 killing of cells of another organism 0.004
GO:0045058 T cell selection 0.035
GO:0003823 antigen binding 0
GO:0001906 cell killing 0.036
GO:0050830 defense response to Gram-positive bacterium 0
GO:0009620 response to fungus 0.009
GO:0006968 cellular defense response 0
GO:0001608 nucleotide receptor activity, G-protein coupled 0.045
GO:0045028 purinergic nucleotide receptor activity, G-protein coupled 0.045
GO:0004715 non-membrane spanning protein tyrosine kinase activity 0.036
GO:0042742 defense response to bacterium 0
GO:0031225 anchored to membrane 0.014
GO:0006935 chemotaxis 0
GO:0042330 taxis 0
GO:0050870 positive regulation of T cell activation 0.015
GO:0009617 response to bacterium 0
GO:0042110 T cell activation 0
GO:0006955 immune response 0
GO:0002376 immune system process 0
GO:0050863 regulation of T cell activation 0.004
GO:0040011 locomotion 0
GO:0046649 lymphocyte activation 0
GO:0007626 locomotory behavior 0
GO:0006952 defense response 0
GO:0050867 positive regulation of cell activation 0.014
GO:0045321 leukocyte activation 0
GO:0051707 response to other organism 0
GO:0009897 external side of plasma membrane 0.044
GO:0002684 positive regulation of immune system process 0
GO:0001775 cell activation 0
GO:0051249 regulation of lymphocyte activation 0.01
GO:0050865 regulation of cell activation 0.002
GO:0002694 regulation of leukocyte activation 0.008
GO:0006954 inflammatory response 0
GO:0002682 regulation of immune system process 0
GO:0007610 behavior 0.002
GO:0009607 response to biotic stimulus 0
GO:0030246 carbohydrate binding 0.038
GO:0009611 response to wounding 0
GO:0009605 response to external stimulus 0.001
GO:0005887 integral to plasma membrane 0
GO:0031226 intrinsic to plasma membrane 0
GO:0051704 multi-organism process 0.003
GO:0004872 receptor activity 0
GO:0004871 signal transducer activity 0
GO:0060089 molecular transducer activity 0
GO:0006950 response to stress 0
GO:0050896 response to stimulus 0
GO:0005886 plasma membrane 0
GO:0044459 plasma membrane part 0
Continued on Next Page. . .
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Table B.2 – Continued
GO ID GO Term P Value
GO:0007166 cell surface receptor linked signaling pathway 0
GO:0004888 transmembrane receptor activity 0.012
GO:0023033 signaling pathway 0
GO:0023052 signaling 0.003
GO:0016020 membrane 0
GO:0044425 membrane part 0
GO:0031224 intrinsic to membrane 0.002
GO:0016021 integral to membrane 0.012
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B.3 Over-expressed genes in brain




















































































































































































Figure B-3: Expression intensity distribution of the top 20 over-expressed blood genes.
Each plot corresponds to the kernel density estimate of expression values for the gene
named above each plot for the three broad tissue types, blood, brain, and soft tissue.
We see that that the expression value of brain specific genes such as HBM, PPBP,
VNN2, SELL, and NFE2 are markedly higher in samples corresponding to blood than
in samples of the other two types.
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Table B.3:
GO ID GO Term P Value
GO:0045110 intermediate filament bundle assembly 0.044
GO:0005883 neurofilament 0.001
GO:0060052 neurofilament cytoskeleton organization 0.013
GO:0007269 neurotransmitter secretion 0.02
GO:0001505 regulation of neurotransmitter levels 0
GO:0006836 neurotransmitter transport 0
GO:0008021 synaptic vesicle 0.013
GO:0043197 dendritic spine 0.032
GO:0044309 neuron spine 0.032
GO:0033267 axon part 0
GO:0030424 axon 0
GO:0007409 axonogenesis 0
GO:0043005 neuron projection 0
GO:0008509 anion transmembrane transporter activity 0.035
GO:0048812 neuron projection morphogenesis 0
GO:0007417 central nervous system development 0
GO:0048858 cell projection morphogenesis 0
GO:0044456 synapse part 0
GO:0045202 synapse 0
GO:0044463 cell projection part 0
GO:0032990 cell part morphogenesis 0.003
GO:0007268 synaptic transmission 0
GO:0022891 substrate-specific transmembrane transporter activity 0.018
GO:0022857 transmembrane transporter activity 0.04
GO:0005215 transporter activity 0.007
GO:0045211 postsynaptic membrane 0.019
GO:0042995 cell projection 0
GO:0030054 cell junction 0
GO:0007399 nervous system development 0
GO:0048731 system development 0
GO:0022838 substrate-specific channel activity 0.036
GO:0051234 establishment of localization 0.02
GO:0007267 cell-cell signaling 0.021
GO:0006810 transport 0.04
GO:0015075 ion transmembrane transporter activity 0.013
GO:0007154 cell communication 0.02
GO:0006811 ion transport 0.017
GO:0044459 plasma membrane part 0.003




C.1 Cross-validation performance of Concordia
The leave-one-out cross validation performance of the 1489 disease and anatomy con-
cepts as computed by the method outlined in Chapter 4
Table C.1: Cross-validation performance of Concordia
Concept AUC Num Samples Num Series
Anatomic structures 0.860795353 2954 154
Body Regions 0.860795353 2954 154
Physical anatomical entity 0.860795353 2954 154
body system 0.852956551 2603 131
Body tissue 0.837848153 2474 112
Body organ structure 0.744149574 2433 118
Body part 0.906311914 1914 83
Body substance 0.835581871 1916 85
Entire subdivision of organ system 0.742509803 1595 100
Musculoskeletal System 0.742132317 1594 100
Skeletal system 0.742132317 1594 100
SKELETAL SYSTEM: GENERAL TERMS 0.742132317 1594 100
Skeletal System (Bones of Head, Rib Cage and Vertebral Column) 0.742132317 1594 100
SOFT TISSUES, SMOOTH MUSCLE AND CARTILAGINOUS TISSUES 0.736962657 1571 98
Soft Tissue, Bone and Cartilage 0.736962657 1571 98
soft tissue 0.685021181 1513 98
Disorder by body site 0.741622966 1194 100
Neck, chest, abdomen, and pelvis 0.897100766 1322 73
Disorder of body system 0.741326811 1141 97
Body space structure 0.848075943 1551 62
Body material 0.694239734 1665 70
Body cavities 0.850792747 1537 60
Neck, chest and abdomen 0.897120386 1269 66
Trunk structure 0.859012735 1234 68
Structure of subregion of trunk 0.858528777 1232 66
Chest, abdomen, and pelvis 0.868753539 1193 66
Chest and abdomen 0.871699619 1140 59
Continued on Next Page. . .
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Table C.1 – Continued
Concept AUC Num Samples Num Series
Cells 0.913694148 710 90
Neoplasms 0.79627514 910 78
Neoplasm and/or hamartoma 0.79627514 910 78
sex 0.756465161 1457 51
Organ part 0.858393737 1199 53
Unspecified Neoplasms and Tumor Cells 0.79737436 902 75
Malignant Neoplasms 0.815926867 855 74
Malignant tumor of unknown origin or ill-defined site 0.815926867 855 74
Malignant neoplasm of other and unspecified site otherwise specified 0.815926867 855 74
Malignant neoplasm of other and unspecified sites 0.815926867 855 74
Malignant Neoplasm (Morphology) 0.812252124 835 67
Primary malignant neoplasm 0.811627883 833 66
Upper body structure 0.896343213 1117 44
Upper body part structure 0.896343213 1117 44
Connective Tissue 0.691873179 917 68
Body tissue material 0.691873179 917 68
Skeletal material 0.691873179 917 68
Neoplasm by body site 0.770455134 755 68
Hemic and Immune Systems 0.968525364 681 56
Neoplasms by Site 0.764899866 717 62
Neoplasms by Histologic Type 0.796900372 773 55
Cellular Structures 0.879070575 575 67
Lower body structure 0.799826114 827 51
Lower body part structure 0.799826114 827 51
Abdomen and pelvis 0.80237391 820 50
Entire cell 0.886090444 566 65
Structure of viscus 0.802896481 834 44
Musculoskeletal Diseases 0.647263327 671 62
Connective Tissue Diseases 0.647263327 671 62
Musculoskeletal and connective tissue disorders 0.647263327 671 62
Abdominal Cavity 0.812552248 767 43
ABDOMEN INCLUDING PERITONEUM AND RETROPERITONEUM 0.812552248 767 43
Abdomen 0.812552248 767 43
Disorder of body cavity 0.725818039 661 49
Fluids and Secretions 0.98873893 526 45
Body Fluids 0.989560932 524 44
Male gender 0.768290336 694 40
Blood 0.99298379 508 41
Female 0.700241563 764 36
Disorder of trunk 0.826006589 546 42
Bone and/or joint structure 0.853841241 487 45
Hematological system 0.907304659 467 44
Hematopoietic System 0.907304659 467 44
Skeletal bone 0.863690184 475 45
Integumentary system 0.827015849 530 42
SKIN AND SKIN APPENDAGES 0.827015849 530 42
INTEGUMENTARY SYSTEM: GENERAL TERMS 0.827015849 530 42
Immune system 0.906197905 437 42
Structure of lymphoreticular system 0.906197905 437 42
Neoplasms, Glandular and Epithelial 0.906278199 503 32
Bone Marrow 0.912430297 407 37
Bone Marrow and Erythropoietic Tissues 0.912430297 407 37
Neck and chest 0.860055289 505 31
Gastrointestinal system 0.918517706 466 31
Gastrointestinal tract structure 0.918517706 466 31
DIGESTIVE SYSTEM: GENERAL TERMS 0.918517706 466 31
Head and neck structure 0.978785357 680 19
Neoplasm of trunk 0.86726834 440 33
Continued on Next Page. . .
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Table C.1 – Continued
Concept AUC Num Samples Num Series
Digestive organ structure 0.928308168 442 30
DIGESTIVE ORGANS: GENERAL TERMS 0.928308168 442 30
DISORDERS OF THE MUSCLES, LIGAMENTS, FASCIAE AND OTHER
SOFT TISSUES
0.724249863 429 39
Skeleton 0.782528241 495 31
Epithelioma 0.925849089 486 26
Entire body organ 0.843848235 554 25
Entire anatomical structure 0.843848235 554 25
Bone and Bones 0.789295752 480 30
Carcinoma 0.937877567 459 25
Malignant epithelial neoplasm - category 0.937877567 459 25
Pelvis and lower extremities 0.869981436 455 27
Pelvis 0.875675176 448 26
Lower trunk structure 0.875675176 448 26
Structure of abdominal viscus 0.889200394 395 29
Head 0.984123118 634 16
Structure of breast and/or endocrine system 0.882905169 431 25
Head part 0.984555368 621 15
Other diseases of blood or blood-forming organs 0.939489687 274 35
Disorder of cellular component of blood 0.939489687 274 35
Disorder of hematopoietic structure 0.939489687 274 35
Hematological Disease 0.939489687 274 35
Genitourinary system 0.876727537 427 23
Urinary tract 0.876727537 427 23
Urinary system 0.876727537 427 23
URINARY TRACT: GENERAL TERMS 0.876727537 427 23
Structure of thorax, including mediastinum and diaphragm 0.884483878 376 23
Upper trunk structure 0.884483878 376 23
Chest 0.884483878 376 23
Digestive System Disorders 0.814596577 333 27
Intra-abdominal digestive structure 0.950259537 319 24
Blood Cells 0.922545955 287 27
Structure of product of conception 0.973690213 486 15
Disorder of abdomen 0.807550896 322 26
Bone marrow part 0.925127094 257 25
Structure of myelopoietic tissue 0.925127094 257 25
Leukocytes 0.925127094 257 25
Urogenital organ 0.884348608 365 18
Structure of anatomical reproductive system 0.884348608 365 18
Genitalia 0.884348608 365 18
Genital system 0.884348608 365 18
Immune System Diseases 0.917118014 207 30
Disorder of pelvis 0.826190109 291 23
Reticuloendothelial System 0.908491689 224 27
Abdominal mass 0.80899537 274 23
Abdominal Neoplasms 0.809412205 273 23
Developmental body structure 0.9814019 435 11
Embryonic Structures 0.9814019 435 11
Gland 0.864800244 301 18
Complex structure derived from epithelium 0.864800244 301 18
Cardiovascular Diseases 0.924081132 222 22
Cultured Cells 0.987418163 152 30
Adenoma AND/OR adenocarcinoma 0.900045077 309 16
ADENOMAS AND ADENOCARCINOMAS 0.898977891 305 16
Cell Line 0.988847222 150 29
Nervous system structure 0.997338868 530 8
Other part of nervous system 0.997338868 530 8
Mononuclear cell (histiocyte, lymphocyte, plasma cell) 0.923247787 207 22
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Reticuloendothelial cell 0.923247787 207 22
Central nervous system part 0.997433424 521 8
Neuraxis 0.997433424 521 8
Brain and spinal cord structure 0.997433424 521 8
Structure of body cavity subdivision 0.879796195 335 14
Pelvic cavity structure 0.879796195 335 14
CLINICAL CLASSIFICATION OF NEOPLASMS OF THE MUSCULOSKELE-
TAL SYSTEM AND SOFT TISSUES
0.807428644 232 22
Disorder of soft tissue 0.768224999 233 23
[X]Other soft tissue disorders 0.768224999 233 23
Cranial cavity structure 0.996742397 497 8
Peripheral blood mononuclear cell 0.923089866 204 21
Malignant neoplasm of abdomen 0.852137791 210 22
Brain 0.997067302 488 8
Intracranial structure 0.997067302 488 8
Pelvic genital structure 0.878519688 315 14
Neoplasm, uncertain whether benign or malignant 0.95582066 193 21
[X]Malignant neoplasms of lymphoid, hematopoietic and related tissue 0.967070052 190 21
Hematopoietic Neoplasms 0.967070052 190 21
Neoplasm of hematopoietic cell type 0.967070052 190 21
Disorder of the genitourinary system 0.85773095 241 18
Disorder of hematopoietic morphology 0.966877674 189 20
Malignant adenomatous neoplasm - category 0.921305759 282 14
Adenocarcinoma 0.91945118 277 14
peripheral blood 0.948089669 180 19
Structure of respiratory system and/or intrathoracic structure 0.785398275 227 18
Intestines 0.954716029 223 15
Lower Gastrointestinal Tract 0.954716029 223 15
Stem cells 0.930699608 179 19
Endocrine system 0.865576316 238 15
Endocrine Glands 0.870520061 236 15
Structure of endocrine system 0.870520061 236 15
Thoracic Diseases 0.883076805 203 17
Respiration Disorders 0.883076805 203 17
DISEASES OF THE SINUSES, NOSE, PHARYNX AND LARYNX 0.883076805 203 17
skin disorder 0.815144635 185 19
Skin and subcutaneous tissue disorders 0.815144635 185 19
Disorder of integument 0.815144635 185 19
RESPIRATORY SYSTEM: GENERAL TERMS 0.90312674 189 16
Respiratory System 0.90312674 189 16
Other female genital tract 0.869372565 277 11
Female genitalia 0.869372565 277 11
Female genitourinary system 0.869372565 277 11
Disorder of digestive organ 0.925218679 165 17
Pelvic organ 0.872254428 270 11
Female internal genitalia structure 0.872649335 268 11
Pelvic cavity female genital structure 0.872649335 268 11
Human material 0.935804891 899 3
Human surgical material 0.935804891 899 3
Human tissue 0.935804891 899 3
Upper female genital structure 0.875670647 260 11
Neuromuscular Diseases 0.853808859 191 15
nervous system disorder 0.853808859 191 15
Neuropathy 0.853808859 191 15
Nervous system and sense organ diseases 0.853808859 191 15
Myopathy 0.853808859 191 15
[X]Other disorders of the nervous system 0.853808859 191 15
Neuromuscular Junction Diseases 0.853808859 191 15
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DISORDERS OF PERIPHERAL NERVOUS SYSTEM: GENERAL TERMS 0.853808859 191 15
Disorder of skeletal muscle 0.853808859 191 15
Nerve, plexus and root disorders 0.853808859 191 15
Peripheral Neuropathy 0.853808859 191 15
Breast 0.928091168 195 13
Disorder of digestive tract 0.921074977 157 16
Disorder of immune structure 0.96008056 133 18
Non-infectious disorder of lymphatics 0.96008056 133 18
Lymphatic Diseases 0.96008056 133 18
Lymphatic Vessel Diseases 0.96008056 133 18
Respiratory tract structure 0.914390521 179 14
Telencephalon 0.985696581 422 5
Prosencephalon 0.985696581 422 5
Brain tissue 0.985696581 422 5
Supratentorial brain part 0.985696581 422 5
Embryonic nervous system structure 0.985696581 422 5
Brain part 0.985696581 422 5
Nervous structure of head 0.985696581 422 5
Regional nervous structure 0.985696581 422 5
Nervous structure of head and neck 0.985696581 422 5
Cerebrum 0.985696581 422 5
Neoplasm of intra-abdominal organs 0.820813464 155 16
Skin AND subcutaneous tissue structure 0.936626656 194 11
Integumentary system part 0.936626656 194 11
Soft tissue lesion 0.791637671 156 16
Hematologic Neoplasms 0.992818515 151 13
Leukemia (category) 0.992818515 151 13
leukemia 0.992818515 151 13
CLINICAL CLASSIFICATION OF NEOPLASMS OF THE HEMATOPOI-
ETIC AND IMMUNE SYSTEMS
0.992818515 151 13
Thoracic Neoplasms 0.948782839 167 12
Mediastinal Diseases 0.948782839 167 12
[D]Chest mass 0.948782839 167 12
DISEASES OF THE PLEURA, MEDIASTINUM AND DIAPHRAGM 0.948782839 167 12
Thoracic cavity structure 0.806660862 181 13
Immunoproliferative neoplasm 0.960789907 123 16
Lymphoreticular tumor 0.960789907 123 16
[M]Miscellaneous myeloproliferative and lymphoproliferative disorders 0.960789907 123 16
Hematopoietic neoplasm of uncertain behavior 0.960789907 123 16
Immunoproliferative Disorders 0.960789907 123 16
Malignant immunoproliferative neoplasm 0.960789907 123 16
Immunoproliferative morphology 0.960789907 123 16
Lymphoid neoplasm 0.960789907 123 16
Lymphoproliferative Disorders 0.960789907 123 16
Cerebral hemisphere structure (body structure) 0.984203701 379 5
Structure of skin and/or surface epithelium 0.929849639 196 10
Primary malignant neoplasm of bone marrow 0.993372685 150 12
Upper digestive tract structure 0.914264264 169 11
Structure of lung and/or mediastinum 0.831865487 170 12
Structure of thoracic viscus 0.833626675 169 12
Large Intestine 0.955636743 156 11
Traumatic abnormality 0.865541486 133 14
GENERAL AND COMPRESSION INJURIES 0.865541486 133 14
GENERAL INJURIES 0.865541486 133 14
Injury 0.865541486 133 14
Integumentary system subdivision 0.938580862 188 9
Entire skin 0.938580862 188 9
Skin 0.938580862 188 9
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CLINICAL CLASSIFICATION OF NEOPLASMS OF THE DIGESTIVE SYS-
TEM
0.849413338 124 15
Endocrine System Diseases 0.910750297 133 13
GENERAL AND POLYGLANDULAR ENDOCRINE DISORDERS 0.910750297 133 13
GENERAL AND GROWTH RELATED DISORDERS 0.910750297 133 13
Acute leukemia 0.992114711 144 11
Acute leukemia (category) 0.992114711 144 11
Female Reproductive System Disorder 0.830014077 172 11
reproductive system disorder 0.830014077 172 11
Female Genital Diseases 0.830014077 172 11
Primary malignant neoplasm of trunk 0.853404172 126 14
Disorder of skeletal system 0.891154898 104 16
Disorder of immune function 0.893311447 97 16
Lower respiratory tract structure 0.94260856 142 10
Lower respiratory system structure 0.94260856 142 10
Large intestine part 0.954574889 140 10
CNS disorder 0.950732979 126 11
Neck 0.926122775 129 11
Scalp and/or neck structure 0.926122775 129 11
Face and/or neck structure 0.926122775 129 11
Complication 0.863676241 117 13
Poisoning / injury 0.863676241 117 13
POISONINGS: GENERAL TYPES 0.863676241 117 13
Poisoning 0.863676241 117 13
Sequela of disorder 0.863676241 117 13
Bone Marrow Cells 0.919730967 129 11
Colon 0.957816236 134 10
Disorder of head 0.940922395 136 10
Digestive System Neoplasms 0.91056671 108 13
Neoplasm of digestive organ 0.91056671 108 13
[X]Malignant neoplasm of digestive organs 0.91056671 108 13
Soft Tissue Neoplasms 0.862589352 122 12
Pulmonary structure including vessels and lymphoid tissue 0.947662442 132 10
Noninflammatory disorder of the female genital organs 0.856026394 142 10
Pelvic mass 0.856026394 142 10
Genitourinary Neoplasms 0.854429494 141 10
Pelvic Neoplasms 0.854429494 141 10
Gastrointestinal Diseases 0.9385517 116 11
Cerebral hemisphere part 0.987087843 290 4
Skin lesion 0.874163434 108 12
Lung 0.952565902 131 9
Uterus 0.916445334 175 7
UTERUS: GENERAL TERMS 0.916445334 175 7
Endocrine Gland Neoplasms 0.918531693 122 10
Female genital organ part 0.917254244 173 7
Immunologic cell 0.953745764 89 13
Uterus part 0.916187934 172 7
[X]Other specified respiratory disorders 0.900153068 134 9
Other disorders of lung 0.900153068 134 9
Other respiratory system diseases NOS 0.900153068 134 9
Disorder of lower respiratory system 0.900153068 134 9
DISEASES OF THE LUNG: GENERAL TERMS 0.900153068 134 9
Lung diseases 0.900153068 134 9
Gonadal structure 0.945116752 126 9
Stomatognathic System 0.942421013 123 9
Mouth and/or pharynx structures 0.942421013 123 9
CLINICAL CLASSIFICATION OF NEOPLASMS OF THE GENITOURI-
NARY SYSTEM
0.831083631 124 10
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Soft tissue tumor AND/OR sarcoma 0.894420302 96 12
Sarcoma - category 0.894420302 96 12
Connective and Soft Tissue Neoplasm 0.894420302 96 12
sarcoma 0.894420302 96 12
Leukocytes, Mononuclear 0.959415318 89 12
Brain Diseases 0.96444927 116 9
Tissue membrane 0.858421184 104 11
Upper aerodigestive tract 0.955354786 113 9
Inflammation of specific body systems 0.789088761 91 13
Inflammation of specific body structures or tissue 0.789088761 91 13
Inflammation of specific body organs 0.789088761 91 13
Inflammatory disorder 0.789088761 91 13
Cerebral cortex 0.988689443 236 4
Layer of cerebrum 0.988689443 236 4
Malignant neoplasm of pelvis 0.886186182 104 10
Malignant neoplasm of genitourinary organ NOS 0.886186182 104 10
Marrow lymphoid tissue 0.982844922 82 11
Lymphocyte 0.982844922 82 11
Face 0.952046729 103 9
Male Genital Organs 0.908565602 88 11
Male genitourinary tract 0.908565602 88 11
Neoplasms, Nerve Tissue 0.942557141 93 10
Neoplasms, Germ Cell and Embryonal 0.942557141 93 10
Neuroectodermal Tumors 0.942557141 93 10
Hematopoietic precursor cell 0.949869526 131 7
Lobe of brain 0.987886124 218 4
Cerebral lobe 0.987886124 218 4
Animal Structures 0.941326491 109 8
Mammalian Oviducts 0.951279092 107 8
animal Oviduct 0.951279092 107 8
Uterine adnexae structure 0.951279092 107 8
Ovary and/or broad ligament structures 0.947738 103 8
Ovary 0.947738 103 8
Digestive organ part 0.85285045 91 10
Regional musculoskeletal structure 0.871264407 79 11
Skin Neoplasms 0.901783328 93 9
Neoplasm of integumentary system 0.901783328 93 9
Limb structure 0.910886673 72 11
Primary malignant neoplasm of soft tissues 0.904030962 88 9
Gastrointestinal Neoplasms 0.923123104 86 9
Oral region 0.949576787 94 8
Oral cavity 0.949576787 94 8
Body of uterus 0.941591198 151 5
CLINICAL CLASSIFICATION OF NEOPLASMS OF THE SKIN 0.904218465 87 9
Malignant neoplasm of skin 0.904218465 87 9
Primary malignant neoplasm of skin 0.904218465 87 9
Malignant neoplasm of thorax 0.953098002 72 10
Extremity part 0.929292929 66 11
Lymphoid leukemia (category) 0.995833737 84 8
Lymphoblastic Leukemia 0.995833737 84 8
Adult Stem Cells 0.935222713 101 7
Disorder of lower gastrointestinal tract 0.94470788 85 8
Intestinal Diseases 0.94470788 85 8
Propensity to adverse reactions 0.842927076 68 11
Hypersensitivity 0.842927076 68 11
Immune hypersensitivity disorder by mechanism 0.842927076 68 11
Hypersensitivity disorder 0.842927076 68 11
Adverse reactions 0.842927076 68 11
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Bone Diseases 0.972210425 70 9
Liver and/or biliary structure 0.932231914 59 11
Mammary Neoplasms 0.965571757 69 9
Malignant neoplasm of breast 0.965571757 69 9
Breast Diseases 0.965571757 69 9
Vascular Diseases 0.924512637 108 6
GENERAL VASCULAR DISORDERS 0.924512637 108 6
Carcinoma of the Large Intestine 0.963114694 69 9
Liver 0.931544995 58 11
Mouth region part 0.962988999 88 7
SKELETAL MUSCULAR SYSTEM: GENERAL TERMS 0.985010901 86 7
Muscle 0.985010901 86 7
Muscle structure 0.985010901 86 7
Types and Parts of Skeletal Muscles 0.985010901 86 7
Skeletal Muscular System (Muscles of Head, Neck, Mouth and Upper Extrem-
ity)
0.985010901 86 7
Skeletal muscle system structure 0.985010901 86 7
Neuroendocrine Tumors 0.95962756 87 7
Regional bone structure 0.872130383 71 9
Skeletal System (Bones of Shoulder Girdle, Pelvis and Extremities) 0.927519696 59 10
Epithelial Cells 0.858768407 42 15
System disorder of the nervous system 0.973479132 111 5
Lower genitourinary tract structure 0.885750122 67 9
Structure of soft tissues of head and neck 0.972995275 78 7
Oral soft tissues 0.972995275 78 7
Structure of soft tissues of head 0.972995275 78 7
Lower male genitourinary tract structure 0.890040213 65 9
Back 0.767798133 94 7
Back structure, including back of neck 0.767798133 94 7
Regional back structure 0.767798133 94 7
Genital Neoplasms, Female 0.906491402 92 6
Anogenital region 0.921632318 54 10
Disorder of upper digestive tract 0.932437729 76 7
Mucous Membrane 0.963991525 80 6
Upper extremity part 0.923096036 61 8
Upper Extremity 0.923096036 61 8
Endometrium 0.95604468 93 5
Kidney and/or ureter structures 0.888950617 60 8
Intra-abdominal urinary structure 0.888950617 60 8
Neurodegenerative Disorders 0.978100363 108 4
Kidney 0.892252223 59 8
Retroperitoneal Space 0.929105471 75 6
T-Lymphocyte 0.99042471 70 6
B-cell neoplasm 0.911092675 44 10
Myeloproliferative disease 0.996339917 66 6
Bone Marrow Diseases 0.996339917 66 6
Myeloid Leukemia 0.996339917 66 6
Leukemia, Myelocytic, Acute 0.996339917 66 6
Skeletal tissue 0.934237452 70 6
Bone Tissue 0.934237452 70 6
Structure of shoulder and/or upper arm 0.923367003 60 7
Shoulder 0.923367003 60 7
Colonic Diseases 0.95768938 57 7
Disorder of large intestine 0.95768938 57 7
Diseases and Syndromes of Colon, Appendix and Rectum 0.95768938 57 7
Degenerative disorder 0.971820447 98 4
CLINICAL CLASSIFICATION OF NEOPLASMS OF THE RESPIRATORY
SYSTEM
0.970887741 98 4
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Respiratory Tract Neoplasms 0.970887741 98 4
Neoplasm of lower respiratory tract 0.970887741 98 4
Lung Neoplasms 0.970887741 98 4
Malignant neoplasm of lung 0.970887741 98 4
Anterior perineum 0.928114094 50 8
External genitalia 0.928114094 50 8
Blast Cell 0.913205095 96 4
Pectoral girdle structure 0.923206641 54 7
Exocrine Glands 0.879361785 65 6
Allergic disorder by body site affected 0.879049525 43 9
Temporal Lobe 0.96914216 117 3
Autoimmune Diseases 0.928837793 40 9
Infectious and parasitic diseases NOS 0.97870768 85 4
INFECTIOUS AND PARASITIC DISEASES: GENERAL TERMS 0.97870768 85 4
Communicable Diseases 0.97870768 85 4
Epithelium 0.881669888 47 8
Lymphoma, Diffuse 0.91590301 40 9
Malignant lymphoma, diffuse 0.91590301 40 9
Diffuse low grade B-cell lymphoma morphology 0.91590301 40 9
Low grade B-cell lymphoma morphology 0.91590301 40 9
B-cell lymphoma morphology 0.91590301 40 9
Unspecified and Diffuse Lymphomas 0.91590301 40 9
Lymphoma, Non-Hodgkin’s 0.91590301 40 9
Lymphoma 0.91590301 40 9
Head and Neck Neoplasms 0.804197324 40 10
Disorder of upper gastrointestinal tract 0.949484821 56 6
Chronic Disease 0.868639252 52 7
[X]Diseases of esophagus, stomach and duodenum 0.951535523 55 6
Intestinal Neoplasms 0.939129106 55 6
Cancer of Intestines 0.939129106 55 6
Limbic System 0.945704783 109 3
Stomach Diseases 0.95120221 54 6
Diseases and Syndromes of Stomach and Duodenum 0.95120221 54 6
Primary malignant neoplasm of intra-abdominal organs 0.909111106 56 6
Lower urinary tract 0.884958781 57 6
Bladder and outflow structure 0.884958781 57 6
Pelvic cavity urinary structure 0.884958781 57 6
Malignant squamous tumor 0.961447259 78 4
Squamous Cell Neoplasms 0.961447259 78 4
Squamous cell carcinoma - category 0.961447259 78 4
[M]Papillary and squamous cell neoplasms 0.961447259 78 4
Urinary outflow structure 0.899006875 55 6
Breast part 0.982384659 75 4
Colorectal Neoplasms 0.962403491 51 6
Colonic Neoplasms 0.962403491 51 6
Malignant tumor of colon 0.962403491 51 6
Mass of colon 0.962403491 51 6
Rectal Diseases 0.962403491 51 6
Malignant neoplasm of large intestine 0.962403491 51 6
Anorectal disorder 0.962403491 51 6
Neoplasms, Ductal, Lobular, and Medullary 0.979846382 58 5
Ductal, lobular AND/OR medullary neoplasm 0.979846382 58 5
ovarian neoplasm 0.985859073 70 4
Ovarian Diseases 0.985859073 70 4
Gonadal Disorders 0.985859073 70 4
Neoplasm of uterine adnexa 0.985859073 70 4
Adnexal Diseases 0.985859073 70 4
Stomach and Omentum 0.880863512 52 6
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Thyroid and/or parathyroid structures 0.99480563 46 6
Malignant neoplasm of female genital organ 0.979987271 56 5
Malignant neoplasm of other and unspecified female genital organs 0.979987271 56 5
Male external genitalia structure 0.933642869 41 7
Bone structure of head and/or neck 0.90272065 59 5
Bone structure of cranium 0.90272065 59 5
Bones of cranium and face 0.90272065 59 5
Musculoskeletal structure of head 0.90272065 59 5
Musculoskeletal structure of head and neck 0.90272065 59 5
Bone structure of head 0.90272065 59 5
Pluripotent Stem Cells 0.996533169 53 5
Mesenchymal Stem Cells 0.998486893 66 4
Inflammatory disorder of musculoskeletal system 0.89003006 36 8
Prostatic and/or seminal vesicle structures 0.891170534 47 6
Minor pelvis 0.891170534 47 6
Male urinary outflow structure 0.891170534 47 6
Prostate and vas deferens structures 0.891170534 47 6
Prostate 0.891170534 47 6
Male internal genital organ 0.891170534 47 6
Pelvic cavity male genital structure 0.891170534 47 6
GENERAL CONVENIENCE TERMS 0.957050207 131 2
Other mental disorders 0.957050207 131 2
Schizophrenia and Disorders with Psychotic Features 0.957050207 131 2
Mental disorders 0.957050207 131 2
9-72 PSYCHOTIC DISORDERS NEC in SNMI98 0.957050207 131 2
Psychotic Disorders 0.957050207 131 2
Adrenal Glands 0.990503356 50 5
General Cytologic Alterations 0.890608599 45 6
Abnormal cell 0.890608599 45 6
Urologic Diseases 0.810384134 49 6
Urologic Neoplasms 0.810384134 49 6
URINARY TRACT DISEASES: GENERAL TERMS 0.810384134 49 6
Malignant tumor of urinary system 0.82529203 48 6
Arthritis 0.894450006 33 8
Other and unspecified arthropathies 0.894450006 33 8
Arthropathies NOS 0.894450006 33 8
DERANGEMENTS OF THE JOINTS OTHER THAN VERTEBRAL COL-
UMN
0.894450006 33 8
Mechanical joint disorder 0.894450006 33 8
Thyroid Gland 0.999657493 44 5
Rheumatism 0.91674193 34 7
Malignant melanoma - category 0.977681674 74 3
Nevi and Melanomas 0.977681674 74 3
Melanocytic neoplasm 0.977681674 74 3
melanoma 0.977681674 74 3
Nevus AND/OR melanoma 0.977681674 74 3
Esophageal and/or gastric structures 0.952011911 45 5
Mouth, esophagus and stomach structures 0.952011911 45 5
Leukocyte Disorders 0.939452575 38 6
Structure of digestive system mucous membrane 0.971257448 55 4
Mediastinum 0.89565277 39 6
Breast Carcinoma 0.969737078 43 5
Primary malignant neoplasm of breast 0.969737078 43 5
frontal lobe 0.962626941 54 4
Extrapyramidal system 0.959566 108 2
Infratentorial brain part 0.949878385 71 3
Brain Stem 0.949878385 71 3
Infratentorial brain structure 0.949878385 71 3
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Rheumatoid Arthritis 0.92804053 31 7
Delayed hypersensitivity disorder 0.92804053 31 7
Secondary inflammatory arthritis 0.92804053 31 7
Arthropathy associated with a hypersensitivity reaction 0.92804053 31 7
Arthropathy associated with another disorder 0.92804053 31 7
Cancer of ovary and other female genital organs 0.98684912 51 4
Malignant neoplasm of ovary 0.98684912 51 4
CLINICAL CLASSIFICATION OF NEOPLASMS OF THE ENDOCRINE SYS-
TEM
0.942647269 35 6
Chronic inflammatory disorder 0.865021403 45 5
Degenerative Diseases, Central Nervous System 0.982250516 95 2
Hereditary AND/OR degenerative disease of central nervous system 0.982250516 95 2
Embryonic Stem Cells 0.994912283 31 6
B-Cell Lymphomas 0.910409174 29 7
Hippocampus (Brain) 0.970426009 63 3
Hippocampal Formation 0.970426009 63 3
Structure of archicortex 0.970426009 63 3
Cancer; other primary 0.923661035 33 6
Cancer of Head and Neck 0.923661035 33 6
Stomach and/or duodenal structures 0.969442212 37 5
Structure of soft tissues of trunk 0.611251251 32 9
Ductal Carcinoma 0.971613624 45 4
Lymphoid system structure 0.924162257 27 7
Lymphoid organ structure 0.924162257 27 7
Lymphatic System 0.924162257 27 7
Lymphoid Tissue 0.924162257 27 7
Stomach 0.967796705 36 5
myometrium 0.995057317 58 3
Smooth muscle (tissue) 0.995057317 58 3
HEART: GENERAL TERMS 0.94233838 36 5
CARDIOVASCULAR SYSTEM: GENERAL TERMS 0.94233838 36 5
Cardiovascular system 0.94233838 36 5
Cardiovascular structure of trunk 0.94233838 36 5
HEART AND PERICARDIUM 0.94233838 36 5
Heart 0.94233838 36 5
Heart AND pericardium structure 0.94233838 36 5
Regional cardiovascular structure 0.94233838 36 5
Intrathoracic cardiovascular structure 0.94233838 36 5
Neurologic Manifestations 0.769576204 44 5
Cerebral cortex part 0.981008689 85 2
Cerebral gyrus 0.981008689 85 2
Gyrus of brain 0.981008689 85 2
Squamous cell carcinoma 0.973136228 56 3
Upper respiratory tract 0.945898453 34 5
Pharynx and/or larynx structures 0.945898453 34 5
Ear, nose and throat 0.945898453 34 5
PHARYNX - OROPHARYNX AND HYPOPHARYNX 0.945898453 34 5
Pharyngeal structure 0.945898453 34 5
Organ dysfunction syndrome 0.988512532 81 2
Bacterial Infections 0.988512532 81 2
Shock 0.988512532 81 2
Bacterial infections - causative organisms 0.988512532 81 2
Systemic Inflammatory Response Syndrome 0.988512532 81 2
Systemic infection 0.988512532 81 2
Acute Disease 0.988512532 81 2
Acute disease of cardiovascular system 0.988512532 81 2
Infection by site 0.988512532 81 2
Connective Tissue Cells 0.952872034 24 7
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Muscle, Striated 0.961394427 23 7
Skeletal muscle structure 0.961394427 23 7
Mature (peripheral) B-cell neoplasm 0.918352051 28 6
Disorder of basophils 0.9886844 31 5
Basophilic leukemia 0.9886844 31 5
Disorder involving basophils and mast cells 0.9886844 31 5
Malignant white blood cell disorder 0.9886844 31 5
Acute Basophilic Leukemia 0.9886844 31 5
DISEASES OF THE LIVER AND BILIARY SYSTEM 0.910833254 28 6
Bone structure of face 0.992281879 50 3
Dentition 0.992281879 50 3
Jaw 0.992281879 50 3
Structure of gum and supporting structure of tooth 0.992281879 50 3
Oral hard tissue structure 0.992281879 50 3
Teeth and Tooth Structures 0.992281879 50 3
Gingiva 0.992281879 50 3
Maxillofacial bone structure 0.992281879 50 3
TEETH, GUMS AND SUPPORTING STRUCTURES: GENERAL TERMS 0.992281879 50 3
Periodontium 0.992281879 50 3
Structure of teeth, gums, and supporting structures 0.992281879 50 3
Tooth structure 0.992281879 50 3
Brain stem part 0.968215416 51 3
Midbrain and pons 0.968215416 51 3
Benign Neoplasm 0.580777863 51 5
Tracheobronchial tree part 0.989084098 29 5
Tracheobronchial structure 0.989084098 29 5
Acute infectious disease 0.989208494 70 2
Cardiovascular Infections 0.989208494 70 2
Septic Shock 0.989208494 70 2
Disorder of neck 0.987936614 28 5
Acute lymphoblastic leukemia - category 0.981072142 28 5
Acute lymphocytic leukemia 0.981072142 28 5
Basal Ganglia 0.957292471 70 2
Basal ganglia and capsules 0.957292471 70 2
Neck Neoplasms 0.991724325 27 5
Layer of adrenal gland 0.993690251 44 3
Endocrine gland part 0.993690251 44 3
Adrenal part 0.993690251 44 3
Adrenal Cortex 0.993690251 44 3
Diseases and Syndromes of Peritoneum, Omentum and Mesentery 0.922423086 35 4
Peritoneal Diseases 0.922423086 35 4
Primary malignant neoplasm of pelvis 0.757257067 28 6
Uterine Diseases 0.852336909 49 3
Myeloid Cells 0.958760115 26 5
Cell content alteration 0.958760115 26 5
Phagocytes 0.958760115 26 5
Inflammatory disorder of digestive system 0.948365397 43 3
Inflammatory disorder of digestive tract 0.948365397 43 3
Midbrain structure 0.966070632 42 3
Precursor Cell Lymphoblastic Leukemia Lymphoma 0.99952862 60 2
Other gastrointestinal cancer 0.91795572 32 4
Tumor of esophagus, stomach and duodenum 0.935483871 31 4
Nervous system tumor morphology 0.940473634 17 7
Central nervous system tumor morphology 0.940473634 17 7
Neoplasms, Neuroepithelial 0.940473634 17 7
Glioma 0.940473634 17 7
Stomach Neoplasms 0.932511111 30 4
Malignant neoplasm of stomach 0.932511111 30 4
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Musculoskeletal structure of limb 0.955653831 19 6
Bronchial 0.987865691 22 5
Organ cavity 0.832953498 26 5
Lower Extremity 0.976372289 18 6
Hematopoietic stem cells 0.994123539 35 3
Cancer of Neck 0.995826078 26 4
[X]Inflammatory polyarthropathies 0.980794838 26 4
Chronic arthritis of juvenile onset 0.980794838 26 4
Chronic polyarticular juvenile rheumatoid arthritis 0.980794838 26 4
Chronic arthropathy 0.980794838 26 4
Chronic arthritis 0.980794838 26 4
Chronic Childhood Arthritis 0.980794838 26 4
Chronic disease of musculoskeletal system 0.980794838 26 4
Polyarthropathy 0.980794838 26 4
Adipose tissue 0.974546758 26 4
Primary malignant neoplasm of urinary system 0.749115082 27 5
Diencephalon part 0.925054759 54 2
Structure of diencephalon 0.925054759 54 2
Airway structure 0.980614618 20 5
Body conduit 0.980614618 20 5
Cervix Uteri 0.907309817 21 5
Normal pregnancy and/or delivery 0.967987732 49 2
Twin Multiple Birth 0.967987732 49 2
Maternal AND/OR fetal condition affecting labor AND/OR delivery 0.967987732 49 2
Abnormal products of conception 0.967987732 49 2
MATERNAL AND FETAL CONDITIONS AFFECTING LABOR AND DE-
LIVERY
0.967987732 49 2
Hemorrhagic complication of pregnancy 0.967987732 49 2
Complications of pregnancy, childbirth and the puerperium 0.967987732 49 2
Disorder of labor / delivery 0.967987732 49 2
Disorder of pregnancy 0.967987732 49 2
Pregnancy, Multiple 0.967987732 49 2
Pregnancy Complications 0.967987732 49 2
Disorder of product of conception 0.967987732 49 2
Delivery AND/OR maternal condition affecting management 0.967987732 49 2
Umbilical Cord Blood 0.98659523 32 3
Cancer of Urinary Tract 0.823079481 23 5
Intestinal Mucosa 0.987446595 47 2
Layers of gastrointestinal wall 0.987446595 47 2
Intestinal wall structure 0.987446595 47 2
Structure of gastrointestinal mucous membrane 0.987446595 47 2
Retroperitoneal mass 0.934945046 33 3
Uterine Neoplasms 0.788099341 39 3
Testis 0.993652492 23 4
Scrotal and testis structures 0.993652492 23 4
Retroperitoneal Neoplasms 0.944369163 32 3
Blood Vessels 0.902209302 20 5
Prostate mass 0.817365812 22 5
Disorder of male reproductive system 0.817365812 22 5
Malignant neoplasm of prostate 0.817365812 22 5
Disorder of the lower urinary tract 0.817365812 22 5
DISEASES OF THE LOWER URINARY TRACT: GENERAL CONDITIONS 0.817365812 22 5
malignant tumor of male genital organ 0.817365812 22 5
Prostatic Diseases 0.817365812 22 5
Prostatic Neoplasms 0.817365812 22 5
Genital Neoplasms, Male 0.817365812 22 5
Genital Diseases, Male 0.817365812 22 5
Small Intestine - Duodenum 0.847446994 26 4
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Intestines, Small 0.847446994 26 4
SMALL INTESTINE: GENERAL TERMS 0.847446994 26 4
Benign epithelial neoplasm - category 0.734011111 30 4
Benign adenomatous neoplasm - category 0.734011111 30 4
adenoma 0.734011111 30 4
Lymphoid precursor cell 0.999611825 44 2
lymphoblast 0.999611825 44 2
[X]Malignant neoplasm of thyroid and other endocrine glands 0.954295051 23 4
Malignant neoplasm of endocrine gland 0.954295051 23 4
Cerebral degeneration presenting primarily with dementia 0.995016423 87 1
Alzheimer’s Disease 0.995016423 87 1
[X]Dementia in other diseases classified elsewhere 0.995016423 87 1
DEMENTIAS IN THE SENIUM AND PRESENIUM 0.995016423 87 1
Other cerebral degeneration NOS 0.995016423 87 1
Degenerative brain disorder 0.995016423 87 1
Delirium, Dementia, Amnestic, Cognitive Disorders 0.995016423 87 1
Tauopathies 0.995016423 87 1
Dementia 0.995016423 87 1
Dementing Neurological Diseases and Syndromes 0.995016423 87 1
Disease of liver and bile duct 0.904857627 19 5
Malignant neoplasm of liver 0.904857627 19 5
Liver neoplasms 0.904857627 19 5
Liver diseases 0.904857627 19 5
Acute Myeloid Leukemia (AML-M2) 0.986247606 21 4
Structure of soft tissues of abdomen 0.561973276 24 6
EMBRYO AND FETUS 0.868641799 13 7
penis 0.875996016 18 5
Malignant Glioma 0.932550208 14 6
Bronchial Diseases 0.973688928 26 3
Lung Diseases, Obstructive 0.973688928 26 3
Pharyngeal part 0.971269077 26 3
Antibody-Producing Cells 0.982384293 11 7
B-Lymphocytes 0.982384293 11 7
Tongue 0.94076412 20 4
Skin tissue 0.999688663 75 1
Hereditary and degenerative nervous system conditions 0.924063591 27 3
Occipital lobe 0.968327822 38 2
Serous sac 0.798288328 18 5
Serous Membrane 0.798288328 18 5
Bronchi 0.989929172 18 4
Corpus striatum structure 0.981235392 35 2
Lentiform nucleus structure 0.981235392 35 2
Neoplasm Metastasis 0.914861897 25 3
Neoplastic Processes 0.914861897 25 3
Hemorrhage 0.877586295 26 3
Hemorrhage of blood vessel 0.877586295 26 3
Myomatous neoplasm 0.975130493 23 3
Peritoneal sac 0.787801878 17 5
Peritoneal Cavity 0.787801878 17 5
Structure of cavity of serous sac 0.787801878 17 5
Structure of serous cavity 0.787801878 17 5
Peritoneum 0.787801878 17 5
Frontal lobe gyrus 0.982731878 34 2
Lactiferous duct 0.999361019 66 1
Mammary lobe 0.999361019 66 1
Glandular structure of breast 0.999361019 66 1
Duct (organ) structure 0.999361019 66 1
Thyroid lump 0.997053312 22 3
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Malignant neoplasm of thyroid 0.997053312 22 3
thyroid neoplasm 0.997053312 22 3
Thyroid Diseases 0.997053312 22 3
Spinal Cord 0.995085995 33 2
Vertebral column 0.995085995 33 2
BONES OF VERTEBRAL COLUMN 0.995085995 33 2
Structure of vertebral region of back 0.995085995 33 2
Spinal cord, roots and ganglia structure 0.995085995 33 2
Primary malignant neoplasm of gastrointestinal tract 0.960565067 34 2
Primary malignant neoplasm of large intestine 0.978705979 33 2
Colon Carcinoma 0.978705979 33 2
Primary malignant neoplasm of colon 0.978705979 33 2
Primary malignant neoplasm of intestinal tract 0.978705979 33 2
Nerve 0.976026532 33 2
Spinal nerve structure 0.976026532 33 2
Nerve part 0.976026532 33 2
Peripheral Nervous System 0.976026532 33 2
Non-Autonomic Spinal Nerves 0.976026532 33 2
Peripheral Nerves 0.976026532 33 2
Extrapyramidal Disorders 0.949830754 22 3
Movement Disorders 0.949830754 22 3
Other and unspecified extrapyramidal diseases and abnormal movement disor-
ders
0.949830754 22 3
Motion and Coordination Diseases and Syndromes 0.949830754 22 3
Liver tumor morphology 0.944840743 16 4
Adenocarcinoma of liver 0.944840743 16 4
Primary carcinoma of the liver cells 0.944840743 16 4
Primary malignant neoplasm of liver 0.944840743 16 4
Neoplasm of body of uterus 0.793317267 38 2
Nose and nasopharynx structure 0.988811111 30 2
Endometriosis, site unspecified 0.980633333 30 2
Disorder characterized by pain 0.980633333 30 2
Hypothalamic structure 0.971711111 30 2
Benign neoplasm of trunk 0.936441179 31 2
Benign neoplasm of abdomen 0.936441179 31 2
Metencephalon 0.982821818 29 2
hindbrain 0.982821818 29 2
Regional skeletal muscle structure 0.936436934 12 5
Kidney part 0.885644653 21 3
Pain 0.927266667 30 2
Sensory and Pain Diseases and Syndromes 0.927266667 30 2
Pain Disorder 0.927266667 30 2
Adrenal mass 0.998125331 27 2
Tumors of Adrenal Cortex 0.998125331 27 2
Adrenal Cortex Diseases 0.998125331 27 2
Adrenal Gland Diseases 0.998125331 27 2
Adrenal Gland Neoplasms 0.998125331 27 2
lymph nodes 0.893914292 12 5
Regional vascular structure 0.95645197 18 3
Serous membrane part 0.80121931 16 4
Omentum 0.80121931 16 4
Ganglia, Sensory 1 25 2
Structure of nervous system ganglion 1 25 2
Ganglia 1 25 2
Leukemia, T-Cell 0.999483221 50 1
Structure of putamen 0.994276206 25 2
Neostriatum 0.994276206 25 2
Temporal lobe gyrus 0.974468337 51 1
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Immediate hypersensitivity 0.992372712 25 2
Asthma 0.992372712 25 2
Obstruction of lower respiratory tract 0.992372712 25 2
Respiratory Hypersensitivity 0.992372712 25 2
Respiratory Insufficiency 0.992372712 25 2
Hypersensitivity disease 0.992372712 25 2
Airway Obstruction 0.992372712 25 2
Stomach part 0.972491751 17 3
Region of stomach 0.972491751 17 3
Lower female genital structure 0.971261787 17 3
Fetus 0.895269355 11 5
GENERAL CONDITIONS OF THE KIDNEY AND URETER 0.944074567 26 2
Kidney Neoplasms 0.944074567 26 2
Kidney Diseases 0.944074567 26 2
Malignant neoplasm of kidney 0.975720466 25 2
Tumor Cells, Cultured 0.99094323 12 4
Cell Line, Tumor 0.99094323 12 4
Disorder of small intestine 0.989756598 24 2
Inflammatory Bowel Diseases 0.989756598 24 2
Gastritis 0.989756598 24 2
Gastroenteritis 0.989756598 24 2
Thalamic structure 0.967356953 24 2
Musculoskeletal structure of lower limb 0.957256461 12 4
Bone of limb 0.957256461 12 4
Bone structure of lower limb 0.957256461 12 4
Bone and/or joint structure of limb 0.957256461 12 4
Musculoskeletal structure of trunk 0.925833886 12 4
Small intestine part 0.919334771 16 3
Nutrition Disorders 0.912193506 12 4
Developmental Disabilities 0.994223041 44 1
Mental disorder of infancy, childhood or adolescence 0.994223041 44 1
Mental disorder usually first evident in infancy, childhood AND/OR adolescence 0.994223041 44 1
Mental Disorders Diagnosed in Childhood 0.994223041 44 1
Developmental mental disorder 0.994223041 44 1
Leiomyomatous neoplasm - category 0.992247945 22 2
Tegmentum Mesencephali 0.983302103 22 2
Midbrain part 0.983302103 22 2
Cerebral Peduncle 0.983302103 22 2
Dermatitis 0.930127142 15 3
Small Intestine - Jejunum and Ileum 0.926390271 15 3
Carcinoma, Papillary 0.941972921 22 2
Cerebellum 1 20 2
Cardiovascular organ part 0.997873754 20 2
Heart part 0.997873754 20 2
Disorder of soft tissue of body cavity 0.996528239 20 2
Disorder of soft tissue of head 0.996528239 20 2
Mouth Diseases 0.996528239 20 2
DISEASES OF THE SALIVARY GLANDS AND ORAL CAVITY 0.996528239 20 2
Disorder of oral soft tissues 0.996528239 20 2
Circulatory system disease NOS 0.996478405 20 2
Malignant neoplasm of soft tissues of thorax 0.989571913 13 3
Disorder of soft tissue of trunk 0.989571913 13 3
Skin disorder of breast 0.989571913 13 3
Primary malignant neoplasm of skin of chest 0.989571913 13 3
Primary malignant neoplasm of soft tissues of trunk 0.989571913 13 3
Primary malignant neoplasm of soft tissues of thorax 0.989571913 13 3
Primary malignant neoplasm of skin of trunk 0.989571913 13 3
Primary malignant neoplasm of chest wall 0.989571913 13 3
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Carcinoma, Lobular 0.989571913 13 3
Malignant neoplasm of skin of trunk 0.989571913 13 3
Neoplasm of skin region 0.989571913 13 3
Disorder of body wall 0.989571913 13 3
Primary malignant neoplasm of skin of breast 0.989571913 13 3
Neoplasm of soft tissues of thorax 0.989571913 13 3
Neoplasm of skin of chest 0.989571913 13 3
Neoplasm of skin of breast 0.989571913 13 3
Neoplasm of skin of trunk 0.989571913 13 3
Disorder of skin AND/OR subcutaneous tissue of trunk 0.989571913 13 3
Neoplasm of soft tissues of trunk 0.989571913 13 3
Neoplasm of chest wall 0.989571913 13 3
Hereditary Diseases 0.855280195 11 4
Parkinson Disease 0.976367355 19 2
Basal Ganglia Diseases 0.976367355 19 2
Parkinsonian Disorders 0.976367355 19 2
Carcinoma of genital organs NOS 0.88089712 14 3
Carcinoma of genitourinary organ 0.88089712 14 3
Endocrine tumor morphology 0.947808572 13 3
Noninfectious, erythematous, papular AND/OR squamous disease 0.929017618 13 3
Cerebral white matter structure 0.996753726 18 2
Corpus Callosum 0.996753726 18 2
White matter structure of brain and spinal cord 0.996753726 18 2
Child Development Disorders, Pervasive 0.992549487 35 1
Psychoses with origin in childhood 0.992549487 35 1
Autistic Disorder 0.992549487 35 1
[X]Unspecified disorder of psychological development 0.992549487 35 1
Pervasive Development Disorder 0.992549487 35 1
Endothelial Cells 0.980341194 7 5
MULTIPLE SYSTEM MALFORMATIONS AND CHROMOSOMAL DIS-
EASES
0.84513245 10 4
Congenital Disorders 0.84513245 10 4
Vascular structure of trunk 0.929865253 12 3
Malignant neuroendocrine neoplasm, neural 0.988888554 11 3
Embryonal neuroepithelial tumor 0.988888554 11 3
Neuronal and mixed neuronal-glial tumor 0.988888554 11 3
Neuroepitheliomatous neoplasm 0.988888554 11 3
Neuroectodermal Tumor, Primitive 0.988888554 11 3
Bacteria 0.903744201 12 3
Prokaryote 0.903744201 12 3
Musculoskeletal structure of pelvis 0.984070583 11 3
Structure of superior frontal gyrus 0.98377165 33 1
Disorder of lipoprotein AND/OR lipid metabolism 0.977235087 11 3
Other disorders of metabolism 0.977235087 11 3
Metabolic Diseases 0.977235087 11 3
HYPERALIMENTATION AND OBESITY 0.973561384 11 3
Overnutrition 0.973561384 11 3
Obesity 0.973561384 11 3
Other endocrine/nutritional/metabolic disorder 0.973561384 11 3
Cranial nerve part 0.943050702 17 2
Cranial Nerves 0.943050702 17 2
Structure of layer of kidney 0.999046118 16 2
Nerve Tissue 0.999004645 16 2
Spinal nerve root structure 0.999004645 16 2
Peripheral nerve part 0.999004645 16 2
Nerve root structure 0.999004645 16 2
Ganglia, Spinal 0.999004645 16 2
Adrenocortical carcinoma 0.997573822 16 2
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Non-Occupational Pulmonary Diseases and Syndromes 0.952362311 11 3
Amygdaloid structure 0.981668879 16 2
Veins 0.864724705 9 4
Venous system 0.864724705 9 4
VEINS - TYPE AND STRUCTURE 0.864724705 9 4
ARTERIES: TYPE AND STRUCTURE 0.928091782 11 3
Systemic vascular structure 0.928091782 11 3
Systemic arterial structure 0.928091782 11 3
Artery of trunk 0.928091782 11 3
Arteries 0.928091782 11 3
Arterial system 0.928091782 11 3
Head Neoplasms 0.762574454 8 5
Extracellular Fluid 0.918034268 11 3
Extracellular Space 0.918034268 11 3
Posterior root of spinal nerve 0.998629077 15 2
Skin part 0.93563865 8 4
SKIN REGION: GENERAL TERM 0.93563865 8 4
Skin region 0.93563865 8 4
Skin of trunk, NOS 0.93563865 8 4
Skin of part of trunk 0.93563865 8 4
Skin AND subcutaneous tissue structure of trunk 0.93563865 8 4
Nervous System Neoplasms 0.854023912 7 5
Central Nervous System Neoplasms 0.854023912 7 5
Intracranial mass 0.854023912 7 5
Brain Neoplasms 0.854023912 7 5
Neoplasms, Intracranial 0.854023912 7 5
Visual Cortex 0.978788889 30 1
Body wall structure 0.807017544 9 4
Salivary Glands 0.933609272 10 3
Cardiac internal structure 0.999668435 14 2
Cardiac chamber structure 0.999668435 14 2
neutrophil 0.998531641 14 2
granulocyte 0.998531641 14 2
Neurosecretory Systems 0.993416067 14 2
Hypothalamus, Middle 0.993416067 14 2
Hypothalamo-Hypophyseal System 0.993416067 14 2
Hypothalamus part 0.993416067 14 2
Pituitary and/or pineal structures 0.993416067 14 2
Pituitary Gland 0.993416067 14 2
Systemic circulatory system 0.86618961 8 4
Afterbirth 0.852043349 8 4
Structure of middle temporal gyrus 0.969936709 28 1
Layer of temporal lobe 0.969936709 28 1
Cerebral dorsum structure 0.969936709 28 1
Gray matter of temporal lobe 0.969936709 28 1
Acute myeloid leukemia without maturation 0.984111221 9 3
Female perineal structure 0.981205635 9 3
Vulva 0.981205635 9 3
Vulval and/or female perineal structures 0.981205635 9 3
Female external genitalia structure 0.981205635 9 3
Esophagus 0.875529801 10 3
Nipples 0.949280959 9 3
Proximal stomach 0.946816727 9 3
Synovial Membrane 0.841680486 15 2
ARTICULAR SYSTEM - JOINTS 0.841680486 15 2
ARTICULAR SYSTEM: GENERAL TERMS 0.841680486 15 2
Joint part 0.841680486 15 2
Membrane organ structure 0.841680486 15 2
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Joints 0.841680486 15 2
Soft tissue joint component 0.841680486 15 2
Joint Capsule 0.841680486 15 2
Types and Parts of Joints 0.841680486 15 2
Articular system 0.841680486 15 2
Cecum 0.907315458 9 3
Primary malignant neoplasm of male genital organ 0.935468244 13 2
Prostate carcinoma 0.935468244 13 2
Primary malignant neoplasm of prostate 0.935468244 13 2
Childhood asthma 0.992958527 24 1
Exanthema 0.990004418 12 2
Disorder of keratinization 0.990004418 12 2
Cell-mediated cytotoxic disorder 0.990004418 12 2
Cutaneous hypersensitivity 0.990004418 12 2
Acquired disorder of keratinization 0.990004418 12 2
Histologic type of inflammatory skin disorder 0.990004418 12 2
Psoriasis 0.990004418 12 2
Other psoriasis 0.990004418 12 2
Skin Diseases, Papulosquamous 0.990004418 12 2
Inflammatory hyperkeratotic dermatosis 0.990004418 12 2
Pain finding at anatomical site 0.945544093 25 1
Ventral Tegmental Area 0.975811796 12 2
Abdominal Pain 0.96174318 24 1
Pain of truncal structure 0.96174318 24 1
Benign neoplasm of other endocrine glands and related structures 0.949856417 12 2
Benign tumor of endocrine gland 0.949856417 12 2
Region of cerebral cortex 0.986104886 23 1
Surface of brain 0.986104886 23 1
Structure of entorhinal cortex 0.986104886 23 1
Cerebral medial surface structure 0.986104886 23 1
Parahippocampal Gyrus 0.986104886 23 1
Region of temporal cortex 0.986104886 23 1
Congenital abnormal shape 0.83184376 9 3
CONGENITAL ANOMALIES: GENERAL TERMS 0.83184376 9 3
Congenital growth alteration 0.83184376 9 3
Deformity 0.83184376 9 3
Other and unspecified congenital anomalies 0.83184376 9 3
Congenital Abnormality 0.83184376 9 3
jejunum 0.929285399 12 2
Nasopharynx 0.998148412 21 1
Parameningeal structure in the context of malignancy 0.998148412 21 1
Reticuloendotheliosis 0.995397351 10 2
Malignant histiocytic neoplasm 0.995397351 10 2
Histiocytosis 0.995397351 10 2
Histiocytic Disorders, Malignant 0.995397351 10 2
Histiocytosis, Langerhans-Cell 0.995397351 10 2
Lung Diseases, Interstitial 0.995397351 10 2
Histiocytic neoplasm (morphology) 0.995397351 10 2
Monocytic leukemia 0.995397351 10 2
Histiocytic syndrome 0.995397351 10 2
Dendritic cell neoplasm 0.995397351 10 2
Acute monocytic/monoblastic leukemia 0.995397351 10 2
Langerhans cell histiocytosis - category 0.995397351 10 2
Acute monocytic leukemia 0.995397351 10 2
Entire viscus 0.99423588 20 1
Hollow viscus 0.99423588 20 1
Abdominal organ 0.99423588 20 1
Entire fallopian tube 0.99423588 20 1
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Entire pelvic organ 0.99423588 20 1
Entire female internal genital organ 0.99423588 20 1
Entire pelvic viscus 0.99423588 20 1
Entire female genital organ 0.99423588 20 1
Intra-abdominal genital structure 0.99423588 20 1
Uterine Fibroids 0.99154485 20 1
Benign myomatous tumor 0.99154485 20 1
Benign neoplasm of female genital organ, site unspecified 0.99154485 20 1
Benign neoplasm of body of uterus 0.99154485 20 1
Benign neoplasm of uterus NOS 0.99154485 20 1
Benign leiomyomatous neoplasm - category 0.99154485 20 1
Benign genital neoplasm 0.99154485 20 1
Benign neoplasm corpus uteri NEC 0.99154485 20 1
Thoracic Arteries 0.940551014 7 3
Structure of brachiocephalic artery 0.940551014 7 3
Artery of mediastinum 0.940551014 7 3
Supraaortic branch of thoracic aorta 0.940551014 7 3
Structure of artery of thorax AND/OR abdomen 0.940551014 7 3
Branch of thoracic aorta 0.940551014 7 3
Substantia nigra structure 0.977218543 10 2
Midbrain nucleus 0.977218543 10 2
Diffuse high grade B-cell lymphoma 0.97031405 5 4
High grade B-cell lymphoma 0.97031405 5 4
Peripheral and visceral atherosclerosis 1 19 1
Peripheral Vascular Diseases 1 19 1
Multiple Myeloma 1 19 1
Paraproteinemias 1 19 1
Skin Manifestations 1 19 1
Vascular Hemostatic Disorders 1 19 1
Purpura and other hemorrhagic conditions 1 19 1
Other paraproteinemias 1 19 1
[X]Diseases of arteries, arterioles and capillaries 1 19 1
Blood Protein Disorders 1 19 1
Blood Coagulation Disorders 1 19 1
Gammopathy 1 19 1
Monoclonal Gammapathies 1 19 1
Plasma Cell Neoplasm 1 19 1
White blood cell abnormality 1 19 1
Purpura 1 19 1
Hemorrhagic Disorders 1 19 1
Plasmacytoma - category 1 19 1
Plasma cell myeloma - category 1 19 1
Immunosecretory disorder 1 19 1
Plasma cell myeloma/plasmacytoma 1 19 1
Myeloma cell 1 19 1
Abnormal hematopoietic cell 1 19 1
Abnormal cellular component of blood 1 19 1
Clotting or bleeding disorder NOS 1 19 1
[X]Coagulation defects, purpura and other hemorrhagic conditions 1 19 1
Plasmacytoma 1 19 1
Malignant immunoproliferative disease (clinical) 1 19 1
Coagulation and hemorrhagic disorders 1 19 1
Other peripheral vascular disease 1 19 1
Purpura, Nonthrombocytopenic 1 19 1
Gingival and periodontal disease NOS 0.999160971 19 1
Jaw Diseases 0.999160971 19 1
Inflammatory disorder of jaw 0.999160971 19 1
Inflammatory disorder of head 0.999160971 19 1
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Disorder of teeth AND/OR supporting structures 0.999160971 19 1
Chronic disease of teeth AND/OR supporting structures 0.999160971 19 1
Chronic digestive system disorder 0.999160971 19 1
Disorder of face 0.999160971 19 1
Periodontal Diseases 0.999160971 19 1
Periodontitis 0.999160971 19 1
Neoplasms, Cystic, Mucinous, and Serous 0.920797342 20 1
Cystic, mucinous AND/OR serous neoplasm 0.920797342 20 1
Spleen 1 9 2
Base of skull structure 0.997940344 9 2
Structure of organ cavity subdivision 0.997940344 9 2
Intracranial ganglion 0.997940344 9 2
Structure of fossa of cranial cavity 0.997940344 9 2
Structure of middle fossa of cranial cavity 0.997940344 9 2
Structure of cranial nerve ganglion 0.997940344 9 2
Trigeminal nerve structure 0.997940344 9 2
Structure of trigeminal ganglion 0.997940344 9 2
Parietal Lobe 0.987016808 9 2
Functional disorder of intestine 0.980911398 9 2
DISEASES OF THE GALLBLADDER AND BILE DUCTS 0.975725477 9 2
Biliary Tract Diseases 0.975725477 9 2
Gall Bladder Diseases 0.975725477 9 2
Endometrial Neoplasms 0.972185333 18 1
Endometrial disorder 0.972185333 18 1
Pontine structure 0.958108058 9 2
Still’s disease with juvenile onset and/or adult onset 0.990628844 17 1
Systemic onset juvenile chronic arthritis 0.990628844 17 1
Endometrioid tumor 0.974073134 17 1
Malignant endometrioid tumor 0.974073134 17 1
Carcinoma, Endometrioid 0.974073134 17 1
ATRIA: GENERAL TERMS 1 8 2
Urethra 1 8 2
Heart Atrium 1 8 2
macrophage 0.999834547 8 2
Structure of medulla of kidney 0.99975182 8 2
Acute Promyelocytic Leukemia 0.999586367 8 2
Acute myeloid leukemia with recurrent genetic abnormality 0.999586367 8 2
Structure of cortex of kidney 0.9987591 8 2
Vagina 0.998676373 8 2
Structure of pyloric portion of stomach 0.99851092 8 2
Part of pyloric region 0.99851092 8 2
Pylorus 0.99851092 8 2
Oral mucous membrane structure 0.998180013 8 2
Body orifice mucosa 0.998180013 8 2
gastric fundus 0.9975182 8 2
Lymph 0.991727333 8 2
Proteobacteria 0.971376572 8 2
Gram-Negative Bacteria 0.971376572 8 2
Structure of bone (organ) 0.963807081 8 2
Type of bone 0.963807081 8 2
Vestibular nucleus structure 0.963352085 8 2
Pons part 0.963352085 8 2
Structure of vestibular system 0.963352085 8 2
Intracranial nerve structure 0.963352085 8 2
Structure of cranial nerve nucleus 0.963352085 8 2
pontine nuclei 0.963352085 8 2
Special sensory system 0.963352085 8 2
Pontine cranial nerve nucleus 0.963352085 8 2
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Fibroblasts 0.960261071 4 4
Coughing 0.959045289 16 1
T-Cell Lymphoma 0.914160608 4 4
T-cell lymphoma morphology 0.914160608 4 4
T-cell AND/OR NK-cell neoplasm 0.914160608 4 4
Persistent cough 0.953300166 15 1
Congenital chromosomal disease 0.893530774 8 2
Other condition due to autosomal anomaly 0.893530774 8 2
Autosomal hereditary disorder 0.893530774 8 2
Neoplasms, Complex and Mixed 0.893034414 8 2
Larynx and/or tracheal structures 0.998865838 7 2
Trachea 0.998865838 7 2
Musculoskeletal structure of upper limb 0.997259109 7 2
Skeletal muscle structure of upper limb 0.997259109 7 2
monocyte 0.995274325 7 2
Marrow Monocytes and Plasma Cells 0.995274325 7 2
Systemic venous structure 0.988752894 7 2
Type of vein 0.988752894 7 2
Lower extremity part 0.89877686 5 3
sperm cell 1 13 1
Meiotic cell 1 13 1
Germ Cells 1 13 1
Skeletal Muscular System (Muscles of Trunk, Perineum and Lower Extremity) 0.825520661 5 3
Skeletal muscle structure of trunk 0.825520661 5 3
Primary malignant neoplasm of endocrine gland 0.871603421 7 2
Structure of region of lymphatic system 0.808595041 5 3
Structure of peripheral vein 1 6 2
Peripheral vascular system 1 6 2
Venous structure of limb 1 6 2
Saphenous Vein 1 6 2
Vascular structure of lower limb 1 6 2
Structure of pelvic and leg veins 1 6 2
Stromal Cells 1 12 1
Structure of vein of lower extremity 1 6 2
Structure of superficial vein of lower extremity 1 6 2
Vascular structure of limb 1 6 2
Structure of superficial vein 1 6 2
Heart Ventricle 0.999889771 6 2
White Adipose Tissue 0.999669312 6 2
Subcutaneous Fat 0.999669312 6 2
Subcutaneous Tissue 0.999669312 6 2
Chronic Lymphocytic Leukemia 0.999503968 6 2
Coronary artery 0.998567019 6 2
Mammary gland 0.992504409 6 2
Skin and subcutaneous tissue structure of genitalia 0.991407799 4 3
Male perineal structure 0.991407799 4 3
Skin and subcutaneous tissue structure of pelvis 0.991407799 4 3
Glans penis and/or preputial structures 0.991407799 4 3
Skin structure of anogenital region 0.991407799 4 3
Skin and subcutaneous tissue structure of perineum 0.991407799 4 3
Male genital organ part 0.991407799 4 3
Penis part 0.991407799 4 3
Structure of soft tissues of perineum 0.991407799 4 3
Soft tissues of pelvis 0.991407799 4 3
Skin structure of lower trunk 0.991407799 4 3
Skin of penis 0.991407799 4 3
Skin structure of male genitalia 0.991407799 4 3
SKIN OF PERINEUM AND GENITALIA 0.991407799 4 3
Continued on Next Page. . .
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Table C.1 – Continued
Concept AUC Num Samples Num Series
Skin structure of perineum 0.991407799 4 3
Skin structure of external genitalia 0.991407799 4 3
Skin of pelvis 0.991407799 4 3
Spermatic cord and/or male perineal structures 0.991407799 4 3
Skin structure of male perineum 0.991407799 4 3
Structure of skin and/or mucosa of anogenital area 0.991407799 4 3
Foreskin of penis 0.991407799 4 3
Skin of part of pelvic region 0.991407799 4 3
Skin of part of anogenital region 0.991407799 4 3
Skin of part of male external genitalia 0.991407799 4 3
Skin of part of genitalia 0.991407799 4 3
Skin of part of penis 0.991407799 4 3
PLACENTA AND MEMBRANES 0.980434303 6 2
Diffuse non-Hodgkin’s lymphoma 0.948777264 4 3
Diffuse Large B-Cell Lymphoma 0.948777264 4 3
Diffuse large B-cell lymphoma - category 0.948777264 4 3
Benign neoplasm of intra-abdominal organs 1 11 1
Benign neoplasm of adrenal gland 1 11 1
Benign neoplasm of adrenal cortex 1 11 1
Adrenal Cortical Adenoma 1 11 1
Benign neoplasm of retroperitoneum 1 11 1
Structure of subthalamic nucleus 0.971152398 11 1
Subthalamic structure 0.971152398 11 1
Neoplasms, Connective Tissue 0.706710744 5 3
Adenocarcinoma, Mucinous 0.954500286 11 1
Large blood vessel structure 0.85587522 6 2
Structure of great blood vessel (organ) 0.85587522 6 2
Type of vessel 0.85587522 6 2
SPECIFIC ENDOMETRIOSES 0.998609272 10 1
Endometriosis of uterus 0.998609272 10 1
Endometriosis of pelvis 0.998609272 10 1
Cervical 0.997019868 10 1
Globus Pallidus 0.995397351 10 1
Malignant retroperitoneal tumor 0.824018959 6 2
Entire putamen 0.987636364 5 2
Neuroblastoma 0.976066116 5 2
Ewings sarcoma-primitive neuroectodermal tumor (PNET) 0.976066116 5 2
[M]Miscellaneous tumor NOS 0.976066116 5 2
Skin tumor of neural origin 0.976066116 5 2
Oropharyngeal 0.966214876 5 2
Papillary adenocarcinoma 0.964635762 10 1
Anorectal structure 0.954834437 10 1
Lower bowel structures 0.954834437 10 1
Rectum 0.954834437 10 1
Pelvic alimentary structure 0.954834437 10 1
Complex mixed AND/OR stromal neoplasm 0.944330579 5 2
Body surface region 0.922049587 5 2
Sense Organs 1 9 1
Nose 1 9 1
Entire skeletal muscle (organ) 0.997136879 3 3
Monozygotic twins 0.994409504 9 1
Neurobehavioral Manifestations 0.990474089 9 1
Mental Retardation 0.990474089 9 1
Chest wall structure 0.888859504 5 2
Part of chest wall 0.888859504 5 2
Entire nucleus of brain 0.926661518 9 1
Structure of large artery 0.828033058 5 2
Type of artery 0.828033058 5 2
Continued on Next Page. . .
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Table C.1 – Continued
Concept AUC Num Samples Num Series
High grade T-cell lymphoma morphology 0.89362405 3 3
Reticulosarcoma 0.89362405 3 3
Thigh structure 1 4 2
Structure of quadriceps femoris muscle 1 4 2
Structure of vastus lateralis muscle 1 4 2
Skeletal muscle structure of thigh 1 4 2
Skeletal muscle structure of hip 1 4 2
Muscle of hip AND thigh 1 4 2
Skeletal muscle structure of perineum 1 4 2
Thigh part 1 4 2
Skeletal muscle structure of lower limb 1 4 2
Entire quadriceps femoris muscle 1 4 2
Hip region structure 1 4 2
Entire vastus lateralis muscle 1 4 2
Skeletal muscle structure of pelvis 1 4 2
Cholelithiasis 0.999669093 8 1
Cholecystolithiasis 0.999669093 8 1
Calculi 0.999669093 8 1
Biliary calculi 0.999669093 8 1
Multiple Sclerosis 0.999214097 8 1
Autoimmune Diseases of the Nervous System 0.999214097 8 1
Demyelinating Autoimmune Diseases, CNS 0.999214097 8 1
Demyelinating Diseases 0.999214097 8 1
Demyelinating disease of central nervous system 0.999214097 8 1
Deficiency anemias NOS 0.989920687 4 2
Anemia 0.989920687 4 2
Refractory anemias 0.989920687 4 2
Refractory anaemia with excess blasts 0.989920687 4 2
Dysmyelopoietic Syndromes 0.989920687 4 2
Other deficiency anemias NOS 0.989920687 4 2
Other anemias NOS 0.989920687 4 2
Red blood cell disorder 0.989920687 4 2
Anemia due to decreased red cell production 0.989920687 4 2
Developmental delay (disorder) 0.989741893 8 1
Leukemia, Myelomonocytic, Acute 0.988873263 8 1
Nucleus Accumbens 0.988087359 8 1
[M]Complex mixed and stromal neoplasms 0.983559154 4 2
Primary malignant neoplasm of retroperitoneum 0.781884298 5 2
Waldeyer’s ring 0.972488434 4 2
Body region wall 0.972488434 4 2
Structure of lymphatic system of head and neck 0.972488434 4 2
Lymphatic vessel 0.972488434 4 2
Wall of oropharynx 0.972488434 4 2
Structure of lymphatic vessel of head and neck 0.972488434 4 2
Tonsil and adenoid structure 0.972488434 4 2
lymphatic system of head 0.972488434 4 2
lateral wall of oropharynx 0.972488434 4 2
Palatine Tonsil 0.972488434 4 2
Low grade B-cell lymphoma 0.964144085 4 2
Uterine Cancer 0.769586777 5 2
Cancer of uterus and cervix 0.769586777 5 2
Virus Diseases 0.95935228 4 2
Specific viral infections 0.95935228 4 2
Firmicutes 0.925644415 4 2
Bacilli class 0.925644415 4 2
Gram-Positive Bacteria 0.925644415 4 2
Extra-embryonic structure 0.781081379 3 3
Bone structure of spine and/or pelvis 1 7 1
Continued on Next Page. . .
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Table C.1 – Continued
Concept AUC Num Samples Num Series
hip bone 1 7 1
Bone structure of ilium 1 7 1
Bone part 1 7 1
Ilium part 1 7 1
Iliac crest structure 1 7 1
Structure of flat bone 1 7 1
Bone structure of pelvic region and/or thigh 1 7 1
Bony pelvis 1 7 1
Campylobacterales 0.999621946 7 1
Helicobacter 0.999621946 7 1
HCT116 Cells 0.999621946 7 1
Helicobacteraceae 0.999621946 7 1
Epsilonproteobacteria 0.999621946 7 1
Colonic epithelium 0.999621946 7 1
Colonic mucous membrane 0.999621946 7 1
Structure of intestinal epithelium 0.999621946 7 1
Subclass Aerobic-Microaerophilic, Motile Curved Gram-Negative Bacteria 0.999621946 7 1
[M]Adenocarcinoma, metastatic, NOS 0.872559563 8 1
Pancreas 0.865251157 4 2
Congenital hypergammaglobulinemia 0.982987571 7 1
Job’s Syndrome 0.982987571 7 1
Congenital immunodeficiency disease 0.982987571 7 1
Qualitative abnormality of granulocyte 0.982987571 7 1
Disorder of neutrophils 0.982987571 7 1
Immunologic Deficiency Syndromes 0.982987571 7 1
Non-malignant white cell disorder 0.982987571 7 1
Chemotactic disorder 0.982987571 7 1
Autosomal recessive hereditary disorder 0.982987571 7 1
Phagocyte Bactericidal Dysfunction 0.982987571 7 1
Abdominal bloating 0.973772506 7 1
Flatulence, eructation, and gas pain 0.973772506 7 1
[D]Gas pain (abdominal) 0.973772506 7 1
Pain of digestive structure 0.973772506 7 1
Metastatic Carcinoma 0.951420065 7 1
Hela Cells 1 3 2
medulloblastoma 1 6 1
Primary malignant neoplasm of thyroid gland 0.999614198 6 1
Papillary thyroid carcinoma 0.999614198 6 1
Primary malignant neoplasm of neck 0.999614198 6 1
Structure of deltoid muscle 0.99928351 6 1
Structure of skeletal muscle of shoulder 0.99928351 6 1
Carcinoma, Transitional Cell 0.998126102 6 1
Transitional Cell Neoplasm 0.998126102 6 1
[M]Transitional cell papilloma or carcinoma NOS 0.998126102 6 1
Upper urinary tract structure 0.998126102 6 1
Upper genitourinary tract structure 0.998126102 6 1
Papillary serous cystadenocarcinoma 0.992504409 6 1
Entire substantia nigra 0.984032596 3 2
Gastrointestinal Hemorrhage 0.968065191 3 2
Maintenance chemotherapy; radiotherapy 0.964891975 6 1
Chemotherapy Regimen 0.964891975 6 1
Upper gastrointestinal disorders 0.944169144 3 2
Neoplasms, Muscle Tissue 0.916969497 3 2
Malignant myomatous tumor 0.916969497 3 2
Superior mediastinum 0.909150975 3 2
Osseous AND/OR chondromatous neoplasm 0.843078956 3 2
Amniotic Fluid 1 5 1
Pneumocyte 0.999867769 5 1
Continued on Next Page. . .
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Table C.1 – Continued
Concept AUC Num Samples Num Series
Macrophages, Alveolar 0.999867769 5 1
Mononuclear phagocyte system 0.999867769 5 1
Colonic Diseases, Functional 0.998942149 5 1
Irritable Bowel Syndrome 0.998942149 5 1
Renal collecting system structure 0.997487603 5 1
Renal pelvis 0.997487603 5 1
Complex epithelial neoplasm 0.926479339 5 1
Hereditary disorder by system 0.685827552 3 2
Cancer of Head 1 4 1
Skin and subcutaneous tissue structure of chest 0.998182419 4 1
Skin structure of breast 0.998182419 4 1
Anterior chest wall structure 0.998182419 4 1
Structure of soft tissues of thorax 0.998182419 4 1
Skin of chest 0.998182419 4 1
Skin structure of nipple 0.998182419 4 1
Skin structure of upper trunk 0.998182419 4 1
Structure of surface region of thorax 0.998182419 4 1
Skin of anterior surface of thorax 0.998182419 4 1
Skin of anterolateral surface of thorax 0.998182419 4 1
Nipple part 0.998182419 4 1
Skin of part of front of thorax 0.998182419 4 1
Skin of part of breast 0.998182419 4 1
Skin of part of thorax 0.998182419 4 1
Skin of part of anterolateral surface of thorax 0.998182419 4 1
Precursor B-cell neoplasm 0.997769332 4 1
Precursor B-cell lymphoblastic leukemia 0.997769332 4 1
Precursor B-lymphoblastic leukemia/lymphoblastic lymphoma 0.997769332 4 1
Other and unspecified gastrointestinal disorders 0.991242564 4 1
Constipation 0.991242564 4 1
Squamous epithelial cell 0.983972241 4 1
Adenocarcinoma of pelvis 0.982650364 4 1
Primary malignant neoplasm of kidney 0.982650364 4 1
Renal glomerular disease 0.982650364 4 1
RENAL GLOMERULAR AND TUBULOINTERSTITIAL DISEASES 0.982650364 4 1
Renal Cell Carcinoma 0.982650364 4 1
Malignant tumor of kidney parenchyma 0.982650364 4 1
Adenosquamous carcinoma 0.943985459 4 1
Neoplasm of cerebrum 0.419337077 3 3
Transitional epithelial cell 0.894828156 4 1
Primary malignant neoplasm of intrathoracic organs 0.593436846 3 2
Primary malignant neoplasm of lung 0.593436846 3 2
Primary malignant neoplasm of respiratory tract 0.593436846 3 2
Tongue part 0.883179114 4 1
Tongue surface region 0.883179114 4 1
Papilla of tongue 0.883179114 4 1
Dorsum of tongue 0.883179114 4 1
Systemic artery of trunk 0.882187707 4 1
Aorta 0.882187707 4 1
Synovial Fluid 1 3 1
Lactobacillales 1 3 1
Streptococcaceae 1 3 1
Streptococcus 1 3 1
Synovial fluid mononuclear cell 1 3 1
ileum 1 3 1
Diffuse low grade B-cell lymphoma 1 3 1
Marginal Zone B-Cell Lymphoma 1 3 1
Catalase-negative Gram-positive coccus 1 3 1
Facultative anaerobic bacteria 1 3 1
Continued on Next Page. . .
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Table C.1 – Continued
Concept AUC Num Samples Num Series
Fastidious bacteria 1 3 1
Gram-Positive Cocci 1 3 1
Fastidious bacterium 1 3 1
Cocci 1 3 1
mucosa-associated lymphoid tissue lymphoma 1 3 1
Rhinovirus infection 0.9994494 3 1
Abnormal coordination 0.9994494 3 1
Dyskinetic syndrome 0.9994494 3 1
Ataxia 0.9994494 3 1
RNA Virus Infections 0.9994494 3 1
Picornaviridae Infections 0.9994494 3 1
Joint and/or tendon synovial structure 0.99867856 3 1
Synovial joint structure 0.99867856 3 1
Structure of synovial tissue of joint 0.99867856 3 1
Rectum and sigmoid colon 0.997467239 3 1
Entire entorhinal cortex 0.996476159 3 1
Hemoptysis 0.980839115 3 1
Respiratory tract hemorrhage 0.980839115 3 1
Myositis 0.971038432 3 1
Polymyositis 0.971038432 3 1
Dermatomyositis 0.971038432 3 1
Rheumatic and Collagen Muscle Diseases and Syndromes 0.971038432 3 1
Dermatomyositis, Childhood Type 0.971038432 3 1
Primary malignant neoplasm of head 0.360973461 3 2
C.2 Concept enrichment of metastasis samples
The top 50 enriched concepts for samples belonging to series containing metastasis
samples. For each sample its series ID (GSE), the tissue type, the primary tumor (if
applicable), and metastasis site (if applicable) are included. For details on how these







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Marker genes their and
over-enriched GO concepts
D.1 Over-enriched GO concepts for breast tissue
marker genes
Table D.1:
GO ID GO Term P Value
GO:0048513 organ development 0
GO:0032502 developmental process 0
GO:0007275 multicellular organismal development 0
GO:0009888 tissue development 0
GO:0048856 anatomical structure development 0
GO:0032501 multicellular organismal process 0
GO:0048731 system development 0
GO:0022612 gland morphogenesis 0
GO:0060429 epithelium development 0
GO:0048729 tissue morphogenesis 0
GO:0060512 prostate gland morphogenesis 0
GO:0002009 morphogenesis of an epithelium 0
GO:0009887 organ morphogenesis 0
GO:0001763 morphogenesis of a branching structure 0
GO:0009725 response to hormone stimulus 0
GO:0061138 morphogenesis of a branching epithelium 0
GO:0035239 tube morphogenesis 0
GO:0048608 reproductive structure development 0
GO:0045444 fat cell differentiation 0
GO:0001655 urogenital system development 0
GO:0008544 epidermis development 0
GO:0060525 prostate glandular acinus development 0
GO:0009719 response to endogenous stimulus 0
GO:0030850 prostate gland development 0
GO:0009653 anatomical structure morphogenesis 0
Continued on Next Page. . .
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Table D.1 – Continued
GO ID GO Term P Value
GO:0048732 gland development 0
GO:0060740 prostate gland epithelium morphogenesis 0.00001
GO:0043627 response to estrogen stimulus 0.00001
GO:0030855 epithelial cell differentiation 0.00001
GO:0032355 response to estradiol stimulus 0.00001
GO:0060562 epithelial tube morphogenesis 0.00001
GO:0048511 rhythmic process 0.00002
GO:0010033 response to organic substance 0.00002
GO:0003401 axis elongation 0.00002
GO:0008593 regulation of Notch signaling pathway 0.00002
GO:0010466 negative regulation of peptidase activity 0.00003
GO:0045137 development of primary sexual characteristics 0.00003
GO:0035282 segmentation 0.00003
GO:0051239 regulation of multicellular organismal process 0.00004
GO:0048545 response to steroid hormone stimulus 0.00005
GO:0060993 kidney morphogenesis 0.00005
GO:0003006 developmental process involved in reproduction 0.00006
GO:0035295 tube development 0.00007
GO:0045747 positive regulation of Notch signaling pathway 0.00007
GO:0070995 NADPH oxidation 0.00009
GO:0072086 specification of loop of Henle identity 0.00009
GO:0072272 proximal/distal pattern formation involved in metanephric nephron development 0.00009
GO:0060560 developmental growth involved in morphogenesis 0.00010
GO:2000026 regulation of multicellular organismal development 0.00010
GO:2000027 regulation of organ morphogenesis 0.00011
GO:0007548 sex differentiation 0.00011
GO:0010771 negative regulation of cell morphogenesis involved in differentiation 0.00014
GO:0009954 proximal/distal pattern formation 0.00014
GO:0018108 peptidyl-tyrosine phosphorylation 0.00014
GO:0022414 reproductive process 0.00015
GO:0046545 development of primary female sexual characteristics 0.00015
GO:0046546 development of primary male sexual characteristics 0.00015
GO:0048646 anatomical structure formation involved in morphogenesis 0.00015
GO:0000003 reproduction 0.00016
GO:0018212 peptidyl-tyrosine modification 0.00016
GO:0042221 response to chemical stimulus 0.00016
GO:0050673 epithelial cell proliferation 0.00018
GO:0016331 morphogenesis of embryonic epithelium 0.00018
GO:0060688 regulation of morphogenesis of a branching structure 0.00019
GO:0046660 female sex differentiation 0.00019
GO:0050730 regulation of peptidyl-tyrosine phosphorylation 0.00019
GO:0051346 negative regulation of hydrolase activity 0.00021
GO:0046661 male sex differentiation 0.00022
GO:0044057 regulation of system process 0.00023
GO:0006415 translational termination 0.00024
GO:0010647 positive regulation of cell communication 0.00025
GO:0007389 pattern specification process 0.00026
GO:0023056 positive regulation of signaling 0.00026
GO:0001649 osteoblast differentiation 0.00027
GO:0048807 female genitalia morphogenesis 0.00027
GO:0060648 mammary gland bud morphogenesis 0.00027
GO:0071481 cellular response to X-ray 0.00027
GO:0072047 proximal/distal pattern formation involved in nephron development 0.00027
GO:0072081 specification of nephron tubule identity 0.00027
GO:0072268 pattern specification involved in metanephros development 0.00027
GO:2000040 regulation of planar cell polarity pathway involved in axis elongation 0.00027
GO:2000041 negative regulation of planar cell polarity pathway involved in axis elongation 0.00027
GO:0048584 positive regulation of response to stimulus 0.00029
Continued on Next Page. . .
302
Table D.1 – Continued
GO ID GO Term P Value
GO:0052548 regulation of endopeptidase activity 0.00029
GO:0040007 growth 0.00030
GO:0030278 regulation of ossification 0.00031
GO:0010951 negative regulation of endopeptidase activity 0.00032
GO:0045927 positive regulation of growth 0.00033
GO:0001736 establishment of planar polarity 0.00037
GO:0044058 regulation of digestive system process 0.00037
GO:0072210 metanephric nephron development 0.00037
GO:0050793 regulation of developmental process 0.00037
GO:0071845 cellular component disassembly at cellular level 0.00037
GO:0052547 regulation of peptidase activity 0.00038
GO:0031667 response to nutrient levels 0.00038
GO:0048754 branching morphogenesis of a tube 0.00038
GO:0022411 cellular component disassembly 0.00040
GO:0031016 pancreas development 0.00041
GO:0048546 digestive tract morphogenesis 0.00042
GO:0007164 establishment of tissue polarity 0.00045
GO:0060572 morphogenesis of an epithelial bud 0.00045
GO:0072088 nephron epithelium morphogenesis 0.00045
GO:0006414 translational elongation 0.00045
GO:0043624 cellular protein complex disassembly 0.00046
GO:0043241 protein complex disassembly 0.00050
GO:0009967 positive regulation of signal transduction 0.00053
GO:0030154 cell differentiation 0.00053
GO:0008584 male gonad development 0.00053
GO:0048610 cellular process involved in reproduction 0.00053
GO:0043616 keratinocyte proliferation 0.00054
GO:0003402 planar cell polarity pathway involved in axis elongation 0.00055
GO:0060028 convergent extension involved in axis elongation 0.00055
GO:0061004 pattern specification involved in kidney development 0.00055
GO:0072048 renal system pattern specification 0.00055
GO:0072070 loop of Henle development 0.00055
GO:2000051 negative regulation of non-canonical Wnt receptor signaling pathway 0.00055
GO:0035148 tube formation 0.00056
GO:0008406 gonad development 0.00057
GO:0002064 epithelial cell development 0.00058
GO:0001503 ossification 0.00062
GO:0048468 cell development 0.00062
GO:0035019 somatic stem cell maintenance 0.00064
GO:0072028 nephron morphogenesis 0.00064
GO:0048565 digestive tract development 0.00064
GO:0009991 response to extracellular stimulus 0.00068
GO:0022602 ovulation cycle process 0.00068
GO:0045995 regulation of embryonic development 0.00069
GO:0034623 cellular macromolecular complex disassembly 0.00075
GO:0010165 response to X-ray 0.00076
GO:0060571 morphogenesis of an epithelial fold 0.00076
GO:0042127 regulation of cell proliferation 0.00079
GO:0032984 macromolecular complex disassembly 0.00081
GO:0006469 negative regulation of protein kinase activity 0.00081
GO:0001656 metanephros development 0.00083
GO:0061180 mammary gland epithelium development 0.00083
GO:0048869 cellular developmental process 0.00083
GO:0008283 cell proliferation 0.00085
GO:0072009 nephron epithelium development 0.00088
GO:0006928 cellular component movement 0.00090
GO:0030540 female genitalia development 0.00090
GO:2000095 regulation of Wnt receptor signaling pathway, planar cell polarity pathway 0.00090
Continued on Next Page. . .
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Table D.1 – Continued
GO ID GO Term P Value
GO:0065008 regulation of biological quality 0.00094
GO:0031018 endocrine pancreas development 0.00097
GO:0042698 ovulation cycle 0.00098
GO:0072001 renal system development 0.00102
GO:0001738 morphogenesis of a polarized epithelium 0.00102
GO:0060445 branching involved in salivary gland morphogenesis 0.00102
GO:0033673 negative regulation of kinase activity 0.00106
GO:0022600 digestive system process 0.00107
GO:0055123 digestive system development 0.00110
GO:0009790 embryo development 0.00122
GO:0032101 regulation of response to external stimulus 0.00130
GO:0071478 cellular response to radiation 0.00134
GO:0010950 positive regulation of endopeptidase activity 0.00135
GO:0034695 response to prostaglandin E stimulus 0.00135
GO:0060526 prostate glandular acinus morphogenesis 0.00135
GO:0060527 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis 0.00135
GO:0090244 Wnt receptor signaling pathway involved in somitogenesis 0.00135
GO:2000050 regulation of non-canonical Wnt receptor signaling pathway 0.00135
GO:0051348 negative regulation of transferase activity 0.00142
GO:0048762 mesenchymal cell differentiation 0.00144
GO:0043434 response to peptide hormone stimulus 0.00146
GO:0035270 endocrine system development 0.00152
GO:0060603 mammary gland duct morphogenesis 0.00153
GO:0072073 kidney epithelium development 0.00153
GO:0043407 negative regulation of MAP kinase activity 0.00156
GO:0007155 cell adhesion 0.00160
GO:0022610 biological adhesion 0.00160
GO:0050873 brown fat cell differentiation 0.00172
GO:0003002 regionalization 0.00173
GO:0030879 mammary gland development 0.00185
GO:0002067 glandular epithelial cell differentiation 0.00187
GO:0009404 toxin metabolic process 0.00187
GO:0060174 limb bud formation 0.00187
GO:0060687 regulation of branching involved in prostate gland morphogenesis 0.00187
GO:0072079 nephron tubule formation 0.00187
GO:0090178 regulation of establishment of planar polarity involved in neural tube closure 0.00187
GO:0090179 planar cell polarity pathway involved in neural tube closure 0.00187
GO:0045667 regulation of osteoblast differentiation 0.00192
GO:0051094 positive regulation of developmental process 0.00204
GO:0048589 developmental growth 0.00209
GO:0022603 regulation of anatomical structure morphogenesis 0.00211
GO:0032103 positive regulation of response to external stimulus 0.00213
GO:0019080 viral genome expression 0.00225
GO:0019083 viral transcription 0.00225
GO:0007584 response to nutrient 0.00228
GO:0044092 negative regulation of molecular function 0.00231
GO:0048598 embryonic morphogenesis 0.00233
GO:0060485 mesenchyme development 0.00233
GO:0007435 salivary gland morphogenesis 0.00240
GO:0010719 negative regulation of epithelial to mesenchymal transition 0.00248
GO:0034694 response to prostaglandin stimulus 0.00248
GO:0060693 regulation of branching involved in salivary gland morphogenesis 0.00248
GO:0072078 nephron tubule morphogenesis 0.00248
GO:0090177 establishment of planar polarity involved in neural tube closure 0.00248
GO:0043405 regulation of MAP kinase activity 0.00250
GO:0016477 cell migration 0.00261
GO:0045595 regulation of cell differentiation 0.00271
GO:0007586 digestion 0.00279
Continued on Next Page. . .
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Table D.1 – Continued
GO ID GO Term P Value
GO:0043193 positive regulation of gene-specific transcription 0.00280
GO:0034097 response to cytokine stimulus 0.00289
GO:0045596 negative regulation of cell differentiation 0.00290
GO:0035107 appendage morphogenesis 0.00291
GO:0035108 limb morphogenesis 0.00291
GO:0030307 positive regulation of cell growth 0.00298
GO:0043069 negative regulation of programmed cell death 0.00310
GO:0010470 regulation of gastrulation 0.00317
GO:0030916 otic vesicle formation 0.00317
GO:0050872 white fat cell differentiation 0.00317
GO:0060487 lung epithelial cell differentiation 0.00317
GO:0060513 prostatic bud formation 0.00317
GO:0061333 renal tubule morphogenesis 0.00317
GO:0071599 otic vesicle development 0.00317
GO:0071600 otic vesicle morphogenesis 0.00317
GO:0007431 salivary gland development 0.00323
GO:0019827 stem cell maintenance 0.00323
GO:0090263 positive regulation of canonical Wnt receptor signaling pathway 0.00323
GO:0010552 positive regulation of gene-specific transcription from RNA polymerase II promoter 0.00329
GO:0001838 embryonic epithelial tube formation 0.00354
GO:0019748 secondary metabolic process 0.00354
GO:0048736 appendage development 0.00359
GO:0060173 limb development 0.00359
GO:2000241 regulation of reproductive process 0.00359
GO:0009605 response to external stimulus 0.00368
GO:0072175 epithelial tube formation 0.00374
GO:0060548 negative regulation of cell death 0.00382
GO:0003208 cardiac ventricle morphogenesis 0.00386
GO:0051216 cartilage development 0.00389
GO:0042249 establishment of planar polarity of embryonic epithelium 0.00394
GO:0043508 negative regulation of JUN kinase activity 0.00394
GO:0060479 lung cell differentiation 0.00394
GO:0060601 lateral sprouting from an epithelium 0.00394
GO:0070741 response to interleukin-6 0.00394
GO:0045793 positive regulation of cell size 0.00395
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation 0.00395
GO:0043086 negative regulation of catalytic activity 0.00415
GO:0048638 regulation of developmental growth 0.00416
GO:0048864 stem cell development 0.00421
GO:0071214 cellular response to abiotic stimulus 0.00421
GO:0072006 nephron development 0.00421
GO:0051270 regulation of cellular component movement 0.00422
GO:0071900 regulation of protein serine/threonine kinase activity 0.00422
GO:0072358 cardiovascular system development 0.00428
GO:0072359 circulatory system development 0.00428
GO:0071901 negative regulation of protein serine/threonine kinase activity 0.00439
GO:0032569 gene-specific transcription from RNA polymerase II promoter 0.00447
GO:0060443 mammary gland morphogenesis 0.00457
GO:0070555 response to interleukin-1 0.00457
GO:0048870 cell motility 0.00459
GO:0051674 localization of cell 0.00459
GO:0007219 Notch signaling pathway 0.00462
GO:0030099 myeloid cell differentiation 0.00465
GO:0006111 regulation of gluconeogenesis 0.00479
GO:0031581 hemidesmosome assembly 0.00479
GO:0035112 genitalia morphogenesis 0.00479
GO:0046689 response to mercury ion 0.00479
GO:0050732 negative regulation of peptidyl-tyrosine phosphorylation 0.00479
Continued on Next Page. . .
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Table D.1 – Continued
GO ID GO Term P Value
GO:0050930 induction of positive chemotaxis 0.00479
GO:0060742 epithelial cell differentiation involved in prostate gland development 0.00479
GO:0009913 epidermal cell differentiation 0.00486
GO:0008285 negative regulation of cell proliferation 0.00488
GO:0045598 regulation of fat cell differentiation 0.00495
GO:0001568 blood vessel development 0.00502
GO:0001822 kidney development 0.00507
GO:0060541 respiratory system development 0.00545
GO:0002076 osteoblast development 0.00571
GO:0060343 trabecula formation 0.00571
GO:0060602 branch elongation of an epithelium 0.00571
GO:0061383 trabecula morphogenesis 0.00571
GO:0046888 negative regulation of hormone secretion 0.00577
GO:0008585 female gonad development 0.00590
GO:0010212 response to ionizing radiation 0.00619
GO:0060349 bone morphogenesis 0.00620
GO:0010038 response to metal ion 0.00622
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway 0.00639
GO:0043067 regulation of programmed cell death 0.00660
GO:0035272 exocrine system development 0.00666
GO:0048145 regulation of fibroblast proliferation 0.00666
GO:0002065 columnar/cuboidal epithelial cell differentiation 0.00670
GO:0060442 branching involved in prostate gland morphogenesis 0.00670
GO:0048514 blood vessel morphogenesis 0.00674
GO:0051048 negative regulation of secretion 0.00709
GO:0002062 chondrocyte differentiation 0.00713
GO:0003231 cardiac ventricle development 0.00713
GO:0007044 cell-substrate junction assembly 0.00713
GO:0048144 fibroblast proliferation 0.00713
GO:0001944 vasculature development 0.00714
GO:0032868 response to insulin stimulus 0.00719
GO:0016049 cell growth 0.00730
GO:0014031 mesenchymal cell development 0.00740
GO:0006355 regulation of transcription, DNA-dependent 0.00746
GO:0010941 regulation of cell death 0.00752
GO:0016337 cell-cell adhesion 0.00760
GO:0030177 positive regulation of Wnt receptor signaling pathway 0.00763
GO:0048705 skeletal system morphogenesis 0.00767
GO:0003338 metanephros morphogenesis 0.00777
GO:0007379 segment specification 0.00777
GO:0010631 epithelial cell migration 0.00777
GO:0035121 tail morphogenesis 0.00777
GO:0060026 convergent extension 0.00777
GO:0060071 Wnt receptor signaling pathway, planar cell polarity pathway 0.00777
GO:0071479 cellular response to ionizing radiation 0.00777
GO:0072080 nephron tubule development 0.00777
GO:0090132 epithelium migration 0.00777
GO:0090175 regulation of establishment of planar polarity 0.00777
GO:0001756 somitogenesis 0.00815
GO:0030334 regulation of cell migration 0.00841
GO:0043066 negative regulation of apoptosis 0.00841
GO:0003206 cardiac chamber morphogenesis 0.00868
GO:0007267 cell-cell signaling 0.00876
GO:0051271 negative regulation of cellular component movement 0.00877
GO:0003151 outflow tract morphogenesis 0.00891
GO:0042517 positive regulation of tyrosine phosphorylation of Stat3 protein 0.00891
GO:0045600 positive regulation of fat cell differentiation 0.00891
GO:0048745 smooth muscle tissue development 0.00891
Continued on Next Page. . .
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Table D.1 – Continued
GO ID GO Term P Value
GO:0061326 renal tubule development 0.00891
GO:0071453 cellular response to oxygen levels 0.00891
GO:0071456 cellular response to hypoxia 0.00891
GO:2000145 regulation of cell motility 0.00897
GO:0051093 negative regulation of developmental process 0.00920
GO:0060606 tube closure 0.00924
GO:0040011 locomotion 0.00961
GO:0001835 blastocyst hatching 0.00964
GO:0009957 epidermal cell fate specification 0.00964
GO:0010804 negative regulation of tumor necrosis factor-mediated signaling pathway 0.00964
GO:0021594 rhombomere formation 0.00964
GO:0021660 rhombomere 3 formation 0.00964
GO:0021664 rhombomere 5 morphogenesis 0.00964
GO:0021666 rhombomere 5 formation 0.00964
GO:0032605 hepatocyte growth factor production 0.00964
GO:0032646 regulation of hepatocyte growth factor production 0.00964
GO:0033210 leptin-mediated signaling pathway 0.00964
GO:0034115 negative regulation of heterotypic cell-cell adhesion 0.00964
GO:0034699 response to luteinizing hormone stimulus 0.00964
GO:0035188 hatching 0.00964
GO:0035690 cellular response to drug 0.00964
GO:0044343 canonical Wnt receptor signaling pathway involved in regulation of type B pancreatic cell
proliferation
0.00964
GO:0044345 stromal-epithelial cell signaling involved in prostate gland development 0.00964
GO:0044346 fibroblast apoptosis 0.00964
GO:0045738 negative regulation of DNA repair 0.00964
GO:0048175 hepatocyte growth factor biosynthetic process 0.00964
GO:0048176 regulation of hepatocyte growth factor biosynthetic process 0.00964
GO:0048178 negative regulation of hepatocyte growth factor biosynthetic process 0.00964
GO:0050674 urothelial cell proliferation 0.00964
GO:0050675 regulation of urothelial cell proliferation 0.00964
GO:0050677 positive regulation of urothelial cell proliferation 0.00964
GO:0050902 leukocyte adhesive activation 0.00964
GO:0051040 regulation of calcium-independent cell-cell adhesion 0.00964
GO:0051041 positive regulation of calcium-independent cell-cell adhesion 0.00964
GO:0060432 lung pattern specification process 0.00964
GO:0060436 bronchiole morphogenesis 0.00964
GO:0060495 cell-cell signaling involved in lung development 0.00964
GO:0060496 mesenchymal-epithelial cell signaling involved in lung development 0.00964
GO:0060649 mammary gland bud elongation 0.00964
GO:0060659 nipple sheath formation 0.00964
GO:0060661 submandibular salivary gland formation 0.00964
GO:0060668 regulation of branching involved in salivary gland morphogenesis by extracellular matrix-
epithelial cell signaling
0.00964
GO:0060741 prostate gland stromal morphogenesis 0.00964
GO:0060876 semicircular canal formation 0.00964
GO:0060879 semicircular canal fusion 0.00964
GO:0061115 lung proximal/distal axis specification 0.00964
GO:0070103 regulation of interleukin-6-mediated signaling pathway 0.00964
GO:0070104 negative regulation of interleukin-6-mediated signaling pathway 0.00964
GO:0070106 interleukin-27-mediated signaling pathway 0.00964
GO:0070346 positive regulation of fat cell proliferation 0.00964
GO:0070352 positive regulation of white fat cell proliferation 0.00964
GO:0070541 response to platinum ion 0.00964
GO:0071104 response to interleukin-9 0.00964
GO:0071105 response to interleukin-11 0.00964
GO:0071335 hair follicle cell proliferation 0.00964
GO:0071336 regulation of hair follicle cell proliferation 0.00964
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GO:0071338 positive regulation of hair follicle cell proliferation 0.00964
GO:0071684 organism emergence from protective structure 0.00964
GO:0071772 response to BMP stimulus 0.00964
GO:0071773 cellular response to BMP stimulus 0.00964
GO:0090245 axis elongation involved in somitogenesis 0.00964
GO:0090246 convergent extension involved in somitogenesis 0.00964
GO:2000035 regulation of stem cell division 0.00964
GO:2000079 regulation of canonical Wnt receptor signaling pathway involved in controlling type B
pancreatic cell proliferation
0.00964
GO:2000080 negative regulation of canonical Wnt receptor signaling pathway involved in controlling
type B pancreatic cell proliferation
0.00964
GO:2000269 regulation of fibroblast apoptosis 0.00964
GO:2000270 negative regulation of fibroblast apoptosis 0.00964
GO:2000271 positive regulation of fibroblast apoptosis 0.00964
GO:2000278 regulation of DNA biosynthetic process 0.00964
GO:2000279 negative regulation of DNA biosynthetic process 0.00964
GO:0008361 regulation of cell size 0.00973
GO:0050729 positive regulation of inflammatory response 0.00981
GO:0061053 somite development 0.00981
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D.2 Over-enriched GO concepts for breast cancer
marker genes
Table D.2:
GO ID GO Term P Value
GO:0035239 tube morphogenesis 0
GO:0035295 tube development 0
GO:0060562 epithelial tube morphogenesis 0
GO:0048754 branching morphogenesis of a tube 0
GO:0010677 negative regulation of cellular carbohydrate metabolic process 1.00E-05
GO:0045912 negative regulation of carbohydrate metabolic process 1.00E-05
GO:0006357 regulation of transcription from RNA polymerase II promoter 1.00E-05
GO:0001763 morphogenesis of a branching structure 2.00E-05
GO:0046546 development of primary male sexual characteristics 3.00E-05
GO:2000026 regulation of multicellular organismal development 3.00E-05
GO:0050793 regulation of developmental process 4.00E-05
GO:0046661 male sex differentiation 4.00E-05
GO:0060444 branching involved in mammary gland duct morphogenesis 4.00E-05
GO:0048731 system development 5.00E-05
GO:0002009 morphogenesis of an epithelium 5.00E-05
GO:0030539 male genitalia development 6.00E-05
GO:0048856 anatomical structure development 9.00E-05
GO:0045884 regulation of survival gene product expression 9.00E-05
GO:0048513 organ development 0.0001
GO:0033148 positive regulation of estrogen receptor signaling pathway 0.00011
GO:0061138 morphogenesis of a branching epithelium 0.00012
GO:0030520 estrogen receptor signaling pathway 0.00012
GO:0006366 transcription from RNA polymerase II promoter 0.00013
GO:0060603 mammary gland duct morphogenesis 0.00014
GO:0009725 response to hormone stimulus 0.00015
GO:0007548 sex differentiation 0.00018
GO:0033145 positive regulation of steroid hormone receptor signaling pathway 0.00018
GO:0048808 male genitalia morphogenesis 0.00018
GO:0060740 prostate gland epithelium morphogenesis 0.0002
GO:0048732 gland development 0.00021
GO:0060512 prostate gland morphogenesis 0.00022
GO:0048729 tissue morphogenesis 0.00024
GO:0048806 genitalia development 0.00025
GO:0010871 negative regulation of receptor biosynthetic process 0.00027
GO:0031953 negative regulation of protein autophosphorylation 0.00027
GO:0060745 mammary gland branching involved in pregnancy 0.00027
GO:0045595 regulation of cell differentiation 0.00027
GO:0001501 skeletal system development 0.00027
GO:0009719 response to endogenous stimulus 0.00032
GO:0007275 multicellular organismal development 0.00034
GO:0022612 gland morphogenesis 0.00039
GO:0003006 developmental process involved in reproduction 0.0004
GO:0030154 cell differentiation 0.00043
GO:0060443 mammary gland morphogenesis 0.00044
GO:0030500 regulation of bone mineralization 0.00048
GO:0008634 negative regulation of survival gene product expression 0.00049
GO:0001655 urogenital system development 0.00051
GO:0006629 lipid metabolic process 0.00052
GO:0048869 cellular developmental process 0.00059
GO:0030879 mammary gland development 0.0006
GO:0033146 regulation of estrogen receptor signaling pathway 0.00063
Continued on Next Page. . .
309
Table D.2 – Continued
GO ID GO Term P Value
GO:0009887 organ morphogenesis 0.00064
GO:0032502 developmental process 0.00065
GO:0070167 regulation of biomineral tissue development 0.00065
GO:0030278 regulation of ossification 0.00071
GO:0045137 development of primary sexual characteristics 0.00071
GO:0030850 prostate gland development 0.00075
GO:0009888 tissue development 0.00078
GO:0060736 prostate gland growth 0.00079
GO:0061180 mammary gland epithelium development 0.00086
GO:2000112 regulation of cellular macromolecule biosynthetic process 0.00091
GO:0010906 regulation of glucose metabolic process 0.00092
GO:0060429 epithelium development 0.00095
GO:0035112 genitalia morphogenesis 0.00096
GO:0060525 prostate glandular acinus development 0.00096
GO:0060742 epithelial cell differentiation involved in prostate gland development 0.00096
GO:0051239 regulation of multicellular organismal process 0.00106
GO:0009653 anatomical structure morphogenesis 0.00109
GO:0030730 sequestering of triglyceride 0.00115
GO:0010556 regulation of macromolecule biosynthetic process 0.00121
GO:0006109 regulation of carbohydrate metabolic process 0.00133
GO:0010675 regulation of cellular carbohydrate metabolic process 0.00133
GO:0051171 regulation of nitrogen compound metabolic process 0.00134
GO:0010745 negative regulation of macrophage derived foam cell differentiation 0.00135
GO:0010869 regulation of receptor biosynthetic process 0.00135
GO:0060749 mammary gland alveolus development 0.00135
GO:0061377 mammary gland lobule development 0.00135
GO:0001503 ossification 0.00146
GO:0022603 regulation of anatomical structure morphogenesis 0.0015
GO:0030282 bone mineralization 0.00157
GO:0060135 maternal process involved in female pregnancy 0.00157
GO:0080090 regulation of primary metabolic process 0.00173
GO:0043401 steroid hormone mediated signaling pathway 0.00181
GO:0006355 regulation of transcription, DNA-dependent 0.0019
GO:0034339 regulation of transcription from RNA polymerase II promoter by nuclear hormone receptor 0.00192
GO:0016042 lipid catabolic process 0.00194
GO:0031952 regulation of protein autophosphorylation 0.00207
GO:0031323 regulation of cellular metabolic process 0.0021
GO:0045449 regulation of transcription 0.00224
GO:0045944 positive regulation of transcription from RNA polymerase II promoter 0.00231
GO:0032800 receptor biosynthetic process 0.00233
GO:0045599 negative regulation of fat cell differentiation 0.00233
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 0.00238
GO:0031326 regulation of cellular biosynthetic process 0.00244
GO:0051252 regulation of RNA metabolic process 0.00257
GO:0010551 regulation of gene-specific transcription from RNA polymerase II promoter 0.00257
GO:0045893 positive regulation of transcription, DNA-dependent 0.0026
GO:0032569 gene-specific transcription from RNA polymerase II promoter 0.00265
GO:0009889 regulation of biosynthetic process 0.00269
GO:0019216 regulation of lipid metabolic process 0.00275
GO:0051254 positive regulation of RNA metabolic process 0.00283
GO:0032868 response to insulin stimulus 0.00304
GO:0008584 male gonad development 0.00316
GO:0019222 regulation of metabolic process 0.0032
GO:0010628 positive regulation of gene expression 0.00334
GO:0006916 anti-apoptosis 0.0034
GO:2000113 negative regulation of cellular macromolecule biosynthetic process 0.00353
GO:0031214 biomineral tissue development 0.00357
GO:0010552 positive regulation of gene-specific transcription from RNA polymerase II promoter 0.0038
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GO:0010033 response to organic substance 0.0039
GO:0042551 neuron maturation 0.00391
GO:0007399 nervous system development 0.00391
GO:0048598 embryonic morphogenesis 0.00397
GO:0030182 neuron differentiation 0.00407
GO:0048469 cell maturation 0.00415
GO:0045596 negative regulation of cell differentiation 0.00419
GO:0007497 posterior midgut development 0.00427
GO:0010804 negative regulation of tumor necrosis factor-mediated signaling pathway 0.00427
GO:0019102 male somatic sex determination 0.00427
GO:0021506 anterior neuropore closure 0.00427
GO:0021995 neuropore closure 0.00427
GO:0032788 saturated monocarboxylic acid metabolic process 0.00427
GO:0032789 unsaturated monocarboxylic acid metabolic process 0.00427
GO:0034115 negative regulation of heterotypic cell-cell adhesion 0.00427
GO:0035690 cellular response to drug 0.00427
GO:0060514 prostate induction 0.00427
GO:0060520 activation of prostate induction by androgen receptor signaling pathway 0.00427
GO:0060741 prostate gland stromal morphogenesis 0.00427
GO:0072363 regulation of glycolysis by positive regulation of transcription from an RNA polymerase II
promoter
0.00427
GO:0072366 regulation of cellular ketone metabolic process by positive regulation of transcription from
an RNA polymerase II promoter
0.00427
GO:0072369 regulation of lipid transport by positive regulation of transcription from an RNA poly-
merase II promoter
0.00427
GO:2000278 regulation of DNA biosynthetic process 0.00427
GO:2000279 negative regulation of DNA biosynthetic process 0.00427
GO:0008209 androgen metabolic process 0.00427
GO:0010558 negative regulation of macromolecule biosynthetic process 0.00441
GO:2000027 regulation of organ morphogenesis 0.00463
GO:0045923 positive regulation of fatty acid metabolic process 0.00465
GO:0060255 regulation of macromolecule metabolic process 0.00471
GO:0033143 regulation of steroid hormone receptor signaling pathway 0.00504
GO:0050873 brown fat cell differentiation 0.00504
GO:0048545 response to steroid hormone stimulus 0.00518
GO:0031327 negative regulation of cellular biosynthetic process 0.00523
GO:0032501 multicellular organismal process 0.00525
GO:0006350 transcription 0.00539
GO:0010743 regulation of macrophage derived foam cell differentiation 0.00544
GO:0030518 steroid hormone receptor signaling pathway 0.0055
GO:0032583 regulation of gene-specific transcription 0.0058
GO:0009890 negative regulation of biosynthetic process 0.00582
GO:0016331 morphogenesis of embryonic epithelium 0.00587
GO:0006351 transcription, DNA-dependent 0.00598
GO:0048699 generation of neurons 0.00601
GO:0032774 RNA biosynthetic process 0.0061
GO:0045444 fat cell differentiation 0.00625
GO:0045776 negative regulation of blood pressure 0.0063
GO:0010742 macrophage derived foam cell differentiation 0.00674
GO:0090077 foam cell differentiation 0.00674
GO:0060688 regulation of morphogenesis of a branching structure 0.00721
GO:0022414 reproductive process 0.0076
GO:0000003 reproduction 0.00787
GO:0045941 positive regulation of transcription 0.0081
GO:0043255 regulation of carbohydrate biosynthetic process 0.00817
GO:0060284 regulation of cell development 0.00822
GO:0048608 reproductive structure development 0.0084
GO:0006710 androgen catabolic process 0.00851
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GO:0010803 regulation of tumor necrosis factor-mediated signaling pathway 0.00851
GO:0018993 somatic sex determination 0.00851
GO:0030505 inorganic diphosphate transport 0.00851
GO:0031444 slow-twitch skeletal muscle fiber contraction 0.00851
GO:0032275 luteinizing hormone secretion 0.00851
GO:0033034 positive regulation of myeloid cell apoptosis 0.00851
GO:0033211 adiponectin-mediated signaling pathway 0.00851
GO:0045719 negative regulation of glycogen biosynthetic process 0.00851
GO:0045820 negative regulation of glycolysis 0.00851
GO:0048386 positive regulation of retinoic acid receptor signaling pathway 0.00851
GO:0060599 lateral sprouting involved in mammary gland duct morphogenesis 0.00851
GO:0060738 epithelial-mesenchymal signaling involved in prostate gland development 0.00851
GO:0072361 regulation of glycolysis by regulation of transcription from an RNA polymerase II promoter 0.00851
GO:0072364 regulation of cellular ketone metabolic process by regulation of transcription from an RNA
polymerase II promoter
0.00851




GO:0030324 lung development 0.00865
GO:0009755 hormone-mediated signaling pathway 0.00868
GO:0046324 regulation of glucose import 0.00868
GO:0010468 regulation of gene expression 0.00869
GO:0045664 regulation of neuron differentiation 0.00871
GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway 0.00876
GO:0050772 positive regulation of axonogenesis 0.00919
GO:0030323 respiratory tube development 0.00938
GO:0030522 intracellular receptor mediated signaling pathway 0.00938
GO:0051093 negative regulation of developmental process 0.00942
GO:0043193 positive regulation of gene-specific transcription 0.00952
GO:0048468 cell development 0.00958
GO:0043467 regulation of generation of precursor metabolites and energy 0.00972
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D.3 Stem cell marker genes
Although there are a total of 189 genes in the stem cell marker gene set, they have
been broken down into four main functional groups: “DNA replication / cell cycle,”
“RNA transcription / protein synthesis,” “metabolism / hormone signaling / protein
synthesis,” and “ multicellular signaling / immune signaling / cell identity.”
D.3.1 Genes in the DNA replication / cell cycle module
Table D.3:
Gene Name Gene ID Score Binomial P Value Percentile
DNMT3B 1789 0.508379888 2.94E-61 0.00296267
MCM6 4175 0.51396648 1.62E-62 0.002666403
CDC25A 993 0.525139665 4.62E-65 0.002024491
PFAS 5198 0.525139665 4.62E-65 0.002024491
MCM4 4173 0.452513966 3.30E-49 0.008641122
XRCC5 7520 0.480446927 4.11E-55 0.005184673
HAUS6 54801 0.458100559 2.28E-50 0.007406676
TET1 80312 0.458100559 2.28E-50 0.007406676
IGF2BP1 10642 0.541899441 5.95E-69 0.001580091
PLAA 9373 0.469273743 1.01E-52 0.006270986
DEPDC1B 55789 0.458100559 2.28E-50 0.007406676
TEX10 54881 0.458100559 2.28E-50 0.007406676
CCDC99 54908 0.558659218 6.26E-73 0.001234446
MSH2 4436 0.480446927 4.11E-55 0.005184673
BUB1B 701 0.480446927 4.11E-55 0.005184673
MSH6 2956 0.463687151 1.53E-51 0.007011653
DLGAP5 9787 0.491620112 1.53E-57 0.004147738
SKIV2L2 23517 0.469273743 1.01E-52 0.006270986
CENPE 1062 0.474860335 6.52E-54 0.005629074
CHEK2 11200 0.525139665 4.62E-65 0.002024491
SOHLH2 54937 0.603351955 5.68E-84 0.000345645
CCNB1 891 0.458100559 2.28E-50 0.007406676
RRAS2 22800 0.581005587 2.26E-78 0.000641912
PRIM1 5557 0.474860335 6.52E-54 0.005629074
PAICS 10606 0.469273743 1.01E-52 0.006270986
CCNA2 890 0.497206704 9.02E-59 0.003703338
CPSF3 51692 0.474860335 6.52E-54 0.005629074
NUSAP1 51203 0.469273743 1.01E-52 0.006270986
LIN28B 389421 0.502793296 5.21E-60 0.00320956
IPO5 3843 0.525139665 4.62E-65 0.002024491
KIF11 3832 0.48603352 2.54E-56 0.004690895
BMPR1A 657 0.452513966 3.30E-49 0.008641122
NDC80 10403 0.491620112 1.53E-57 0.004147738
BCAT1 586 0.519553073 8.75E-64 0.002419514
CCNG1 900 0.508379888 2.94E-61 0.00296267
ZNF788 388507 0.469273743 1.01E-52 0.006270986
ASCC3 10973 0.452513966 3.30E-49 0.008641122
FANCB 2187 0.458100559 2.28E-50 0.007406676
MCM10 55388 0.525139665 4.62E-65 0.002024491
HMGA2 8091 0.469273743 1.01E-52 0.006270986
SKP2 6502 0.469273743 1.01E-52 0.006270986
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TRIM24 8805 0.541899441 5.95E-69 0.001580091
ORC1L 4998 0.480446927 4.11E-55 0.005184673
HDAC2 3066 0.458100559 2.28E-50 0.007406676
HESX1 8820 0.480446927 4.11E-55 0.005184673
C1orf135 79000 0.51396648 1.62E-62 0.002666403
INHBE 83729 0.497206704 9.02E-59 0.003703338
C21orf45 54069 0.463687151 1.53E-51 0.007011653
DCUN1D5 84259 0.463687151 1.53E-51 0.007011653
POLE2 5427 0.48603352 2.54E-56 0.004690895
MRPL3 11222 0.469273743 1.01E-52 0.006270986
CENPH 64946 0.463687151 1.53E-51 0.007011653
MYCN 4613 0.458100559 2.28E-50 0.007406676
HAUS1 115106 0.474860335 6.52E-54 0.005629074
GDF3 9573 0.458100559 2.28E-50 0.007406676
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D.3.2 Stem cell genes in the RNA transcription / protein
synthesis module
Table D.4:
Gene Name Gene ID Score Binomial P Value Percentile
TBCE 6905 0.491620112 1.53E-57 0.004147738
RIOK2 55781 0.597765363 1.48E-82 0.000395023
BCKDHB 594 0.458100559 2.28E-50 0.007406676
RAD1 5810 0.458100559 2.28E-50 0.007406676
C5orf13 9315 0.458100559 2.28E-50 0.007406676
ADH5 128 0.648044693 1.16E-95 0.000197511
PLRG1 5356 0.519553073 8.75E-64 0.002419514
ROR1 4919 0.670391061 9.24E-102 4.94E-05
RAB3B 5865 0.553072626 1.36E-71 0.001431957
LOC285431 285431 0.491620112 1.53E-57 0.004147738
DBC1 1620 0.48603352 2.54E-56 0.004690895
KIF23 9493 0.452513966 3.30E-49 0.008641122
DIAPH3 81624 0.502793296 5.21E-60 0.00320956
GNL2 29889 0.491620112 1.53E-57 0.004147738
FGF2 2247 0.681564246 7.10E-105 0
TARDBP 23435 0.458100559 2.28E-50 0.007406676
NMNAT2 23057 0.452513966 3.30E-49 0.008641122
ZNF167 55888 0.491620112 1.53E-57 0.004147738
KIF20A 10112 0.463687151 1.53E-51 0.007011653
CENPI 2491 0.480446927 4.11E-55 0.005184673
DDX1 1653 0.469273743 1.01E-52 0.006270986
C3orf21 152002 0.525139665 4.62E-65 0.002024491
GPR176 11245 0.664804469 3.21E-100 9.88E-05
FBXO22 26263 0.469273743 1.01E-52 0.006270986
BBS9 27241 0.51396648 1.62E-62 0.002666403
C14orf166 51637 0.541899441 5.95E-69 0.001580091
BOD1 91272 0.519553073 8.75E-64 0.002419514
CDC123 8872 0.469273743 1.01E-52 0.006270986
SNRPD3 6634 0.502793296 5.21E-60 0.00320956
FAM118B 79607 0.56424581 2.82E-74 0.000987557
DPH3 285381 0.474860335 6.52E-54 0.005629074
EIF2B3 8891 0.469273743 1.01E-52 0.006270986
KDELC1 79070 0.586592179 9.33E-80 0.000543156
RPF2 84154 0.458100559 2.28E-50 0.007406676
APLP1 333 0.474860335 6.52E-54 0.005629074
DACT1 51339 0.536312849 1.20E-67 0.001777602
PDHB 5162 0.586592179 9.33E-80 0.000543156
C14orf119 55017 0.575418994 5.37E-77 0.000790045
DTD1 92675 0.469273743 1.01E-52 0.006270986
SAMM50 25813 0.497206704 9.02E-59 0.003703338
CCL26 10344 0.491620112 1.53E-57 0.004147738
C4orf52 389203 0.458100559 2.28E-50 0.007406676
CCDC90B 60492 0.458100559 2.28E-50 0.007406676
MED20 9477 0.56424581 2.82E-74 0.000987557
UTP6 55813 0.469273743 1.01E-52 0.006270986
RARS2 57038 0.458100559 2.28E-50 0.007406676
KIAA0020 9933 0.474860335 6.52E-54 0.005629074
ARMCX2 9823 0.569832402 1.25E-75 0.000839423
RARS 5917 0.491620112 1.53E-57 0.004147738
MTHFD2 10797 0.469273743 1.01E-52 0.006270986
DHX15 1665 0.452513966 3.30E-49 0.008641122
HTR7 3363 0.558659218 6.26E-73 0.001234446
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HIST1H4C 8364 0.48603352 2.54E-56 0.004690895
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D.3.3 Genes in the metabolism / hormone signaling / pro-
tein synthesis module
Table D.5:
Gene Name Gene ID Score Binomial P Value Percentile
MTHFD1L 25902 0.541899441 5.95E-69 0.001580091
ARMC9 80210 0.569832402 1.25E-75 0.000839423
XPOT 11260 0.51396648 1.62E-62 0.002666403
IARS 3376 0.497206704 9.02E-59 0.003703338
HDX 139324 0.56424581 2.82E-74 0.000987557
ARPM1 84517 0.530726257 2.39E-66 0.001925736
ERCC2 2068 0.458100559 2.28E-50 0.007406676
TBC1D16 125058 0.452513966 3.30E-49 0.008641122
GARS 2617 0.497206704 9.02E-59 0.003703338
KIF7 374654 0.61452514 7.83E-87 0.000296267
UBE2K 3093 0.508379888 2.94E-61 0.00296267
SLC25A3 5250 0.48603352 2.54E-56 0.004690895
ICMT 23463 0.530726257 2.39E-66 0.001925736
UGGT2 55757 0.48603352 2.54E-56 0.004690895
ATP11C 286410 0.48603352 2.54E-56 0.004690895
SLC24A1 9187 0.497206704 9.02E-59 0.003703338
EIF2AK4 440275 0.474860335 6.52E-54 0.005629074
GPX8 493869 0.491620112 1.53E-57 0.004147738
ALX1 8092 0.51396648 1.62E-62 0.002666403
OSTC 58505 0.525139665 4.62E-65 0.002024491
TRPC4 7223 0.458100559 2.28E-50 0.007406676
HAS2 3037 0.51396648 1.62E-62 0.002666403
FZD2 2535 0.452513966 3.30E-49 0.008641122
TRNT1 51095 0.519553073 8.75E-64 0.002419514
MMADHC 27249 0.536312849 1.20E-67 0.001777602
SNX8 29886 0.502793296 5.21E-60 0.00320956
CDH6 1004 0.458100559 2.28E-50 0.007406676
HAT1 8520 0.458100559 2.28E-50 0.007406676
SEC11A 23478 0.519553073 8.75E-64 0.002419514
DIMT1L 27292 0.452513966 3.30E-49 0.008641122
TM2D2 83877 0.452513966 3.30E-49 0.008641122
FST 10468 0.536312849 1.20E-67 0.001777602
GBE1 2632 0.480446927 4.11E-55 0.005184673
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D.3.4 Genes in the multicellular signaling / immune signal-
ing / cell identity module
Table D.6:
Gene Name Gene ID Score Binomial P Value Percentile
NA 80047 0.452513966 3.30E-49 0.008641122
MLL3 58508 0.508379888 2.94E-61 0.00296267
MXI1 4601 0.480446927 4.11E-55 0.005184673
FKSG49 400949 0.569832402 1.25E-75 0.000839423
FAM185B 641808 0.48603352 2.54E-56 0.004690895
ARRB2 409 0.56424581 2.82E-74 0.000987557
SMARCC2 6601 0.497206704 9.02E-59 0.003703338
WASH3P 374666 0.491620112 1.53E-57 0.004147738
PILRB 29990 0.463687151 1.53E-51 0.007011653
CTSH 1512 0.48603352 2.54E-56 0.004690895
SAT1 6303 0.553072626 1.36E-71 0.001431957
JUNB 3726 0.452513966 3.30E-49 0.008641122
CD53 963 0.508379888 2.94E-61 0.00296267
PECAM1 5175 0.597765363 1.48E-82 0.000395023
IL10RA 3587 0.502793296 5.21E-60 0.00320956
RCSD1 92241 0.452513966 3.30E-49 0.008641122
ARHGDIB 397 0.452513966 3.30E-49 0.008641122
GIMAP5 55340 0.581005587 2.26E-78 0.000641912
GIMAP6 474344 0.474860335 6.52E-54 0.005629074
HLA-DMB 3109 0.597765363 1.48E-82 0.000395023
PTPRC 5788 0.502793296 5.21E-60 0.00320956
C10orf128 170371 0.502793296 5.21E-60 0.00320956
CMBL 134147 0.474860335 6.52E-54 0.005629074
HLA-DRB5 3127 0.558659218 6.26E-73 0.001234446
HLA-DPA1 3113 0.558659218 6.26E-73 0.001234446
ABCG1 9619 0.642458101 3.65E-94 0.000246889
GIMAP7 168537 0.480446927 4.11E-55 0.005184673
HLA-DQA1 3117 0.502793296 5.21E-60 0.00320956
TSHZ2 128553 0.463687151 1.53E-51 0.007011653
C13orf15 28984 0.502793296 5.21E-60 0.00320956
CCR1 1230 0.502793296 5.21E-60 0.00320956
NPR3 4883 0.458100559 2.28E-50 0.007406676
RSAD2 91543 0.491620112 1.53E-57 0.004147738
GIMAP1 170575 0.474860335 6.52E-54 0.005629074
TNFSF10 8743 0.497206704 9.02E-59 0.003703338
AFTPH 54812 0.581005587 2.26E-78 0.000641912
NA 643187 0.458100559 2.28E-50 0.007406676
MALAT1 378938 0.497206704 9.02E-59 0.003703338
UBXN2A 165324 0.463687151 1.53E-51 0.007011653
PDE4C 5143 0.56424581 2.82E-74 0.000987557
GIMAP8 155038 0.474860335 6.52E-54 0.005629074
FYB 2533 0.547486034 2.87E-70 0.001530713
MS4A7 58475 0.525139665 4.62E-65 0.002024491
C5orf56 441108 0.458100559 2.28E-50 0.007406676
LOC400931 400931 0.474860335 6.52E-54 0.005629074
MLLT6 4302 0.664804469 3.21E-100 9.88E-05
CTSS 1520 0.48603352 2.54E-56 0.004690895
ZBTB20 26137 0.458100559 2.28E-50 0.007406676
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Table D.7:
GO ID P Value GO Term
GO:0000280 7.52E-14 nuclear division
GO:0007067 7.52E-14 mitosis
GO:0048285 1.22E-13 organelle fission
GO:0000087 1.28E-13 M phase of mitotic cell cycle
GO:0022403 3.70E-13 cell cycle phase
GO:0000279 1.26E-12 M phase
GO:0000278 1.92E-12 mitotic cell cycle
GO:0022402 2.78E-12 cell cycle process
GO:0051301 3.40E-12 cell division
GO:0007049 3.88E-12 cell cycle
GO:0000070 6.02E-09 mitotic sister chromatid segregation
GO:0000819 7.13E-09 sister chromatid segregation
GO:0000226 2.29E-08 microtubule cytoskeleton organization
GO:0006996 4.19E-08 organelle organization
GO:0007059 6.75E-08 chromosome segregation
GO:0007051 7.94E-08 spindle organization
GO:0051276 8.06E-08 chromosome organization
GO:0000075 1.92E-07 cell cycle checkpoint
GO:0051656 3.08E-07 establishment of organelle localization
GO:0050000 4.99E-07 chromosome localization
GO:0051303 4.99E-07 establishment of chromosome localization
GO:0051726 9.53E-07 regulation of cell cycle
GO:0007017 1.09E-06 microtubule-based process
GO:0007093 1.63E-06 mitotic cell cycle checkpoint
GO:0051640 1.78E-06 organelle localization
GO:0006259 1.81E-06 DNA metabolic process
GO:0008608 3.22E-06 attachment of spindle microtubules to kinetochore
GO:0051313 3.22E-06 attachment of spindle microtubules to chromosome
GO:0007346 4.21E-06 regulation of mitotic cell cycle
GO:0040001 4.82E-06 establishment of mitotic spindle localization
GO:0006261 9.11E-06 DNA-dependent DNA replication
GO:0007080 9.42E-06 mitotic metaphase plate congression
GO:0051293 9.42E-06 establishment of spindle localization
GO:0051653 9.42E-06 spindle localization
GO:0007079 1.53E-05 mitotic chromosome movement towards spindle pole
GO:0051984 1.53E-05 positive regulation of chromosome segregation
GO:0051987 1.53E-05 positive regulation of attachment of spindle microtubules to kinetochore
GO:0051329 1.58E-05 interphase of mitotic cell cycle
GO:0051310 1.62E-05 metaphase plate congression
GO:0051325 2.26E-05 interphase
GO:0034453 2.57E-05 microtubule anchoring
GO:0010564 3.29E-05 regulation of cell cycle process
GO:0010638 3.35E-05 positive regulation of organelle organization
GO:0006260 3.41E-05 DNA replication
GO:0006189 4.59E-05 ’de novo’ IMP biosynthetic process
GO:0045842 4.59E-05 positive regulation of mitotic metaphase/anaphase transition
GO:0051305 4.59E-05 chromosome movement towards spindle pole
GO:0051988 4.59E-05 regulation of attachment of spindle microtubules to kinetochore
GO:0042770 5.20E-05 DNA damage response, signal transduction
GO:0070925 6.40E-05 organelle assembly
GO:0007052 7.38E-05 mitotic spindle organization
GO:0000077 8.44E-05 DNA damage checkpoint
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GO:0045840 8.53E-05 positive regulation of mitosis
GO:0051225 8.53E-05 spindle assembly
GO:0051785 8.53E-05 positive regulation of nuclear division
GO:0006188 9.16E-05 IMP biosynthetic process
GO:0046040 9.16E-05 IMP metabolic process
GO:0031570 0.000102493 DNA integrity checkpoint
GO:0006270 0.000126262 DNA-dependent DNA replication initiation
GO:0045787 0.000138788 positive regulation of cell cycle
GO:0007095 0.000152304 mitotic cell cycle G2/M transition DNA damage checkpoint
GO:0034501 0.000152304 protein localization to kinetochore
GO:0043570 0.000152304 maintenance of DNA repeat elements
GO:0051096 0.000152304 positive regulation of helicase activity
GO:0071780 0.000152304 mitotic cell cycle G2/M transition checkpoint
GO:0007010 0.000158535 cytoskeleton organization
GO:0006974 0.000162218 response to DNA damage stimulus
GO:0002566 0.000227877 somatic diversification of immune receptors via somatic mutation
GO:0016446 0.000227877 somatic hypermutation of immunoglobulin genes
GO:0051383 0.000227877 kinetochore organization
GO:0000086 0.000242661 G2/M transition of mitotic cell cycle
GO:0031123 0.000242661 RNA 3’-end processing
GO:0000132 0.00031822 establishment of mitotic spindle orientation
GO:0051095 0.00031822 regulation of helicase activity
GO:0051294 0.00031822 establishment of spindle orientation
GO:0051297 0.00052015 centrosome organization
GO:0008340 0.000542761 determination of adult lifespan
GO:0010389 0.000542761 regulation of G2/M transition of mitotic cell cycle
GO:0045910 0.000542761 negative regulation of DNA recombination
GO:0031023 0.000559652 microtubule organizing center organization
GO:0090068 0.000644305 positive regulation of cell cycle process
GO:0016043 0.000661968 cellular component organization
GO:0090304 0.000751504 nucleic acid metabolic process
GO:0051716 0.000765834 cellular response to stimulus
GO:0006268 0.000825026 DNA unwinding involved in replication
GO:0051983 0.000987526 regulation of chromosome segregation
GO:0010259 0.001164124 multicellular organismal aging
GO:0031058 0.001164124 positive regulation of histone modification
GO:0071174 0.001164124 mitotic cell cycle spindle checkpoint
GO:0006139 0.001184437 nucleobase, nucleoside, nucleotide and nucleic acid metabolic process
GO:0033554 0.001264272 cellular response to stress
GO:0071103 0.001274869 DNA conformation change
GO:0034641 0.001471331 cellular nitrogen compound metabolic process
GO:0007088 0.001545082 regulation of mitosis
GO:0051783 0.001545082 regulation of nuclear division
GO:0032507 0.001787196 maintenance of protein location in cell
GO:0009127 0.00200931 purine nucleoside monophosphate biosynthetic process
GO:0009168 0.00200931 purine ribonucleoside monophosphate biosynthetic process
GO:0031577 0.00200931 spindle checkpoint
GO:0000082 0.002145096 G1/S transition of mitotic cell cycle
GO:0051130 0.002169458 positive regulation of cellular component organization
GO:0045185 0.002241011 maintenance of protein location
GO:0032392 0.002254764 DNA geometric change
GO:0032508 0.002254764 DNA duplex unwinding
GO:0006807 0.002269381 nitrogen compound metabolic process
GO:0051651 0.002440746 maintenance of location in cell
GO:0033043 0.002513612 regulation of organelle organization
GO:0016458 0.002651184 gene silencing
GO:0006298 0.002785911 mismatch repair
GO:0031572 0.002785911 G2/M transition DNA damage checkpoint
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GO:0009126 0.003071393 purine nucleoside monophosphate metabolic process
GO:0009167 0.003071393 purine ribonucleoside monophosphate metabolic process
GO:0031056 0.003071393 regulation of histone modification
GO:0031124 0.003071393 mRNA 3’-end processing
GO:0000710 0.003955576 meiotic mismatch repair
GO:0003272 0.003955576 endocardial cushion formation
GO:0007100 0.003955576 mitotic centrosome separation
GO:0010610 0.003955576 regulation of mRNA stability involved in response to stress
GO:0021998 0.003955576 neural plate mediolateral regionalization
GO:0033129 0.003955576 positive regulation of histone phosphorylation
GO:0043146 0.003955576 spindle stabilization
GO:0043148 0.003955576 mitotic spindle stabilization
GO:0046680 0.003955576 response to DDT
GO:0048338 0.003955576 mesoderm structural organization
GO:0048352 0.003955576 paraxial mesoderm structural organization
GO:0060623 0.003955576 regulation of chromosome condensation
GO:0071281 0.003955576 cellular response to iron ion
GO:0071283 0.003955576 cellular response to iron(III) ion
GO:0002204 0.004006215 somatic recombination of immunoglobulin genes involved in immune response
GO:0002208 0.004006215 somatic diversification of immunoglobulins involved in immune response
GO:0007091 0.004006215 mitotic metaphase/anaphase transition
GO:0009156 0.004006215 ribonucleoside monophosphate biosynthetic process
GO:0030010 0.004006215 establishment of cell polarity
GO:0030071 0.004006215 regulation of mitotic metaphase/anaphase transition
GO:0031576 0.004006215 G2/M transition checkpoint
GO:0045190 0.004006215 isotype switching
GO:0010605 0.004216709 negative regulation of macromolecule metabolic process
GO:0008283 0.004296653 cell proliferation
GO:0002381 0.004343602 immunoglobulin production involved in immunoglobulin mediated immune response
GO:0006342 0.004693708 chromatin silencing
GO:0030261 0.004693708 chromosome condensation
GO:0051129 0.004995788 negative regulation of cellular component organization
GO:0009161 0.005431668 ribonucleoside monophosphate metabolic process
GO:0016447 0.005431668 somatic recombination of immunoglobulin gene segments
GO:0000018 0.005819321 regulation of DNA recombination
GO:0045814 0.005819321 negative regulation of gene expression, epigenetic
GO:0040029 0.005896798 regulation of gene expression, epigenetic
GO:0006281 0.006387647 DNA repair
GO:0009892 0.006597795 negative regulation of metabolic process
GO:0010639 0.006626223 negative regulation of organelle organization
GO:0016445 0.006631468 somatic diversification of immunoglobulins
GO:0008630 0.007492078 DNA damage response, signal transduction resulting in induction of apoptosis
GO:0000236 0.007895805 mitotic prometaphase
GO:0003203 0.007895805 endocardial cushion morphogenesis
GO:0009082 0.007895805 branched chain family amino acid biosynthetic process
GO:0010041 0.007895805 response to iron(III) ion
GO:0010424 0.007895805 DNA methylation on cytosine within a CG sequence
GO:0032776 0.007895805 DNA methylation on cytosine
GO:0033127 0.007895805 regulation of histone phosphorylation
GO:0048369 0.007895805 lateral mesoderm morphogenesis
GO:0048370 0.007895805 lateral mesoderm formation
GO:0048371 0.007895805 lateral mesodermal cell differentiation
GO:0048372 0.007895805 lateral mesodermal cell fate commitment
GO:0048377 0.007895805 lateral mesodermal cell fate specification
GO:0048378 0.007895805 regulation of lateral mesodermal cell fate specification
GO:0048382 0.007895805 mesendoderm development
GO:0051571 0.007895805 positive regulation of histone H3-K4 methylation
GO:0060897 0.007895805 neural plate regionalization
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GO:0070562 0.007895805 regulation of vitamin D receptor signaling pathway
GO:0090307 0.007895805 spindle assembly involved in mitosis
GO:0032269 0.008382756 negative regulation of cellular protein metabolic process
GO:0002562 0.008872146 somatic diversification of immune receptors via germline recombination within a single
locus
GO:0016444 0.008872146 somatic cell DNA recombination
GO:0048477 0.008872146 oogenesis
GO:0051235 0.009127171 maintenance of location
GO:0050767 0.009727988 regulation of neurogenesis
GO:0002200 0.009850495 somatic diversification of immune receptors
GO:0048863 0.010356874 stem cell differentiation
GO:0051248 0.010368518 negative regulation of protein metabolic process
GO:0006344 0.011820745 maintenance of chromatin silencing
GO:0010586 0.011820745 miRNA metabolic process
GO:0010587 0.011820745 miRNA catabolic process
GO:0031442 0.011820745 positive regulation of mRNA 3’-end processing
GO:0046499 0.011820745 S-adenosylmethioninamine metabolic process
GO:0048368 0.011820745 lateral mesoderm development
GO:0050685 0.011820745 positive regulation of mRNA processing
GO:0051299 0.011820745 centrosome separation
GO:0051573 0.011820745 negative regulation of histone H3-K9 methylation
GO:0060896 0.011820745 neural plate pattern specification
GO:0060914 0.011820745 heart formation
GO:0070507 0.011943695 regulation of microtubule cytoskeleton organization
GO:0031324 0.012021243 negative regulation of cellular metabolic process
GO:0006310 0.012383973 DNA recombination
GO:0033044 0.012494885 regulation of chromosome organization
GO:0051960 0.013012966 regulation of nervous system development
GO:0051053 0.013630083 negative regulation of DNA metabolic process
GO:0002377 0.015413557 immunoglobulin production
GO:0000089 0.015730456 mitotic metaphase
GO:0000281 0.015730456 cytokinesis after mitosis
GO:0001880 0.015730456 Mullerian duct regression
GO:0006269 0.015730456 DNA replication, synthesis of RNA primer
GO:0006346 0.015730456 methylation-dependent chromatin silencing
GO:0031062 0.015730456 positive regulation of histone methylation
GO:0031440 0.015730456 regulation of mRNA 3’-end processing
GO:0042661 0.015730456 regulation of mesodermal cell fate specification
GO:0045347 0.015730456 negative regulation of MHC class II biosynthetic process
GO:0051570 0.015730456 regulation of histone H3-K9 methylation
GO:0060218 0.015730456 hemopoietic stem cell differentiation
GO:0060236 0.015730456 regulation of mitotic spindle organization
GO:0070561 0.015730456 vitamin D receptor signaling pathway
GO:0072132 0.015730456 mesenchyme morphogenesis
GO:0032886 0.016029199 regulation of microtubule-based process
GO:0051495 0.017291676 positive regulation of cytoskeleton organization
GO:0040007 0.017363157 growth
GO:0042493 0.017388016 response to drug
GO:0031400 0.01786688 negative regulation of protein modification process
GO:0008629 0.017938333 induction of apoptosis by intracellular signals
GO:0060284 0.019513871 regulation of cell development
GO:0009628 0.01952189 response to abiotic stimulus
GO:0003197 0.019624993 endocardial cushion development
GO:0007501 0.019624993 mesodermal cell fate specification
GO:0010870 0.019624993 positive regulation of receptor biosynthetic process
GO:0030916 0.019624993 otic vesicle formation
GO:0031061 0.019624993 negative regulation of histone methylation
GO:0031573 0.019624993 intra-S DNA damage checkpoint
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GO:0051382 0.019624993 kinetochore assembly
GO:0051569 0.019624993 regulation of histone H3-K4 methylation
GO:0070934 0.019624993 CRD-mediated mRNA stabilization
GO:0071305 0.019624993 cellular response to vitamin D
GO:0071398 0.019624993 cellular response to fatty acid
GO:0071453 0.019624993 cellular response to oxygen levels
GO:0071456 0.019624993 cellular response to hypoxia
GO:0071599 0.019624993 otic vesicle development
GO:0071600 0.019624993 otic vesicle morphogenesis
GO:0090224 0.019624993 regulation of spindle organization
GO:0007163 0.019938926 establishment or maintenance of cell polarity
GO:0014070 0.021040728 response to organic cyclic substance
GO:0009987 0.022113253 cellular process
GO:0044260 0.022685343 cellular macromolecule metabolic process
GO:0032268 0.022850588 regulation of cellular protein metabolic process
GO:0006398 0.023504417 histone mRNA 3’-end processing
GO:0031054 0.023504417 pre-microRNA processing
GO:0033762 0.023504417 response to glucagon stimulus
GO:0046498 0.023504417 S-adenosylhomocysteine metabolic process
GO:0051567 0.023504417 histone H3-K9 methylation
GO:0060033 0.023504417 anatomical structure regression
GO:0000079 0.024205165 regulation of cyclin-dependent protein kinase activity
GO:0009411 0.024205165 response to UV
GO:0031323 0.024229028 regulation of cellular metabolic process
GO:0016570 0.025724865 histone modification
GO:0002440 0.026466249 production of molecular mediator of immune response
GO:0006302 0.026466249 double-strand break repair
GO:0031145 0.026466249 anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein
catabolic process
GO:0016569 0.026555857 covalent chromatin modification
GO:0016310 0.026882049 phosphorylation
GO:0034661 0.027368783 ncRNA catabolic process
GO:0051323 0.027368783 metaphase
GO:0060391 0.027368783 positive regulation of SMAD protein nuclear translocation
GO:0071396 0.027368783 cellular response to lipid
GO:0007292 0.028019516 female gamete generation
GO:0032270 0.028347257 positive regulation of cellular protein metabolic process
GO:0030900 0.029134926 forebrain development
GO:0010212 0.029608727 response to ionizing radiation
GO:0051439 0.029608727 regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle
GO:0032880 0.030472794 regulation of protein localization
GO:0044237 0.03110202 cellular metabolic process
GO:0009113 0.031218149 purine base biosynthetic process
GO:0010224 0.031218149 response to UV-B
GO:0017085 0.031218149 response to insecticide
GO:0019047 0.031218149 provirus integration
GO:0030069 0.031218149 lysogeny
GO:0031060 0.031218149 regulation of histone methylation
GO:0034508 0.031218149 centromere complex assembly
GO:0048340 0.031218149 paraxial mesoderm morphogenesis
GO:0048532 0.031218149 anatomical structure arrangement
GO:0048853 0.031218149 forebrain morphogenesis
GO:0055015 0.031218149 ventricular cardiac muscle cell development
GO:0060045 0.031218149 positive regulation of cardiac muscle cell proliferation
GO:0060390 0.031218149 regulation of SMAD protein nuclear translocation
GO:0071407 0.031218149 cellular response to organic cyclic substance
GO:0016064 0.031233241 immunoglobulin mediated immune response
GO:0019724 0.032058539 B cell mediated immunity
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GO:0007420 0.032187216 brain development
GO:0051247 0.033532315 positive regulation of protein metabolic process
GO:0009950 0.035052572 dorsal/ventral axis specification
GO:0010453 0.035052572 regulation of cell fate commitment
GO:0010470 0.035052572 regulation of gastrulation
GO:0016572 0.035052572 histone phosphorylation
GO:0031503 0.035052572 protein complex localization
GO:0033205 0.035052572 cell cycle cytokinesis
GO:0042659 0.035052572 regulation of cell fate specification
GO:0010243 0.036312306 response to organic nitrogen
GO:0051641 0.037096512 cellular localization
GO:0045786 0.037642407 negative regulation of cell cycle
GO:0051246 0.038616306 regulation of protein metabolic process
GO:0001710 0.03887211 mesodermal cell fate commitment
GO:0006301 0.03887211 postreplication repair
GO:0006303 0.03887211 double-strand break repair via nonhomologous end joining
GO:0006349 0.03887211 regulation of gene expression by genetic imprinting
GO:0006378 0.03887211 mRNA polyadenylation
GO:0010869 0.03887211 regulation of receptor biosynthetic process
GO:0031057 0.03887211 negative regulation of histone modification
GO:0043584 0.03887211 nose development
GO:0045346 0.03887211 regulation of MHC class II biosynthetic process
GO:0071241 0.03887211 cellular response to inorganic substance
GO:0071248 0.03887211 cellular response to metal ion
GO:0071514 0.03887211 genetic imprinting
GO:0046661 0.041686743 male sex differentiation
GO:0051438 0.041686743 regulation of ubiquitin-protein ligase activity
GO:0048015 0.042610059 phosphoinositide-mediated signaling
GO:0006379 0.042676819 mRNA cleavage
GO:0045342 0.042676819 MHC class II biosynthetic process
GO:0048333 0.042676819 mesodermal cell differentiation
GO:0055012 0.042676819 ventricular cardiac muscle cell differentiation
GO:0051128 0.043302372 regulation of cellular component organization
GO:0051340 0.044479666 regulation of ligase activity
GO:0048519 0.045547242 negative regulation of biological process
GO:0034645 0.045691844 cellular macromolecule biosynthetic process
GO:0007281 0.046379426 germ cell development
GO:0031099 0.046379426 regeneration
GO:0001556 0.046466754 oocyte maturation
GO:0002021 0.046466754 response to dietary excess
GO:0007076 0.046466754 mitotic chromosome condensation
GO:0007094 0.046466754 mitotic cell cycle spindle assembly checkpoint
GO:0009083 0.046466754 branched chain family amino acid catabolic process
GO:0010714 0.046466754 positive regulation of collagen metabolic process
GO:0032967 0.046466754 positive regulation of collagen biosynthetic process
GO:0046112 0.046466754 nucleobase biosynthetic process
GO:0051568 0.046466754 histone H3-K4 methylation
GO:0051094 0.046704657 positive regulation of developmental process
GO:0006950 0.047411532 response to stress
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D.3.6 GO terms associated with the RNA transcription /
protein synthesis module
Table D.8:
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GO:0006420 2.84E-05 arginyl-tRNA aminoacylation
GO:0018198 0.000197338 peptidyl-cysteine modification
GO:0009108 0.001505193 coenzyme biosynthetic process
GO:0008380 0.002033993 RNA splicing
GO:0006397 0.002458656 mRNA processing
GO:0022613 0.002766281 ribonucleoprotein complex biogenesis
GO:0007192 0.003118819 activation of adenylate cyclase activity by serotonin receptor signaling pathway
GO:0017014 0.003118819 protein amino acid nitrosylation
GO:0018119 0.003118819 peptidyl-cysteine S-nitrosylation
GO:0042660 0.003118819 positive regulation of cell fate specification
GO:0046294 0.003118819 formaldehyde catabolic process
GO:0048936 0.003118819 peripheral nervous system neuron axonogenesis
GO:0044281 0.003169195 small molecule metabolic process
GO:0051188 0.004581947 cofactor biosynthetic process
GO:0006520 0.005315717 cellular amino acid metabolic process
GO:0016071 0.005476853 mRNA metabolic process
GO:0000022 0.006228148 mitotic spindle elongation
GO:0000189 0.006228148 nuclear translocation of MAPK
GO:0019478 0.006228148 D-amino acid catabolic process
GO:0042699 0.006228148 follicle-stimulating hormone signaling pathway
GO:0046185 0.006228148 aldehyde catabolic process
GO:0046292 0.006228148 formaldehyde metabolic process
GO:0051231 0.006228148 spindle elongation
GO:0060128 0.006228148 adrenocorticotropin hormone secreting cell differentiation
GO:0060591 0.006228148 chondroblast differentiation
GO:0009987 0.006259244 cellular process
GO:0006396 0.00728534 RNA processing
GO:0006446 0.007904176 regulation of translational initiation
GO:0017157 0.008264316 regulation of exocytosis
GO:0006418 0.008631734 tRNA aminoacylation for protein translation
GO:0043038 0.008631734 amino acid activation
GO:0043039 0.008631734 tRNA aminoacylation
GO:0019752 0.009318116 carboxylic acid metabolic process
GO:0043436 0.009318116 oxoacid metabolic process
GO:0014889 0.009328015 muscle atrophy
GO:0017182 0.009328015 peptidyl-diphthamide metabolic process
GO:0017183 0.009328015 peptidyl-diphthamide biosynthetic process from peptidyl-histidine
GO:0018125 0.009328015 peptidyl-cysteine methylation
GO:0046416 0.009328015 D-amino acid metabolic process
GO:0060129 0.009328015 thyroid-stimulating hormone-secreting cell differentiation
GO:0070935 0.009328015 3’-UTR-mediated mRNA stabilization
GO:0044282 0.009730879 small molecule catabolic process
GO:0006082 0.009845979 organic acid metabolic process
GO:0042180 0.010395066 cellular ketone metabolic process
GO:0006732 0.012350571 coenzyme metabolic process
GO:0048511 0.012350571 rhythmic process
GO:0007008 0.012418447 outer mitochondrial membrane organization
GO:0043922 0.012418447 negative regulation by host of viral transcription
GO:0048935 0.012418447 peripheral nervous system neuron development
GO:0051409 0.012418447 response to nitrosative stress
GO:0070096 0.012418447 mitochondrial outer membrane translocase complex assembly
GO:0006413 0.014514097 translational initiation
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GO:0044106 0.014817902 cellular amine metabolic process
GO:0021534 0.015499473 cell proliferation in hindbrain
GO:0021924 0.015499473 cell proliferation in the external granule layer
GO:0021930 0.015499473 granule cell precursor proliferation
GO:0032057 0.015499473 negative regulation of translational initiation in response to stress
GO:0048934 0.015499473 peripheral nervous system neuron differentiation
GO:0006067 0.018571121 ethanol metabolic process
GO:0006069 0.018571121 ethanol oxidation
GO:0007210 0.018571121 serotonin receptor signaling pathway
GO:0032055 0.018571121 negative regulation of translation in response to stress
GO:0032897 0.018571121 negative regulation of viral transcription
GO:0034308 0.018571121 monohydric alcohol metabolic process
GO:0060644 0.018571121 mammary gland epithelial cell differentiation
GO:0009063 0.019515168 cellular amino acid catabolic process
GO:0043921 0.021633418 modulation by host of viral transcription
GO:0046668 0.021633418 regulation of retinal cell programmed cell death
GO:0051775 0.021633418 response to redox state
GO:0052312 0.021633418 modulation of transcription in other organism involved in symbiotic interaction
GO:0052472 0.021633418 modulation by host of symbiont transcription
GO:0022618 0.022249871 ribonucleoprotein complex assembly
GO:0010001 0.022814877 glial cell differentiation
GO:0051301 0.023268534 cell division
GO:0006519 0.02370024 cellular amino acid and derivative metabolic process
GO:0009396 0.024686392 folic acid and derivative biosynthetic process
GO:0009435 0.024686392 NAD biosynthetic process
GO:0018202 0.024686392 peptidyl-histidine modification
GO:0043558 0.024686392 regulation of translational initiation in response to stress
GO:0046653 0.024686392 tetrahydrofolate metabolic process
GO:0046666 0.024686392 retinal cell programmed cell death
GO:0060045 0.024686392 positive regulation of cardiac muscle cell proliferation
GO:0009310 0.025133766 amine catabolic process
GO:0042698 0.025728003 ovulation cycle
GO:0051186 0.026128322 cofactor metabolic process
GO:0034622 0.026162461 cellular macromolecular complex assembly
GO:0002042 0.027730071 cell migration involved in sprouting angiogenesis
GO:0010453 0.027730071 regulation of cell fate commitment
GO:0019359 0.027730071 nicotinamide nucleotide biosynthetic process
GO:0021936 0.027730071 regulation of granule cell precursor proliferation
GO:0021940 0.027730071 positive regulation of granule cell precursor proliferation
GO:0030815 0.027730071 negative regulation of cAMP metabolic process
GO:0030818 0.027730071 negative regulation of cAMP biosynthetic process
GO:0042659 0.027730071 regulation of cell fate specification
GO:0043555 0.027730071 regulation of translation in response to stress
GO:0007188 0.028161812 G-protein signaling, coupled to cAMP nucleotide second messenger
GO:0042063 0.03068472 gliogenesis
GO:0030800 0.030764483 negative regulation of cyclic nucleotide metabolic process
GO:0030803 0.030764483 negative regulation of cyclic nucleotide biosynthetic process
GO:0030809 0.030764483 negative regulation of nucleotide biosynthetic process
GO:0043537 0.030764483 negative regulation of blood vessel endothelial cell migration
GO:0006412 0.03284547 translation
GO:0007128 0.033789655 meiotic prophase I
GO:0021984 0.033789655 adenohypophysis development
GO:0032855 0.033789655 positive regulation of Rac GTPase activity
GO:0051324 0.033789655 prophase
GO:0051851 0.033789655 modification by host of symbiont morphology or physiology
GO:0034660 0.03423083 ncRNA metabolic process
GO:0045761 0.034630745 regulation of adenylate cyclase activity
GO:0009308 0.035832323 amine metabolic process
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GO:0000377 0.035987987 RNA splicing, via transesterification reactions with bulged adenosine as nucleophile
GO:0000398 0.035987987 nuclear mRNA splicing, via spliceosome
GO:0031279 0.035987987 regulation of cyclase activity
GO:0051339 0.036674296 regulation of lyase activity
GO:0006086 0.036805614 acetyl-CoA biosynthetic process from pyruvate
GO:0009083 0.036805614 branched chain family amino acid catabolic process
GO:0010510 0.036805614 regulation of acetyl-CoA biosynthetic process from pyruvate
GO:0045980 0.036805614 negative regulation of nucleotide metabolic process
GO:0051046 0.03692867 regulation of secretion
GO:0019933 0.038062107 cAMP-mediated signaling
GO:0010608 0.038117727 posttranscriptional regulation of gene expression
GO:0018193 0.038921335 peptidyl-amino acid modification
GO:0043536 0.039812388 positive regulation of blood vessel endothelial cell migration
GO:0045947 0.039812388 negative regulation of translational initiation
GO:0046782 0.039812388 regulation of viral transcription
GO:0055021 0.039812388 regulation of cardiac muscle tissue growth
GO:0055024 0.039812388 regulation of cardiac muscle tissue development
GO:0060043 0.039812388 regulation of cardiac muscle cell proliferation
GO:0044237 0.040070335 cellular metabolic process
GO:0000375 0.042344467 RNA splicing, via transesterification reactions
GO:0006085 0.042810004 acetyl-CoA biosynthetic process
GO:0006700 0.042810004 C21-steroid hormone biosynthetic process
GO:0006760 0.042810004 folic acid and derivative metabolic process
GO:0051193 0.042810004 regulation of cofactor metabolic process
GO:0051196 0.042810004 regulation of coenzyme metabolic process
GO:0034621 0.043195956 cellular macromolecular complex subunit organization
GO:0030817 0.045295615 regulation of cAMP biosynthetic process
GO:0014003 0.04579849 oligodendrocyte development
GO:0017158 0.04579849 regulation of calcium ion-dependent exocytosis
GO:0019080 0.04579849 viral genome expression
GO:0019083 0.04579849 viral transcription
GO:0019363 0.04579849 pyridine nucleotide biosynthetic process
GO:0060420 0.04579849 regulation of heart growth
GO:0006171 0.046799216 cAMP biosynthetic process
GO:0030814 0.046799216 regulation of cAMP metabolic process
GO:0051726 0.047999309 regulation of cell cycle
GO:0007018 0.048321133 microtubule-based movement
GO:0050709 0.048777871 negative regulation of protein secretion
GO:0051702 0.048777871 interaction with symbiont
GO:0006399 0.049088873 tRNA metabolic process
GO:0007187 0.04986109 G-protein signaling, coupled to cyclic nucleotide second messenger
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GO:0034660 0.001322169 ncRNA metabolic process
GO:0006399 0.001776558 tRNA metabolic process
GO:0042278 0.002085852 purine nucleoside metabolic process
GO:0046128 0.002085852 purine ribonucleoside metabolic process
GO:0006409 0.002129925 tRNA export from nucleus
GO:0009642 0.002129925 response to light intensity
GO:0015957 0.002129925 bis(5’-nucleosidyl) oligophosphate biosynthetic process
GO:0015960 0.002129925 diadenosine polyphosphate biosynthetic process
GO:0015965 0.002129925 diadenosine tetraphosphate metabolic process
GO:0015966 0.002129925 diadenosine tetraphosphate biosynthetic process
GO:0032289 0.002129925 myelin formation in the central nervous system
GO:0051031 0.002129925 tRNA transport
GO:0001942 0.003573516 hair follicle development
GO:0022404 0.003573516 molting cycle process
GO:0022405 0.003573516 hair cycle process
GO:0006418 0.00409276 tRNA aminoacylation for protein translation
GO:0042303 0.00409276 molting cycle
GO:0042633 0.00409276 hair cycle
GO:0043038 0.00409276 amino acid activation
GO:0043039 0.00409276 tRNA aminoacylation
GO:0006348 0.004255476 chromatin silencing at telomere
GO:0006426 0.004255476 glycyl-tRNA aminoacylation
GO:0006428 0.004255476 isoleucyl-tRNA aminoacylation
GO:0006481 0.004255476 C-terminal protein amino acid methylation
GO:0015942 0.004255476 formate metabolic process
GO:0018410 0.004255476 peptide or protein carboxyl-terminal blocking
GO:0042780 0.004255476 tRNA 3’-end processing
GO:0009119 0.004836233 ribonucleoside metabolic process
GO:0055086 0.005692612 nucleobase, nucleoside and nucleotide metabolic process
GO:0006475 0.00637666 internal protein amino acid acetylation
GO:0015956 0.00637666 bis(5’-nucleosidyl) oligophosphate metabolic process
GO:0015959 0.00637666 diadenosine polyphosphate metabolic process
GO:0022010 0.00637666 myelination in the central nervous system
GO:0032291 0.00637666 ensheathment of axons in the central nervous system
GO:0035315 0.00637666 hair cell differentiation
GO:0043628 0.00637666 ncRNA 3’-end processing
GO:0046499 0.00637666 S-adenosylmethioninamine metabolic process
GO:0051798 0.00637666 positive regulation of hair follicle development
GO:0009116 0.007645128 nucleoside metabolic process
GO:0007199 0.008493487 G-protein signaling, coupled to cGMP nucleotide second messenger
GO:0032276 0.008493487 regulation of gonadotropin secretion
GO:0032277 0.008493487 negative regulation of gonadotropin secretion
GO:0040016 0.008493487 embryonic cleavage
GO:0046880 0.008493487 regulation of follicle-stimulating hormone secretion
GO:0046882 0.008493487 negative regulation of follicle-stimulating hormone secretion
GO:0051797 0.008493487 regulation of hair follicle development
GO:0060218 0.008493487 hemopoietic stem cell differentiation
GO:0035264 0.009928836 multicellular organism growth
GO:0032288 0.010605965 myelin assembly
GO:0032926 0.010605965 negative regulation of activin receptor signaling pathway
GO:0042634 0.010605965 regulation of hair cycle
GO:0006283 0.012714102 transcription-coupled nucleotide-excision repair
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GO:0032274 0.012714102 gonadotropin secretion
GO:0046498 0.012714102 S-adenosylhomocysteine metabolic process
GO:0046884 0.012714102 follicle-stimulating hormone secretion
GO:0070509 0.012714102 calcium ion import
GO:0070588 0.012714102 calcium ion transmembrane transport
GO:0000154 0.014817908 rRNA modification
GO:0030825 0.014817908 positive regulation of cGMP metabolic process
GO:0033683 0.014817908 nucleotide-excision repair, DNA incision
GO:0044237 0.016838242 cellular metabolic process
GO:0006465 0.01691739 signal peptide processing
GO:0009396 0.01691739 folic acid and derivative biosynthetic process
GO:0043249 0.01691739 erythrocyte maturation
GO:0043558 0.01691739 regulation of translational initiation in response to stress
GO:0045684 0.01691739 positive regulation of epidermis development
GO:0046653 0.01691739 tetrahydrofolate metabolic process
GO:0044281 0.017394375 small molecule metabolic process
GO:0009163 0.019012558 nucleoside biosynthetic process
GO:0019934 0.019012558 cGMP-mediated signaling
GO:0042451 0.019012558 purine nucleoside biosynthetic process
GO:0042455 0.019012558 ribonucleoside biosynthetic process
GO:0043555 0.019012558 regulation of translation in response to stress
GO:0044060 0.019012558 regulation of endocrine process
GO:0046129 0.019012558 purine ribonucleoside biosynthetic process
GO:0009650 0.021103419 UV protection
GO:0018196 0.021103419 peptidyl-asparagine modification
GO:0018279 0.021103419 protein amino acid N-linked glycosylation via asparagine
GO:0048820 0.021103419 hair follicle maturation
GO:0030823 0.023189983 regulation of cGMP metabolic process
GO:0060986 0.023189983 endocrine hormone secretion
GO:0007164 0.025272258 establishment of tissue polarity
GO:0006486 0.026347976 protein amino acid glycosylation
GO:0043413 0.026347976 macromolecule glycosylation
GO:0070085 0.026347976 glycosylation
GO:0032925 0.027350252 regulation of activin receptor signaling pathway
GO:0048821 0.027350252 erythrocyte development
GO:0044249 0.027781463 cellular biosynthetic process
GO:0044260 0.028257369 cellular macromolecule metabolic process
GO:0006760 0.029423975 folic acid and derivative metabolic process
GO:0034645 0.030926132 cellular macromolecule biosynthetic process
GO:0001502 0.031493433 cartilage condensation
GO:0014003 0.031493433 oligodendrocyte development
GO:0006730 0.032794344 one-carbon metabolic process
GO:0046483 0.032943656 heterocycle metabolic process
GO:0006725 0.033244252 cellular aromatic compound metabolic process
GO:0032924 0.033558636 activin receptor signaling pathway
GO:0009058 0.034305782 biosynthetic process
GO:0009416 0.03460864 response to light stimulus
GO:0002244 0.035619593 hemopoietic progenitor cell differentiation
GO:0043616 0.035619593 keratinocyte proliferation
GO:0071695 0.035619593 anatomical structure maturation
GO:0009059 0.035896956 macromolecule biosynthetic process
GO:0008152 0.036403368 metabolic process
GO:0010558 0.036475033 negative regulation of macromolecule biosynthetic process
GO:0031069 0.037676311 hair follicle morphogenesis
GO:0006519 0.038301916 cellular amino acid and derivative metabolic process
GO:0031327 0.040019133 negative regulation of cellular biosynthetic process
GO:0030968 0.041777065 endoplasmic reticulum unfolded protein response
GO:0034620 0.041777065 cellular response to unfolded protein
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GO:0043009 0.041931225 chordate embryonic development
GO:0009890 0.042699542 negative regulation of biosynthetic process
GO:0009792 0.043082223 embryo development ending in birth or egg hatching
GO:0000718 0.043821118 nucleotide-excision repair, DNA damage removal
GO:0007223 0.043821118 Wnt receptor signaling pathway, calcium modulating pathway
GO:0045682 0.043821118 regulation of epidermis development
GO:0046068 0.043821118 cGMP metabolic process
GO:0009987 0.045108181 cellular process
GO:0009101 0.045768921 glycoprotein biosynthetic process
GO:0042558 0.045860967 pteridine and derivative metabolic process
GO:0006412 0.049386928 translation
GO:0045055 0.049928082 regulated secretory pathway
GO:0048730 0.049928082 epidermis morphogenesis
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GO:0006955 1.69E-08 immune response
GO:0002376 2.37E-08 immune system process
GO:0002504 4.25E-06 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0001910 2.04E-05 regulation of leukocyte mediated cytotoxicity
GO:0001911 3.22E-05 negative regulation of leukocyte mediated cytotoxicity
GO:0031341 3.34E-05 regulation of cell killing
GO:0031342 5.36E-05 negative regulation of cell killing
GO:0042492 5.36E-05 gamma-delta T cell differentiation
GO:0045586 5.36E-05 regulation of gamma-delta T cell differentiation
GO:0045588 5.36E-05 positive regulation of gamma-delta T cell differentiation
GO:0046643 5.36E-05 regulation of gamma-delta T cell activation
GO:0046645 5.36E-05 positive regulation of gamma-delta T cell activation
GO:0001909 6.18E-05 leukocyte mediated cytotoxicity
GO:0002704 0.00011219 negative regulation of leukocyte mediated immunity
GO:0002707 0.00011219 negative regulation of lymphocyte mediated immunity
GO:0002925 0.00011219 positive regulation of humoral immune response mediated by circulating immunoglobulin
GO:0033687 0.00011219 osteoblast proliferation
GO:0046629 0.00011219 gamma-delta T cell activation
GO:0002922 0.000149366 positive regulation of humoral immune response
GO:0002923 0.000149366 regulation of humoral immune response mediated by circulating immunoglobulin
GO:0002706 0.000215899 regulation of lymphocyte mediated immunity
GO:0019882 0.000271484 antigen processing and presentation
GO:0002714 0.000292106 positive regulation of B cell mediated immunity
GO:0002891 0.000292106 positive regulation of immunoglobulin mediated immune response
GO:0001906 0.000302434 cell killing
GO:0002703 0.00035299 regulation of leukocyte mediated immunity
GO:0002920 0.000413044 regulation of humoral immune response
GO:0065007 0.000531015 biological regulation
GO:0050789 0.000672523 regulation of biological process
GO:0002715 0.000715957 regulation of natural killer cell mediated immunity
GO:0042269 0.000715957 regulation of natural killer cell mediated cytotoxicity
GO:0001912 0.00080427 positive regulation of leukocyte mediated cytotoxicity
GO:0002698 0.00080427 negative regulation of immune effector process
GO:0050794 0.000941615 regulation of cellular process
GO:0050896 0.001113031 response to stimulus
GO:0031343 0.001207177 positive regulation of cell killing
GO:0046635 0.001207177 positive regulation of alpha-beta T cell activation
GO:0002683 0.001214137 negative regulation of immune system process
GO:0002712 0.001438112 regulation of B cell mediated immunity
GO:0002889 0.001438112 regulation of immunoglobulin mediated immune response
GO:0002252 0.001521832 immune effector process
GO:0002228 0.001560873 natural killer cell mediated immunity
GO:0042267 0.001560873 natural killer cell mediated cytotoxicity
GO:0002697 0.001840539 regulation of immune effector process
GO:0002824 0.001958061 positive regulation of adaptive immune response based on somatic recombination of im-
mune receptors built from immunoglobulin superfamily domains
GO:0050777 0.001958061 negative regulation of immune response
GO:0002449 0.00205033 lymphocyte mediated immunity
GO:0002821 0.002100019 positive regulation of adaptive immune response
GO:0045582 0.002100019 positive regulation of T cell differentiation
GO:0002705 0.002246722 positive regulation of leukocyte mediated immunity
GO:0002708 0.002246722 positive regulation of lymphocyte mediated immunity
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GO:0002158 0.002358132 osteoclast proliferation
GO:0002361 0.002358132 CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation
GO:0002370 0.002358132 natural killer cell cytokine production
GO:0002727 0.002358132 regulation of natural killer cell cytokine production
GO:0002729 0.002358132 positive regulation of natural killer cell cytokine production
GO:0009720 0.002358132 detection of hormone stimulus
GO:0009726 0.002358132 detection of endogenous stimulus
GO:0032829 0.002358132 regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differentiation
GO:0032831 0.002358132 positive regulation of CD4-positive, CD25-positive, alpha-beta regulatory T cell differen-
tiation
GO:0034436 0.002358132 glycoprotein transport
GO:0045838 0.002358132 positive regulation of membrane potential
GO:0050904 0.002358132 diapedesis
GO:0060448 0.002358132 dichotomous subdivision of terminal units involved in lung branching
GO:0045621 0.002398149 positive regulation of lymphocyte differentiation
GO:0046634 0.002398149 regulation of alpha-beta T cell activation
GO:0002455 0.003404688 humoral immune response mediated by circulating immunoglobulin
GO:0007204 0.003545142 elevation of cytosolic calcium ion concentration
GO:0002443 0.003699526 leukocyte mediated immunity
GO:0065008 0.004027722 regulation of biological quality
GO:0002700 0.004167465 regulation of production of molecular mediator of immune response
GO:0051480 0.004272108 cytosolic calcium ion homeostasis
GO:0001915 0.004710882 negative regulation of T cell mediated cytotoxicity
GO:0002716 0.004710882 negative regulation of natural killer cell mediated immunity
GO:0034314 0.004710882 Arp2/3 complex-mediated actin nucleation
GO:0045591 0.004710882 positive regulation of regulatory T cell differentiation
GO:0045953 0.004710882 negative regulation of natural killer cell mediated cytotoxicity
GO:0050855 0.004710882 regulation of B cell receptor signaling pathway
GO:0051607 0.004786756 defense response to virus
GO:0002699 0.005221786 positive regulation of immune effector process
GO:0060402 0.005221786 calcium ion transport into cytosol
GO:0046631 0.005445889 alpha-beta T cell activation
GO:0060401 0.005674356 cytosolic calcium ion transport
GO:0045580 0.005907169 regulation of T cell differentiation
GO:0002822 0.006385745 regulation of adaptive immune response based on somatic recombination of immune recep-
tors built from immunoglobulin superfamily domains
GO:0032879 0.006415683 regulation of localization
GO:0002819 0.006631468 regulation of adaptive immune response
GO:0002032 0.007058262 desensitization of G-protein coupled receptor protein signaling pathway by arrestin
GO:0002378 0.007058262 immunoglobulin biosynthetic process
GO:0045542 0.007058262 positive regulation of cholesterol biosynthetic process
GO:0045589 0.007058262 regulation of regulatory T cell differentiation
GO:0045896 0.007058262 regulation of transcription, mitotic
GO:0045897 0.007058262 positive regulation of transcription, mitotic
GO:0046021 0.007058262 regulation of transcription from RNA polymerase II promoter, mitotic
GO:0046022 0.007058262 positive regulation of transcription from RNA polymerase II promoter, mitotic
GO:0006917 0.00726145 induction of apoptosis
GO:0012502 0.007337971 induction of programmed cell death
GO:0045619 0.007923631 regulation of lymphocyte differentiation
GO:0048878 0.008359535 chemical homeostasis
GO:0045088 0.009319878 regulation of innate immune response
GO:0002710 0.009400284 negative regulation of T cell mediated immunity
GO:0033688 0.009400284 regulation of osteoblast proliferation
GO:0034113 0.009400284 heterotypic cell-cell adhesion
GO:0090205 0.009400284 positive regulation of cholesterol metabolic process
GO:0002440 0.009906968 production of molecular mediator of immune response
GO:0002521 0.010351705 leukocyte differentiation
GO:0006874 0.010942755 cellular calcium ion homeostasis
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GO:2000021 0.011129305 regulation of ion homeostasis
GO:0045010 0.011736959 actin nucleation
GO:0045019 0.011736959 negative regulation of nitric oxide biosynthetic process
GO:0045066 0.011736959 regulatory T cell differentiation
GO:0050857 0.011736959 positive regulation of antigen receptor-mediated signaling pathway
GO:0016064 0.011764243 immunoglobulin mediated immune response
GO:0055074 0.012023642 calcium ion homeostasis
GO:0019724 0.012087588 B cell mediated immunity
GO:0006875 0.012668084 cellular metal ion homeostasis
GO:0050870 0.013762313 positive regulation of T cell activation
GO:0001916 0.0140683 positive regulation of T cell mediated cytotoxicity
GO:0007171 0.0140683 activation of transmembrane receptor protein tyrosine kinase activity
GO:0010887 0.0140683 negative regulation of cholesterol storage
GO:0031953 0.0140683 negative regulation of protein amino acid autophosphorylation
GO:0032366 0.0140683 intracellular sterol transport
GO:0032367 0.0140683 intracellular cholesterol transport
GO:0045059 0.0140683 positive thymic T cell selection
GO:0048304 0.0140683 positive regulation of isotype switching to IgG isotypes
GO:0055091 0.0140683 phospholipid homeostasis
GO:0060136 0.0140683 embryonic process involved in female pregnancy
GO:0055065 0.014365205 metal ion homeostasis
GO:0002573 0.015170568 myeloid leukocyte differentiation
GO:0010740 0.015260172 positive regulation of intracellular protein kinase cascade
GO:0006959 0.015531987 humoral immune response
GO:0001914 0.016394319 regulation of T cell mediated cytotoxicity
GO:0002031 0.016394319 G-protein coupled receptor internalization
GO:0006198 0.016394319 cAMP catabolic process
GO:0032689 0.016394319 negative regulation of interferon-gamma production
GO:0045060 0.016394319 negative thymic T cell selection
GO:0045824 0.016394319 negative regulation of innate immune response
GO:0060600 0.016394319 dichotomous subdivision of an epithelial terminal unit
GO:0035556 0.01664198 intracellular signal transduction
GO:0019221 0.017777681 cytokine-mediated signaling pathway
GO:0023036 0.017777681 initiation of signal transduction
GO:0023038 0.017777681 signal initiation by diffusible mediator
GO:0023049 0.017777681 signal initiation by protein/peptide mediator
GO:0043410 0.017777681 positive regulation of MAPKKK cascade
GO:0010872 0.018715026 regulation of cholesterol esterification
GO:0032365 0.018715026 intracellular lipid transport
GO:0043011 0.018715026 myeloid dendritic cell differentiation
GO:0043368 0.018715026 positive T cell selection
GO:0043383 0.018715026 negative T cell selection
GO:0046641 0.018715026 positive regulation of alpha-beta T cell proliferation
GO:0048302 0.018715026 regulation of isotype switching to IgG isotypes
GO:0030005 0.018740757 cellular di-, tri-valent inorganic cation homeostasis
GO:0006952 0.019140405 defense response
GO:0050776 0.01936046 regulation of immune response
GO:0030217 0.020972695 T cell differentiation
GO:0002820 0.021030435 negative regulation of adaptive immune response
GO:0002823 0.021030435 negative regulation of adaptive immune response based on somatic recombination of im-
mune receptors built from immunoglobulin superfamily domains
GO:0009214 0.021030435 cyclic nucleotide catabolic process
GO:0010893 0.021030435 positive regulation of steroid biosynthetic process
GO:0042987 0.021030435 amyloid precursor protein catabolic process
GO:0043372 0.021030435 positive regulation of CD4-positive, alpha beta T cell differentiation
GO:0045540 0.021030435 regulation of cholesterol biosynthetic process
GO:0045830 0.021030435 positive regulation of isotype switching
GO:0046902 0.021030435 regulation of mitochondrial membrane permeability
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GO:0048291 0.021030435 isotype switching to IgG isotypes
GO:0045597 0.021730044 positive regulation of cell differentiation
GO:0055066 0.021730044 di-, tri-valent inorganic cation homeostasis
GO:0043065 0.021732802 positive regulation of apoptosis
GO:0043068 0.022200664 positive regulation of programmed cell death
GO:0007165 0.022734777 signal transduction
GO:0010942 0.022994253 positive regulation of cell death
GO:0001913 0.023340555 T cell mediated cytotoxicity
GO:0030146 0.023340555 diuresis
GO:0033700 0.023340555 phospholipid eﬄux
GO:0034374 0.023340555 low-density lipoprotein particle remodeling
GO:0045911 0.023340555 positive regulation of DNA recombination
GO:0030003 0.024489935 cellular cation homeostasis
GO:0051251 0.024830961 positive regulation of lymphocyte activation
GO:0001773 0.0256454 myeloid dendritic cell activation
GO:0002029 0.0256454 desensitization of G-protein coupled receptor protein signaling pathway
GO:0002720 0.0256454 positive regulation of cytokine production involved in immune response
GO:0010634 0.0256454 positive regulation of epithelial cell migration
GO:0022401 0.0256454 negative adaptation of signaling pathway
GO:0023058 0.0256454 adaptation of signaling pathway
GO:0031648 0.0256454 protein destabilization
GO:0031952 0.0256454 regulation of protein amino acid autophosphorylation
GO:0034433 0.0256454 steroid esterification
GO:0034434 0.0256454 sterol esterification
GO:0034435 0.0256454 cholesterol esterification
GO:0045061 0.0256454 thymic T cell selection
GO:0045123 0.0256454 cellular extravasation
GO:0050732 0.0256454 negative regulation of peptidyl-tyrosine phosphorylation
GO:0050853 0.0256454 B cell receptor signaling pathway
GO:0046907 0.026085117 intracellular transport
GO:0009967 0.026679788 positive regulation of signal transduction
GO:0051235 0.027090738 maintenance of location
GO:0023056 0.027940783 positive regulation of signaling process
GO:0001960 0.027944981 negative regulation of cytokine-mediated signaling pathway
GO:0002711 0.027944981 positive regulation of T cell mediated immunity
GO:0003091 0.027944981 renal water homeostasis
GO:0009125 0.027944981 nucleoside monophosphate catabolic process
GO:0010885 0.027944981 regulation of cholesterol storage
GO:0046640 0.027944981 regulation of alpha-beta T cell proliferation
GO:0046697 0.027944981 decidualization
GO:0090181 0.027944981 regulation of cholesterol metabolic process
GO:0002460 0.02943091 adaptive immune response based on somatic recombination of immune receptors built from
immunoglobulin superfamily domains
GO:0002696 0.02990841 positive regulation of leukocyte activation
GO:0007187 0.02990841 G-protein signaling, coupled to cyclic nucleotide second messenger
GO:0001829 0.030239309 trophectodermal cell differentiation
GO:0006607 0.030239309 NLS-bearing substrate import into nucleus
GO:0010745 0.030239309 negative regulation of macrophage derived foam cell differentiation
GO:0010878 0.030239309 cholesterol storage
GO:0043370 0.030239309 regulation of CD4-positive, alpha beta T cell differentiation
GO:0045191 0.030239309 regulation of isotype switching
GO:0045577 0.030239309 regulation of B cell differentiation
GO:0050891 0.030239309 multicellular organismal water homeostasis
GO:0002250 0.030389025 adaptive immune response
GO:0050863 0.030872742 regulation of T cell activation
GO:0048585 0.03234233 negative regulation of response to stimulus
GO:0050867 0.03234233 positive regulation of cell activation
GO:0002717 0.032528396 positive regulation of natural killer cell mediated immunity
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GO:0010631 0.032528396 epithelial cell migration
GO:0010632 0.032528396 regulation of epithelial cell migration
GO:0010888 0.032528396 negative regulation of lipid storage
GO:0034375 0.032528396 high-density lipoprotein particle remodeling
GO:0042147 0.032528396 retrograde transport, endosome to Golgi
GO:0042994 0.032528396 cytoplasmic sequestering of transcription factor
GO:0045954 0.032528396 positive regulation of natural killer cell mediated cytotoxicity
GO:0050854 0.032528396 regulation of antigen receptor-mediated signaling pathway
GO:0050995 0.032528396 negative regulation of lipid catabolic process
GO:0060716 0.032528396 labyrinthine layer blood vessel development
GO:0090132 0.032528396 epithelium migration
GO:0055080 0.032742446 cation homeostasis
GO:0046058 0.032838285 cAMP metabolic process
GO:0001893 0.034812254 maternal placenta development
GO:0002702 0.034812254 positive regulation of production of molecular mediator of immune response
GO:0032091 0.034812254 negative regulation of protein binding
GO:0046633 0.034812254 alpha-beta T cell proliferation
GO:0070661 0.034852141 leukocyte proliferation
GO:0019216 0.036393627 regulation of lipid metabolic process
GO:0051649 0.036897528 establishment of localization in cell
GO:0002709 0.037090894 regulation of T cell mediated immunity
GO:0042982 0.037090894 amyloid precursor protein metabolic process
GO:0046676 0.037090894 negative regulation of insulin secretion
GO:0051208 0.037090894 sequestering of calcium ion
GO:0090130 0.037090894 tissue migration
GO:0030097 0.03765206 hemopoiesis
GO:0030098 0.03796129 lymphocyte differentiation
GO:0045595 0.038541331 regulation of cell differentiation
GO:0032844 0.039020736 regulation of homeostatic process
GO:0043691 0.039364327 reverse cholesterol transport
GO:0045058 0.039364327 T cell selection
GO:0045940 0.039364327 positive regulation of steroid metabolic process
GO:0090278 0.039364327 negative regulation of peptide hormone secretion
GO:0006606 0.039554713 protein import into nucleus
GO:0019935 0.0406311 cyclic-nucleotide-mediated signaling
GO:0042592 0.040906208 homeostatic process
GO:0010627 0.041021136 regulation of intracellular protein kinase cascade
GO:0051170 0.041173479 nuclear import
GO:0002792 0.041632566 negative regulation of peptide secretion
GO:0006516 0.041632566 glycoprotein catabolic process
GO:0030104 0.041632566 water homeostasis
GO:0030838 0.041632566 positive regulation of actin filament polymerization
GO:0046638 0.041632566 positive regulation of alpha-beta T cell differentiation
GO:0051220 0.041632566 cytoplasmic sequestering of protein
GO:0051412 0.041632566 response to corticosterone stimulus
GO:0060441 0.041632566 epithelial tube branching involved in lung morphogenesis
GO:0019222 0.042224827 regulation of metabolic process
GO:0031400 0.042817175 negative regulation of protein modification process
GO:0048534 0.043888965 hemopoietic or lymphoid organ development
GO:0001825 0.043895621 blastocyst formation
GO:0002718 0.043895621 regulation of cytokine production involved in immune response
GO:0042992 0.043895621 negative regulation of transcription factor import into nucleus
GO:0043029 0.043895621 T cell homeostasis
GO:0060674 0.043895621 placenta blood vessel development
GO:0009187 0.044485396 cyclic nucleotide metabolic process
GO:0043367 0.046153505 CD4-positive, alpha beta T cell differentiation
GO:0006810 0.04615684 transport
GO:0007243 0.046177765 intracellular protein kinase cascade
Continued on Next Page. . .
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Table D.10 – Continued
GO ID P Value GO Term
GO:0023014 0.046177765 signal transmission via phosphorylation event
GO:0051094 0.046521539 positive regulation of developmental process
GO:0042308 0.048406228 negative regulation of protein import into nucleus
GO:0045744 0.048406228 negative regulation of G-protein coupled receptor protein signaling pathway
GO:0015031 0.048818151 protein transport
GO:0034504 0.049050825 protein localization in nucleus
GO:0051707 0.049921612 response to other organism
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Appendix E
Transcriptomic analysis of drugs
E.1 CMAP sample breakdown
HL60 MCF7 PC3 SKMEL5 ssMCF7 Total
Control 177 492 277 5 5 956
Treatment 1229 3095 1741 17 18 6100
Total 1406 3587 2018 22 23 7056
Table E.1: Cross-tab of the number of CMAP samples that were controls and treat-
ments and the corresponding cell lines.
HL60 MCF7 PC3 SKMEL5 ssMCF7 Total
HG-U133A 396 218 148 22 23 807
High Throughput HG-U133A 1010 3149 1870 0 0 6029
High Throughput HG-U133A EA 0 220 0 0 0 220
Total 1406 3587 2018 22 23 7056
Table E.2: Cross-tab of the number of CMAP samples that were performed on the
various gene expression platforms and the corresponding cell lines.
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DMSO ethanol medium Total
HG-U133A 732 15 60 807
High Throughput HG-U133A 6029 0 0 6029
High Throughput HG-U133A EA 220 0 0 220
Total 6981 15 60 7056
Table E.3: Cross-tab of the number of CMAP samples that were performed on the
various gene expression platforms and the corresponding treatment mediums.
HL60 MCF7 PC3 SKMEL5 ssMCF7 Total
DMSO 1401 3532 2008 22 18 6981
ethanol 0 15 0 0 0 15
medium 5 40 10 0 5 60
Total 1406 3587 2018 22 23 7056
Table E.4: Cross-tab of the number of CMAP samples that were performed using the
various treatment mediums and the corresponding cell lines.
338
E.2 Stem cell marker genes
We showed in Section 4.4 how we can make use of 189 stem cell marker genes to not
only stratify pluripotentiality and malignancy, but also to provide clinical gradings
for various types of tumors. Naturally, one would inquire as to how these genes fair
in the context of the Connectivity Map [69]. As the stem cell marker genes were
derived from data performed on the HG-U133 Plus 2.0 array, there unfortunately is
not a complete overlap with the set of genes for which data is available in CMAP
(which was performed using the HG-U133A array). As such, the CMAP based stem
cell analyses were performed using only the 140 genes out of the 189 genes that were
common to both platforms.
Also, as CMAP requires a list of up- and down-regulated genes for an input query
signature, we computed mean difference of expression for the each of the 140 genes
as compared to the background expression intensity. For example, one of the marker
genes in the list is FGF2 fibroblast growth factor. To compute whether FGF2 is up- or
down-regulated in stem cells, we took all samples associated with stem cells (the same
ones used to derive the stem cell marker gene set) and computed the mean expression
for FGF2. Similarly, using all samples not associated with stem cells we computed
the mean background expression for FGF2. The set of up-regulated stem cell genes
was thus the ones that had a mean expression level greater than the background, and
conversely, the set of down-regulated genes were those that had a mean expression
that was lower than the background. Table E.5 contains the set of 140 genes along
with their respective differences from the background distributions.
Table E.5:
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